U.S. patent application number 16/673383 was filed with the patent office on 2020-06-04 for antibodies binding axl.
The applicant listed for this patent is GENMAB A/S. Invention is credited to Esther BREIJ, Rob N. DE JONG, Paul PARREN, David SATIJN, Edward Norbert VAN DEN BRINK, Riemke VAN DIJKHUIZEN RADERSMA, Dennis VERZIJL.
Application Number | 20200171152 16/673383 |
Document ID | / |
Family ID | 53673928 |
Filed Date | 2020-06-04 |
![](/patent/app/20200171152/US20200171152A1-20200604-C00001.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00002.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00003.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00004.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00005.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00006.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00007.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00008.png)
![](/patent/app/20200171152/US20200171152A1-20200604-C00009.png)
![](/patent/app/20200171152/US20200171152A1-20200604-D00000.png)
![](/patent/app/20200171152/US20200171152A1-20200604-D00001.png)
View All Diagrams
United States Patent
Application |
20200171152 |
Kind Code |
A1 |
BREIJ; Esther ; et
al. |
June 4, 2020 |
ANTIBODIES BINDING AXL
Abstract
The present invention relates to anti-AXL antibodies,
immunoconjugates, compositions and method of treatment of cancer
with such anti-AXL antibodies, immunoconjugates, or
compositions.
Inventors: |
BREIJ; Esther; (Utrecht,
NL) ; SATIJN; David; (Utrecht, NL) ; VAN DEN
BRINK; Edward Norbert; (Halfweg, NL) ; VERZIJL;
Dennis; (Amstelveen, NL) ; DE JONG; Rob N.;
(Utrecht, NL) ; PARREN; Paul; (Odijk, NL) ;
VAN DIJKHUIZEN RADERSMA; Riemke; (Zeist, NL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GENMAB A/S |
Copenhagen V |
|
DK |
|
|
Family ID: |
53673928 |
Appl. No.: |
16/673383 |
Filed: |
November 4, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15325364 |
Jan 10, 2017 |
10512688 |
|
|
PCT/EP2015/065900 |
Jul 10, 2015 |
|
|
|
16673383 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/56 20130101;
C07K 16/2863 20130101; C07K 2317/92 20130101; A61K 2039/505
20130101; A61K 47/6801 20170801; A61P 43/00 20180101; C07K 2317/732
20130101; C07K 2317/33 20130101; A61P 25/00 20180101; A61P 13/12
20180101; A61P 1/04 20180101; A61P 21/00 20180101; C07K 2317/34
20130101; A61K 47/6869 20170801; A61P 1/18 20180101; A61K 39/39558
20130101; A61P 1/16 20180101; A61P 15/00 20180101; A61P 19/08
20180101; A61P 11/00 20180101; A61P 17/00 20180101; A61P 35/00
20180101; A61P 35/02 20180101; A61K 2121/00 20130101; A61P 7/00
20180101; A61P 13/10 20180101; C07K 2317/77 20130101; A61K 47/6855
20170801; A61P 19/04 20180101; C07K 16/3061 20130101; A61K 47/6857
20170801 |
International
Class: |
A61K 39/395 20060101
A61K039/395; C07K 16/28 20060101 C07K016/28; A61K 47/68 20060101
A61K047/68; C07K 16/30 20060101 C07K016/30 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 11, 2014 |
DK |
PA 2014 00380 |
Sep 1, 2014 |
DK |
PA 2014 00489 |
Dec 22, 2014 |
DK |
PA 2014 00746 |
May 12, 2015 |
DK |
PA 2015 00283 |
Claims
1-62. (canceled)
63. A nucleic acid encoding an antibody which binds to AXL, wherein
the antibody does not compete for AXL binding with Growth
Arrest-Specific 6 (Gas6).
64. The nucleic acid according to claim 63, wherein maximal binding
of the antibody to AXL in the presence of Gas6 is at least 90% of
binding in the absence of Gas6 as determined by the method
disclosed in Example 2, or as determined by a competition assay,
wherein competition between the antibody binding to AXL and Gas6 is
determined on A431 cells preincubated with Gas6 and without
Gas6.
65. The nucleic acid according to claim 63, wherein (a) the
antibody has a binding affinity (K.sub.D) in the range of
0.3.times.10.sup.-9 to 63.times.10.sup.-9 M to human AXL, and
wherein said binding affinity is measured using a Bio-layer
Interferometry using soluble AXL extracellular domain, and/or (b)
wherein the antibody has a dissociation rate of 9.7.times.10.sup.-5
to 4.4.times.10.sup.-3 s.sup.-1 to human AXL, and wherein the
dissociation rate is measured by Bio-layer Interferometry using
soluble recombinant AXL extracellular domain.
66. The nucleic acid according to claim 63, wherein the antibody
comprises at least one binding region comprising a pair of variable
heavy chain (VH) and variable light chain (VL) regions selected
from the group consisting of: a) a VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs: 36, 37, and 38,
respectively, and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NOs: 39, GAS, and 40, respectively; b) a VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
46, 47, and 48, respectively, and a VL region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs: 49, AAS, and 50,
respectively; c) a VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NOs: 114, 115, and 116, respectively, and a VL
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
117, DAS, and 118, respectively; d) a VH region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 51, 52, and
53, respectively, and a VL region comprising the CDR1, CDR2, and
CDR3 sequences set forth in SEQ ID NOs: 55, GAS, and 56,
respectively; e) a VH region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 51, 52, and 54, respectively,
and a VL region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 55, GAS, and 56, respectively; f) a VH region
comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID
NOs: 57, 58, and 59, respectively, and a VL region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 60, GAS,
and 61, respectively; g) a VH region comprising the CDR1, CDR2, and
CDR3 sequences set forth in SEQ ID NOs: 62, 63, and 64,
respectively, and a VL region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 65, GAS, and 66, respectively;
h) a VH region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 67, 68, and 69, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID
NOs: 70, GAS, and 71, respectively; i) a VH region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 72, 73, and
75, respectively, and a VL region comprising the CDR1, CDR2, and
CDR3 sequences set forth in SEQ ID NOs: 76, ATS, and 77,
respectively; j) a VH region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 72, 74, and 75, respectively,
and a VL region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 76, ATS, and 77, respectively; k) a VH region
comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID
NOs: 78, 79, and 80, respectively, and a VL region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 81, AAS,
and 82, respectively; l) a VH region comprising the CDR1, CDR2, and
CDR3 sequences set forth in SEQ ID NOs: 83, 84, and 85,
respectively, and a VL region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 86, GAS, and 87, respectively;
m) a VH region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 88, 89, and 90, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID
NOs: 91, GAS, and 92, respectively; n) a VH region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 93, 94, and
95, respectively, and a VL region comprising the CDR1, CDR2, and
CDR3 sequences set forth in SEQ ID NOs: 96, GAS, and 97,
respectively; o) a VH region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 98, 99, and 100, respectively,
and a VL region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 101, DAS, and 102, respectively; p) a VH
region comprising the CDR1, CDR2, and CDR3 sequences set forth in
SEQ ID NOs: 103, 104, and 105, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID
NOs: 106, GAS, and 107, respectively; q) a VH region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 108, 109,
and 110, respectively, and a VL region comprising the CDR1, CDR2,
and CDR3 sequences set forth in SEQ ID NOs: 112, AAS, and 113,
respectively; r) a VH region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 108, 109, and 111, respectively,
and a VL region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 112, AAS, and 113, respectively; s) a VH
region comprising the CDR1, CDR2, and CDR3 sequences set forth in
SEQ ID NOs: 41, 42, and 43, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID
NOs: 44, AAS, and 45, respectively; t) a VH region comprising the
CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 93, 94, and
95, respectively, and a VL region comprising the CDR1, CDR2, and
CDR3 sequences set forth in SEQ ID NOs: 128, XAS, wherein X is D or
G, and 129, respectively; u) a VH region comprising the CDR1, CDR2,
and CDR3 sequences set forth in SEQ ID NOs: 46, 119, and 120,
respectively, and a VL region comprising CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 49, AAS, and 50, respectively;
v) a VH region comprising the CDR1, CDR2, and CDR3 sequences set
forth in SEQ ID NOs: 123, 124, and 125, respectively, and a VL
region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ
ID NOs: 60, GAS, and 61, respectively; w) a VH region comprising
the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs: 121,
109, and 122, respectively, and a VL region comprising the CDR1,
CDR2, and CDR3 sequences set forth in SEQ ID NOs: 112, AAS, and
113, respectively; and x) a VH region comprising the CDR1, CDR2,
and CDR3 sequences set forth in SEQ ID NOs:93, 126, and 127,
respectively, and a VL region comprising the CDR1, CDR2, and CDR3
sequences set forth in SEQ ID NOs: 96, GAS, and 97.
67. The nucleic acid according to claim 63, wherein the antibody
comprises at least one binding region comprising a pair of variable
heavy chain (VH) and variable light chain (VL) regions selected
from the group consisting of: a) VH and VL regions comprising the
amino acid sequences of SEQ ID NOs: 1 and 2, respectively; b) VH
and VL regions comprising the amino acid sequences of SEQ ID NOs: 5
and 6, respectively; c) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 34 and 35, respectively; d) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 7 and 9,
respectively; e) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 10 and 11, respectively; f) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 16 and
18, respectively; g) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 25 and 26, respectively; h) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 31 and
33, respectively; i) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 3 and 4, respectively; j) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 8 and 9,
respectively; k) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 12 and 13, respectively; l) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 14 and
15, respectively; m) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 17 and 18, respectively; n) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 19 and
20, respectively; o) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 21 and 22, respectively; p) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 23 and
24, respectively; q) VH and VL regions comprising the amino acid
sequences of SEQ ID NOs: 27 and 28, respectively; r) VH and VL
regions comprising the amino acid sequences of SEQ ID NOs: 29 and
30, respectively; and s) VH and VL regions comprising the amino
acid sequences of SEQ ID NOs: 32 and 33, respectively.
68. The nucleic acid according to claim 63, wherein the antibody
comprises a heavy chain of an isotype selected from the group
consisting of IgG1, IgG2, IgG3, and IgG4.
69. The nucleic acid according to claim 63, wherein the antibody is
a full length monoclonal antibody.
70. The nucleic acid according to claim 63, wherein the antibody is
a single-chain antibody.
71. The nucleic acid according to claim 63, wherein the antibody is
an effector-function deficient antibody, a stabilized IgG4
antibody, or a monovalent antibody.
72. The nucleic acid according to claim 63, wherein the antibody is
a bispecific antibody.
73. A nucleic acid construct encoding at least one amino acid
sequence selected from the group consisting of SEQ ID Nos.: 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,
104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,
117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129,
130, 131, 132, 133, 134, and 135.
74. A nucleic acid construct encoding a pair of amino acid
sequences selected from the group consisting of: a) SEQ ID Nos.: 1
and 2, b) SEQ ID Nos.: 3 and 4, c) SEQ ID Nos.: 5 and 6, d) SEQ ID
Nos.: 7 and 9, e) SEQ ID Nos.: 8 and 9, f) SEQ ID Nos.: 10 and 11,
g) SEQ ID Nos.: 12 and 13, h) SEQ ID Nos.: 14 and 15, i) SEQ ID
Nos.: 16 and 18, j) SEQ ID Nos.: 17 and 18, k) SEQ ID Nos.: 19 and
20, l) SEQ ID Nos.: 21 and 22, m) SEQ ID Nos.: 23 and 24, n) SEQ ID
Nos.: 25 and 26, o) SEQ ID Nos.: 27 and 28, p) SEQ ID Nos.: 29 and
30, q) SEQ ID Nos.: 31 and 33, r) SEQ ID Nos.: 31 and 32, s) SEQ ID
Nos.: 33 and 35, and t) SEQ ID Nos.: 136 and 140.
75. A nucleic acid construct encoding a heavy chain variable region
or light chain variable region comprising three CDR sequences
selected from the group consisting of: a) SEQ ID Nos.: 36, 37 and
38, b) SEQ ID Nos.: 41, 42 and 43, c) SEQ ID Nos.: 46, 47 and 48,
d) SEQ ID Nos.: 51, 52 and 53, e) SEQ ID Nos.: 51, 52 and 54, f)
SEQ ID Nos.: 57, 58 and 59, g) SEQ ID Nos.: 62, 63 and 64, h) SEQ
ID Nos.: 67, 68 and 69, i) SEQ ID Nos.: 72, 73 and 74, j) SEQ ID
Nos.: 72, 73 and 75, k) SEQ ID Nos.: 78, 79 and 80, l) SEQ ID Nos.:
83, 84 and 85, m) SEQ ID Nos.: 88, 89 and 90, n) SEQ ID Nos.: 93,
94 and 95, o) SEQ ID Nos.: 98, 99 and 100, p) SEQ ID Nos.: 103, 104
and 105, q) SEQ ID Nos.: 108, 109 and 110, r) SEQ ID Nos.: 108, 109
and 111, s) SEQ ID Nos.: 114, 115 and 116, t) SEQ ID Nos.: 137, 138
and 139, u) SEQ ID No.: 39, GAS and SEQ ID No.: 32, v) SEQ ID No.:
44, AAS and SEQ ID No.: 45, w) SEQ ID No.: 49, AAS and SEQ ID No.:
50, x) SEQ ID No.: 55, GAS and SEQ ID No.: 56, y) SEQ ID No.: 60,
GAS and SEQ ID No.: 61, z) SEQ ID No.: 65, GAS and SEQ ID No.: 66,
aa) SEQ ID No.: 70, GAS and SEQ ID No.: 71, bb) SEQ ID No.: 76, ATS
and SEQ ID No.: 77, cc) SEQ ID No.: 81, AAS and SEQ ID No.: 82, dd)
SEQ ID No.: 86, GAS and SEQ ID No.: 87, ee) SEQ ID No.: 91, GAS and
SEQ ID No.: 92, ff) SEQ ID No.: 96, GAS and SEQ ID No.: 97, gg) SEQ
ID No.: 101, DAS and SEQ ID No.: 102, hh) SEQ ID No.: 106, GAS and
SEQ ID No.: 107, ii) SEQ ID No.: 117, DAS and SEQ ID No.: 118, and
jj) SEQ ID No.: 141, AAS and SEQ ID No.: 142.
76. An expression vector comprising the nucleic acid according to
claim 63.
77. An expression vector comprising the nucleic acid construct
according to claim 73.
78. A host cell comprising the vector according to claim 76.
79. A host cell comprising the vector according to claim 77.
80. A method for producing an antibody which binds to AXL, wherein
the antibody does not compete for AXL binding with Growth
Arrest-Specific 6 (Gas6), said method comprising the steps of: a)
culturing a host cell according to claim 78, and b) purifying the
antibody from the culture media.
81. A method for producing an antibody which binds to AXL, wherein
the antibody does not compete for AXL binding with Growth
Arrest-Specific 6 (Gas6), said method comprising the steps of: a)
culturing a host cell according to claim 79, and b) purifying the
antibody from the culture media.
82. A method of detecting the presence of AXL antibody, or a cell
expressing AXL, in a sample comprising the steps of; a) contacting
the sample with an antibody which binds to AXL, wherein the
antibody does not compete for AXL binding with the ligand Growth
Arrest-Specific 6 (Gas6), under conditions that allow for formation
of a complex between the antibody and AXL; and b) analyzing whether
a complex has been formed.
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 15/325,364, filed Jan. 10, 2017 (now U.S. Pat. No.
10,512,688), which is a 35 U.S.C. 371 national stage filing of
International Application No. PCT/EP2015/065900, filed Jul. 10,
2015, which claims priority to Danish Patent Application Nos. PA
2015 00283, PA 2014 00746, PA 2014 00489, and PA 2014 00380, filed
on May 12, 2015, Dec. 22, 2014, Sep. 1, 2014, and Jul. 11, 2014,
respectively. The contents of the aforementioned applications are
hereby incorporated by reference.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Nov. 4, 2019, is named GMI_161DUSDV_Sequence_Listing.txt and is
114,075 bytes in size.
FIELD OF INVENTION
[0003] The present invention relates to antibodies binding AXL,
immunoconjugates, compositions comprising such antibodies or
immunoconjugates, and uses of said antibodies and
immunoconjugates.
BACKGROUND
[0004] The TAM subfamily of mammalian Receptor Tyrosine Kinases
(RTKs) consists of AXL, Tyro3 and Mer. AXL is a 104-140 kDa
transmembrane protein which has transforming abilities [1]. AXL can
be activated upon binding of its ligand, the vitamin K-dependent
growth arrest-specific factor 6 (Gas6). Gas6 binding to AXL leads
to AXL dimerization, autophosphorylation and subsequent activation
of intracellular signaling pathways, such as the PI3K/AKT,
mitogen-activated protein kinase (MAPK), STAT and NF-.kappa.B
cascades [2]. In cancer cells, AXL enhances tumor cell motility,
invasion, migration, and is involved in epithelial-to-mesenchymal
transition (EMT) [3]. Furthermore, AXL expression has been
implicated in resistance to chemotherapy and targeted therapy, such
as Epidermal Growth Factor Recptor (EGFR) targeted therapy (Wilson
2014, Brand 2013, Zhang 2012) or inhibitors of the B-raf (BRAF)
pathway (Muller, 2014).
[0005] The extracellular domain of TAM receptor family members is
composed of a combination of two N-terminal immunoglobulin
(Ig)-like domains and two fibronectin Type III (FNIII) repeats [1].
The ligand Gas6 binds to the Ig-like domains I and II of AXL
[14].
[0006] Upregulation of AXL has been reported in a variety of
cancers, including gastric, prostate, ovarian, and lung cancer [1].
Furthermore, AXL is overexpressed in breast and pancreatic cancers
and is significantly associated with higher metastasis frequency
and with poor overall survival [2].
[0007] Targeted inhibition of RTKs may be effective as anti-tumor
and/or metastatic therapy. Such targeted inhibition of AXL and/or
the ligand Gas6 comprises both small molecules and anti-AXL
antibodies [3]. Anti-AXL antibodies have been described that
attenuate non-small cell lung carcinoma xenograft growth in vivo by
downregulation of receptor expression, reducing tumor cell
proliferation and inducing apoptosis [4]. Furthermore, various
monoclonal antibodies have been described that block binding of the
ligand Gas6 to AXL [2], [5], and [7].
[0008] Anti-AXL antibodies have been described previously [8]-[13].
However, a need for anti-AXL antibodies having improved anti-tumor
activity remains.
SUMMARY OF INVENTION
[0009] It is an object of the present invention to provide anti-AXL
antibodies. Thus, in one aspect, the present invention relates to
an antibody which binds to AXL, wherein the antibody, does not
compete for AXL binding with the ligand Growth Arrest-Specific 6
(Gas6).
[0010] In another aspect, the present invention relates to a
bispecific antibody comprising a first binding region of an
antibody according to the invention, and a second binding region
which binds a different target or epitope than said first
antigen-binding region.
[0011] In another aspect, the present invention relates to an
immunoconjugate comprising the antibody or bispecific antibody
according to the invention, and a therapeutic moiety, such as a
cytotoxic agent, a chemotherapeutic drug, a cytokine, an
immunosuppressant, antibiotic, or a radioisotope.
[0012] In another aspect, the present invention relates to a
composition comprising the antibody, bispecific antibody, or
immunoconjugate according to the invention.
[0013] In another aspect, the present invention relates to a
pharmaceutical composition comprising the antibody, bispecific
antibody, or immunoconjugate according to the invention, and a
pharmaceutically acceptable carrier.
[0014] In another aspect, the present invention relates to a
nucleic acid construct encoding an antibody according to the
invention.
[0015] In another aspect, the present invention relates to an
expression vector comprising one or more nucleic acid constructs
according to the invention.
[0016] In another aspect, the present invention relates to a host
cell comprising a vector according to the invention.
[0017] In another aspect, the present invention relates to a
hybridoma which produces the antibody according to the
invention.
[0018] In another aspect, the present invention relates to the
antibody, bispecific antibody, or immunoconjugate according to the
invention for use as a medicament.
[0019] In another aspect, the present invention relates to the
antibody, bispecific antibody, or immunoconjugate according to the
invention for use in the treatment of cancer.
[0020] In another aspect, the present invention relates to a method
of treatment of cancer comprising administering the antibody,
bispecific antibody, immunoconjugate, composition, or
pharmaceutical composition according to the invention, to a subject
in need thereof.
[0021] In another aspect, the present invention relates to a method
of diagnosing a disease characterized by involvement or
accumulation of AXL-expressing cells, comprising administering an
antibody, bispecific antibody, immunoconjugate, composition, or a
pharmaceutical composition according to the invention, to a
subject, optionally wherein the antibody is labeled with a
detectable agent, and wherein the amount of AXL-expressing cells
correlates with or is indicative of disease.
[0022] In another aspect, the present invention relates to a method
for inhibiting growth and/or proliferation of a tumor cell
expressing AXL, comprising administration, to an individual in need
thereof, of an antibody, bispecific antibody, immunoconjugate,
composition, or pharmaceutical composition according to the
invention.
[0023] In another aspect, the present invention relates to a method
for producing an antibody according to the invention, the method
comprising the steps a) culturing a host cell or hybridoma
according to the invention, and b) purifying the antibody from the
culture media.
[0024] In another aspect, the present invention relates to a
diagnostic composition comprising an antibody or bispecific
antibody according to the invention.
[0025] In another aspect, the present invention relates to a method
for detecting the presence of AXL antibody, or a cell expressing
AXL, in a sample comprising the steps of a) contacting the sample
with an antibody, bispecific antibody, immunoconjugate according to
the invention, under conditions that allow for formation of a
complex between the antibody, bispecific antibody, or
immunoconjugate and AXL; and b) analyzing whether a complex has
been formed.
[0026] In another aspect, the present invention relates to a kit
for detecting the presence of AXL antigen, or a cell expressing
AXL, in a sample comprising i) an antibody, bispecific antibody, or
immunoconjugate according to the invention; and ii) instructions
for use of the kit.
[0027] In another aspect, the present invention relates to an
anti-idiotypic antibody which binds to an anti-AXL antibody
according to the invention. s
BRIEF DESCRIPTION OF FIGURES
[0028] FIGS. 1A-1C: Binding curves of anti-AXL antibodies to HEK293
cells transfected with (FIG. 1A) human AXL-ECD, (FIG. 1B)
cynomolgus AXL-ECD, or (FIG. 1C) mouse AXL-ECD. Data shown are mean
fluorescence intensities (MFI) of one representative experiment, as
described in Example 2.
[0029] FIGS. 2A-2F: Binding of anti-AXL antibodies to mouse-human
AXL chimeras was performed as described in Example 3. The following
Homo sapiens AXL (hsAXL) and Mus musculus AXL (mmAXL) chimeric
proteins were tested: (FIG. 2A) hsAXL and mock, (FIG. 2B)
hsAXL-mmECD, (FIG. 2C) hsAXL-mmIg1, (FIG. 2D) hsAXL-mmIg2, (FIG.
2E) hsAXL-mmFN1, (FIG. 2F) hsAXL-mmFN2.
[0030] FIG. 3: Anti-AXL antibody-dependent cell-mediated
cytotoxicity in A431 cells. Antibody-dependent cell-mediated
cytotoxicity by anti-AXL antibodies in A431 cells was determined as
described in Example 4.
[0031] FIG. 4: Binding characteristics of AXL antibody-drug
conjugates (AXL-ADCs). Binding of AXL-ADCs on HEK293T cells
transiently transfected with human AXL was determined as described
in Example 5. Data shown are mean fluorescence intensities (MFI) of
one representative experiment.
[0032] FIGS. 5A and 5B: In vitro cytotoxicity induced by AXL
antibody-drug conjugates. Induction of cytotoxicity by AXL
antibody-drug conjugates was determined as explained in Example
6.
[0033] FIGS. 6A-6E: Antibody VH and VL variants that allow binding
to AXL. Antibodies with identical VL or VH regions were aligned and
differences in VH (FIGS. 6A-6D) or VL (FIG. 6E) sequences,
respectively, were identified and indicated by boxes in the
figures. CDR regions are underlined.
[0034] FIG. 7: Induction of cytotoxicity by ADCs in LCLC-103H cells
was determined as described in Example 8.
[0035] FIG. 8: Anti-tumor activity by MMAE-conjugated AXL
antibodies in a therapeutic LCLC-103H xenograft model as described
in Example 9.
[0036] FIG. 9: Immunohistochemical staining of frozen PAXF1657
tumor sections (pancreas cancer PDX model) using a pool of AXL
monoclonal antibodies as described in Example 10.
[0037] FIGS. 10A-10C: (FIG. 10A) Average tumor size after
therapeutic treatment with AXL-ADCs the PAXF1657 model. An
unconjugated AXL Humab (FIG. 10B) and an untargeted ADC (FIG. 10C)
do not show anti-tumor activity, indicating that the therapeutic
capacity of AXL-ADCs was dependent on the cytotoxic activity of
MMAE and on target binding, error bars represent S.E.M.
[0038] FIGS. 11A-11F: Binding of anti-AXL antibodies to mouse-human
AXL chimeras was performed as described in Example 11. The
following Homo sapiens AXL (hsAXL) and Mus musculus AXL (mmAXL)
chimeric proteins were tested: (FIG. 11A) hsAXL and mock, (FIG.
11B) hsAXL-mmECD, (FIG. 11C) hsAXL-mmIg1, (FIG. 11D) hsAXL-mmIg2,
(FIG. 11E) hsAXL-mmFN1, (FIG. 11F) hsAXL-mmFN2.
[0039] FIG. 12: Binding of human Gas6 (hGas6) on A431 cells that
had been pre-incubated with antibodies binding to the Ig1 domain of
AXL. Data shown are mean fluorescence intensities (MFI) of one
representative experiment.
[0040] FIGS. 13A and 13B: Anti-tumor activity of MMAE-conjugated
AXL antibodies in a therapeutic A431 xenograft model, that produces
high levels of endogeneous Gas6, as described in Example 13. FIGS.
13A and 13B show results from 2 independent experiments.
[0041] FIGS. 14A and 14B: Anti-tumor activity of MMAE-conjugated
AXL antibodies in a therapeutic LCLC-103H xenograft model, that
expresses low levels of endogenous Gas6, as described in Example
13.
[0042] FIGS. 14A and 14B show results from 2 independent
experiments.
[0043] FIGS. 15A and 15B: Induction of cytotoxicity by AXL-ADCs in
A431 cells (FIG. 15A) and MDA-MB231 cells (FIG. 15B) was determined
as described in Example 8.
[0044] FIG. 16. AXL staining in thyroid, esophageal, ovarian,
breast, lung, pancreatic, cervical and endometrial cancer. The
average AXL staining intensity (OD) of AXL-positive cells is
plotted on the X-axis, and the percentage of AXL-positive tumor
cells is plotted on the Y-axis. Each dot represents a tumor core,
derived from an individual patent.
[0045] FIG. 17. Representative examples of AXL-immunostained tumor
cores for different tumor indication.
[0046] FIGS. 18A-18G. AXL antibodies specifically bind AXL but not
to other TAM receptor family members. Binding of HuMab-AXL
antibodies to HEK293 cells transfected with human AXL (FIG. 18A),
human MER (FIG. 18B), human TYRO3 (FIG. 18C), or untransfected
HEK293 cells (FIG. 18D). To confirm proper expression of
transfected cells, untransfected HEK293F cells and cells
transfected with AXL (FIG. 18E), MER (FIG. 18F), or TYRO3 (FIG.
18G) were stained with MER- and TYRO3-specific antibodies. Data
shown are mean fluorescence intensities (MFI) of one representative
experiment, as described in Example 15.
[0047] FIGS. 19A-19D. Detection of AXL antibodies on the plasma
membrane of tumor cell lines that had been incubated with
AXL-antibodies for 1 hour at 4.degree. C., followed by an overnight
incubation 4.degree. C. or 37.degree. C. In both MDA-MB-231 (FIGS.
19A and 19B) and Calu-1 cells (FIGS. 19C and 19D), more antibody
was detected on the plasma membrane of cells that had been
incubated at 4.degree. C. than on cells that had been incubated at
37.degree. C., illustrating internalization of membrane-bound
antibody at 37.degree. C.
[0048] FIG. 20. Geomean fluorescence intensity of LCLC-103H cells
after incubation with AXL antibodies that had been complexed to
Fab-TAMRA/QSY7. IgG1-b12 and Fab-TAMRA/QSY7 alone were included as
negative controls.
[0049] FIGS. 21A and 21B. (FIG. 21A) Average tumor size after
therapeutic treatment with IgG1-AXL-107-vcMMAE in the esophageal
cancer PDX model ES0195. IgG1-b12 and IgG1-b12-MMAE were included
as isotype control antibody and isotype control ADC, respectively.
(FIG. 21B) Tumor size in individual mice on day 32 after injection
of MDA-MB-231-luc D3H2LN tumor cells in the mammary fat pads of
female SCID mice. * p<0.05; ** p<0.0001 FIGS. 22A and 22B.
Therapeutic effect of AXL-ADCs in a patient-derived cervical cancer
xenograft model. (FIG. 22A) Average tumor size after therapeutic
treatment with IgG1-AXL-183-vcMMAE or IgG1-AXL-726-vcMMAE in the
cervical cancer PDX model CEXF 773. IgG1-b12 and IgG1-b12-MMAE were
included as isotype control antibody and isotype control ADC,
respectively. (FIG. 22B) Tumor size in individual mice on day 28
after initiation of treatment in the cervical cancer PDX model CEXF
773. * p<0.001.
[0050] FIGS. 23A and 23B. Therapeutic activity of AXL-ADCs in an
orthotopic breast cancer xenograft model. (FIG. 23A) Average tumor
size after therapeutic treatment with IgG1-AXL-183-vcMMAE or
IgG1-AXL-726-vcMMAE in an orthotopic MDA-MB-231-luc D3H2LN
xenograft model. IgG1-b12 and IgG1-b12-MMAE were included as
isotype control antibody and isotype control ADC, respectively.
(FIG. 23B) Tumor size in individual mice on day 32 after injection
of MDA-MB-231-luc D3H2LN tumor cells in the mammary fat pads of
female SCID mice. * p<0.001.
[0051] FIG. 24. Cytotoxicity of IgG1-AXL-107-vcMMAE in human tumor
cell lines with different levels of AXL expression on the plasma
membrane. AXL expression in the plasma membrane of human tumor cell
lines was assessed using Qifikit analysis, and the cytotoxicity of
IgG1-AXL-107-vcMMAE was expressed as the percentage of viable tumor
cells that remained in the cell cultures after exposure to 1
.mu.g/mL IgG1-AXL-107-vcM MAE.
DETAILED DESCRIPTION
Antibodies
[0052] In one aspect, the present invention relates to an antibody
which binds to AXL, wherein the antibody, does not compete for AXL
binding with the ligand Growth Arrest-Specific 6 (Gas6).
[0053] The term "antibody" as used herein is intended to refer to
an immunoglobulin molecule, a fragment of an immunoglobulin
molecule, or a derivative of either thereof, which has the ability
to specifically bind to an antigen under typical physiological
and/or tumor-specific conditions with a half-life of significant
periods of time, such as at least about 30 minutes, at least about
45 minutes, at least about one hour, at least about two hours, at
least about four hours, at least about 8 hours, at least about 12
hours, about 24 hours or more, about 48 hours or more, about 3, 4,
5, 6, 7 or more days, etc., or any other relevant
functionally-defined period (such as a time sufficient to induce,
promote, enhance, and/or modulate a physiological response
associated with antibody binding to the antigen and/or time
sufficient for the antibody to be internalized). The binding region
(or binding domain which may be used herein, both having the same
meaning) which interacts with an antigen, comprises variable
regions of both the heavy and light chains of the immunoglobulin
molecule. The constant regions of the antibodies (Abs) may mediate
the binding of the immunoglobulin to host tissues or factors,
including various cells of the immune system (such as effector
cells) and components of the complement system such as Clq, the
first component in the classical pathway of complement activation.
As indicated above, the term antibody as used herein, unless
otherwise stated or clearly contradicted by context, includes
fragments of an antibody that retain the ability to specifically
interact, such as bind, to the antigen. It has been shown that the
antigen-binding function of an antibody may be performed by
fragments of a full-length antibody. Examples of binding fragments
encompassed within the term "antibody" include (i) a Fab' or Fab
fragment, a monovalent fragment consisting of the VL, VH, CL and
CH1 domains, or a monovalent antibody as described in [15]; (ii)
F(ab').sub.2 fragments, bivalent fragments comprising two Fab
fragments linked by a disulfide bridge at the hinge region; (iii)
an Fd fragment consisting essentially of the VH and CH1 domains;
(iv) an Fv fragment consisting essentially of the VL and VH domains
of a single arm of an antibody, (v) a dAb fragment [16], which
consists essentially of a VH domain and is also called domain
antibody [17]; (vi) camelid or nanobodies [18] and (vii) an
isolated complementarity determining region (CDR). Furthermore,
although the two domains of the Fv fragment, VL and VH, are coded
for by separate genes, they may be joined, using recombinant
methods, by a synthetic linker that enables them to be made as a
single protein chain in which the VL and VH regions pair to form
monovalent molecules (known as single chain antibodies or single
chain Fv (scFv), see for instance [19] and [20]). Such single chain
antibodies are encompassed within the term antibody unless
otherwise noted or clearly indicated by context. Although such
fragments are generally included within the meaning of antibody,
they collectively and each independently are unique features of the
present invention, exhibiting different biological properties and
utility. These and other useful antibody fragments in the context
of the present invention are discussed further herein. It also
should be understood that the term antibody, unless specified
otherwise, also includes polyclonal antibodies, monoclonal
antibodies (mAbs), antibody-like polypeptides, such as chimeric
antibodies and humanized antibodies, as well as `antibody
fragments` or `fragments thereof` retaining the ability to
specifically bind to the antigen (antigen-binding fragments)
provided by any known technique, such as enzymatic cleavage,
peptide synthesis, and recombinant techniques, and retaining the
ability to be conjugated to a toxin. An antibody as generated can
possess any isotype.
[0054] The term "immunoglobulin heavy chain" or "heavy chain of an
immunoglobulin" as used herein is intended to refer to one of the
heavy chains of an immunoglobulin. A heavy chain is typically
comprised of a heavy chain variable region (abbreviated herein as
VH) and a heavy chain constant region (abbreviated herein as CH)
which defines the isotype of the immunoglobulin. The heavy chain
constant region typically is comprised of three domains, CH1, CH2,
and CH3. The term "immunoglobulin" as used herein is intended to
refer to a class of structurally related glycoproteins consisting
of two pairs of polypeptide chains, one pair of light (L) low
molecular weight chains and one pair of heavy (H) chains, all four
potentially inter-connected by disulfide bonds. The structure of
immunoglobulins has been well characterized (see for instance
[21]). Within the structure of the immunoglobulin, the two heavy
chains are inter-connected via disulfide bonds in the so-called
"hinge region". Equally to the heavy chains each light chain is
typically comprised of several regions; a light chain variable
region (abbreviated herein as VL) and a light chain constant
region. The light chain constant region typically is comprised of
one domain, CL. Furthermore, the VH and VL regions may be further
subdivided into regions of hypervariability (or hypervariable
regions which may be hypervariable in sequence and/or form of
structurally defined loops), also termed complementarity
determining regions (CDRs), interspersed with regions that are more
conserved, termed framework regions (FRs). Each VH and VL is
typically composed of three CDRs and four FRs, arranged from
amino-terminus to carboxy-terminus in the following order: FR1,
CDR1, FR2, CDR2, FR3, CDR3, FR4. CDR sequences are defined
according to IMGT (see [22] and [23]).
[0055] The term "antigen-binding region" or "binding region" as
used herein, refers to a region of an antibody which is capable of
binding to the antigen. The antigen can be any molecule, such as a
polypeptide, e.g. present on a cell, bacterium, or virion. The
terms "antigen" and "target" may, unless contradicted by the
context, be used interchangeably in the context of the present
invention.
[0056] The term "binding" as used herein refers to the binding of
an antibody to a predetermined antigen or target, typically with a
binding affinity corresponding to a K.sub.D of about 10.sup.-6 M or
less, e.g. 10.sup.-7 M or less, such as about 10.sup.-8 M or less,
such as about 10.sup.-9 M or less, about 10.sup.-10 M or less, or
about 10.sup.-11 M or even less when determined by for instance
surface plasmon resonance (SPR) technology in a BIAcore 3000
instrument using the antigen as the ligand and the protein as the
analyte, and binds to the predetermined antigen with an affinity
corresponding to a K.sub.D that is at least ten-fold lower, such as
at least 100 fold lower, for instance at least 1,000 fold lower,
such as at least 10,000 fold lower, for instance at least 100,000
fold lower than its affinity for binding to a non-specific antigen
(e.g., BSA, casein) other than the predetermined antigen or a
closely-related antigen. The amount with which the affinity is
lower is dependent on the K.sub.D of the protein, so that when the
K.sub.D of the protein is very low (that is, the protein is highly
specific), then the amount with which the affinity for the antigen
is lower than the affinity for a non-specific antigen may be at
least 10,000 fold. The term "K.sub.D" (M), as used herein, refers
to the dissociation equilibrium constant of a particular
antibody-antigen interaction, and is obtained by dividing k.sub.d
by k.sub.a.
[0057] The term "k.sub.d" (sec.sup.-1), as used herein, refers to
the dissociation rate constant of a particular antibody-antigen
interaction. Said value is also referred to as the k.sub.off value
or off-rate.
[0058] The term "k.sub.a" (M.sup.-1.times.sec.sup.-1), as used
herein, refers to the association rate constant of a particular
antibody-antigen interaction. Said value is also referred to as the
k.sub.on value or on-rate.
[0059] The term "K.sub.A" (M.sup.-1), as used herein, refers to the
association equilibrium constant of a particular antibody-antigen
interaction and is obtained by dividing k.sub.a by k.sub.d.
[0060] The term "AXL" as used herein, refers to the protein
entitled AXL, which is also referred to as UFO or JTK11, a 894
amino acid protein with a molecular weight of 104-140 kDa that is
part of the subfamily of mammalian TAM Receptor Tyrosine Kinases
(RTKs). The molecular weight is variable due to potential
differences in glycosylation of the protein. The AXL protein
consists of two extracellular immunoglobulin-like (Ig-like) domains
on the N-terminal end of the protein, two membrane-proximal
extracellular fibronectin type III (FNIII) domains, a transmembrane
domain and an intracellular kinase domain. AXL is activated upon
binding of its ligand Gas6, by ligand-independent homophilic
interactions between AXL extracellular domains, by
autophosphorylation in presence of reactive oxygen species [24] or
by transactivation through EGFR (Meyer, 2013), and is aberrantly
expressed in several tumor types. In humans, the AXL protein is
encoded by a nucleic acid sequence encoding the amino acid sequence
shown in SEQ ID NO:130 (human AXL protein: Swissprot P30530;
cynomolgus AXL protein: Genbank accession HB387229.1)).
[0061] The term "ligand-independent homophilic interactions" as
used herein, refers to association between two AXL molecules
(expressed on neighboring cells) that occurs in absence of the
ligand.
[0062] The term "antibody binding AXL" as used herein, refers to
any antibody binding an epitope on the extracellular part of
AXL.
[0063] The term "epitope" means a protein determinant capable of
specific binding to an antibody. Epitopes usually consist of
surface groupings of molecules such as amino acids, sugar side
chains or a combination thereof and usually have specific three
dimensional structural characteristics, as well as specific charge
characteristics. Conformational and non-conformational epitopes are
distinguished in that the binding to the former but not the latter
is lost in the presence of denaturing solvents. The epitope may
comprise amino acid residues which are directly involved in the
binding, and other amino acid residues, which are not directly
involved in the binding, such as amino acid residues which are
effectively blocked or covered by the specific antigen binding
peptide (in other words, the amino acid residue is within the
footprint of the specific antigen binding peptide).
[0064] The term "ligand" as used herein, refers to a substance,
such as a hormone, peptide, ion, drug or protein, that binds
specifically and reversibly to another protein, such as a receptor,
to form a larger complex. Ligand binding to a receptor may alter
its chemical conformation, and determines its functional state. For
instance, a ligand may function as agonist or antagonist.
[0065] The term "Growth Arrest-Specific 6" or "Gas6" as used
herein, refers to a 721 amino acid protein, with a molecular weight
of 75-80 kDa, that functions as a ligand for the TAM family of
receptors, including AXL. Gas6 is composed of an N-terminal region
containing multiple gamma-carboxyglutamic acid residues (Gla),
which are responsible for the specific interaction with the
negatively charged phospholipid membrane. Although the Gla domain
is not necessary for binding of Gas6 to AXL, it is required for
activation of AXL. Gas6 may also be termed as the "ligand to
AXL".
[0066] The terms "monoclonal antibody", "monoclonal Ab",
"monoclonal antibody composition", "mAb", or the like, as used
herein refer to a preparation of antibody molecules of single
molecular composition. A monoclonal antibody composition displays a
single binding specificity and affinity for a particular epitope.
Accordingly, the term "human monoclonal antibody" refers to
antibodies displaying a single binding specificity which have
variable and constant regions derived from human germline
immunoglobulin sequences. The human monoclonal antibodies may be
produced by a hybridoma which includes a B cell obtained from a
transgenic or transchromosomal non-human animal, such as a
transgenic mouse, having a genome comprising a human heavy chain
transgene and a light chain transgene, fused to an immortalized
cell.
[0067] In one embodiment, maximal antibody binding in the presence
of Gas6 is at least 90%, such as at least 95%, such as at least
97%, such as at least 99%, such as 100%, of binding in absence of
Gas6, as determined by the method disclosed in Example 2.
[0068] Competition between anti-AXL and the ligand Gas6 to AXL may
be determined as described in Example 2 under the heading
"Interference of anti-AXL binding with Gas6 binding". Thus, in one
embodiment, the antibody does not compete for AXL binding with the
ligand Gas6, wherein the competing for binding is determined in an
assay comprising the steps of
[0069] i) incubating AXL-expressing cells with Gas6,
[0070] ii) adding anti-AXL antibodies to be tested,
[0071] iii) adding a fluorescently labelled secondary reagent
detecting anti-AXL antibodies and
[0072] iv) analyzing the cells by FACS.
[0073] In another embodiment, the antibody does not compete for
binding with the ligand Gas6, wherein the competing for binding is
determined in an assay comprising the steps of
[0074] i) incubating AXL-expressing cells with anti-AXL
antibodies,
[0075] ii) adding Gas6,
[0076] iii) adding a fluorescently labelled secondary reagent
detecting Gas6, and
[0077] iv) analyzing the cells by FACS.
[0078] In one embodiment, the antibody has a binding affinity
(K.sub.D) in the range of 0.3.times.10.sup.-9 to 63.times.10.sup.-9
M to AXL, and wherein said binding affinity is measured using a
Bio-layer Interferometry using soluble AXL extracellular
domain.
[0079] The binding affinity may be determined as described in
Example 2. Thus, in one embodiment, the antibody has a binding
affinity of 0.3.times.10.sup.-9 to 63.times.10.sup.-9 M to the
antigen, wherein the binding affinity is determined by a method
comprising the steps of;
[0080] i) loading anti-human Fc Capture biosensors with anti-AXL
antibodies, and
[0081] ii) determining association and dissociation of soluble
recombinant AXL extracellular domain by Bio-Layer Interferometry at
different concentrations.
[0082] The term "soluble recombinant AXL extracellular domain" as
used herein, refers to an AXL extracellular domain that has been
expressed recombinantly. Due to absence of the transmembrane and
intracellular domain, recombinant AXL extracellular domain is not
attached to a, e.g. cell surface and stays in solution. It is
well-known how to express a protein recombinantly, see e.g. [25],
and thus, it is within the knowledge of the skilled person to
provide such recombinant AXL extracellular domain.
[0083] In one embodiment, the antibody has a dissociation rate of
6.9.times.10.sup.-5 s.sup.-1 to 9.7.times.10.sup.3 s.sup.-1 to AXL,
and wherein the dissociation rate is measured by Bio-layer
Interferometry using soluble recombinant AXL extracellular
domain.
[0084] The binding affinity may be determined as described above
(and in Example 2). Thus, in one embodiment, the antibody has a
dissociation rate of 6.9.times.10.sup.-5 s to 9.7.times.10.sup.3
s.sup.-1 to AXL, and wherein the dissociation rate is measured by a
method comprising the steps of
[0085] i) loading anti-human Fc Capture biosensors with anti-AXL
antibodies, and
[0086] ii) determining association and dissociation of recombinant
AXL extracellular domain by Bio-Layer Interferometry at different
concentrations.
[0087] The term "dissociation rate" as used herein, refers to the
rate at which an antigen-specific antibody bound to its antigen,
dissociates from that antigen, and is expressed as s.sup.-1. Thus,
in the context of an antibody binding AXL, the term "dissociation
rate", refers to the antibody binding AXL dissociates from the
recombinant extracellular domain of AXL, and is expressed as
s.sup.-1.
[0088] In one embodiment, AXL is human AXL. The amino acid sequence
of AXL is according to Swissprot P30530.
[0089] In one embodiment, AXL is cynomolgus monkey AXL (Genbank
accession HB387229.1).
[0090] In one embodiment, the antibody comprises at least one
binding region comprising variable heavy chain (VH) CDR1, CDR2, and
CDR3 sequences having at least 95%, such as at least 96%, such as
at least 97%, such as at least 98%, such as at least 99%, sequence
identity to sequences are selected from the group consisting
of:
[0091] a) SEQ ID Nos.: 36, 37, and 38, respectively [107];
[0092] b) SEQ ID Nos.: 93, 94, and 95, respectively [613];
[0093] c) SEQ ID Nos.: 93, 126, and 127, respectively
[613/608-01/610-01/620-06];
[0094] d) SEQ ID Nos.: 46, 47, and 48, respectively [148];
[0095] e) SEQ ID Nos.: 57, 58, and 59, respectively [171];
[0096] f) SEQ ID Nos.: 78, 79, and 80, respectively [187];
[0097] g) SEQ ID Nos.: 46, 119, and 120, respectively
[148/140];
[0098] h) SEQ ID Nos.: 51, 52, and 53, respectively [154];
[0099] i) SEQ ID Nos.: 72, 73, and 75, respectively [183];
[0100] j) SEQ ID Nos.: 72, 74, and 75, respectively [183-N52Q];
[0101] k) SEQ ID Nos.: 114, 115, and 116, respectively [733];
[0102] l) SEQ ID Nos.: 123, 124, and 125, respectively
[171/172/181];
[0103] m) SEQ ID Nos.: 108, 109, and 110, respectively [726];
[0104] n) SEQ ID Nos.: 108, 121, and 122, respectively
[726/187];
[0105] o) SEQ ID Nos.: 41, 42, and 43, respectively [140];
[0106] p) SEQ ID Nos.: 62, 63, and 64, respectively [172];
[0107] q) SEQ ID Nos.: 67, 68, and 69, respectively [181];
[0108] r) SEQ ID Nos.: 51, 52, and 54, respectively
[154-M103L];
[0109] s) SEQ ID Nos.:78, 79, and 80, respectively [187];
[0110] t) SEQ ID Nos.: 83, 84, and 85, respectively [608-01];
[0111] u) SEQ ID Nos.: 88, 89, and 90, respectively [610-01];
[0112] v) SEQ ID Nos.: 98, 99, and 100, respectively, [613-08];
[0113] w) SEQ ID Nos.: 103, 104, and 105, respectively [620-06];
and
[0114] x) SEQ ID Nos.: 108, 109, and 111, respectively
[726-M101L].
[0115] In one embodiment, the antibody comprises at least one
binding region comprising variable heavy chain (VH) CDR1, CDR2, and
CDR3 sequences having at most 5 mutations or substitutions, such as
at most 4 mutations or substitutions, such as at most 3 mutations
or substitutions, such as at most 2 mutations or substitutions,
such as at most 1 mutation or substitution, in total across the CDR
sequences in said variable heavy chain selected from the group
consisting of:
[0116] a) SEQ ID Nos.: 36, 37, and 38, respectively [107];
[0117] b) SEQ ID Nos.: 93, 94, and 95, respectively [613];
[0118] c) SEQ ID Nos.: 93, 126, and 127, respectively
[613/608-01/610-01/620-06];
[0119] d) SEQ ID Nos.: 46, 47, and 48, respectively [148];
[0120] e) SEQ ID Nos.: 57, 58, and 59, respectively [171];
[0121] f) SEQ ID Nos.: 78, 79, and 80, respectively [187];
[0122] g) SEQ ID Nos.: 46, 119, and 120, respectively
[148/140];
[0123] h) SEQ ID Nos.: 51, 52, and 53, respectively [154];
[0124] i) SEQ ID Nos.: 72, 73, and 75, respectively [183];
[0125] j) SEQ ID Nos.: 72, 74, and 75, respectively [183-N52Q];
[0126] k) SEQ ID Nos.: 114, 115, and 116, respectively [733];
[0127] l) SEQ ID Nos.: 123, 124, and 125, respectively
[171/172/181];
[0128] m) SEQ ID Nos.: 108, 109, and 110, respectively [726];
[0129] n) SEQ ID Nos.: 108, 121, and 122, respectively
[726/187];
[0130] o) SEQ ID Nos.: 41, 42, and 43, respectively [140];
[0131] p) SEQ ID Nos.: 62, 63, and 64, respectively [172];
[0132] q) SEQ ID Nos.: 67, 68, and 69, respectively [181];
[0133] r) SEQ ID Nos.: 51, 52, and 54, respectively
[154-M103L];
[0134] s) SEQ ID Nos.:78, 79, and 80, respectively [187];
[0135] t) SEQ ID Nos.: 83, 84, and 85, respectively [608-01];
[0136] u) SEQ ID Nos.: 88, 89, and 90, respectively [610-01];
[0137] v) SEQ ID Nos.: 98, 99, and 100, respectively, [613-08];
[0138] w) SEQ ID Nos.: 103, 104, and 105, respectively [620-06];
and
[0139] x) SEQ ID Nos.: 108, 109, and 111, respectively
[726-M101L].
[0140] Hereby embodiments are provided wherein mutations or
substitutions of up to five mutations or substitutions are allowed
across the three CDR sequences in the variable heavy chain. The
mutations or substitutions may be of conservative, physical or
functional amino acids such that mutations or substitutions do not
change the epitope or preferably do not modify binding affinity to
the epitope more than 30%, such as more than 20% or such as more
than 10%. The conservative, physical or functional amino acids are
selected from the 20 natural amino acids i.e. Arg, His, Lys, Asp,
Glu, Ser, Thr, Asn, Gln, Cys, Gly, Pro, Ala, Ile, Leu, Met, Phe,
Trp, Tyr and Val.
[0141] In one embodiment, the antibody comprises at least one
binding region comprising variable heavy chain (VH) CDR1, CDR2, and
CDR3 sequences are selected from the group consisting of;
[0142] a) SEQ ID Nos.: 36, 37, and 38, respectively [107];
[0143] b) SEQ ID Nos.: 93, 94, and 95, respectively [613];
[0144] c) SEQ ID Nos.: 93, 126, and 127, respectively
[613/608-01/610-01/620-06];
[0145] d) SEQ ID Nos.: 46, 47, and 48, respectively [148];
[0146] e) SEQ ID Nos.: 57, 58, and 59, respectively [171];
[0147] f) SEQ ID Nos.: 78, 79, and 80, respectively [187];
[0148] g) SEQ ID Nos.: 46, 119, and 120, respectively
[148/140];
[0149] h) SEQ ID Nos.: 51, 52, and 53, respectively [154];
[0150] i) SEQ ID Nos.: 72, 73, and 75, respectively [183];
[0151] j) SEQ ID Nos.: 72, 74, and 75, respectively [183-N52Q];
[0152] k) SEQ ID Nos.: 114, 115, and 116, respectively [733];
[0153] l) SEQ ID Nos.: 123, 124, and 125, respectively
[171/172/181];
[0154] m) SEQ ID Nos.: 108, 109, and 110, respectively [726];
[0155] n) SEQ ID Nos.: 108, 121, and 122, respectively
[726/187];
[0156] o) SEQ ID Nos.: 41, 42, and 43, respectively [140];
[0157] p) SEQ ID Nos.: 62, 63, and 64, respectively [172];
[0158] q) SEQ ID Nos.: 67, 68, and 69, respectively [181];
[0159] r) SEQ ID Nos.: 51, 52, and 54, respectively
[154-M103L];
[0160] s) SEQ ID Nos.:78, 79, and 80, respectively [187];
[0161] t) SEQ ID Nos.: 83, 84, and 85, respectively [608-01];
[0162] u) SEQ ID Nos.: 88, 89, and 90, respectively [610-01];
[0163] v) SEQ ID Nos.: 98, 99, and 100, respectively, [613-08];
[0164] w) SEQ ID Nos.: 103, 104, and 105, respectively [620-06];
and
[0165] x) SEQ ID Nos.: 108, 109, and 111, respectively
[726-M101L].
[0166] In one particular embodiment, the VH CDR1, CDR2, and CDR3
are selected from either a), d), g), or k).
[0167] In one embodiment, the at least one binding region comprises
a VH region and a variable light chain (VL) region having at least
95%, such as at least 97%, such as at least 99%, such as 100%,
sequence identity with the sequences independently selected from
the group consisting of;
[0168] a) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39,
GAS, and 40, respectively, [107];
[0169] b) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 47, and 48, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148];
[0170] c) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 114, 115, and 116, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively [733];
[0171] d) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 53, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154];
[0172] e) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 54, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154-M103L];
[0173] f) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 57, 58, and 59, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60,
GAS, and 61, respectively, [171];
[0174] g) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 62, 63, and 64, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65,
GAS, and 66, respectively, [172];
[0175] h) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 67, 68, and 69, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70,
GAS, and 71, respectively, [181];
[0176] i) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 73, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183];
[0177] j) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 74, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183-N52Q];
[0178] k) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 78, 79, and 80, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81,
AAS, and 82, respectively, [187];
[0179] l) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 83, 84, and 85, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86,
GAS, and 87, respectively, [608-01];
[0180] m) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 88, 89, and 90, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91,
GAS, and 92, respectively, [610-01];
[0181] n) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively, [613];
[0182] o) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 98, 99, and 100, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 10,
DAS, and 102, respectively, [613-08];
[0183] p) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 103, 104, and 105, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106,
GAS, and 107, respectively, [620-06];
[0184] q) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 110, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726];
[0185] r) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 111, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726-M101L];
[0186] s) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 41, 42, and 43, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44,
AAS, and 45, respectively, [140];
[0187] t) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 128,
XAS, wherein X is D or G, and 129, respectively, [613/613-08];
[0188] u) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 119, and 120, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS,
and 50, respectively, [148/140];
[0189] v) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 123, 124, and 125, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS,
and 61, respectively [171/172/181]; and
[0190] w) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 121, 109, and 122, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively [726/187]; and
[0191] x) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.:93, 126, and 127, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively [613/608-01/610-01/620-06].
[0192] In one embodiment, the at least one binding region comprises
a VH region and a variable light chain (VL) region having, at most
5 mutations or substitutions selected from conservative, physical
or functional amino acids, such as at most 4 mutations or
substitutions selected from conservative, physical or functional
amino acids, such as at most 3 mutations or substitutions selected
from conservative, physical or functional amino acids, such as at
most 2 mutations selected from conservative, physical or functional
amino acids or substitutions, such as at most 1 mutation or
substitution selected from a conservative, physical or functional
amino acid, in total across the CDR sequences in said variable
heavy chain and variable light chain selected from the group
consisting of;
[0193] a) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39,
GAS, and 40, respectively, [107];
[0194] b) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 47, and 48, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148];
[0195] c) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 114, 115, and 116, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively [733];
[0196] d) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 53, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154];
[0197] e) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 54, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154-M103L];
[0198] f) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 57, 58, and 59, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60,
GAS, and 61, respectively, [171];
[0199] g) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 62, 63, and 64, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65,
GAS, and 66, respectively, [172];
[0200] h) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 67, 68, and 69, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70,
GAS, and 71, respectively, [181];
[0201] i) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 73, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183];
[0202] j) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 74, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183-N52Q];
[0203] k) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 78, 79, and 80, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81,
AAS, and 82, respectively, [187];
[0204] l) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 83, 84, and 85, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86,
GAS, and 87, respectively, [608-01];
[0205] m) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 88, 89, and 90, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91,
GAS, and 92, respectively, [610-01];
[0206] n) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively, [613];
[0207] o) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 98, 99, and 100, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 10,
DAS, and 102, respectively, [613-08];
[0208] p) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 103, 104, and 105, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106,
GAS, and 107, respectively, [620-06];
[0209] q) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 110, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726];
[0210] r) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 111, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726-M101L];
[0211] s) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 41, 42, and 43, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44,
AAS, and 45, respectively, [140];
[0212] t) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 128,
XAS, wherein X is D or G, and 129, respectively, [613/613-08];
[0213] u) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 119, and 120, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS,
and 50, respectively, [148/140];
[0214] v) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 123, 124, and 125, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS,
and 61, respectively [171/172/181]; and
[0215] w) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 121, 109, and 122, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively [726/187]; and
[0216] x) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.:93, 126, and 127, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively [613/608-01/610-01/620-06].
[0217] Hereby embodiments are provided wherein mutations or
substitutions of up to five mutations or substitutions are allowed
across the three CDR sequences in the variable heavy chain and
variable light chain. The up to five mutations or substitutions may
be distributed across the three CDR sequences of the variable heavy
chain and the three CDR sequences of the variable light chain. The
up to five mutations or substitutions may be distributed across the
six CDR sequences of the binding region. The mutations or
substitutions may be of conservative, physical or functional amino
acids such that mutations or substitutions do not change the
epitope or preferably do not modify binding affinity to the epitope
more than 30%, such as more than 20% or such as more than 10%. The
conservative, physical or functional amino acids are selected from
the 20 natural amino acids found i.e, Arg, His, Lys, Asp, Glu, Ser,
Thr, Asn, Gln, Cys, Gly, Pro, Ala, Ile, Leu, Met, Phe, Trp, Tyr and
Val.
[0218] In a particular embodiment, the at least one binding region
comprises a VH region and a variable light chain (VL) region
selected from the group consisting of;
[0219] a) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39,
GAS, and 40, respectively, [107];
[0220] b) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 47, and 48, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148];
[0221] c) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 114, 115, and 116, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively [733];
[0222] d) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 53, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154];
[0223] e) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 54, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154-M103L];
[0224] f) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 57, 58, and 59, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60,
GAS, and 61, respectively, [171];
[0225] g) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 62, 63, and 64, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65,
GAS, and 66, respectively, [172];
[0226] h) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 67, 68, and 69, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70,
GAS, and 71, respectively, [181];
[0227] i) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 73, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183];
[0228] j) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 74, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183-N52Q];
[0229] k) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 78, 79, and 80, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81,
AAS, and 82, respectively, [187];
[0230] l) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 83, 84, and 85, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86,
GAS, and 87, respectively, [608-01];
[0231] m) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 88, 89, and 90, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91,
GAS, and 92, respectively, [610-01];
[0232] n) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively, [613];
[0233] o) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 98, 99, and 100, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 10,
DAS, and 102, respectively, [613-08];
[0234] p) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 103, 104, and 105, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106,
GAS, and 107, respectively, [620-06];
[0235] q) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 110, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726];
[0236] r) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 111, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726-M101L];
[0237] s) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 41, 42, and 43, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44,
AAS, and 45, respectively, [140];
[0238] t) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 128,
XAS, wherein X is D or G, and 129, respectively, [613/613-08];
[0239] u) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 119, and 120, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS,
and 50, respectively, [148/140];
[0240] v) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 123, 124, and 125, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS,
and 61, respectively [171/172/181]; and
[0241] w) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 121, 109, and 122, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively [726/187]; and
[0242] x) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.:93, 126, and 127, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively [613/608-01/610-01/620-06].
[0243] In one embodiment, the at least one binding region comprises
a VH region and a VL region selected from the group consisting
of;
[0244] a) a VH region comprising SEQ ID No: 1 and a VL region
comprising SEQ ID No: 2 [107];
[0245] b) a VH region comprising SEQ ID No: 5 and a VL region
comprising SEQ ID No: 6 [148];
[0246] c) a VH region comprising SEQ ID No: 34 and a VL region
comprising SEQ ID No: 35 [733]
[0247] d) a VH region comprising SEQ ID No: 7 and a VL region
comprising SEQ ID No: 9 [154];
[0248] e) a VH region comprising SEQ ID No: 10 and a VL region
comprising SEQ ID No: 11 [171];
[0249] f) a VH region comprising SEQ ID No: 16 and a VL region
comprising SEQ ID No: 18 [183];
[0250] g) a VH region comprising SEQ ID No: 25 and a VL region
comprising SEQ ID No: 26 [613];
[0251] h) a VH region comprising SEQ ID No: 31 and a VL region
comprising SEQ ID No: 33 [726];
[0252] i) a VH region comprising SEQ ID No: 3 and a VL region
comprising SEQ ID No: 4 [140];
[0253] j) a VH region comprising SEQ ID No:8 and a VL region
comprising SEQ ID No:9 [154-M103L];
[0254] k) a VH region comprising SEQ ID No:12 and a VL region
comprising SEQ ID No:13 [172];
[0255] l) a VH region comprising SEQ ID No:14 and a VL region
comprising SEQ ID No:15 [181];
[0256] m) a VH region comprising SEQ ID No:17 and a VL region
comprising SEQ ID No:18 [183-N52Q];
[0257] n) a VH region comprising SEQ ID No:19 and a VL region
comprising SEQ ID No:20 [187];
[0258] o) a VH region comprising SEQ ID No:21 and a VL region
comprising SEQ ID No:22 [608-01];
[0259] p) a VH region comprising SEQ ID No:23 and a VL region
comprising SEQ ID No:24 [610-01];
[0260] q) a VH region comprising SEQ ID No:27 and a VL region
comprising SEQ ID No:28 [613-08];
[0261] r) a VH region comprising SEQ ID No:29 and a VL region
comprising SEQ ID No:30 [620-06]; and
[0262] s) a VH region comprising SEQ ID No:32 and a VL region
comprising SEQ ID No:33 [726-M101L].
[0263] In one embodiment, the at least one binding region comprises
a variable heavy chain (VH) region and a variable light chain (VL)
region having at most 10 mutations or substitutions, at most 5
mutations or substitutions, such as at most 4 mutations or
substitutions, such as at most 3 mutations or substitutions, such
as at most 2 mutations or substitutions, such as at most 1 mutation
or substitution, across said variable heavy chain and variable
light chain sequences selected from the group consisting of; In one
embodiment, the at least one binding region comprises a VH region
and a VL region selected from the group consisting of;
[0264] a) a VH region comprising SEQ ID No: 1 and a VL region
comprising SEQ ID No: 2 [107];
[0265] b) a VH region comprising SEQ ID No: 5 and a VL region
comprising SEQ ID No: 6 [148];
[0266] c) a VH region comprising SEQ ID No: 34 and a VL region
comprising SEQ ID No: 35 [733]
[0267] d) a VH region comprising SEQ ID No: 7 and a VL region
comprising SEQ ID No: 9 [154];
[0268] e) a VH region comprising SEQ ID No: 10 and a VL region
comprising SEQ ID No: 11 [171];
[0269] f) a VH region comprising SEQ ID No: 16 and a VL region
comprising SEQ ID No: 18 [183];
[0270] g) a VH region comprising SEQ ID No: 25 and a VL region
comprising SEQ ID No: 26 [613];
[0271] h) a VH region comprising SEQ ID No: 31 and a VL region
comprising SEQ ID No: 33 [726];
[0272] i) a VH region comprising SEQ ID No: 3 and a VL region
comprising SEQ ID No: 4 [140];
[0273] j) a VH region comprising SEQ ID No:8 and a VL region
comprising SEQ ID No:9 [154-M103L];
[0274] k) a VH region comprising SEQ ID No:12 and a VL region
comprising SEQ ID No:13 [172];
[0275] l) a VH region comprising SEQ ID No:14 and a VL region
comprising SEQ ID No:15 [181];
[0276] m) a VH region comprising SEQ ID No:17 and a VL region
comprising SEQ ID No:18 [183-N52Q];
[0277] n) a VH region comprising SEQ ID No:19 and a VL region
comprising SEQ ID No:20 [187];
[0278] o) a VH region comprising SEQ ID No:21 and a VL region
comprising SEQ ID No:22 [608-01];
[0279] p) a VH region comprising SEQ ID No:23 and a VL region
comprising SEQ ID No:24 [610-01];
[0280] q) a VH region comprising SEQ ID No:27 and a VL region
comprising SEQ ID No:28 [613-08];
[0281] r) a VH region comprising SEQ ID No:29 and a VL region
comprising SEQ ID No:30 [620-06]; and
[0282] s) a VH region comprising SEQ ID No:32 and a VL region
comprising SEQ ID No:33 [726-M101L].
[0283] Hereby embodiments are provided wherein mutations or
substitutions of up to 10 mutations or substitutions are allowed
across the variable heavy chain and variable light chain. The up to
10 mutations or substitutions may be distributed across the full
length of the variable heavy chain and the variable light chain of
each binding region. The mutations or substitutions may be of
conservative, physical or functional amino acids such that the
mutations or substitutions do not change the epitope and preferably
do not modify binding affinity to the epitope more than 30%, such
as more than 20% or such as more than 10%. The conservative,
physical or functional amino acids are selected from the 20 natural
amino acids found i.e. Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gln,
Cys, Gly, Pro, Ala, Ile, Leu, Met, Phe, Trp, Tyr and Val.
[0284] In one embodiment, the at least one binding region comprises
a variable heavy chain (VH) region and a variable light chain (VL)
region having at most 10 mutations or substitutions selected from
conservative, physical or functional amino acids, at most 5
mutations or substitutions selected from conservative, physical or
functional amino acids, such as at most 4 mutations or
substitutions selected from conservative, physical or functional
amino acids, such as at most 3 mutations or substitutions selected
from conservative, physical or functional amino acids, such as at
most 2 mutations selected from conservative, physical or functional
amino acids or substitutions, such as at most 1 mutation or
substitution selected from a conservative, physical or functional
amino acid, across said variable heavy chain and variable light
chain sequences selected from the group consisting of; In one
embodiment, the at least one binding region comprises a VH region
and a VL region selected from the group consisting of;
[0285] a) a VH region comprising SEQ ID No: 1 and a VL region
comprising SEQ ID No: 2 [107];
[0286] b) a VH region comprising SEQ ID No: 5 and a VL region
comprising SEQ ID No: 6 [148];
[0287] c) a VH region comprising SEQ ID No: 34 and a VL region
comprising SEQ ID No: 35 [733]
[0288] d) a VH region comprising SEQ ID No: 7 and a VL region
comprising SEQ ID No: 9 [154];
[0289] e) a VH region comprising SEQ ID No: 10 and a VL region
comprising SEQ ID No: 11 [171];
[0290] f) a VH region comprising SEQ ID No: 16 and a VL region
comprising SEQ ID No: 18 [183];
[0291] g) a VH region comprising SEQ ID No: 25 and a VL region
comprising SEQ ID No: 26 [613];
[0292] h) a VH region comprising SEQ ID No: 31 and a VL region
comprising SEQ ID No: 33 [726];
[0293] i) a VH region comprising SEQ ID No: 3 and a VL region
comprising SEQ ID No: 4 [140];
[0294] j) a VH region comprising SEQ ID No:8 and a VL region
comprising SEQ ID No:9 [154-M103L];
[0295] k) a VH region comprising SEQ ID No:12 and a VL region
comprising SEQ ID No:13 [172];
[0296] l) a VH region comprising SEQ ID No:14 and a VL region
comprising SEQ ID No:15 [181];
[0297] m) a VH region comprising SEQ ID No:17 and a VL region
comprising SEQ ID No:18 [183-N52Q];
[0298] n) a VH region comprising SEQ ID No:19 and a VL region
comprising SEQ ID No:20 [187];
[0299] o) a VH region comprising SEQ ID No:21 and a VL region
comprising SEQ ID No:22 [608-01];
[0300] p) a VH region comprising SEQ ID No:23 and a VL region
comprising SEQ ID No:24 [610-01];
[0301] q) a VH region comprising SEQ ID No:27 and a VL region
comprising SEQ ID No:28 [613-08];
[0302] r) a VH region comprising SEQ ID No:29 and a VL region
comprising SEQ ID No:30 [620-06]; and
[0303] s) a VH region comprising SEQ ID No:32 and a VL region
comprising SEQ ID No:33 [726-M101L].
[0304] Hereby embodiments are provided wherein mutations or
substitutions of up to 10 mutations or substitutions are allowed
across the variable heavy chain and variable light chain. The up to
10 mutations or substitutions may be distributed across the
variable heavy chain and the variable light chain. The up to 10
mutations or substitutions may be distributed across the binding
region. The mutations or substitutions may be of conservative,
physical or functional amino acids such that mutations or
substitutions do not change the epitope or modify binding to the
epitope.
[0305] In one aspect, the present invention relates to antibodies
which binds to an extracellular domain of AXL without competing or
interfering with Gas6 binding to AXL. In a particular embodiment,
the antibody binds to the extracellular domain Ig1-like domain
without competing or interfering with Gas6 binding to AXL. In one
embodiment, the antibody binds to the extracellular domain Ig1-like
and show no more than a 20% reduction in maximal Gas6 binding to
AXL. In one embodiment, the antibody show no more than a 15%
reduction in maximal Gas6 binding to AXL. In one embodiment, the
antibody show no more than a 10% reduction in maximal Gas6 binding
to AXL. In one embodiment, the antibody show no more than a 5%
reduction in maximal Gas6 binding to AXL. In one embodiment, the
antibody show no more than a 4% reduction in maximal Gas6 binding
to AXL In one embodiment, the antibody show no more than a 2%
reduction in maximal Gas6 binding to AXL. In one embodiment, the
antibody show no more than a 1% reduction in maximal Gas6 binding.
In one embodiment the antibody binds to the extracellular domain
Ig2-like domain without competing or interfering with Gas6 binding
to AXL. In one embodiment, the antibody binds to the extracellular
domain Ig2-like and show no more than a 20%, such as no more than
15%, such as no more than 10%, such as no more than 5%, such as no
more than 4%, such as no more than 2%, such as no more than 1%,
reduction in maximal Gas6 binding to AXL. The embodiment's ability
to compete with or reduce Gas6 binding may be determined as
disclosed in Example 2 or Example 12. In one embodiment the
antibody binds to the extracellular domain Ig2-like domain without
competing or interfering with maximal Gas6 binding to AXL.
[0306] In one embodiment, the antibody binds to an epitope on AXL
which epitope is recognized by an antibody herein described.
[0307] Methods of determining an epitope to which an antibody binds
is well-known in the art, and thus, the skilled person would know
how to determine such an epitope. However, an example of
determining whether an antibody binds within any epitope herein
defined would be by point mutations of the AXL extracellular
domain. It is within the knowledge of the skilled person to
introduce point mutation(s) in the AXL extracellular domain and
test for antibody binding to point mutated AXL extracellular
domains. When referring to amino acid positions within the AXL
protein in the context of epitopes, the numbering has been
determined as described in Example 7. Thus, numbering of amino acid
positions defining the epitope was done based on the sequences put
forth in FIG. 6, i.e. the first amino acid in the shown sequence
was numbered as position `1`, the second as position `2`, etc.
[0308] In one embodiment, the antibody binds to an epitope within
the Ig1-like domain of AXL, the epitope comprises or requires the
amino acids corresponding to positions L121 to Q129 or T112 to Q124
of human AXL. In one embodiment, the antibody binds to an epitope
within the Ig1-like domain of AXL, the epitope comprises or
requires one or more amino acids corresponding to positions L121 to
Q129 or T112 to Q124 of human AXL. In one embodiment the epitope
comprises one or more amino acid in position L121, G122, H123,
Q124, T125, F126, V127, S128, Q129 or more amino acid in position
T112, G113, Q114, Y115, Q116, C117, L118, V119, F120, L121, G122,
H123, Q124.
[0309] In another embodiment, the antibody binds to an epitope
within the Ig2-like domain of AXL which epitope comprises or
requires the amino acids corresponding to position D170 or the
combination of D179 and T182 to R190 of human AXL.
[0310] In one embodiment, the antibody binds to an epitope within
the Ig2-like domain of AXL which epitope comprises or requires the
amino acids corresponding to position D170 or the combination of
D179 and one or more amino acids corresponding to positions T182 to
R190 of human AXL. In one embodiment the epitope comprises one or
more amino acid in position T182, A183, P183, G184, H185, G186,
P187, Q189, R190.
[0311] In another embodiment, the antibody binds to an epitope
within the FN1-like domain of human AXL which epitope comprises or
requires the amino acids corresponding to positions Q272 to A287
and G297 to P301 of human AXL.
[0312] In another embodiment, the antibody binds to an epitope
within the FN2-like domain of human AXL which epitope comprises or
requires the amino acids corresponding to positions A359, R386, and
Q436 to K439 of human AXL.
[0313] In one embodiment, the antibody binds to an epitope within
the FN1-like domain of human AXL.
[0314] In one embodiment, the antibody binds to an epitope on AXL
which epitope is recognized by any one of the antibodies defined
by
[0315] a) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 36, 37, and 38, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39,
GAS, and 40, respectively, [107];
[0316] b) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 47, and 48, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148];
[0317] c) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 114, 115, and 116, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively [733];
[0318] d) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 53, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154];
[0319] e) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 51, 52, and 54, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively [154-M103L];
[0320] f) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 57, 58, and 59, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60,
GAS, and 61, respectively, [171];
[0321] g) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 62, 63, and 64, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65,
GAS, and 66, respectively, [172];
[0322] h) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 67, 68, and 69, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70,
GAS, and 71, respectively, [181];
[0323] i) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 73, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183];
[0324] j) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 72, 74, and 75, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183-N52Q];
[0325] k) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 78, 79, and 80, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81,
AAS, and 82, respectively, [187];
[0326] l) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 83, 84, and 85, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86,
GAS, and 87, respectively, [608-01];
[0327] m) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 88, 89, and 90, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91,
GAS, and 92, respectively, [610-01];
[0328] n) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively, [613];
[0329] o) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 98, 99, and 100, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 10,
DAS, and 102, respectively, [613-08];
[0330] p) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 103, 104, and 105, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106,
GAS, and 107, respectively, [620-06];
[0331] q) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 110, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726];
[0332] r) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 108, 109, and 111, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726-M101L];
[0333] s) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 41, 42, and 43, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44,
AAS, and 45, respectively, [140];
[0334] t) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 93, 94, and 95, respectively, and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 128,
XAS, wherein X is D or G, and 129, respectively, [613/613-08];
[0335] u) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 46, 119, and 120, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS,
and 50, respectively, [148/140];
[0336] v) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 123, 124, and 125, respectively; and a VL region
comprising CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS,
and 61, respectively [171/172/181]; and
[0337] w) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 121, 109, and 122, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively [726/187]; and
[0338] x) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.:93, 126, and 127, respectively; and a VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively [613/608-01/610-01/620-06].
[0339] In one embodiment, the antibody comprises a heavy chain of
an isotype selected from the group consisting of IgG1, IgG2, IgG3,
and IgG4.
[0340] The term "isotype" as used herein refers to the
immunoglobulin class (for instance IgG1, IgG2, IgG3, IgG4, IgD,
IgA, IgE, or IgM) or any allotypes thereof, such as IgG1m(za) and
IgG1m(f)) that is encoded by heavy chain constant region genes.
Further, each heavy chain isotype can be combined with either a
kappa (.kappa.) or lambda (.lamda.) light chain.
[0341] In one embodiment, the isotype is IgG1, optionally allotype
IgG1m(f).
[0342] In one embodiment, the antibody is a full-length monoclonal
antibody, optionally a full-length monoclonal IgG1,.kappa.
antibody.
[0343] The term "full-length antibody" when used herein, refers to
an antibody (e.g., a parent or variant antibody) which contains all
heavy and light chain constant and variable domains corresponding
to those that are normally found in a wild-type antibody of that
isotype. A full-length antibody according to the present invention
may be produced by a method comprising the steps of (i) cloning the
CDR sequences into a suitable vector comprising complete heavy
chain sequences and complete light chain sequence, and (ii)
expressing the complete heavy and light chain sequences in suitable
expression systems. It is within the knowledge of the skilled
person to produce a full-length antibody when starting out from
either CDR sequences or full variable region sequences. Thus, the
skilled person would know how to generate a full-length antibody
according to the present invention.
[0344] In one embodiment, the antibody is a human antibody.
[0345] The term "human antibody", as used herein, is intended to
include antibodies having variable and framework regions derived
from human germline immunoglobulin sequences and a human
immunoglobulin constant domain. The human antibodies of the
invention may include amino acid residues not encoded by human
germline immunoglobulin sequences (e.g., mutations, insertions or
deletions introduced by random or site-specific mutagenesis in
vitro or by somatic mutation in vivo). However, the term "human
antibody", as used herein, is not intended to include antibodies in
which CDR sequences derived from the germline of another non-human
species, such as a mouse, have been grafted onto human framework
sequences.
[0346] As used herein, a human antibody is "derived from" a
particular germline sequence if the antibody is obtained from a
system using human immunoglobulin sequences, for instance by
immunizing a transgenic mouse carrying human immunoglobulin genes
or by screening a human immunoglobulin gene library, and wherein
the selected human antibody is at least 90%, such as at least 95%,
for instance at least 96%, such as at least 97%, for instance at
least 98%, or such as at least 99% identical in amino acid sequence
to the amino acid sequence encoded by the germline immunoglobulin
gene. Typically, outside the heavy chain CDR3, a human antibody
derived from a particular human germline sequence will display no
more than 20 amino acid differences, e.g. no more than 10 amino
acid differences, such as no more than 9, 8, 7, 6 or 5, for
instance no more than 4, 3, 2, or 1 amino acid difference from the
amino acid sequence encoded by the germline immunoglobulin
gene.
[0347] The antibody according to the present invention may comprise
amino acid modifications in the immunoglobulin heavy and/or light
chains. In a particular embodiment, amino acids in the Fc region of
the antibody may be modified.
[0348] The term "Fc region" as used herein, refers to a region
comprising, in the direction from the N- to C-terminal end of the
antibody, at least a hinge region, a CH2 region and a CH3 region.
An Fc region of the antibody may mediate the binding of the
immunoglobulin to host tissues or factors, including various cells
of the immune system (such as effector cells) and components of the
complement system.
[0349] The term "hinge region" as used herein refers to the hinge
region of an immunoglobulin heavy chain. Thus, for example the
hinge region of a human IgG1 antibody corresponds to amino acids
216-230 according to the Eu numbering as set forth in Kabat [26].
However, the hinge region may also be any of the other subtypes as
described herein.
[0350] The term "CH1 region" or "CH1 domain" as used herein refers
to the CH1 region of an immunoglobulin heavy chain. Thus, for
example the CH1 region of a human IgG1 antibody corresponds to
amino acids 118-215 according to the Eu numbering as set forth in
Kabat [26]. However, the CH1 region may also be any of the other
subtypes as described herein.
[0351] The term "CH2 region" or "CH2 domain" as used herein refers
to the CH2 region of an immunoglobulin heavy chain. Thus, for
example the CH2 region of a human IgG1 antibody corresponds to
amino acids 231-340 according to the Eu numbering as set forth in
Kabat [26]. However, the CH2 region may also be any of the other
subtypes as described herein.
[0352] The term "CH3 region" or "CH3 domain" as used herein refers
to the CH3 region of an immunoglobulin heavy chain. Thus for
example the CH3 region of a human IgG1 antibody corresponds to
amino acids 341-447 according to the Eu numbering as set forth in
Kabat [26]. However, the CH3 region may also be any of the other
subtypes as described herein.
[0353] In another embodiment, the antibody is an
effector-function-deficient antibody, a stabilized IgG4 antibody or
a monovalent antibody.
[0354] In one particular embodiment, the heavy chain has been
modified such that the entire hinge region has been deleted.
[0355] In one embodiment, the sequence of the antibody has been
modified so that it does not comprise any acceptor sites for
N-linked glycosylation.
[0356] In one embodiment, the antibody is a single-chain
antibody.
[0357] In further aspect, the present invention relates to a
multispecific antibody comprising at least a first binding region
of an antibody according to any aspect or embodiment herein
described, and a second binding region which binds a different
target or epitope than the first binding region. The term
"multispecific antibody" as used herein, refers to antibodies
wherein the binding regions two to at least two, such as at least
three, different antigens or at least two, such as at least three,
different epitopes on the same antigen.
[0358] In one embodiment, the present invention relates to a
bispecific antibody comprising a first binding region of an
antibody according to any aspect or embodiments herein described,
and a second binding region which binds a different target or
epitope than the first binding region.
[0359] The term "bispecific" as used herein, refers to binding
molecules, such as antibodies wherein the binding regions of the
binding molecule bind to two different antigens or two different
epitopes on the same antigen.
[0360] The term "bispecific antibody" refers to an antibody having
specificities for at least two different, typically
non-overlapping, epitopes. Such epitopes may be on the same or
different targets.
[0361] If the epitopes are on different targets, such targets may
be on the same cell or different cells, cell types or structures,
such as extracellular tissue.
[0362] The term "different target" as used herein, refers to
another protein, molecule or the like than AXL or an AXL
fragment.
[0363] Examples of bispecific antibody molecules which may be used
in the present invention comprise (i) a single antibody that has
two arms comprising different antigen-binding regions, (ii) a
single chain antibody that has specificity to two different
epitopes, e.g., via two scFvs linked in tandem by an extra peptide
linker; (iii) a dual-variable-domain antibody (DVD-Ig.TM.), where
each light chain and heavy chain contains two variable domains in
tandem through a short peptide linkage [29]; (iv) a
chemically-linked bispecific (Fab')2 fragment; (v) a Tandab.RTM.,
which is a fusion of two single chain diabodies resulting in a
tetravalent bispecific antibody that has two binding sites for each
of the target antigens; (vi) a flexibody, which is a combination of
scFvs with a diabody resulting in a multivalent molecule; (vii) a
so called "dock and lock" molecule (Dock-and-Lock.RTM.), based on
the "dimerization and docking domain" in Protein Kinase A, which,
when applied to Fabs, can yield a trivalent bispecific binding
protein consisting of two identical Fab fragments linked to a
different Fab fragment; (viii) a so-called Scorpion molecule,
comprising, e.g., two scFvs fused to both termini of a human
Fab-arm; and (ix) a diabody.
[0364] In one embodiment, the bispecific antibody of the present
invention is a diabody, a cross-body, such as CrossMabs, or a
bispecific antibody obtained via a controlled Fab arm exchange
(such as described in [30]).
[0365] Examples of different classes of bispecific antibodies
include but are not limited to (i) IgG-like molecules with
complementary CH3 domains to force heterodimerization; (ii)
recombinant IgG-like dual targeting molecules, wherein the two
sides of the molecule each contain the Fab fragment or part of the
Fab fragment of at least two different antibodies; (iii) IgG fusion
molecules, wherein full length IgG antibodies are fused to extra
Fab fragment or parts of Fab fragment; (iv) Fc fusion molecules,
wherein single chain Fv molecules or stabilized diabodies are fused
to heavy-chain constant-domains, Fc-regions or parts thereof; (v)
Fab fusion molecules, wherein different Fab-fragments are fused
together, fused to heavy-chain constant-domains, Fc-regions or
parts thereof; and (vi) ScFv- and diabody-based and heavy chain
antibodies (e.g., domain antibodies, Nanobodies.RTM.) wherein
different single chain Fv molecules or different diabodies or
different heavy-chain antibodies (e.g. domain antibodies,
Nanobodies.RTM.) are fused to each other or to another protein or
carrier molecule fused to heavy-chain constant-domains, Fc-regions
or parts thereof.
[0366] Examples of IgG-like molecules with complementary CH3
domains molecules include but are not limited to the Triomab.RTM.
(Trion Pharma/Fresenius Biotech, [31]), the Knobs-into-Holes
(Genentech, [32]), CrossMAbs (Roche, [33]) and the
electrostatically-matched (Amgen, [34] and [35]; Chugai, [36];
Oncomed, [37]), the LUZ-Y (Genentech), DIG-body and PIG-body
(Pharmabcine), the Strand Exchange Engineered Domain body
(SEEDbody)(EMD Serono, [38]), the Biclonics (Merus), FcAAdp
(Regeneron, [39]), bispecific IgG1 and IgG2 (Pfizer/Rinat, [40]),
Azymetric scaffold (Zymeworks/Merck, [41]), mAb-Fv (Xencor, [42]),
bivalent bispecific antibodies (Roche [43]) and DuoBody.RTM.
molecules (Genmab A/S, [30]).
[0367] Examples of recombinant IgG-like dual targeting molecules
include but are not limited to Dual Targeting (DT)-Ig
(GSK/Domantis), Two-in-one Antibody (Genentech), Cross-linked Mabs
(Karmanos Cancer Center), mAb2 (F-Star, [44]), Zybodies.TM.
(Zyngenia), approaches with common light chain (Crucell/Merus,
[45]), KABodies (Novlmmune) and CovX-body (CovX/Pfizer).
[0368] Examples of IgG fusion molecules include but are not limited
to Dual Variable Domain (DVD)-Ig.TM. (Abbott, [46]), Dual domain
double head antibodies (Unilever; Sanofi Aventis, [47]), IgG-like
Bispecific (ImClone/Eli Lilly), Ts2Ab (Medlmmune/AZ) and BsAb
(Zymogenetics), HERCULES (Biogen Idec, [48]), scFv fusion
(Novartis), scFv fusion (Changzhou Adam Biotech Inc, [49]) and TvAb
(Roche, [50], [51]).
[0369] Examples of Fc fusion molecules include but are not limited
to ScFv/Fc Fusions (Academic Institution), SCORPION (Emergent
BioSolutions/Trubion, Zymogenetics/BMS), Dual Affinity Retargeting
Technology (Fc-DART.TM.) (MacroGenics, [52], [53]) and
Dual(ScFv)2-Fab (National Research Center for Antibody
Medicine--China).
[0370] Examples of Fab fusion bispecific antibodies include but are
not limited to F(ab)2 (Medarex/AMGEN), Dual-Action or Bis-Fab
(Genentech), Dock-and-Lock.RTM. (DNL) (ImmunoMedics), Bivalent
Bispecific (Biotecnol) and Fab-Fv (UCB-Celltech).
[0371] Examples of ScFv-, diabody-based and domain antibodies
include but are not limited to Bispecific T Cell Engager
(BiTE.RTM.) (Micromet, Tandem Diabody (Tandab.TM.) (Affimed), Dual
Affinity Retargeting Technology (DART) (MacroGenics), Single-chain
Diabody (Academic), TCR-like Antibodies (AIT, ReceptorLogics),
Human Serum Albumin ScFv Fusion (Merrimack) and COMBODY (Epigen
Biotech), dual targeting Nanobodies.RTM. (Ablynx), dual targeting
heavy chain only domain antibodies.
[0372] A bispecific antibody according the present invention may be
generated by introducing modifications in the constant region of
the antibody.
[0373] Unless otherwise stated or contradicted by context, the
amino acids of the constant region sequences are herein numbered
according to the Eu-index of numbering (described in [26]). The
terms "Eu-index of numbering" and "Eu numbering as set forth in
Kabat" may be used interchangeably and have the same meaning and
purpose. Thus, an amino acid or segment in one sequence that
"corresponds to" an amino acid or segment in another sequence is
one that aligns with the other amino acid or segment using a
standard sequence alignment program such as ALIGN, ClustalW or
similar, typically at default settings and has at least 50%, at
least 80%, at least 90%, or at least 95% identity to a human IgG1
heavy chain. It is well-known in the art how to align a sequence or
segment in a sequence and thereby determine the corresponding
position in a sequence to an amino acid position according to the
present invention.
[0374] The term "amino acid corresponding to positions" as used
herein refers to an amino acid position number in a human IgG1
heavy chain.
[0375] The present invention also provides antibodies comprising
functional variants of the VL region, VH region, or one or more
CDRs of the antibodies of the examples. A functional variant of a
VL, VH, or CDR used in the context of an AXL antibody still allows
the antibody to retain at least a substantial proportion (at least
about 50%, 60%, 70%, 80%, 90%, 95%, 99% or more) of the
affinity/avidity and/or the specificity/selectivity of the parent
antibody and in some cases such an AXL antibody may be associated
with greater affinity, selectivity and/or specificity than the
parent antibody.
[0376] Such functional variants typically retain significant
sequence identity to the parent antibody. The percent identity
between two sequences is a function of the number of identical
positions shared by the sequences (i.e., % homology=# of identical
positions/total # of positions.times.100), taking into account the
number of gaps, and the length of each gap, which need to be
introduced for optimal alignment of the two sequences. The
comparison of sequences and determination of percent identity
between two sequences may be accomplished using a mathematical
algorithm, which is well-known in the art.
[0377] The VH, VL and/or CDR sequences of variants may differ from
those of the parent antibody sequences through mostly conservative
substitutions; for instance at least about 35%, about 50% or more,
about 60% or more, about 70% or more, about 75% or more, about 80%
or more, about 85% or more, about 90% or more, (e.g., about 65-95%,
such as about 92%, 93% or 94%) of the substitutions in the variant
are conservative amino acid residue replacements.
[0378] The VH, VL and/or CDR sequences of variants may differ from
those of the parent antibody sequences through mostly conservative
substitutions; for instance 10 or less, such as 9 or less, 8 or
less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or
less or 1 of the substitutions in the variant are conservative
amino acid residue replacements.
[0379] The term "amino acid" and "amino acid residue" may herein be
used interchangeably, and are not to be understood limiting.
[0380] In the context of the present invention, the amino acid may
be defined by conservative or non-conservative amino acids, and may
therefore be classified accordingly. Amino acid residues may also
be divided into classes defined by alternative physical and
functional properties. Thus, classes of amino acids may be
reflected in one or both of the following tables:
[0381] Amino Acid Residue of Conservative Class [0382] Acidic
Residues D and E [0383] Basic Residues K, R, and H [0384]
Hydrophilic Uncharged Residues S, T, N, and Q [0385] Aliphatic
Uncharged Residues G, A, V, L, and I [0386] Non-polar Uncharged
Residues C, M, and P [0387] Aromatic Residues F, Y, and W
[0388] Alternative Physical and Functional Classifications of Amino
Acid Residues [0389] Alcohol group-containing residues S and T
[0390] Aliphatic residues I, L, V, and M [0391]
Cycloalkenyl-associated residues F, H, W, and Y [0392] Hydrophobic
residues A, C, F, G, H, I, L, M, R, T, V, W, and Y [0393]
Negatively charged residues D and E [0394] Polar residues C, D, E,
H, K, N, Q, R, S, and T [0395] Positively charged residues H, K,
and R [0396] Small residues A, C, D, G, N, P, S, T, and V [0397]
Very small residues A, G, and S [0398] Residues involved in turn
formation A, C, D, E, G, H, K, N, Q, R, S, P, and T [0399] Flexible
residues Q, T, K, S, G, P, D, E, and R
[0400] In the context of the present invention, a substitution in
an antibody is indicated as:
[0401] Original amino acid--position--substituted amino acid;
[0402] Referring to the well-recognized nomenclature for amino
acids, the three letter code, or one letter code, is used,
including the codes "Xaa" or "X" to indicate any amino acid
residue. Thus, Xaa or X may typically represent any of the 20
naturally occurring amino acids. The term "naturally occurring" as
used herein refers to any one of the following amino acid residues;
glycine, alanine, valine, leucine, isoleucine, serine, threonine,
lysine, arginine, histidine, aspartic acid, asparagine, glutamic
acid, glutamine, proline, tryptophan, phenylalanine, tyrosine,
methionine, and cysteine.
[0403] Accordingly, the notation "K409R" or "Lys409Arg" means, that
the antibody comprises a substitution of Lysine with Arginine in
amino acid position 409.
[0404] Substitution of an amino acid at a given position to any
other amino acid is referred to as:
[0405] Original amino acid--position; or e.g. "K409"
[0406] For a modification where the original amino acid(s) and/or
substituted amino acid(s) may comprise more than one, but not all
amino acid(s), the more than one amino acid may be separated by ","
or "/". E.g. the substitution of Lysine with Arginine, Alanine, or
Phenylalanine in position 409 is:
[0407] "Lys409Arg,Ala,Phe" or "Lys409Arg/Ala/Phe" or "K409R,A,F" or
"K409R/A/F" or "K409 to R, A, or F".
[0408] Such designation may be used interchangeably in the context
of the invention but have the same meaning and purpose.
[0409] Furthermore, the term "a substitution" embraces a
substitution into any one or the other nineteen natural amino
acids, or into other amino acids, such as non-natural amino acids.
For example, a substitution of amino acid K in position 409
includes each of the following substitutions: 409A, 409C, 409D,
409E, 409F, 409G, 409H, 409I, 409L, 409M, 409N, 409Q, 409R, 409S,
409T, 409V, 409W, 409P, and 409Y. This is, by the way, equivalent
to the designation 409X, wherein the X designates any amino acid
other than the original amino acid. These substitutions may also be
designated K409A, K409C, etc. or K409A,C, etc. or K409A/C/etc. The
same applies by analogy to each and every position mentioned
herein, to specifically include herein any one of such
substitutions.
[0410] The antibody according to the invention may also comprise a
deletion of an amino acid residue. Such deletion may be denoted
"del", and includes, e.g., writing as K409del. Thus, in such
embodiments, the Lysine in position 409 has been deleted from the
amino acid sequence.
[0411] In one particular embodiment, the bispecific antibody
comprises a first and a second heavy chain, each of the first and
second heavy chain comprises at least a hinge region, a CH2 and CH3
region, wherein in the first heavy chain at least one of the amino
acids in the positions corresponding to positions selected from the
group consisting of K409, T366, L368, K370, D399, F405, and Y407 in
a human IgG1 heavy chain has been substituted, and in the second
heavy chain at least one of the amino acids in the positions
corresponding to a position selected from the group consisting of
F405, T366, L368, K370, D399, Y407, and K409 in a human IgG1 heavy
chain has been substituted, and wherein the first and the second
heavy chains are not substituted in the same positions.
[0412] In one embodiment, in the first heavy chain the amino acid
in the position corresponding to K409 in a human IgG1 heavy chain
is not K, L or M and optionally the amino acid in the position
corresponding to F405 in a human IgG1 heavy chain is F, and in the
second heavy chain the amino acid in the position corresponding to
F405 in a human IgG1 heavy chain is not F and the amino acid in the
position corresponding to K409 in a human IgG1 heavy chain is
K.
[0413] In one embodiment, in the first heavy chain, the amino acid
in the position corresponding to F405 in a human IgG1 heavy chain
is not F, R, and G, and in the second heavy chain the amino acids
in the positions corresponding to a position selected from the
group consisting of; T366, L368, K370, D399, Y407, and K409 in a
human IgG1 heavy chain has been substituted.
[0414] In one embodiment, the amino acid in position corresponding
to K409 in a human IgG1 heavy chain is another than K, L or M in
the first heavy chain, and in the second heavy chain the amino acid
in position corresponding to F405 in a human IgG1 heavy chain is
not F and optionally the amino acid in the position corresponding
to K409 in a human IgG1 heavy chain is K.
[0415] In one embodiment, the amino acid in the position
corresponding to F405 in a human IgG1 heavy chain is L in said
first heavy chain, and the amino acid in the position corresponding
to K409 in a human IgG1 heavy chain is R in said second heavy
chain, or vice versa.
[0416] Thus, in one embodiment, the amino acid in the position
corresponding to K409 in a human IgG1 heavy chain is R in the first
heavy chain, and the amino acid in the position corresponding to
F405 in a human IgG1 heavy chain is L in the second heavy
chain.
[0417] In another embodiment, both the first and the second binding
region of the bispecific antibody bind AXL. However, the first
binding region comprises a different set of CDR sequences than the
second binding region. Thus, in a particular embodiment, the
bispecific antibody comprising a first and a second binding region,
and a first and a second heavy chain, wherein the first and the
second binding regions each comprise a VH and VL region selected
from the group consisting of; [0418] a) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively,
[148]; [0419] b) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 114, 115, and 116, respectively, and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively [733]; [0420] c) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 41, 42, and 43,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 44, AAS, and 45, respectively,
[140]; [0421] d) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 51, 52, and 55, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively. [154]; [0422] e) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 54,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively.
[154-M103L]; [0423] f) a first VH region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively;
and a first VL region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second
VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 57, 58, and 59, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60,
GAS, and 61, respectively, [171]; [0424] g) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 62, 63, and 64,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 65, GAS, and 66, respectively,
[172]; [0425] h) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 67, 68, and 69, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70,
GAS, and 71, respectively, [181]; [0426] i) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 72, 73, and 75,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77, respectively,
[183]; [0427] j) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 72, 74, and 75, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183-N52Q]; [0428] k) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 78, 79, and 80,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 81, AAS, and 82, respectively,
[187]; [0429] l) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 83, 84, and 85, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86,
GAS, and 87, respectively, [608-01]; [0430] m) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 88, 89, and 90,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 91, GAS, and 92, respectively,
[610-01]; [0431] n) a first VH region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively;
and a first VL region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second
VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 94, 95, and 95, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96,
GAS, and 97, respectively, [613]; [0432] o) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 98, 99, and 100,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 101, DAS, and 102, respectively,
[613-08]; [0433] p) a first VH region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively;
and a first VL region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second
VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 103, 104, and 105, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106,
GAS, and 107, respectively, [620-06]; [0434] q) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 36,
37, and 38, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 39, GAS, and 40,
respectively, [107]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 108, 109, and 110,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113, respectively,
[726]; [0435] r) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 36, 37, and 38, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 39, GAS, and 40, respectively, [107]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 108, 109, and 111, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112,
AAS, and 113, respectively, [726-M101L]; [0436] s) a first VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 46, 47, and 48, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148]; and a second VH region comprising
the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and
116, respectively, and a second VL region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118,
respectively [733]; [0437] t) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively,
[148]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 41, 42, and 43, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 44, AAS, and 45, respectively, [107]; [0438] u) a
first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 46, 47, and 48, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148]; and a second VH region comprising
the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 55,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively.
[154]; [0439] v) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 49, AAS, and 50, respectively, [148]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 51, 52, and 54, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively. [154-M103L]; [0440] w) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46,
47, and 48, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50,
respectively, [148]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 57, 58, and 59,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 60, GAS, and 61, respectively,
[171]; [0441] x) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 49, AAS, and 50, respectively, [148]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 62, 63, and 64, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 65,
GAS, and 66, respectively, [172]; [0442] y) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46,
47, and 48, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50,
respectively, [148]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 67, 68, and 69,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 70, GAS, and 71, respectively,
[181]; [0443] z) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively; and a
first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 49, AAS, and 50, respectively, [148]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 72, 73, and 75, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76,
ATS, and 77, respectively, [183]; [0444] aa) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46,
47, and 48, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50,
respectively, [148]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 72, 74, and 75,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77, respectively,
[183-N52Q]; [0445] bb) a first VH region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively;
and a first VL region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 49, AAS, and 50, respectively, [148]; and a second
VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 78, 79, and 80, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 81,
AAS, and 82, respectively, [187]; [0446] cc) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46,
47, and 48, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50,
respectively, [148]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 83, 84, and 85,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 86, GAS, and 87, respectively,
[608-01]; [0447] dd) a first VH region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48, respectively;
and a first VL region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 49, AAS, and 50, respectively, [148]; and a second
VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 88, 89, and 90, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 91,
GAS, and 92, respectively, [610-01]; [0448] ee) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46,
47, and 48, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50,
respectively, [148]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 94, 95, and 95,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 96, GAS, and 97, respectively,
[613];
[0449] ff) a first VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 46, 47, and 48, respectively; and a first
VL region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 49, AAS, and 50, respectively, [148]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 98,
99, and 100, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 101, DAS, and 102,
respectively, [613-08]; [0450] gg) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively,
[148]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 103, 104, and 105, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 106, GAS, and 107, respectively, [620-06]; [0451] hh)
a first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 46, 47, and 48, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 49,
AAS, and 50, respectively, [148]; and a second VH region comprising
the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 108, 109, and
110, respectively; and a second VL region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113,
respectively, [726]; [0452] ii) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 46, 47, and 48,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 49, AAS, and 50, respectively,
[148]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 108, 109, and 111, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 112, AAS, and 113, respectively, [726-M101L]; [0453]
jj) a first VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 117, DAS, and 118, respectively, [733]; and a second VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 41, 42, and 43, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 44,
AAS, and 45, respectively, [140]; [0454] kk) a first VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114,
115, and 116, respectively; and a first VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118,
respectively, [733]; and a second VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID Nos.: 51, 52, and 55,
respectively; and a second VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 55, GAS, and 56, respectively.
[154]; [0455] ll) a first VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 114, 115, and 116, respectively; and
a first VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 117, DAS, and 118, respectively, [733]; and a second
VH region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 51, 52, and 54, respectively; and a second VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 55,
GAS, and 56, respectively. [154-M103L]; [0456] mm) a first VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 57,
58, and 59, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 60, GAS, and 61,
respectively, [171]; [0457] nn) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively,
[733]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 62, 63, and 64, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 65, GAS, and 66, respectively, [172]; [0458] oo) a
first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 67,
68, and 69, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 70, GAS, and 71,
respectively, [181]; [0459] pp) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively,
[733]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 72, 73, and 75, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 76, ATS, and 77, respectively, [183]; [0460] qq) a
first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 72,
74, and 75, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 76, ATS, and 77,
respectively, [183-N52Q]; [0461] rr) a first VH region comprising
the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and
116, respectively; and a first VL region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively,
[733]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 78, 79, and 80, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 81, AAS, and 82, respectively, [187]; [0462] ss) a
first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 83,
84, and 85, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 86, GAS, and 87,
respectively, [608-01]; [0463] tt) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively,
[733]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 88, 89, and 90, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 91, GAS, and 92, respectively, [610-01]; [0464] uu) a
first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 94,
95, and 95, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 96, GAS, and 97,
respectively, [613]; [0465] vv) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively,
[733]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 98, 99, and 100, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 101, DAS, and 102, respectively, [613-08]; [0466] ww)
a first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 103,
104, and 105, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 106, GAS, and 107,
respectively, [620-06]; [0467] xx) a first VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 114, 115, and 116,
respectively; and a first VL region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID Nos.: 117, DAS, and 118, respectively,
[733]; and a second VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID Nos.: 108, 109, and 110, respectively; and a
second VL region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 112, AAS, and 113, respectively, [726]; and [0468] yy)
a first VH region comprising the CDR1, CDR2, and CDR3 sequences of
SEQ ID Nos.: 114, 115, and 116, respectively; and a first VL region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 117,
DAS, and 118, respectively, [733]; and a second VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 108,
109, and 111, respectively; and a second VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID Nos.: 112, AAS, and 113,
respectively, [726-M101L];
Anti-AXL Antibody Drug Conjugate--Immunoconjugates
[0469] The antibodies according to any aspect or embodiment of the
present invention may be conjugated to a therapeutic or diagnostic
moiety, such as a cytotoxic agent, a chemotherapeutic drug, a
cytokine, an immunosuppressant, antibiotic, or a radioisotope. Such
conjugates are referred to herein as "immunoconjugates".
Immunoconjugates which include one or more cytotoxins are referred
to as "immunotoxins". Antibodies conjugated to a cytotoxic agent,
drug or the like are also known as antibody-drug conjugates (ADC).
An immunoconjugate may have a half-life of sufficient periods of
time for the antibody-drug conjugate to be internalized, degraded
and induce cell killing by the released toxin.
[0470] Thus, in another aspect, the present invention relates to an
immunoconjugate comprising the antibody according to any aspect or
embodiment herein described, or a bispecific antibody according to
any aspect or embodiment herein described, and a therapeutic
moiety, such as a cytotoxic agent, a chemotherapeutic drug, a
cytokine, an immunosuppressant, antibiotic, or a radioisotope. The
cytotoxic agent, chemotherapeutic drug, cytokine,
immunosuppressant, antibiotic, or radioisotope may be conjugated to
the antibody or the bispecific antibody via a linker.
[0471] ADCs are often designed such that the cytotoxic payload is
inactive when conjugated to the antibody. The cytotoxic payload may
be released intracellularly upon internalization of the ADC after
binding to the plasma-membrane of cells, or alternatively in
response to proteolytic activity in the tumor microenvironment. The
term "internalized" or "internalization" as used herein, refers to
a biological process in which molecules such as the antibody
according to the present invention, are engulfed by the cell
membrane and drawn into the interior of the cell. It may also be
referred to as "endocytosis".
[0472] Thus, the antibodies according to any aspect or embodiment
of the present invention may be internalized into the cell upon
binding to the target, AXL.
[0473] In some instances it may be desired to use antibodies which
undergo internalization. Such antibodies that have good
internalization properties may be suited for conjugation to a
cytotoxic agent, drug, or the like, optionally via a linker, which
is designed to be cleaved intracellularly.
[0474] Once internalized, the ADC may be delivered to lysosomes in
most cases, where effective drug release takes advantage of the
catabolic environment found with these organelles. It is typically
a linker that connects the antibody with a cytotoxic agent. Thus,
specialized linkers have been designed to be cleaved only in a
specific microenvironment found in or on the target tumor cell or
in the tumor microenvironment. Examples include linkers that are
cleaved by acidic conditions, reducing conditions, or specific
proteases.
[0475] Stability of the antibody-linker-drug in circulation is
important because this allows antibody-mediated delivery of the
drug to specific target cells. In addition, the long circulating
half-life of the ADC provides exposure for several days to weeks
post injection. Drugs that are conjugated through non-cleavable
linkers and protease-cleavable linkers are generally more stable in
circulation than disulfide and hydrazone linkers, although the
stability of the latter two linkers can be tuned by altering the
neighboring chemical structure [6].
[0476] In one embodiment, the therapeutic moiety is a cytotoxic
agent.
[0477] A cytotoxin or cytotoxic agent includes any agent that is
detrimental to (e.g., kills) cells. Suitable cytotoxic agents for
forming immunoconjugates of the present invention include taxol,
tubulysins, duostatins, cytochalasin B, gramicidin D, ethidium
bromide, emetine, mitomycin, etoposide, tenoposide, vincristine,
vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy
anthracin dione, maytansine or an analog or derivative thereof,
mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone,
glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and
puromycin; calicheamicin or analogs or derivatives thereof;
antimetabolites (such as methotrexate, 6-mercaptopurine,
6-thioguanine, cytarabine, fludarabin, 5-fluorouracil, decarbazine,
hydroxyurea, asparaginase, gemcitabine, cladribine), alkylating
agents (such as mechlorethamine, thioepa, chlorambucil, melphalan,
carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan,
dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine,
mitomycin C, cisplatin and other platinum derivatives, such as
carboplatin; as well as duocarmycin A, duocarmycin SA, CC-1065
(a.k.a. rachelmycin), or analogs or derivatives of CC-1065),
dolastatin, auristatin, pyrrolo[2,1-c][1,4]benzodiazepins (PDBs),
indolinobenzodiazepine (IGNs) or analogues thereof, antibiotics
(such as dactinomycin (formerly actinomycin), bleomycin,
daunorubicin (formerly daunomycin), doxorubicin, idarubicin,
mithramycin, mitomycin, mitoxantrone, plicamycin, anthramycin
(AMC)), anti-mitotic agents (e.g., tubulin-targeting agents), such
as diphtheria toxin and related molecules (such as diphtheria A
chain and active fragments thereof and hybrid molecules); ricin
toxin (such as ricin A or a deglycosylated ricin A chain toxin),
cholera toxin, a Shiga-like toxin (SLT-I, SLT-II, SLT-IIV), LT
toxin, C3 toxin, Shiga toxin, pertussis toxin, tetanus toxin,
soybean Bowman-Birk protease inhibitor, Pseudomonas exotoxin,
alorin, saporin, modeccin, gelanin, abrin A chain, modeccin A
chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins,
Phytolacca americana proteins (PAPI, PAPII, and PAP-S), Momordica
charantia inhibitor, curcin, crotin, Sapaonaria officinalis
inhibitor, gelonin, mitogellin, restrictocin, phenomycin, and
enomycin toxins. Other suitable conjugated molecules include
antimicrobial/lytic peptides such as CLIP, Magainin 2, mellitin,
Cecropin, and P18; ribonuclease (RNase), DNase I, Staphylococcal
enterotoxin-A, pokeweed antiviral protein, diphtherin toxin, and
Pseudomonas endotoxin. See, for example, Pastan et al., Cell 47 641
(1986) and Goldenberg, Calif. A Cancer Journal for Clinicians 44 43
(1994). Therapeutic agents that may be administered in combination
with anti-AXL antibodies or antibody-drug conjugates of the present
invention as described elsewhere herein, such as, e.g., anti-cancer
cytokines or chemokines, are also candidates for therapeutic
moieties useful for conjugation to an antibody disclosed in the
present invention.
[0478] The term "cytotoxic agent" as used herein, refers to any
agent that is detrimental to (e.g., kills) cells. For a description
of these classes of drugs which are well known in the art, and
their mechanisms of action, see [54]. Additional techniques
relevant to the preparation of antibody immunotoxins are provided
in for instance [55] and [56].
[0479] In one embodiment, the cytotoxic agent is linked to said
antibody, or fragment thereof, with a cleavable linker, such as
N-succinimydyl 4-(2-pyridyldithio)-pentanoate (SSP),
maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
(mc-vc-PAB) or AV-1 K-lock valine-citrulline.
[0480] The term "cleavable linker" as used herein, refers to a
subset of linkers that are catalyzed by specific proteases in the
targeted cell or in the tumor microenvironment, resulting in
release of the cytotoxic agent. Examples of cleavable linkers are
linkers based on chemical motifs including disulfides, hydrazones
or peptides. Another subset of cleavable linker, adds an extra
linker motif between the cytotoxic agent and the primary linker,
i.e. the site that attaches the linker-drug combination to the
antibody. In some embodiments, the extra linker motif is cleavable
by a cleavable agent that is present in the intracellular
environment (e. g. within a lysosome or endosome or caveola). The
linker can be, e. g. a peptidyl linker that is cleaved by an
intracellular peptidase or protease enzyme, including but not
limited to, a lysosomal or endosomal protease. In some embodiments,
the peptidyl linker is at least two amino acids long or at least
three amino acids long. Cleaving agents can include cathepsins B
and D and plasmin, all of which are known to hydrolyze dipeptide
drug derivatives resulting in the release of active drug inside the
target cells (see e. g. Dubowchik and Walker, 1999, Pharm.
Therapeutics 83:67-123). In a specific embodiment, the peptidyl
linker cleavable by an intracellular protease is a Val-Cit
(valine-citrulline) linker or a Phe-Lys (phenylalanine-lysine)
linker (see e.g. U.S. Pat. No. 6,214,345, which describes the
synthesis of doxorubicin with the Val-Cit linker). An advantage of
using intracellular proteolytic release of the therapeutic agent is
that the agent is typically attenuated when conjugated and the
serum stabilities of the conjugates are typically high.
[0481] In another embodiment, the cytotoxic agent is linked to said
antibody, or fragment thereof, with a non-cleavable linker, such as
succinimidyl-4(N-maleimidomethyl)cyclohexane-1-carboxylate (MCC) or
maleimidocaproyl (MC).
[0482] The term "noncleavable linker" as used herein, refers to a
subset of linkers which, in contrast to cleavable linkers, do not
comprise motifs that are specifically and predictably recognized by
intracellular or extracellular proteases. Thus, ADCs based on
non-cleavable linkers are not released or cleaved form the antibody
until the complete antibody-linker-drug complex is degraded in the
lysosomal compartment. Examples of a non-cleavable linker are
thioethers. In yet another embodiment, the linker unit is not
cleavable and the drug is released by antibody degradation (see
[57]). Typically, such a linker is not substantially sensitive to
the extracellular environment. As used herein, "not substantially
sensitive to the extracellular environment" in the context of a
linker means that no more than 20%, typically no more than about
15%, more typically no more than about 10%, and even more typically
no more than about 5%, no more than about 3%, or no more than about
1% of the linkers, in a sample of antibody drug conjugate compound,
are cleaved when the antibody drug conjugate compound is present in
an extracellular environment (e.g. plasma). Whether a linker is not
substantially sensitive to the extracellular environment can be
determined for example by incubating with plasma the antibody drug
conjugate compound for a predetermined time period (e.g. 2, 4, 8,
16 or 24 hours) and then quantitating the amount of free drug
present in the plasma.
[0483] In one embodiment, cytotoxic agent is selected from the
group: DNA-targeting agents, e.g. DNA alkylators and cross-linkers,
such as calicheamicin, duocarmycin, rachelmycin (CC-1065),
pyrrolo[2,1-c][1,4] benzodiazepines (PBDs), and
indolinobenzodiazepine (IGN); microtubule-targeting agents, such as
duostatin, such as duostatin-3, auristatin, such as
monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF),
dolastatin, maytansine,
N(2')-deacetyl-N(2')-(3-marcapto-1-oxopropyl)-maytansine (DM1), and
tubulysin; and nucleoside analogs; or an analogs, derivatives, or
prodrugs thereof.
[0484] In one embodiment, the immunoconjugate comprise a
combination of;
i) the cytotoxic agent and said cleavable linker having bystander
kill capacity; ii) the cytotoxic agent and said cleavable linker
not having bystander kill capacity; iii) the cytotoxic agent and
said non-cleavable linker having bystander kill capacity; or iv)
the cytotoxic agent and said non-cleavable linker not having
bystander kill capacity.
[0485] The term "bystander killing effect", "bystander kill",
"bystander kill capacity" or "bystander cytotoxicity" as used
herein, refers to the effect where the cytotoxic agent that is
conjugated to the antibody by either a cleavable or non-cleavable
linker has the capacity to diffuse across cell membranes after the
release from the antibody and thereby cause killing of neighboring
cells. When the cytotoxic agent is conjugated by a cleavable or
non-cleavable linker, it may be either the cytotoxic agent only or
the cytotoxic agent with a part of the linker that has the
bystander kill capacity. The capacity to diffuse across cell
membranes is related to the hydrophobicity of the the cytotoxic
agent or the combination of the cytotoxic agent and the linker.
Such cytotoxic agents may advantageously be membrane-permeable
toxins, such as MMAE that has been released from the antibody by
proteases. Especially in tumors with heterogeneous target
expression and in solid tumors where antibody penetration may be
limited, a bystander killing effect may be desirable.
[0486] The term "no bystander kill capacity", "no bystander killing
effect", "no-bystander kill" or "no bystander cytotoxicity" as used
herein, refers to the effect where the cytotoxic agent that is
conjugated to the antibody by either a cleavable or non-cleavable
linker does not have the capacity to diffuse across cell membranes
after release from the antibody. Thus, such cytotoxic agents or
combinations of the cytotoxic agent with the linker, will not be
able to kill neighboring cells upon release from the antibody. It
is believed without being bound by theory, that such combinations
of a cytotoxic agent and either a cleavable or non-cleavable linker
will only kill cells expressing the target that the antibody
binds.
[0487] A stable link between the antibody and cytotoxic agent is an
important factor of an ADC. Both cleavable and non-cleavable types
of linkers have been proven to be safe in preclinical and clinical
trials.
[0488] In one embodiment, the cytotoxic agent is chosen from the
group of microtubule targeting agents, such as auristatins and
maytansinoids.
[0489] The term "microtubule-targeting agent" as used herein,
refers to an agent or drug which inhibits mitosis (cell division).
Microtubules are structures that are essential for proper
separation of DNA during cell division, and microtubule function
critically depends on `dynamic instability`, i.e. the process in
which microtubule structures are continuously elongated and
shortened. Microtubule-targeting agents disrupt or stabilize
microtubules, which prevents formation of the mitotic spindle,
resulting in mitotic arrest and apoptosis. The
microtubule-targeting agents can be derived from e.g. natural
substances such as plant alkaloids, and prevent cells from
undergoing mitosis by disrupting or stabilizing microtubule
polymerization, thus preventing formation of the mitotic spindle
and subsequent cell division, resulting in inhibition of cancerous
growth. Examples of microtubule-targeting agents are paclitaxel,
docetaxel, vinblastine, vincristine, vinorelbine, duostatins,
auristatins, maytansanoids, tubulysins, and dolastatin.
[0490] In one embodiment, the cytotoxic agent is auristatins or
auristatin peptide analogs and derivates ([131]; [132]).
Auristatins have been shown to interfere with microtubule dynamics,
GTP hydrolysis and nuclear and cellular division [133] and have
anti-cancer [134] and anti-fungal activity [135]. The auristatin
drug moiety may be attached to the antibody via a linker, through
the N (amino) terminus or the C (terminus) of the peptidic drug
moiety.
[0491] Exemplary auristatin embodiments include the
N-terminus-linked monomethyl auristatin drug moieties DE and DF,
disclosed in [136] and described in [137].
[0492] In a particular embodiment, the cytotoxic agent is
monomethyl auristatin E (MMAE);
##STR00001##
[0493] wherein the antibody is linked to MMAE at the nitrogen (N)
on the left-hand side of the chemical structure above by the
appropriate linker.
[0494] In one embodiment, the cytotoxic agent monomethyl auristatin
E (MMAE) is linked to the antibody via a valine-citrulline (VC)
linker.
[0495] In another embodiment, the cytotoxic agent monomethyl
auristatin E (MMAE) is linked to the antibody via a
valine-citrulline (VC) linker and the maleimidocaproyl (MC)linker,
wherein the combination of the cytotoxic agent and the linkers has
the chemical structure;
##STR00002##
[0496] wherein MAb is the antibody.
[0497] In one embodiment, the cytotoxic agent is monomethyl
auristatin F (MMAF);
##STR00003##
[0498] wherein the antibody is linked to MMAF at the nitrogen (N)
on the left-hand side of the chemical structure above by the
appropriate linker.
[0499] In one embodiment, the cytotoxic agent monomethyl auristatin
F (MMAF) is linked to the antibody via a maleimidocaproyl
(mc)-linker, wherein the combination of the cytotoxic agent and
linker has the chemical structure;
##STR00004##
[0500] wherein MAb is the antibody.
[0501] In one embodiment, the cytotoxic agent is duostatin3.
[0502] In another particular embodiment, the cytotoxic agent is a
DNA-targeting agent.
[0503] The term "DNA-acting agent" as used herein, refers to a
specific class of cytotoxic agents which are able to alkylate
and/or cross-link DNA. An example of such a DNA-acting agent is IGN
agents comprising indolino-benzodiazepinedimers and
pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) which are highly potent
by virtue of their ability to alkylate and cross-link DNA. Another
example is IGN agents comprising indolino-benzodiazepinemonomers
which are highly potent by virtue of the ability to alkylate only
DNA. Duocarmycins are another class of DNA-acting agents.
Duocarmycins are small-molecule, synthetic DNA minor groove binding
alkylating agents. These compounds are suitable to target solid
tumors as well as hematological tumors.
[0504] In one embodiment, the immunoconjugate comprises two to four
cytotoxic molecules per antibody. Depending on the chemical
properties of the toxin and the linker-toxin combination, two to
four cytotoxic molecules per antibody may be superior to more
heavily loaded conjugates that are cleared more rapidly from the
circulation than less loaded conjugates. The cytotoxic agent
loading is represented by p and is the average number of cytotoxic
agent moieties per antibody in a molecule (also designated as the
drug to antibody ratio, DAR). The cytotoxic agent loading may range
from 1 to 20 drug moieties per antibody and may occur on amino
acids with useful functional groups such as, but not limited to,
amino or sulfhydryl groups, as in lysine or cysteine.
[0505] In one embodiment, the number of cytotoxic agents per
antibody is from 1 to 8, such as 2 to 7, such as 2 to 6, such as 2
to 5, such as 2 to 4, and such as 2 to 3.
[0506] In another embodiment, the immunoconjugate comprises four to
eight cytotoxic molecules per antibody. In another embodiment, the
immunoconjugate comprises six to ten cytotoxic molecules per
antibody. In yet another embodiment, the immunoconjugate comprises
10 to 30, such as 15 to 25, such as 20, cytotoxic molecules per
antibody.
[0507] Depending on the way of conjugation, p may be limited by the
number of attachment sites on the antibody, for example where the
attachment is a cysteine thiol or a lysine. Generally, antibodies
do not contain many free and reactive cysteine thiol groups which
may be linked to a drug moiety as most cysteine thiol residues in
antibodies exist as disulfide bridges. Therefore, in those
embodiments, where the cytotoxic agent is conjugated via a cysteine
thiol, the antibody may be reduced with reducing agent such as
dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP), under
partial or fully reducing conditions, to generate reactive cysteine
thiol groups. In certain embodiments, the drug loading for an ADC
of the invention ranges from 1 to about 8, as a maximum of 8 free
cysteine thiol groups becomes available after (partial) reduction
of the antibody (there are 8 cysteines involved in inter-chain
disulfide bonding).
[0508] In one embodiment, the drug linker moiety is vcMMAE. The
vcMMAE drug linker moiety and conjugation methods are disclosed in
[27]; [28]; [145], [146]; and [147], (which are incorporated herein
by reference) vcMMAE is form by conjugation of the linker mc-vc-PAB
and the cytotoxic moiety MMAE, and the vcMMAE drug linker moiety is
bound to the anti-AXL antibodies at the cysteine residues using a
method similar to those disclosed therein.
[0509] In one embodiment, the drug linker moiety is mcMMAF. The
mcMMAF drug linker moiety and conjugation methods are disclosed in
[138]; [139], and [140] (which are incorporated herein by
reference), and the mcMMAF drug linker moiety is bound to the
anti-AXL antibodies at the cysteine residues using a method similar
to those disclosed therein.
[0510] In one embodiment, the cytotoxic agent is linked to 1 or 2
lysines within the antibody amino acid sequence by K-Lock.TM.
conjugation as described in [58], [148], and [149], and the
duostatin3 (also known as Duo3) is bound to the anti-AXL antibodies
at the lysine residues using a method similar to those described
therein.
[0511] Other linker technologies may be used in the anti-AXL
antibody drug conjugates of the invention, such as linkers
comprising a hydroxyl group.
[0512] In one embodiment, the linker is attached to free cysteine
residues of the anti-AXL antibody obtained by (partial) reduction
of the anti-AXL antibody.
[0513] In a particular embodiment, the linker is mc-vc-PAB and the
cytotoxic agent is MMAE; or the linker SSP and the cytotoxic agent
is DM1.
[0514] In a particular embodiment, the linker is MMC and the
cytotoxic agent is DM1; or the linker is MC and the cytotoxic agent
is MMAF.
[0515] In a particular embodiment, the linker is the cleavable
linker AV1-K lock and the cytotoxic agent is duostatin3.
[0516] In one embodiment the immunoconjugate comprises the linker
mc-vc-PAB, the cytotoxic agent MMAE and an antibody wherein the at
least one binding region comprises a VH region and a VL region
selected from the group consisting of;
[0517] a) a VH region comprising SEQ ID No: 1 and a VL region
comprising SEQ ID No: 2 [107];
[0518] b) a VH region comprising SEQ ID No: 5 and a VL region
comprising SEQ ID No: 6 [148];
[0519] c) a VH region comprising SEQ ID No: 34 and a VL region
comprising SEQ ID No: 35 [733]
[0520] d) a VH region comprising SEQ ID No: 7 and a VL region
comprising SEQ ID No: 9 [154];
[0521] e) a VH region comprising SEQ ID No: 10 and a VL region
comprising SEQ ID No: 11 [171];
[0522] f) a VH region comprising SEQ ID No: 16 and a VL region
comprising SEQ ID No: 18 [183];
[0523] g) a VH region comprising SEQ ID No: 25 and a VL region
comprising SEQ ID No: 26 [613];
[0524] h) a VH region comprising SEQ ID No: 31 and a VL region
comprising SEQ ID No: 33 [726];
[0525] i) a VH region comprising SEQ ID No: 3 and a VL region
comprising SEQ ID No: 4 [140];
[0526] j) a VH region comprising SEQ ID No:8 and a VL region
comprising SEQ ID No:9 [154-M103L];
[0527] k) a VH region comprising SEQ ID No:12 and a VL region
comprising SEQ ID No:13 [172];
[0528] l) a VH region comprising SEQ ID No:14 and a VL region
comprising SEQ ID No:15 [181];
[0529] m) a VH region comprising SEQ ID No:17 and a VL region
comprising SEQ ID No:18 [183-N52Q];
[0530] n) a VH region comprising SEQ ID No:19 and a VL region
comprising SEQ ID No:20 [187];
[0531] o) a VH region comprising SEQ ID No:21 and a VL region
comprising SEQ ID No:22 [608-01];
[0532] p) a VH region comprising SEQ ID No:23 and a VL region
comprising SEQ ID No:24 [610-01];
[0533] q) a VH region comprising SEQ ID No:27 and a VL region
comprising SEQ ID No:28 [613-08];
[0534] r) a VH region comprising SEQ ID No:29 and a VL region
comprising SEQ ID No:30 [620-06]; and
[0535] s) a VH region comprising SEQ ID No:32 and a VL region
comprising SEQ ID No:33 [726-M101L].
[0536] In another alternative embodiment, an anti-AXL antibody drug
conjugate disclosed in the present invention comprises a conjugated
nucleic acid or nucleic acid-associated molecule. In one such
embodiment, the conjugated nucleic acid is a cytotoxic
ribonuclease, an antisense nucleic acid, an inhibitory RNA molecule
(e.g., a siRNA molecule) or an immunostimulatory nucleic acid
(e.g., an immunostimulatory CpG motif-containing DNA molecule).
[0537] In another alternative embodiment, an anti-AXL antibody of
the invention is conjugated to an aptamer or a ribozyme or a
functional peptide analog or derivate thereof.
[0538] In another alternative embodiment, anti-AXL antibody drug
conjugates comprising one or more radiolabeled amino acids are
provided. A radiolabeled anti-AXL antibody may be used for both
diagnostic and therapeutic purposes (conjugation to radiolabeled
molecules is another possible feature). Non-limiting examples of
labels for polypeptides include .sup.3H, .sup.14C, .sup.15N,
.sup.35S, .sup.90Y, .sup.99Tc, and .sup.125I, .sup.131I, and
.sup.186Re. Methods for preparing radiolabeled amino acids and
related peptide derivatives are known in the art (see for instance
[59] and [60], [61], [62], [63], [64] and [65]U.S. Pat. No.
5,697,902. For example, a radioisotope may be conjugated by a
chloramine T method.
[0539] In one embodiment, the antibody is conjugated to a
radioisotope or to a radioisotope-containing chelate. For example,
the antibody can be conjugated to a chelator linker, e.g. DOTA,
DTPA or tiuxetan, which allows for the antibody to be complexed
with a radioisotope. The antibody may also or alternatively
comprise or be conjugated to one or more radiolabeled amino acids
or other radiolabeled molecules. A radiolabeled anti-AXL antibody
may be used for both diagnostic and therapeutic purposes.
Non-limiting examples of radioisotopes include .sup.3H, .sup.14C,
.sup.15N, .sup.35S, .sup.90Y, .sup.99Tc, .sup.125I, .sup.111In,
.sup.131I, .sup.186Re, .sup.213Bs, .sup.225Ac and .sup.227Th.
[0540] Anti-AXL antibodies may also be chemically modified by
covalent conjugation to a polymer to for instance increase their
circulating half-life. Exemplary polymers, and methods to attach
them to peptides, are illustrated in for instance [66]; [67]; [68];
and [69]. Additional polymers include polyoxyethylated polyols and
polyethylene glycol (PEG) (e.g., a PEG with a molecular weight of
between about 1,000 and about 40,000, such as between about 2,000
and about 20,000). This may for example be used if the anti-AXL
antibody is a fragment.
[0541] Any method known in the art for conjugating the anti-AXL
antibody according to the present invention to the conjugated
molecule(s), such as those described above, may be employed,
including the methods described by [70], [71] and [72]. Such
antibodies may be produced by chemically conjugating the other
moiety to the N-terminal side or C-terminal side of the anti-AXL
antibody (e.g., an anti-AXL antibody H or L chain) (see, e.g.,
[73]). Such conjugated antibody derivatives may also be generated
by conjugation at internal residues or sugars, or non-naturally
occurring amino acids or additional amino acids that have been
introduced into the antibody constant domain, where
appropriate.
[0542] The agents may be coupled either directly or indirectly to
an anti-AXL antibody disclosed in the present invention. One
example of indirect coupling of a second agent is coupling via a
spacer moiety to cysteine or lysine residues in the antibody. In
one embodiment, an anti-AXL antibody is conjugated, via a spacer or
linker, to a prodrug molecule that can be activated in vivo to a
therapeutic drug. After administration, the spacers or linkers are
cleaved by tumor cell-associated enzymes or other tumor-specific
conditions, by which the active drug is formed. Examples of such
pro-drug technologies and linkers are described in [74], [75],
[76], [77], [78] and [79] (all incorporated herein by reference)
Suitable antibody-pro-drug technology and duocarmycin analogs can
also be found in [80](incorporated herein by reference).
[0543] In one embodiment, the anti-AXL antibody of the present
invention is attached to a chelator linker, e.g. tiuxetan, which
allows for the antibody to be conjugated to a radioisotope.
Compositions
[0544] In a further aspect, the invention relates to a composition
comprising the antibody, the bispecific antibody, or the
immunoconjugate of the invention.
[0545] In another aspect, the invention relates to a pharmaceutical
composition comprising the antibody, bispecific or immunoconjugate
according to the invention and a pharmaceutical carrier.
[0546] The pharmaceutical compositions may be formulated with
pharmaceutically acceptable carriers or diluents as well as any
other known adjuvants and excipients in accordance with
conventional techniques such as those disclosed in [81].
[0547] The pharmaceutically acceptable carriers or diluents as well
as any other known adjuvants and excipients should be suitable for
the antibody or antibody conjugate of the present invention and the
chosen mode of administration. Suitability for carriers and other
components of pharmaceutical compositions is determined based on
the lack of significant negative impact on the desired biological
properties of the chosen compound or pharmaceutical composition of
the present invention (e.g., less than a substantial impact (10% or
less relative inhibition, 5% or less relative inhibition, etc.)
upon antigen binding).
[0548] A pharmaceutical composition of the present invention may
also include diluents, fillers, salts, buffers, detergents (e. g.,
a nonionic detergent, such as Tween-20 or Tween-80), stabilizers
(e.g., sugars or protein-free amino acids), preservatives, tissue
fixatives, solubilizers, and/or other materials suitable for
inclusion in a pharmaceutical composition.
[0549] The actual dosage levels of the active ingredients in the
pharmaceutical compositions of the present invention may be varied
so as to obtain an amount of the active ingredient which is
effective to achieve the desired therapeutic response for a
particular patient, composition, and mode of administration,
without being toxic to the patient. The selected dosage level will
depend upon a variety of pharmacokinetic factors including the
activity of the particular compositions of the present invention
employed, or the amide thereof, the route of administration, the
time of administration, the rate of excretion of the particular
compound being employed, the duration of the treatment, other
drugs, compounds and/or materials used in combination with the
particular compositions employed, the age, sex, weight, condition,
general health and prior medical history of the patient being
treated, and like factors well known in the medical arts.
[0550] The pharmaceutical composition may be administered by any
suitable route and mode. Suitable routes of administering a
compound of the present invention in vivo and in vitro are well
known in the art and may be selected by those of ordinary skill in
the art.
[0551] In one embodiment, the pharmaceutical composition of the
present invention is administered parenterally.
[0552] The terms "parenteral administration" and "administered
parenterally" as used herein refers to modes of administration
other than enteral and topical administration, usually by
injection, and include epidermal, intravenous, intramuscular,
intra-arterial, intrathecal, intracapsular, intra-orbital,
intracardiac, intradermal, intraperitoneal, intratendinous,
transtracheal, subcutaneous, subcuticular, intra-articular,
subcapsular, subarachnoid, intraspinal, intracranial,
intrathoracic, epidural and intrasternal injection and
infusion.
[0553] In one embodiment, the pharmaceutical composition of the
present invention is administered by intravenous or subcutaneous
injection or infusion.
[0554] Pharmaceutically acceptable carriers include any and all
suitable solvents, dispersion media, coatings, antibacterial and
antifungal agents, isotonicity agents, antioxidants and
absorption-delaying agents, and the like that are physiologically
compatible with a compound of the present invention.
[0555] Examples of suitable aqueous and non-aqueous carriers which
may be employed in the pharmaceutical compositions of the present
invention include water, saline, phosphate-buffered saline,
ethanol, dextrose, polyols (such as glycerol, propylene glycol,
polyethylene glycol, and the like), and suitable mixtures thereof,
vegetable oils, such as olive oil, corn oil, peanut oil, cottonseed
oil, and sesame oil, carboxymethyl cellulose colloidal solutions,
tragacanth gum and injectable organic esters, such as ethyl oleate,
and/or various buffers. Other carriers are well known in the
pharmaceutical arts.
[0556] Pharmaceutically acceptable carriers include sterile aqueous
solutions or dispersions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or dispersion. The use
of such media and agents for pharmaceutically active substances is
known in the art. Except insofar as any conventional media or agent
is incompatible with the active compound, use thereof in the
pharmaceutical compositions of the present invention is
contemplated.
[0557] Proper fluidity may be maintained, for example, by the use
of coating materials, such as lecithin, by the maintenance of the
required particle size in the case of dispersions, and by the use
of surfactants.
[0558] Pharmaceutical compositions of the present invention may
also comprise pharmaceutically acceptable antioxidants for instance
(1) water-soluble antioxidants, such as ascorbic acid, cysteine
hydrochloride, sodium bisulfate, sodium metabisulfite, sodium
sulfite and the like; (2) oil-soluble antioxidants, such as
ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated
hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol,
and the like; and (3) metal-chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid,
phosphoric acid, and the like.
[0559] Pharmaceutical compositions of the present invention may
also comprise isotonicity agents, such as sugars, polyalcohols,
such as mannitol, sorbitol, glycerol or sodium chloride in the
compositions.
[0560] The pharmaceutical compositions of the present invention may
also contain one or more adjuvants appropriate for the chosen route
of administration such as preservatives, wetting agents,
emulsifying agents, dispersing agents, preservatives or buffers,
which may enhance the shelf life or effectiveness of the
pharmaceutical composition. The compounds of the present invention
may be prepared with carriers that will protect the compound
against rapid release, such as a controlled release formulation,
including implants, transdermal patches, and micro-encapsulated
delivery systems. Such carriers may include gelatin, glyceryl
monostearate, glyceryl distearate, biodegradable, biocompatible
polymers such as ethylene vinyl acetate, polyanhydrides,
polyglycolic acid, collagen, poly-ortho-esters, and polylactic acid
alone or with a wax, or other materials well known in the art.
Methods for the preparation of such formulations are generally
known to those skilled in the art. See e.g., [82].
[0561] In one embodiment, the compounds of the present invention
may be formulated to ensure proper distribution in vivo.
Pharmaceutically acceptable carriers for parenteral administration
include sterile aqueous solutions or dispersions and sterile
powders for the extemporaneous preparation of sterile injectable
solutions or dispersion. The use of such media and agents for
pharmaceutically active substances is known in the art. Except
insofar as any conventional media or agent is incompatible with the
active compound, use thereof in the pharmaceutical compositions of
the present invention is contemplated. Other active or therapeutic
compounds may also be incorporated into the compositions.
[0562] Pharmaceutical compositions for injection must typically be
sterile and stable under the conditions of manufacture and storage.
The composition may be formulated as a solution, micro-emulsion,
liposome, or other ordered structure suitable to high drug
concentration. The carrier may be an aqueous or a non-aqueous
solvent or dispersion medium containing for instance water,
ethanol, polyols (such as glycerol, propylene glycol, polyethylene
glycol, and the like), and suitable mixtures thereof, vegetable
oils, such as olive oil, and injectable organic esters, such as
ethyl oleate. The proper fluidity may be maintained, for example,
by the use of a coating such as lecithin, by the maintenance of the
required particle size in the case of dispersion and by the use of
surfactants. In many cases, it will be preferable to include
isotonic agents, for example, sugars, polyalcohols such as
glycerol, mannitol, sorbitol, or sodium chloride in the
composition. Prolonged absorption of the injectable compositions
may be brought about by including in the composition an agent that
delays absorption, for example, monostearate salts and gelatin.
Sterile injectable solutions may be prepared by incorporating the
active compound in the required amount in an appropriate solvent
with one or a combination of ingredients e.g. as enumerated above,
as required, followed by sterilization microfiltration. Generally,
dispersions are prepared by incorporating the active compound into
a sterile vehicle that contains a basic dispersion medium and the
required other ingredients e.g. from those enumerated above. In the
case of sterile powders for the preparation of sterile injectable
solutions, examples of methods of preparation are vacuum-drying and
freeze-drying (lyophilization) that yield a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
[0563] Sterile injectable solutions may be prepared by
incorporating the active compound in the required amount in an
appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by sterilization
microfiltration. Generally, dispersions are prepared by
incorporating the active compound into a sterile vehicle that
contains a basic dispersion medium and the required other
ingredients from those enumerated above. In the case of sterile
powders for the preparation of sterile injectable solutions,
examples of methods of preparation are vacuum-drying and
freeze-drying (lyophilization) that yield a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
[0564] The pharmaceutical composition of the present invention may
contain one antibody, bispecific antibody or ADC of the present
invention, a combination of an antibody, a bispecific antibody or
ADC according to the invention with another therapeutic compound,
or a combination of compounds of the present invention.
Nucleic Acid Constructs, Expression Vectors, and Host Cells
[0565] In one aspect, the present invention relates to a nucleic
acid construct encoding one or more sequences set out in Table 1.
Thus, the present invention relates to nucleic acid constructs
encoding any one of the sequences set out in SEQ ID Nos.: 1 to 135.
In one embodiment, the nucleic acid construct encodes at least one
of the amino acid sequence selected from the group consisting of
SEQ ID Nos.: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,
51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,
68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100,
101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113,
114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,
127, 128, 129, 130, 131, 132, 133, 134, and 135. Thus, in one
embodiment, the nucleic acid construct encodes an antibody
according to any aspect or embodiment herein described.
[0566] In a particular embodiment, the nucleic acid construct
encodes at least one of the amino acid sequences selected from the
group consisting of SEQ ID Nos.: 46, 47, 48, 49, 50, 36, 37, 38,
39, 40, 114, 115, 116, 117, and 118.
[0567] In a further aspect, the invention relates to an expression
vector encoding an antibody of the invention. Thus, the expression
vector comprises one or more nucleic acid constructs according to
any aspect or embodiment herein described. Such expression vectors
may in one embodiment be used to express the anti-AXL antibody of
the present invention. The expressed anti-AXL antibody may
subsequently be conjugated to a moiety as described herein. In
another embodiment the anti-AXL antibody may subsequently be used
to generate a bispecific antibody as described herein.
[0568] In one embodiment, the expression vector of the invention
comprises a nucleic acid sequence encoding one or more of the heavy
chain (VH) CDR3 amino acid sequences selected from the group
consisting of: SEQ ID Nos.: 38, 43, 48, 53, 54, 59, 64, 69, 75, 80,
85, 90, 95, 100, 105, 110, 111, 116, 120, 122, 125, and 127.
[0569] In a particular embodiment, the expression vector of the
invention comprises a nucleic acid sequence encoding one or more of
the VH CDR1, CDR2, and CDR3 amino acid sequences selected from the
group consisting of: SEQ ID Nos.: 36-38, 41-43, 46-48, 51-54,
57-59, 62-64, 67-69, 72-75, 78-80, 83-85, 88-90, 93-95, 98-100,
103-105, 108-110, and 114-116.
[0570] In one embodiment, the expression vector of the invention
comprises a nucleic acid sequence encoding one or more of the light
chain (VL) CDR3 amino acid sequences selected from the group
consisting of: SEQ ID Nos.: 40, 45, 50, 56, 61, 66, 71, 77, 82, 87,
92, 97, 102, 107, 113, and 118.
[0571] In another particular embodiment, the expression vector of
the invention comprises a nucleic acid sequence encoding one or
more of the VH amino acid sequences selected from the group
consisting of: SEQ ID Nos.: 1, 3, 5, 7, 8, 10, 12, 14, 16, 17, 19,
21, 23, 25, 27, 29, 31, 32, and 34.
[0572] In another particular embodiment, the expression vector of
the invention comprises a nucleic acid sequence encoding one or
more of the VL amino acid sequences selected from the group
consisting of: SEQ ID Nos.: 2, 4, 6, 9, 11, 13, 15, 18, 20, 22, 24,
26, 28, 30, 33, and 35.
[0573] In one embodiment, the expression vector of the invention
comprises a nucleic acid sequence encoding one or more of the amino
acid sequences selected from the group consisting of: SEQ ID Nos.:
1 to 35.
[0574] In a particular embodiment, the expression vector of the
invention comprises a nucleic acid sequence encoding variants of
one or more of the above amino acid sequences, said variants having
at most 25 amino acid modifications, such as 20, such as at most
15, 14, 13, 12, or 11 amino acid modifications, such as 10, 9, 8,
7, 6, 5, 4, 3, 2, or 1 amino acid modifications, such as deletions
or insertions, preferably substitutions, such as conservative or
non-conservative substitutions, or at least 80% identity to any of
said sequences, such as at least 85% identity or 90% identity or
95% identity, such as 96% identity or 97% identity or 98% identity
or 99% identity to any of the aforementioned amino acid sequences.
The present invention also relates to nucleic acid sequences
different from the above mentioned nucleic acid sequences but which
due to the variance of the genetic code encode the same amino acid
sequence as an antibody of the present invention. E.g. the nucleic
acid sequence may vary but result in an identical amino acid
sequence as any amino acid sequence herein described. It is
well-known for the skilled person how to identify such further
nucleic acid sequences based on the genetic code.
[0575] In a further embodiment, the expression vector further
comprises a nucleic acid sequence encoding the constant region of a
light chain, a heavy chain or both light and heavy chains of an
antibody, e.g. a human IgG1, K monoclonal antibody.
[0576] Such expression vectors as described above may be used for
recombinant production of antibodies of the invention.
[0577] An expression vector in the context of the present invention
may be any suitable vector, including chromosomal, non-chromosomal,
and synthetic nucleic acid vectors (a nucleic acid sequence
comprising a suitable set of expression control elements). Examples
of such vectors include derivatives of SV40, bacterial plasmids,
phage DNA, baculovirus, yeast plasmids, vectors derived from
combinations of plasmids and phage DNA, and viral nucleic acid (RNA
or DNA) vectors. In one embodiment, an anti-AXL antibody-encoding
nucleic acid is comprised in a naked DNA or RNA vector, including,
for example, a linear expression element (as described in for
instance [83]), a compacted nucleic acid vector (as described in
for instance [84] and/or [85]), a plasmid vector such as pBR322,
pUC 19/18, or pUC 118/119, a "midge" minimally-sized nucleic acid
vector (as described in for instance [86]), or as a precipitated
nucleic acid vector construct, such as a CaP04-precipitated
construct (as described in for instance [87], [88], [89], and
[90]). Such nucleic acid vectors and the usage thereof are well
known in the art (see for instance [91] and [92]).
[0578] In one embodiment, the vector is suitable for expression of
the anti-AXL antibody in a bacterial cell. Examples of such vectors
include expression vectors such as BlueScript (Stratagene), plN
vectors ([93], pET vectors (Novagen, Madison Wis.) and the
like).
[0579] An expression vector may also or alternatively be a vector
suitable for expression in a yeast system. Any vector suitable for
expression in a yeast system may be employed. Suitable vectors
include, for example, vectors comprising constitutive or inducible
promoters such as alpha factor, alcohol oxidase and PGH (reviewed
in: [94], and [95]).
[0580] A nucleic acid construct and/or vector may also comprises a
nucleic acid sequence encoding a secretion/localization sequence,
which can target a polypeptide, such as a nascent polypeptide
chain, to the periplasmic space or into cell culture media. Such
sequences are known in the art, and include secretion leader or
signal peptides, organelle targeting sequences (e. g., nuclear
localization sequences, ER retention signals, mitochondrial transit
sequences, chloroplast transit sequences), membrane
localization/anchor sequences (e. g., stop transfer sequences, GPI
anchor sequences), and the like.
[0581] In an expression vector of the invention, anti-AXL
antibody-encoding nucleic acids may comprise or be associated with
any suitable promoter, enhancer, and other expression-facilitating
elements. Examples of such elements include strong expression
promoters (e. g., human CMV IE promoter/enhancer as well as RSV,
SV40, SL3-3, MMTV, and HIV LTR promoters), effective poly (A)
termination sequences, an origin of replication for plasmid product
in E. coli, an antibiotic resistance gene as selectable marker,
and/or a convenient cloning site (e.g., a polylinker). Nucleic
acids may also comprise an inducible promoter as opposed to a
constitutive promoter such as CMV IE (the skilled artisan will
recognize that such terms are actually descriptors of a degree of
gene expression under certain conditions).
[0582] In one embodiment, the anti-AXL-antibody-encoding expression
vector may be positioned in and/or delivered to the host cell or
host animal via a viral vector.
[0583] In an even further aspect, the invention relates to a
recombinant eukaryotic or prokaryotic host cell, such as a
transfectoma, which produces an anti-AXL antibody of the invention
as defined herein or a bispecific molecule of the invention as
defined herein. Examples of host cells include yeast, bacterial and
mammalian cells, such as CHO or HEK cells or derivatives thereof.
For example, in one embodiment, the present invention provides a
cell comprising a nucleic acid stably integrated into the cellular
genome that comprises a sequence coding for expression of an
anti-AXL antibody of the present invention. In another embodiment,
the present invention provides a cell comprising a non-integrated
nucleic acid, such as a plasmid, cosmid, phagemid, or linear
expression element, which comprises a sequence coding for
expression of an anti-AXL antibody of the invention.
[0584] In a further aspect, the present invention relates to a host
cell comprising a vector according to any aspect and embodiments
herein described. In one embodiment, the anti-AXL antibodies
described herein are provided by use of recombinant eukaryotic,
prokaryotic or microbial host cell which produces the antibody.
Accordingly, the invention provides a recombinant host cell, such
as a recombinant prokaryotic, recombinant eukaryotic, or
recombinant microbial host cell. Examples of host cells include
yeast, bacterial and mammalian cells, such as CHO or HEK-293 cells.
For example, in one embodiment, the host cell comprises a nucleic
acid stably integrated into the cellular genome that comprises a
sequence coding for expression of an anti-AXL antibody described
herein. In one embodiment, the host cell comprises a nucleic acid
stably integrated into the cellular genome that comprise a sequence
coding for expression of a first or a second polypeptide described
herein. In another embodiment, the host cell comprises a
non-integrated nucleic acid, such as a plasmid, cosmid, phagemid,
or linear expression element, which comprises a sequence coding for
expression of an anti-AXL antibody, a first or a second polypeptide
described herein.
[0585] The term "recombinant host cell" (or simply "host cell"), as
used herein, is intended to refer to a cell into which an
expression vector has been introduced. It should be understood that
such terms are intended to refer not only to the particular subject
cell, but also to the progeny of such a cell. Because certain
modifications may occur in succeeding generations due to either
mutation or environmental influences, such progeny may not, in
fact, be identical to the parent cell, but are still included
within the scope of the term "host cell" as used herein.
Recombinant host cells include, for example, transfectomas, such as
CHO cells, HEK-293 cells, PER.C6, NSO cells, and lymphocytic cells,
and prokaryotic cells such as E. coli and other eukaryotic hosts
such as plant cells and fungi.
[0586] The term "transfectoma", as used herein, includes
recombinant eukaryotic host cells expressing the antibody or a
target antigen, such as CHO cells, PER.C6, NSO cells, HEK-293
cells, plant cells, or fungi, including yeast cells.
[0587] In another aspect, the present invention relates to a
hybridoma which produces an antibody according to any aspect or
embodiment herein described. Thus, an antibody may be obtained from
hybridomas prepared from murine splenic B cells obtained from mice
immunized with an antigen of interest, for instance in form of
cells expressing the antigen on the surface, or a nucleic acid
encoding an antigen of interest. Monoclonal antibodies may also be
obtained from hybridomas derived from antibody-expressing cells of
immunized humans or non-human mammals such as rabbits, rats, dogs,
primates, etc.
[0588] Human antibodies may be generated using transgenic or
transchromosomal mice, e.g. HuMAb mice, carrying parts of the human
immune system rather than the mouse system. The HuMAb mouse
contains a human immunoglobulin gene minilocus that encodes
unrearranged human heavy (.mu. and .gamma.) and .kappa. light chain
immunoglobulin sequences, together with targeted mutations that
inactivate the endogenous .mu. and .kappa. chain loci [96].
Accordingly, the mice exhibit reduced expression of mouse IgM or
.kappa. and in response to immunization, the introduced human heavy
and light chain transgenes, undergo class switching and somatic
mutation to generate high affinity human IgG,.kappa. monoclonal
antibodies [96], [97], [98] and [99]. The preparation of HuMAb mice
is described in detail in [100], [101], [102], [103], and [104].
See also [105] to [121]. Splenocytes from these transgenic mice may
be used to generate hybridomas that secrete human monoclonal
antibodies according to well-known techniques.
[0589] Further, human antibodies of the present invention or
antibodies of the present invention from other species may be
identified through display-type technologies, including, without
limitation, phage display, retroviral display, ribosomal display,
mammalian display, yeast display and other techniques known in the
art, and the resulting molecules may be subjected to additional
maturation, such as affinity maturation, as such techniques are
well known in the art.
[0590] Thus, in one aspect, the present invention relates to a
method for producing an antibody according to any aspect or
embodiment herein described, comprising the steps [0591] a)
culturing a host cell or hybridoma according to any aspect or
embodiment herein described; and [0592] b) purifying the antibody
from the culture media.
Therapeutic Applications
[0593] In another aspect, the invention relates to the antibody,
bispecific antibody, or immunoconjugate or ADC of the present
invention, as defined in any aspect or embodiment herein, for use
as a medicament.
[0594] The anti-AXL antibodies of the present invention can be used
in the treatment or prevention of disorders involving cells
expressing AXL. For example, the antibodies may be administered to
cells in culture, e.g., in vitro or ex vivo, or to human subjects,
e.g., in vivo, to treat or prevent disorders involving
AXL-expressing cells. As used herein, the term "subject" is
typically a human to whom the anti-AXL antibody or ADC is
administered. Subjects may for instance include human patients
having disorders that may be corrected or ameliorated by modulating
AXL function or by killing of the AXL-expressing cell, directly or
indirectly.
[0595] In one aspect, the present invention relates to the
antibody, bispecific antibody, or immunoconjugate of the present
invention, as defined in any aspect or embodiment herein, for use
in the treatment of cancer.
[0596] In one aspect, the invention provides a method for
modulating AXL-associated signaling in an AXL-expressing cell by
contacting the cell with an anti-AXL antibody or ADC according to
any aspect or embodiment herein described.
[0597] In one embodiment, the invention provides a method for
killing an AXL-expressing cell by contacting the cell with an
anti-AXL antibody or ADC of the invention. Without being limited to
theory, antibody-mediated or ADC-mediated crosslinking or
clustering (e.g., due to the Fc-region of AXL-bound antibodies
binding to FcR-expressing cells) of AXL molecules on the surface of
a cell can lead to apoptosis of the cell.
[0598] In one embodiment, the invention provides a method for
killing an AXL-expressing cell by contacting the cell with an
AXL-specific antibody or ADC of the invention in the presence of
effector cells capable of inducing an Fc-dependent cellular
response such as ADCC or ADCP. In this embodiment, the antibody is
typically full-length and of an isotype leading to an ADCC or ADCP
response, such as, e.g., an IgG1,.kappa. isotype.
[0599] In one embodiment, the invention provides a method for
killing an AXL-expressing cell by contacting the cell with an
AXL-specific antibody or ADC of the invention in the presence of
complement proteins, such as complement proteins present in normal
human serum, that may be activated and thereby inducing CDC after
binding of AXL-specific antibody or ADC to the plasma membrane of
AXL-expressing cells. In this embodiment, the antibody is typically
full-length and of an isotype capable of inducing activation of the
complement system, such as, e.g., an IgG1,.kappa. isotype.
[0600] The anti-AXL antibodies of the invention may be
characterized by internalization upon binding to AXL, making them
suitable for an ADC approach using an ADC as described in any
aspect or embodiment described herein.
[0601] Accordingly, in one embodiment, the invention provides a
method for killing an AXL-expressing cell by contacting the cell
with an ADC of the invention which requires internalization and
trafficking to lysosomes for specific (i.e. cleavable linker) or
non-specific (non-cleavable linker) proteolytic cleavage of the
anti-AXL antibody-linker-drug complex.
[0602] In one embodiment, the present invention relates to a method
for interfering with AXL-mediated regulation of the innate or
adaptive immune response, such as by binding of an AXL-specific
antibody or ADC according to the invention to AXL-expressing
macrophages, dendritic cells or NK cells.
[0603] In another embodiment, the invention provides for a method
of killing an AXL-expressing cell by contacting the cell with an
ADC of the invention wherein the anti-AXL antibody is linked to a
therapeutic moiety via a linker allowing for release of the drug
once the ADC is internalized, e.g., by a change in pH or reducing
conditions. Suitable linker technology is known in the art, as
described above.
[0604] In another aspect, the present invention provides methods
for treating or preventing a disorder involving cells expressing
AXL in a subject, which method comprises administration of a
therapeutically effective amount of an anti-AXL antibody,
bispecific antibody or ADC of the present invention to a subject in
need thereof. The method typically involves administering to a
subject an anti-AXL antibody, a bispecific antibody or ADC
according to the present invention in an amount effective to treat
or prevent the disorder.
[0605] In a particular aspect, an anti-AXL antibody or ADC is
administered prophylactically in order to reduce the risk of
developing cancer, delay the onset of an event in cancer
progression or reduce the risk of recurrence when a cancer is in
remission and/or a primary tumor has been surgically removed. In
the latter case, the anti-AXL antibody could, for example, be
administered in association with (i.e., before, during, or after)
the surgery. Prophylactic administration may also be useful in
patients wherein it is difficult to locate a tumor that is believed
to be present due to other biological factors.
[0606] Cells with high AXL expression, such as over-expression or
aberrant expression of AXL, as found in some cancer cells, are
particularly good targets for the anti-AXL antibodies, bispecific
antibodies or ADCs of the invention, since more antibodies or ADCs
may be bound per tumor cell.
[0607] Tissues that heterogeneously express AXL such as tumor
tissue may also be a suitable target for the anti-AXL antibodies,
bispecific antibodies, ADCs or anti-AXL-ADCs of the invention.
Thus, in one aspect, the disorder involving cells expressing AXL is
cancer, i.e., a tumorigenic disorder, such as a disorder
characterized by the presence of tumor cells expressing AXL
including, for example, disorders where the cells are from a solid
tumor or hematological tumor. AXL expression has been described in,
e.g., non-small-cell lung cancer (NSCLC; [122]), pancreatic cancer
[123], esophageal cancer [124], endometrial cancer [125].
[0608] Exemplary cells expressing AXL thus include cancer cells
such as, e.g., cells from non-small cell lung cancer, pancreatic
cancer and esophageal cancer.
[0609] In one aspect, the present invention provides methods for
treating or preventing cancer comprising administering the
antibody, the bispecific antibody, the immunoconjugate, the
composition, or the pharmaceutical composition according to the
present invention to a subject in need thereof.
[0610] In one embodiment, the cancer is a solid tumor expressing
AXL or an AXL-expressing hematological cancer. In one embodiment,
the hematological cancer is Acute Myeloid Leukemia (AML). In one
embodiment, the solid tumor expressing AXL is lung cancer or
epidermoid carcinoma.
[0611] Thus, the present invention relates to methods comprising
administration of a therapeutically effective amount of an anti-AXL
antibodyor ADC of the present invention to a subject in need
thereof.
[0612] In one aspect, the present invention relates to a method for
inhibiting growth and/or proliferation of a tumor cell expressing
AXL, comprising administration, to an individual in need thereof,
of an antibody, bispecific antibody, immunoconjugate, composition,
or pharmaceutical composition according to any aspect or embodiment
herein described.
[0613] In one aspect, the present invention relates to a method for
inhibiting migration and/or invasion of a tumor cell expressing
AXL, comprising administration, to an individual in need thereof,
of an antibody, bispecific antibody, immunoconjugate, composition,
or pharmaceutical composition according to any aspect or embodiment
herein described.
[0614] In one aspect, the present invention relates to a method for
inhibiting resistance to targeted therapy, such as EGFR- or
BRAF-targeted therapy, or to chemotherapeutic agents, comprising
administration, to an individual in need thereof, of an antibody,
bispecific antibody, immunoconjugate, composition, or
pharmaceutical composition according to any aspect or embodiment
herein described.
[0615] In one aspect, the present invention relates to a method for
targeting or inhbiting tumor-associated macrophages, comprising
administration, to an individual in need thereof, of an antibody,
bispecific antibody, immunoconjugate, composition, or
pharmaceutical composition according to any aspect or embodiment
herein described.
[0616] In one aspect, the present invention provides methods for
treating or preventing a solid tumor, which method comprises
administration of a therapeutically effective amount of an anti-AXL
antibody or ADC of the present invention to a subject in need
thereof, and wherein the solid tumor is a melanoma, carcinoma,
sarcoma, adenoma and/or a glioma. In one embodiment, the cancer is
selected from the group consisting of endometrial/cervical cancer,
lung cancer (such as, e.g., small cell lung cancer or non-small
cell lung cancer), thyroid cancer, colon cancer, kidney cancer,
ovary cancer, breast cancer, esophagus cancer, skin cancer,
malignant melanoma and pancreatic cancer.
[0617] In one embodiment, the cancer is pancreatic cancer, such as
unresectable advanced or metastatic pancreatic cancer. In other
separate and specific embodiments, the cancer is
endometrial/cervical cancer, or lung cancer. In one embodiment the
cancer is a thyroid cancer. In one embodiment the cancer is a colon
cancer. In one embodiment the cancer is a kidney cancer. In one
embodiment the cancer is ovarian cancer. In one embodiment the
cancer is breast cancer such as estrogen receptor alpha negative
cancer or estrogen receptor alpha positive. In one embodiment the
cancer is triple negative breast cancer (i.e. breast cancer tested
negative for estrogen receptors (ER-), progesterone receptors
(PR-), and human epidermal growth factor receptor 2 (HER2-). In one
embodiment the cancer is esophagus cancer. In one embodiment the
cancer is skin cancer. In one embodiment the cancer is melanoma
such as malignant melanoma. In one embodiment the cancer is Acute
Myeloid Leukemia (AML). In one embodiment the cancer is resistant
to chemotherapy, thyrosine kinase inhibitors and or BRAF
inhibitors. In one embodimenet the cancer is resistant to EGFR
targeted therapy.
[0618] In one aspect, the present invention relates to an antibody
binding to the extracellular domain of AXL such as the Ig1-like
domain of AXL, such as the Ig2-like domain of AXL, such as the FN1
domain of AXL, or such as the FN2 domain of AXL, wherein said
antibody is for use as a medicament.
[0619] In a particular embodiment the antibody comprises at least
one binding region comprising a VH region and a VL region, wherein
the VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is for use as a
medicament.
[0620] In a particular embodiment the antibody comprises at least
one binding region comprising a VH region and a VL region, wherein
the VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of cancer.
[0621] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of thyroid cancer.
[0622] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of colon cancer.
[0623] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of kidney cancer.
[0624] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of ovarian cancer.
[0625] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of breast cancer.
[0626] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of triple negative breast cancer.
[0627] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of esophagus cancer.
[0628] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of skin cancer.
[0629] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of melanoma such as malignant melanoma.
[0630] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of lung cancer (such as, e.g., small cell
lung cancer or non-small cell lung cancer (NSCLC)).
[0631] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
36, 37 and 38, and the VL region comprises the sequences of SEQ ID
Nos.: 39, GAS, and 40, wherein said antibody is for use in
treatment or prevention of Acute Myeloid Leukemia (AML).
[0632] Hereby embodiments are provided for the treatment or
prevention of cancer. Said embodiments may be coupled or linked to
a cytotoxic agent to increase the efficacy or effect of the
treatment.
[0633] In a particular aspect of the present invention the
antibodies disclosed herein may be linked to a cytotoxic agent such
as an auristatin (such as, e.g monomethyl auristatin E (MMAE)) to
form an immunoconjugate for use as a medicament, such as e.g. for
the treatment or prevention of cancer.
[0634] In one aspect the present invention relates to an
immunoconjugate comprising an antibody which binds to AXL, wherin
the antbody does not compete for AXL binding with the ligand
Gas6.
[0635] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use as a medicament.
[0636] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of cancer. In
one embodiment thereof said antibody is linked to monomethyl
auristatin E by the linker mc-vc-PAB.
[0637] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of thyroid
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0638] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of colon
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0639] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of kidney
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0640] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of ovarian
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0641] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of breast
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0642] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of triple
negative breast cancer. In one embodiment thereof said antibody is
linked to monomethyl auristatin E by the linker mc-vc-PAB.
[0643] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of lung
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0644] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of esophagus
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0645] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of melanoma
such as malignant melanoma. In one embodiment thereof said antibody
is linked to monomethyl auristatin E by the linker mc-vc-PAB.
[0646] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of lung
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0647] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 36, 37 and 38, and the VL region comprises the sequences of
SEQ ID Nos.: 39, GAS, and 40, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of Acute
Myeloid Leukemia. In one embodiment thereof said antibody is linked
to monomethyl auristatin E by the linker mc-vc-PAB.
[0648] Hereby embodiments are provided wherein the antibody is
linked to a cytotoxic agent such as an auristatin to form an
immunoconjugate. The antibody and the cytotoxic agent may be linked
by a maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
(mc-vc-PAB) linker.
[0649] In an additional aspect of the invention, the invention
relates to antibodies that bind to the extracellular domain of AXL
such as the Ig2-like domain of AXL, wherein said antibody is for
use as a medicament.
[0650] In a particular embodiment the antibody comprises at least
one binding region comprising a VH region and a VL region, wherein
the VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is for use as a
medicament.
[0651] In a particular embodiment the antibody comprises at least
one binding region comprising a VH region and a VL region, wherein
the VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of cancer.
[0652] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of thyroid cancer.
[0653] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of colon cancer.
[0654] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of kidney cancer.
[0655] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of ovarian cancer.
[0656] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of breast cancer.
[0657] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of triple negative breast cancer.
[0658] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of esophagus cancer.
[0659] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of skin cancer.
[0660] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of melanoma such as malignant melanoma.
[0661] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50 wherein said antibody is for use in treatment
or prevention of lung cancer (such as, e.g., small cell lung cancer
or non-small cell lung cancer).
[0662] In on embodiment the antibody comprises at least one binding
region comprising a VH region and a VL region, wherein the VH
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID Nos.:
46, 47 and 48, and the VL region comprises the sequences of SEQ ID
Nos.: 49, AAS, and 50, wherein said antibody is for use in
treatment or prevention of Acute Myeloid Leukemia (AML).
[0663] Hereby embodiments are provided for the treatment or
prevention of cancer. Said embodiments may be coupled or linked
with a cytotoxic agent to increase the efficacy or effect of the
treatment.
[0664] In a particular aspect of the present invention the
antibodies disclosed herein may be linked with a cytotoxic agent
such as an auristatin (such as, e.g monomethyl auristatin E (MMAE))
to form an immunoconjugate for use as a medicament, such as e.g.
for the treatment or prevention of cancer.
[0665] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use as a medicament.
[0666] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for in treatment or prevention of cancer.
[0667] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of thyroid
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0668] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of colon
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0669] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of kidney
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0670] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of ovarian
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0671] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of breast
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0672] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of triple
negative breast cancer. In one embodiment thereof said antibody is
linked to monomethyl auristatin E by the linker mc-vc-PAB.
[0673] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of lung
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0674] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of esophagus
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0675] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of melanoma
such as malignant melanoma. In one embodiment thereof said antibody
is linked to monomethyl auristatin E by the linker mc-vc-PAB.
[0676] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50, wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of lung
cancer. In one embodiment thereof said antibody is linked to
monomethyl auristatin E by the linker mc-vc-PAB.
[0677] In one embodiment the invention relates to an
immunoconjugate comprising an antibody comprising at least one
binding region comprising a VH region and a VL region, wherein the
VH region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID
Nos.: 46, 47 and 48, and the VL region comprises the sequences of
SEQ ID Nos.: 49, AAS, and 50 wherein said antibody is linked to
monomethyl auristatin E to form an immunoconjugate, and said
immunoconjugate is for use in treatment or prevention of Acute
Myeloid Leukemia. In one embodiment thereof said antibody is linked
to monomethyl auristatin E by the linker mc-vc-PAB.
[0678] Hereby embodiments are provided wherein the antibody is
linked to a cytotoxic agent such as an auristatin to form an
immunoconjugate. The antibody and the cytotoxic agent may be linked
by a maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
(mc-vc-PAB) linker.
[0679] In an embodiment selection of patients to be treated with
anti-AXL antibodies is based on the level of AXL expression in a
sample, such as a sample containing tumor cells, or by detecting
AXL-expressing tumors using labeled anti-AXL antibodies or antibody
fragments, e.g., those of the invention. Exemplary diagnostic
assays for determining AXL-expression using AXL antibodies of the
invention are described herein. The efficient dosages and dosage
regimens for the anti-AXL antibody or ADC depend on the disease or
condition to be treated and may be determined by the persons
skilled in the art.
[0680] A physician having ordinary skill in the art may readily
determine and prescribe the effective amount of the pharmaceutical
composition required. In relation hereto, when referring to a
pharmaceutical composition it is to be understood also to comprise
a composition as such, or vice versa. For example, the physician
could start doses of the anti-AXL antibody employed in the
pharmaceutical composition at levels lower than that required in
order to achieve the desired therapeutic effect and gradually
increase the dosage until the desired effect is achieved. In
general, a suitable dose of a pharmaceutical composition of the
present invention will be that amount of the compound which is the
lowest dose effective to produce a therapeutic effect according to
a particular dosage regimen. Such an effective dose will generally
depend upon the factors described above.
[0681] For example, an "effective amount" for therapeutic use may
be measured by its ability to stabilize the progression of disease.
The ability of a compound to inhibit cancer may, for example, be
evaluated in an animal model system predictive of efficacy in human
tumors. Alternatively, this property of a composition may be
evaluated by examining the ability of the compound to inhibit cell
growth or to induce cytotoxicity by in vitro assays known to the
skilled practitioner. A therapeutically effective amount of a
therapeutic compound may decrease tumor size, or otherwise
ameliorate symptoms in a subject. One of ordinary skill in the art
would be able to determine such amounts based on such factors as
the subject's size, the severity of the subject's symptoms, and the
particular composition or route of administration selected.
[0682] An exemplary, non-limiting range for a therapeutically
effective amount of an anti-AXL antibody of the present invention
is about 0.1-100 mg/kg, such as about 0.1-50 mg/kg, for example
about 0.1-20 mg/kg, such as about 0.1-10 mg/kg, for instance about
0.5, about such as 0.3, about 1, about 3 mg/kg, about 5 mg/kg or
about 8 mg/kg.
[0683] An exemplary, non-limiting range for a therapeutically
effective amount of an anti-AXL ADC of the invention is 0.02-100
mg/kg, such as about 0.02-30 mg/kg, such as about 0.05-10 mg/kg or
0.1-3 mg/kg, for example about 0.5-2 mg/kg.
[0684] Administration may e.g. be intravenous, intramuscular,
intraperitoneal, or subcutaneous, and for instance administered
proximal to the site of the target.
[0685] Dosage regimens in the above methods of treatment and uses
are adjusted to provide the optimum desired response (e.g., a
therapeutic response). For example, a single bolus may be
administered, several divided doses may be administered over time
or the dose may be proportionally reduced or increased as indicated
by the exigencies of the therapeutic situation.
[0686] In one embodiment, the efficacy-safety window is optimized
by lowering specific toxicity such as for example by lowering the
drug-antibody ratio (DAR) and/or mixing of anti-AXL ADC with
unlabeled anti-AXL antibody.
[0687] In one embodiment, the efficacy of the treatment is
monitored during the therapy, e.g. at predefined points in time. In
one embodiment, the efficacy may be monitored by measuring the
level of AXL in a sample containing tumor cells, by visualization
of the disease area, or by other diagnostic methods described
further herein, e.g. by performing one or more PET-CT scans, for
example using a labeled anti-AXL antibody, fragment or
mini-antibody derived from the AXL-specific antibody of the present
invention.
[0688] If desired, an effective daily dose of a pharmaceutical
composition may be administered as two, three, four, five, six or
more sub-doses administered separately at appropriate intervals
throughout the day, optionally, in unit dosage forms. In another
embodiment, the anti-AXL antibodies are administered by slow
continuous infusion over a long period, such as more than 24 hours,
in order to minimize any unwanted side effects.
[0689] While it is possible for a compound of the present invention
to be administered alone, it is preferable to administer the
compound as a pharmaceutical composition as described above.
[0690] An effective dose of an anti-AXL antibody, bispecific
antibody or ADC of the invention may also be administered using a
weekly, biweekly or triweekly dosing period. The dosing period may
be restricted to, e.g., 8 weeks, 12 weeks or until clinical
progression has been established.
[0691] For example, in one embodiment, the anti-AXL antibody,
bispecific antibody or ADC is administered by infusion in a weekly
dosage of between 10 and 500 mg/m.sup.2, such as between 200 and
400 mg/m.sup.2. Such administration may be repeated, e.g., 1 to 8
times, such as 3 to 5 times. The administration may be performed by
continuous infusion over a period of from 1 to 24 hours, such as of
from 1 to 12 hours.
[0692] In another embodiment, the anti-AXL antibody, bispecific
antibody or ADC is administered by infusion every three weeks in a
dosage of between 10 and 500 mg/m.sup.2, such as between 50-200
mg/m.sup.2. Such administration may be repeated, e.g., 1 to 8
times, such as 3 to 5 times.
[0693] The administration may be performed by continuous infusion
over a period of from 1 to 24 hours, such as of from 1 to 12
hours.
[0694] In one embodiment, an anti-AXL ADC is administered as a
single dose of about 0.1-10 mg/kg, such as about 1-3 mg/kg, every
week or every third week for up to twelve times, up to eight times,
or until clinical progression. The administration may be performed
by continuous infusion over a period of from 1 to 24 hours, such as
of from 1 to 12 hours. Such regimens may be repeated one or more
times as necessary, for example, after 6 months or 12 months. The
dosage may be determined or adjusted by measuring the amount of
compound of the present invention in the blood upon administration
by for instance taking out a biological sample and using
anti-idiotypic antibodies which target the antigen binding region
of the anti-AXL antibodies of the present invention.
[0695] In one embodiment, the anti-AXL antibodies are administered
as maintenance therapy, such as, e.g., once a week for a period of
six months or more.
[0696] As non-limiting examples, treatment according to the present
invention may be provided as a daily dosage of a compound of the
present invention in an amount of about 0.1-100 mg/kg, such as 0.2,
0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
40, 45, 50, 60, 70, 80, 90 or 100 mg/kg, per day, on at least one
of days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, or 40, or alternatively, at least one of weeks
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
or 20 after initiation of treatment, or any combination thereof,
using single or divided doses every 24, 12, 8, 6, 4, or 2 hours, or
any combination thereof.
[0697] Parenteral compositions may be formulated in dosage unit
form for ease of administration and uniformity of dosage. Dosage
unit form as used herein refers to physically discrete units suited
as unitary dosages for the subjects to be treated; each unit
contains a predetermined quantity of active compound calculated to
produce the desired therapeutic effect in association with the
required pharmaceutical carrier. The specification for the dosage
unit forms of the present invention are dictated by and directly
dependent on (a) the unique characteristics of the active compound
and the particular therapeutic effect to be achieved, and (b) the
limitations inherent in the art of compounding such an active
compound for the treatment of sensitivity in individuals.
Diagnostic Applications
[0698] The anti-AXL antibodies of the invention may also be used
for diagnostic purposes, using a composition comprising an anti-AXL
antibody as described herein. Accordingly, the invention provides
diagnostic methods and compositions using the anti-AXL antibodies
described herein. Such methods and compositions can be used for
purely diagnostic purposes, such as detecting or identifying a
disease involving AXL-expressing cells, as well as for monitoring
of the progress of therapeutic treatments, monitoring disease
progression, assessing status after treatment, monitoring for
recurrence of disease, evaluating risk of developing a disease, and
the like.
[0699] In one aspect, the anti-AXL antibodies of the present
invention are used ex vivo, such as in diagnosing a disease in
which cells expressing AXL are indicative of disease or involved in
the pathogenesis, by detecting levels of AXL or levels of cells
which express AXL on their cell surface in a sample taken from a
patient. This may be achieved, for example, by contacting the
sample to be tested, optionally along with a control sample, with
the anti-AXL antibody under conditions that allow for binding of
the antibody to AXL. Complex formation can then be detected (e.g.,
using an ELISA).
[0700] When using a control sample along with the test sample, the
level of anti-AXL antibody or anti-AXL antibody-AXL complex is
analyzed in both samples and a statistically significant higher
level of anti-AXL antibody or anti-AXL antibody-AXL complex in the
test sample indicates a higher level of AXL in the test sample
compared with the control sample.
[0701] Examples of conventional immunoassays in which anti-AXL
antibodies of the present invention can be used include, without
limitation, ELISA, RIA, FACS assays, plasmon resonance assays,
chromatographic assays, tissue immunohistochemistry, Western blot,
and/or immunoprecipitation.
[0702] Accordingly, in one embodiment, the present invention
relates to a method of diagnosing a disease characterized by
involvement or accumulation of AXL-expressing cells, comprising
administering an antibody, bispecific antibody, immunoconjugate,
composition or pharmaceutical composition according to any aspect
or embodiment herein described, to a subject, optionally wherein
the antibody is labeled with a detectable label, and wherein the
amount of AXL-expressing cells correlates with or is indicative of
disease.
[0703] In one embodiment, the invention relates to a method for
detecting the presence of AXL antigen, or a cell expressing AXL, in
a sample comprising: [0704] contacting the sample with an anti-AXL
antibody of the invention under conditions that allow for binding
of the anti-AXL antibody to AXL in the sample; and [0705] analyzing
whether a complex has been formed. Typically, the sample is a
biological sample. The term "AXL antigen" as used in this context,
refers both soluble and cell bound AXL antigen.
[0706] In one embodiment, the sample is a tissue sample known or
suspected of containing AXL antigen and/or cells expressing AXL.
For example, in situ detection of AXL expression may be
accomplished by removing a histological specimen from a patient,
and providing the antibody of the present invention to such a
specimen. The antibody may be provided by applying or by overlaying
the antibody to the specimen, which is then detected using suitable
means. It is then possible to determine not only the presence of
AXL or AXL-expressing cells, but also the distribution of AXL or
AXL-expressing cells in the examined tissue (e.g., in the context
of assessing the spread of cancer cells).
[0707] Using the present invention, those of ordinary skill will
readily perceive that any of a wide variety of histological methods
(such as staining procedures) may be modified in order to achieve
such in situ detection.
[0708] In the above assays, the anti-AXL antibody can be labeled
with a detectable substance to allow AXL-bound antibody to be
detected. Alternatively, bound (primary) anti-AXL antibody may be
detected by a secondary antibody which is labeled with a detectable
substance and which binds to the primary antibody. Furthermore, in
the above assays, a diagnostic composition comprising an antibody
or bispecific antibody according to any aspect or embodiments
herein described may be used. Thus, in one aspect, the present
invention relates to a diagnostic composition comprising an
antibody or bispecific antibody according to any aspect or
embodiment herein described.
[0709] The level of AXL in a sample can also be estimated by a
competition immunoassay utilizing AXL standards labeled with a
detectable substance and an unlabeled anti-AXL antibody. In this
type of assay, the biological sample, the labeled AXL standard(s)
and the anti-AXL antibody are combined, and the amount of labeled
AXL standard bound to the unlabeled anti-AXL antibody is
determined. The amount of AXL in the biological sample is inversely
proportional to the amount of labeled AXL standard bound to the
anti-AXL antibody.
[0710] Suitable labels for the anti-AXL antibody, secondary
antibody and/or AXL standard used in in vitro diagnostic techniques
include, without limitation, various enzymes, prosthetic groups,
fluorescent materials, luminescent materials, and radioactive
materials. Examples of suitable enzymes include horseradish
peroxidase, alkaline phosphatase, .beta.-galactosidase, and
acetylcholinesterase; examples of suitable prosthetic group
complexes include streptavidin/biotin and avidin/biotin; examples
of suitable fluorescent materials include umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine,
dichlorotriazinylamine fluorescein, dansyl chloride and
phycoerythrin; an example of a luminescent material includes
luminol; and examples of suitable radioactive material include
.sup.125I, .sup.131I, .sup.35S, and .sup.3H.
[0711] In one aspect, the anti-AXL antibodies of the invention are
used in the in vivo imaging of AXL-expressing tissues such as
tumors. For in vivo methods, antibody fragments such as, e.g.,
(Fab').sub.2, Fab and Fab' fragments, are particularly advantageous
because of their rapid distribution kinetics.
[0712] In vivo imaging can be performed by any suitable technique.
For example, an anti-AXL antibody (such as, e.g., a fragment)
labeled with .sup.99Tc, .sup.131I, .sup.111In or other gamma-ray
emitting isotope may be used to image anti-AXL antibody
accumulation or distribution in AXL-expressing tissues such as
tumors with a gamma scintillation camera (e.g., an Elscint Apex
409ECT device), typically using low-energy, high resolution
collimator or a low-energy all-purpose collimator. Alternatively,
labeling with .sup.89Zr, .sup.76Br, .sup.18F or other
positron-emitting radionuclide may be used to image anti-AXL
antibody or antibody fragment distribution in tumors using positron
emission tomography (PET). The images obtained by the use of such
techniques may be used to assess biodistribution of AXL in a
patient, mammal, or tissue, for example in the context of using AXL
as a biomarker for the presence of cancer cells. Variations on this
technique may include the use of magnetic resonance imaging (MRI)
to improve imaging over gamma camera techniques. Conventional
immunoscintigraphy methods and principles are described in, e.g.,
[126], [127], and [128]. Moreover, such images may also, or
alternatively, serve as the basis for surgical techniques to remove
tumors. Furthermore, such in vivo imaging techniques may allow for
the identification and localization of a tumor in a situation where
a patient is identified as having a tumor (due to the presence of
other biomarkers, metastases, etc.), but the tumor cannot be
identified by traditional analytical techniques. All of these
methods are features of the present invention.
[0713] The in vivo imaging and other diagnostic methods provided by
the present invention are particularly useful in the detection of
micrometastases in a human patient (e.g., a patient not previously
diagnosed with cancer or a patient in a period of
recovery/remission from a cancer).
[0714] In one embodiment, the present invention provides an in vivo
imaging method wherein an anti-AXL antibody of the present
invention is conjugated to a detection-promoting radio-opaque
agent, the conjugated antibody is administered to a host, such as
by injection into the bloodstream, and the presence and location of
the labeled antibody in the host is assayed. Through this technique
and any other diagnostic method provided herein, the present
invention provides a method for screening for the presence of
disease-related cells in a human patient or a biological sample
taken from a human patient and/or for assessing the distribution of
anti-AXL antibody prior to anti-AXL ADC therapy.
[0715] For diagnostic imaging, radioisotopes may be bound to an
anti-AXL antibody either directly or indirectly by using an
intermediary functional group. Useful intermediary functional
groups include chelators, such as ethylenediaminetetraacetic acid
and diethylenetriaminepentaacetic acid (see for instance
[129]).
[0716] In addition to radioisotopes and radio-opaque agents,
diagnostic methods may be performed using anti-AXL antibodies that
are conjugated to dyes (such as with the biotin-streptavidin
complex), contrast agents, fluorescent compounds or molecules and
enhancing agents (e.g. paramagnetic ions) for magnetic resonance
imaging (MRI) (see, e.g., [130], which describes MRI techniques and
the preparation of antibodies conjugated to a MRI enhancing agent).
Such diagnostic/detection agents may be selected from agents for
use in MRI, and fluorescent compounds. In order to load an anti-AXL
antibody with radioactive metals or paramagnetic ions, it may be
necessary to react it with a reagent having a long tail to which a
multiplicity of chelating groups are attached for binding the ions.
Such a tail may be a polymer such as a polylysine, polysaccharide,
or another derivatized or derivatizable chain having pendant groups
to which may be bound chelating groups such as, e.g., porphyrins,
polyamines, crown ethers, bisthiosemicarbazones, polyoximes, and
like groups known to be useful for this purpose. Chelates may be
coupled to anti-AXL antibodies using standard chemistries.
[0717] Thus, the present invention provides a diagnostic anti-AXL
antibody, wherein the anti-AXL antibody is conjugated to a contrast
agent (such as for magnetic resonance imaging, computed tomography,
or ultrasound contrast-enhancing agent) or a radionuclide that may
be, for example, a gamma-, beta-, alpha-, Auger electron-, or
positron-emitting isotope.
[0718] In a further aspect, the invention relates to a kit for
detecting the presence of AXL antigen or a cell expressing AXL, in
a sample, comprising: [0719] an anti-AXL antibody, bispecific
antibody, or immunoconjugate or ADC of the invention; and [0720]
instructions for use of the kit.
[0721] In one embodiment, the present invention provides a kit for
diagnosis of cancer comprising a container comprising an anti-AXL
antibody, and one or more reagents for detecting binding of the
anti-AXL antibody to AXL. Reagents may include, for example,
fluorescent tags, enzymatic tags, or other detectable tags. The
reagents may also include secondary or tertiary antibodies or
reagents for enzymatic reactions, wherein the enzymatic reactions
produce a product that may be visualized. In one embodiment, the
present invention provides a diagnostic kit comprising one or more
anti-AXL antibodies, of the present invention in labeled or
unlabeled form in suitable container(s), reagents for the
incubations for an indirect assay, and substrates or derivatizing
agents for detection in such an assay, depending on the nature of
the label. Control reagent(s) and instructions for use also may be
included.
[0722] Diagnostic kits may also be supplied for use with an
anti-AXL antibody, such as a conjugated/labeled anti-AXL antibody,
for the detection of the presence of AXL in a tissue sample or
host. Thus, the anti-AXL antibody according to the present
invention may also be used as, e.g. part of a, companion
diagnostic, for example as the primary antibody in an
immunohistochemistry assay designed to detect AXL expression in
solid tumor, lymph node or other tissue biopsies. Alternatively,
the anti-AXL antibodies according to the present invention may be
used as the primary antibody in a flow cytometry-based or
immunocytochemistry assay to identify AXL-expressing cells in
blood, bone marrow, fine needles aspirates, e.g. lymph node
aspirates, or peritoneal fluid to identify AXL-expressing tumor
cells. Anti-AXL antibodies according to the present invention may
be used to identify soluble AXL, e.g. in an ELISA-based assay.
Anti-AXL antibodies according to the present invention may be used
as a companion diagnostic, for instance as radioconjugates, that
can be used for imaging studies in patients. In such diagnostic
kits, as well as in kits for therapeutic uses described elsewhere
herein, an anti-AXL antibody typically may be provided in a
lyophilized form in a container, either alone or in conjunction
with additional antibodies specific for a target cell or peptide.
Typically, a pharmaceutically acceptable carrier (e.g., an inert
diluent) and/or components thereof, such as a Tris, phosphate, or
carbonate buffer, stabilizers, preservatives, biocides, inert
proteins, e.g., serum albumin, or the like, also are included
(typically in a separate container for mixing) and additional
reagents (also typically in separate container(s)). In certain
kits, a secondary antibody capable of binding to the AXL-specific
Ab, which typically is present in a separate container, is also
included. The second antibody is typically conjugated to a label
and formulated in a manner similar to the anti-AXL antibody of the
present invention. Using the methods described above and elsewhere
herein, anti-AXL antibodies may be used to define subsets of
cancer/tumor cells and characterize such cells and related tumor
tissues.
Anti-Idiotypic Antibodies
[0723] In a further aspect, the invention relates to an
anti-idiotypic antibody which binds to an anti-AXL antibody of the
invention as described herein.
[0724] An anti-idiotypic (Id) antibody is an antibody which
recognizes unique determinants generally associated with the
antigen-binding site of an antibody. An anti-Id antibody may be
prepared by immunizing an animal of the same species and genetic
type as the source of an anti-AXL monoclonal antibody with the
monoclonal antibody against which an anti-Id is being prepared. The
immunized animal typically can recognize and respond to the
idiotypic determinants of the immunizing antibody by producing an
antibody to these idiotypic determinants (the anti-Id antibody).
Such antibodies are described in for instance U.S. Pat. No.
4,699,880. Such antibodies are further features of the present
invention.
[0725] An anti-Id antibody may also be used as an "immunogen" to
induce an immune response in yet another animal, producing a
so-called anti-anti-Id antibody. An anti-anti-Id antibody may be
epitopically identical to the original monoclonal antibody, which
induced the anti-Id antibody. Thus, by using antibodies to the
idiotypic determinants of a monoclonal antibody, it is possible to
identify other clones expressing antibodies of identical
specificity. Anti-Id antibodies may be varied (thereby producing
anti-Id antibody variants) and/or derivatized by any suitable
technique, such as those described elsewhere herein with respect to
AXL-specific antibodies of the present invention. For example, a
monoclonal anti-Id antibody may be coupled to a carrier such as
keyhole limpet hemocyanin (KLH) and used to immunize BALB/c mice.
Sera from these mice typically will contain anti-anti-Id antibodies
that have the binding properties similar, if not identical, to an
original/parent anti-AXL antibody.
Sequences
TABLE-US-00001 [0726] TABLE 1 SEQ ID NO: Name Amino acid sequence
Comments SEQ ID NO: 1 107 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWV
HCo12-BalbC RQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNS Ig1 domain
KNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMV binding Ab TVSS SEQ ID NO: 2
107 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSPYTFGQGTKLEIK SEQ ID NO: 3 140 VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVR
QAPGKGLEWVSAISISGASTFYADSVKGRFTISRDNSKN
TLSLQMNSLRAEDTAVYFCRGYSGYVYDAFDIWGQGT MVTVSS SEQ ID NO: 4 140 VL
DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQ
QKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL
QPEDFATYYCQQYNSYPLTFGGGTKVEIK SEQ ID NO: 5 148 VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVR HCo12-BalbC
QAPGKGLEWVSAISISGGSTFYADSVKGRFTISRDNSKN Ig2 domain
TLYLQMNSLRAEDTAVYYCRGYSGYVYDAFDFWGQGT binding Ab MVTVSS SEQ ID NO:
6 148 VL DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQ
QKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL
QPEDFATYYCQQYNSYPLTFGGGTKVEIK SEQ ID NO: 7 154 VH
EVQLLDSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR HCo12-BalbC
QAPGKGLEWVSAISIGGGNAYYADSVKGRFTISRDNSK FN1 domain
NTLYLQMNSLRAADTAVYYCAKPGFIMVRGPLDYWG binding Ab QGALVTVSS SEQ ID
NO: 8 154-M103L VH EVQLLDSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR
QAPGKGLEWVSAISIGGGNAYYADSVKGRFTISRDNSK
NTLYLQMNSLRAADTAVYYCAKPGFILVRGPLDYWGQ GALVTVSS SEQ ID NO: 9 154 VL
EIVLTQSPGTLSLSPGERATLSCRASQSVSNSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSPYTFGQGTKLEIK SEQ ID NO: 10 171 VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR HCo17-BalbC
QAPGKGLEWVSDISVSGGSTYYADSVKGRFTISRDNSK Ig2 domain
NTLYLQMNSLRAEDTAVYYCAKEGYIWFGESLSYAFDI binding Ab WGQGTMVTVSS SEQ
ID NO: 11 171 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGRSFTFGPGTKVDIK SEQ ID NO: 12 172 VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWV
RQAPGKGLEWVSDISVSGGSTYYADSVKGRFTISRDNS
KNTLYLQMNSLRAEDTAVYYCAKEGYIWFGESLSYAFDI WGQGTMVTVSS SEQ ID NO: 13
172 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGRSFTFGPGTKVDIK SEQ ID NO: 14 181 VH
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVR
QAPGKGLEWVSDISVSGGSTYYADSVKGRFTISRDNSK
NTLYLHMNSLRAEDTAVYYCAKEGYIWFGESLSYAFDI WGQGTMVTVSS SEQ ID NO: 15
181 VH EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGRSFTFGPGTKVDIK SEQ ID NO: 16 183 VH
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWI HCo17-BalbC
RQPPGKGLEWIGEINQSGSTNYNPSLKSRVTISVDTSKN FN1 domain
QFSLKLSSVTAADTSVYYCASGNWDHFFDYWGQGTLV binding Ab TVSS SEQ ID NO: 17
183-N52Q VH QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWI
RQPPGKGLEWIGEIQQSGSTNYNPSLKSRVTISVDTSKN
QFSLKLSSVTAADTSVYYCASGNWDHFFDYWGQGTLV TVSS SEQ ID NO: 18 183 VL
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ
HKPGKAPKLLIYATSSLQSGVTSRFSGSGSGTDFTLTISSL
QPEDFATYYCQQAKSFPWTFGQGTKVEIK SEQ ID NO: 19 187 VH
QVPLQQWGAGLLKPSETLSLTCAVYGGSFSGYHWSWI
RQPPGKGLEWIGEISHSGRTNYNPSLKSRVTISIDTSKNQ
FSLKLSSVTAADTAVYYCASFITMIRGTIITHFDYWGQGT LVTVSS SEQ ID NO: 20 187
VL DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQ
KPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQ
PEDFATYYCQQYHSYPYTFGQGTKLEIK SEQ ID NO: 21 608-01 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVR
QAPGQGLEWMGRIIPIFGIANYVQKFQGRVTITADKST
STAYMELSSLRAEDTAVYYCARRGDYYGSGSPDVFDIW GQGTMVTVSS SEQ ID NO: 22
608-01 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSYTFGQGTKLEIK SEQ ID NO: 23 610-01 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVR
QAPGQGLEWMGRIIPIFGIANYVQKFQGRVTITADKST
STAYMELSSLRAEDTAVYYCARRGNYYGSGSPDVFDIW GQGTMVTVSS SEQ ID NO: 24
610-01 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSYTFGQGTKLEIK SEQ ID NO: 25 613 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWM HCo20
RQAPGQGLEWMGRIIPIFGIVNYAQKFQGRVTLTADKS Ig1 domain
TSTAYMELSSLRSEDTAVYYCARRGNYYGSGSPDVFDI binding Ab WGQGTMVTVSS SEQ
ID NO: 26 613 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSYTFGQGTKLEIK SEQ ID NO: 27 613-08 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAINWM
RQAPGQGLEWMGRIIPIFGIVNYAQKFQGRVTLTADKS
TSTAYMELSSLRSEDTAVYYCARRGNYYGSGSPDVFDI WGQGTMVTVSS SEQ ID NO: 28
613-08 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQK
PGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP
EDFAVYYCQQRSNWLTFGGGTKVEIK SEQ ID NO: 29 620-06 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVR
QAPGQGLEWMGRIIPIFGIANYAQKFQGRVTITADKST
STAYMELSSLRSEDTAVYYCARRGNYYGSGSPDVFDIW GQGTMVTVSS SEQ ID NO: 30
620-06 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSYTFGQGTKLEIK SEQ ID NO: 31 726 VH
QVQLQQWGAGLLKPSETLSLTCAIDGGSFSGYYWSWIR HCo17-BalbC
QPPGKGLEWIGEISHSGRTNYNPSLKSRVTISIDTSKNQF FN2 domain
SLKLSSVAAADTAVYYCARFITMIRGAIITHFDYWGQGA binding Ab LVTVSS SEQ ID
NO: 32 726-M101L VH QVQLQQWGAGLLKPSETLSLTCAIDGGSFSGYYWSWIR
QPPGKGLEWIGEISHSGRTNYNPSLKSRVTISIDTSKNQF
SLKLSSVAAADTAVYYCARFITLIRGAIITHFDYWGQGAL VTVSS SEQ ID NO: 33 726 VL
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQ
KPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQ
PEDFATYYCQQYHSYPYTFGQGTKLEIK SEQ ID NO: 34 733 VH
QVQLVESGGGVVQPGRSLRLSCAASGFSFSTYAMHWV HCo17-BalbC
RQAPGKGLEWVAVISYDGDNKYSADSVKGRFTISRDNS FN1 domain
KNTLYLQMNSLRAEDTAVYYCARGRKLGIDAFDIWGQ binding Ab GTMVTVSS SEQ ID
NO: 35 733 VL AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQK
PGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISGLQP
EDFATYYCQQFNSYPFTFGPGTKVDIK SEQ ID NO: 36 107 VH CDR1 GFTFSSYA SEQ
ID NO: 37 107 VH CDR2 TSGSGAST SEQ ID NO: 38 107 VH CDR3 AKIWIAFDI
SEQ ID NO: 39 107 VL CDR1 QSVSSSY 107 VL CDR2 GAS SEQ ID NO: 40 107
VL CDR3 QQYGSSPYT SEQ ID NO: 41 140 VH CDR1 GFTFSSYA SEQ ID NO: 42
140 VH CDR2 ISISGAST SEQ ID NO: 43 140 VH CDR3 RGYSGYVYDAFDI SEQ ID
NO: 44 140 VL CDR1 QGISNW 140 VL CDR2 AAS SEQ ID NO: 45 140 VL CDR3
QQYNSYPLT SEQ ID NO: 46 148 VH CDR1 GFTFSSYA SEQ ID NO: 47 148 VH
CDR2 ISISGGST SEQ ID NO: 48 148 VH CDR3 RGYSGYVYDAFDF SEQ ID NO: 49
148 VL CDR1 QGISNW 148 VL CDR2 AAS SEQ ID NO: 50 148 VL CDR3
QQYNSYPLT SEQ ID NO: 51 154 VH CDR1 GFTFSSYA SEQ ID NO: 52 154 VH
CDR2 ISIGGGNA SEQ ID NO: 53 154 VH CDR3 AKPGFIMVRGPLDY SEQ ID NO:
54 154-M103L VH AKPGFILVRGPLDY CDR3 SEQ ID NO: 55 154 VL CDR1
QSVSNSY 154 VL CDR2 GAS SEQ ID NO: 56 154 VL CDR3 QQYGSSPYT SEQ ID
NO: 57 171 VH CDR1 GFTFSSYA SEQ ID NO: 58 171 VH CDR2 ISVSGGST SEQ
ID NO: 59 171 VH CDR3 AKEGYIWFGESLSYAFDI SEQ ID NO: 60 171 VL CDR1
QSVSSSY 171 VL CDR2 GAS SEQ ID NO: 61 171 VL CDR3 QQYGRSFT SEQ ID
NO: 62 172 VH CDR1 GFTFSNYA SEQ ID NO: 63 172 VH CDR2 ISVSGGST SEQ
ID NO: 64 172 VH CDR3 AKEGYIWFGESLSYAFDI SEQ ID NO: 65 172 VL CDR1
QSVSSSY 172 VL CDR2 GAS SEQ ID NO: 66 172 VL CDR3 QQYGRSFT SEQ ID
NO: 67 181 VH CDR1 GFTFSSYA SEQ ID NO: 68 181 VH CDR2 ISVSGGST SEQ
ID NO: 69 181 VH CDR3 AKEGYIWFGESLSYAFDI SEQ ID NO: 70 181 VL CDR1
QSVSSSY 181 VL CDR2 GAS SEQ ID NO: 71 181 VL CDR3 QQYGRSFT SEQ ID
NO: 72 183 VH CDR1 GGSFSGYY SEQ ID NO: 73 183 VH CDR2 INQSGST SEQ
ID NO: 74 183-N52Q VH CDR2 IQQSGST SEQ ID NO: 75 183 VH CDR3
ASGNWDHFFDY
SEQ ID NO: 76 183 VL CDR1 QGISSW 183 VL CDR2 ATS SEQ ID NO: 77 183
VL CDR3 QQAKSFPWT SEQ ID NO: 78 187 VH CDR1 GGSFSGYH SEQ ID NO: 79
187 VH CDR2 ISHSGRT SEQ ID NO: 80 187 VH CDR3 ASFITMIRGTIITHFDY SEQ
ID NO: 81 187 VL CDR1 QGISSW 187 VL CDR2 AAS SEQ ID NO: 82 187 VL
CDR3 QQYHSYPYT SEQ ID NO: 83 608-01 VH CDR1 GGTFSSYA SEQ ID NO: 84
608-01 VH CDR2 IIPIFGIA SEQ ID NO: 85 608-01 VH CDR3
ARRGDYYGSGSPDVFDI SEQ ID NO: 86 608-01 VL CDR1 QSVSSSY 608-01 VL
CDR2 GAS SEQ ID NO: 87 608-01 VL CDR3 QQYGSSYT SEQ ID NO: 88 610-01
VH CDR1 GGTFSSYA SEQ ID NO: 89 610-01 VH CDR2 IIPIFGIA SEQ ID NO:
90 610-01 VH CDR3 ARRGNYYGSGSPDVFDI SEQ ID NO: 91 610-01 VL CDR1
QSVSSSY 610-01 VL CDR2 GAS SEQ ID NO: 92 610-01 VL CDR3 QQYGSSYT
SEQ ID NO: 93 613 VH CDR1 GGTFSSYA SEQ ID NO: 94 613 VH CDR2
IIPIFGIV SEQ ID NO: 95 613 VH CDR3 ARRGNYYGSGSPDVFDI SEQ ID NO: 96
613 VL CDR1 QSVSSSY 613 VL CDR2 GAS SEQ ID NO: 97 613 VL CDR3
QQYGSSYT SEQ ID NO: 98 613-08 VH CDR1 GGTFSSYA SEQ ID NO: 99 613-08
VH CDR2 IIPIFGIV SEQ ID NO: 100 613-08 VH CDR3 ARRGNYYGSGSPDVFDI
SEQ ID NO: 101 613-08 VL CDR1 QSVSSY 613-08 VL CDR2 DAS SEQ ID NO:
102 613-08 VL CDR3 QQRSNWLT SEQ ID NO: 103 620-06 VH CDR1 GGTFSSYA
SEQ ID NO: 104 620-06 VH CDR2 IIPIFGIA SEQ ID NO: 105 620-06 VH
CDR3 ARRGNYYGSGSPDVFDI SEQ ID NO: 106 620-06 VL CDR1 QSVSSSY 620-06
VL CDR2 GAS SEQ ID NO: 107 620-06 VL CDR3 QQYGSSYT SEQ ID NO: 108
726 VH CDR1 GGSFSGYY SEQ ID NO: 109 726 VH CDR2 ISHSGRT SEQ ID NO:
110 726 VH CDR3 ARFITMIRGAIITHFDY SEQ ID NO: 111 726-M101L VH
ARFITLIRGAIITHFDY CDR3 SEQ ID NO: 112 726 VL CDR1 QGISSW 726 VL
CDR2 AAS SEQ ID NO: 113 726 VL CDR3 QQYHSYPYT SEQ ID NO: 114 733 VH
CDR1 GFSFSTYA SEQ ID NO: 115 733 VH CDR2 ISYDGDNK SEQ ID NO: 116
733 VH CDR3 ARGRKLGIDAFDI SEQ ID NO: 117 733 VL CDR1 QGISSA 733 VL
CDR2 DAS SEQ ID NO: 118 733 VL CDR3 QQFNSYPFT SEQ ID NO: 119 Ig2
domain VH ISISGXST-wherein X is A or G CDR2 SEQ ID NO: 120 Ig2
domain VH RGYSGYVYDAFDX-wherein X is I or F CDR3 SEQ ID NO: 121 FN2
domain VH GGSFSGYX-wherein X is H or Y CDR1 SEQ ID NO: 122 FN2
domain VH AX1FITMIRGX2IITHFDY-wherein X1 is S or R; CDR3 and X2 is
T or A SEQ ID NO: 123 FN1 domain VH GFTFSXYA-wherein X is S or N
CDR1 SEQ ID NO: 124 FN1 domain VH ISVSGGST CDR2 SEQ ID NO: 125 FN1
domain VH AKEGYIWFGESLSYAFDI CDR3 SEQ ID NO: 126 Ig1 domain VH
IIPIFGIX-wherein X is A or V CDR2 SEQ ID NO: 127 Ig1 domain VH
ARRGXYYGSGSPDVFDI-wherein X is D or N CDR3 SEQ ID NO: 128 Ig1
domain VL QSVXSSY-wherein X is S or del CDR1 Ig1 domain VL
XAS-wherein X is D or G CDR2 SEQ ID NO: 129 Ig1 domain VL
QQX1X2X3X4X5T-wherein X1 is R or Y; X2 is CDR3 S or G; X3 is N or
S; X4 is W or S; and X5 is L or Y SEQ ID NO: 130 Human AXL protein
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEES (Swissprot P30530)
PFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSD
TGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDRTV
AANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHG
PQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQ
QPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLS
DDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHT
PYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISA
TRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEV
LMDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGP
WSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWY
VLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERG
ELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVD
RHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTM
KIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGS
ERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQ
MLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENM
SVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLAD
RVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDY
LRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTE
LREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGA
AGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTP SPAQPADRGSPAAPGQEDGA SEQ ID
NO: 131 Mus musculus AXL MAWRCPRMGRVPLAWCLALCGWACMYPYDVPDYAA
HKDTQTEAGSPFVGNPGNITGARGLTGTLRCELQVQGE
PPEVVWLRDGQILELADNTQTQVPLGEDWQDEWKVV
SQLRISALQLSDAGEYQCMVHLEGRTFVSQPGFVGLEG
LPYFLEEPEDKAVPANTPFNLSCQAQGPPEPVTLLWLQ
DAVPLAPVTGHSSQHSLQTPGLNKTSSFSCEAHNAKGV
TTSRTATITVLPQRPHHLHVVSRQPTELEVAWTPGLSGI
YPLTHCNLQAVLSDDGVGIWLGKSDPPEDPLTLQVSVP
PHQLRLEKLLPHTPYHIRISCSSSQGPSPWTHWLPVETTE
GVPLGPPENVSAMRNGSQVLVRWQEPRVPLQGTLLGY
RLAYRGQDTPEVLMDIGLTREVTLELRGDRPVANLTVSV
TAYTSAGDGPWSLPVPLEPWRPGQGQPLHHLVSEPPP
RAFSWPWWYVLLGAVVAAACVLILALFLVHRRKKETRY
GEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEEL
KEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQD
DSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNV
MRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRL
GDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAA
RNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMP
VKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPY
PGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWEL
NPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEG
GGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAG
RYVLCPSTTPSPAQPADRGSPAAPGQEDGA SEQ ID NO: 132 Homo sapiens AXL-
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEES Mus musculus Ig1
PFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD domain
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSD
TGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDKAV
PANTPFNLSCQAQGPPEPVTLLWLQDAVPLAPVTGHSS
QHSLQTPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQ
PRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSD
DGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHTP
YHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISAT
RNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVL
MDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPW
SLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYV
LLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGE
LVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDR
HKVALGKTLGEGEFGAVMEGQLNQDDS ILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMR
LIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGD
QPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARN
CMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVK
WIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPG
VENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNP
QDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGG
GYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRY VLCPSTTPSPAQPADRGSPAAPGQEDGA
SEQ ID NO: 133 Homo sapiens AXL-
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEES Mus musculus Ig2
PFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD domain
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSD
TGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDKAV
PANTPFNLSCQAQGPPEPVTLLWLQDAVPLAPVTGHSS
QHSLQTPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQ
PRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSD
DGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHTP
YHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISAT
RNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVL
MDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPW
SLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYV
LLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGE
LVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDR
HKVALGKTLGEGEFGAVMEGQLNQDDS ILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMR
LIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGD
QPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARN
CMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVK
WIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPG
VENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNP
QDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGG
GYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRY VLCPSTTPSPAQPADRGSPAAPGQEDGA
SEQ ID NO: 134 Homo sapiens AXL-
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEES Mus musculus
PFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD FN1 domain
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSD
TGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDRTV
AANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHG
PQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQ
RPHHLHVVSRQPTELEVAWTPGLSGIYPLTHCNLQAVLS
DDGVGIWLGKSDPPEDPLTLQVSVPPHQLRLEKLLPHTP
YHIRISCSSSQGPSPWTHWLPVETTEGVPLGPPENISAT
RNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVL
MDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPW
SLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYV
LLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGE
LVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDR
HKVALGKTLGEGEFGAVMEGQLNQDDS ILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMR
LIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGD
QPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARN
CMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVK
WIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPG
VENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNP
QDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGG
GYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRY VLCPSTTPSPAQPADRGSPAAPGQEDGA
SEQ ID NO: 135 Homo sapiens AXL-
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEES Mus musculus
PFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD FN2 domain
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSD
TGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDRTV
AANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHG
PQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQ
QPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLS
DDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHT
PYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENVS
AMRNGSQVLVRWQEPRVPLQGTLLGYRLAYRGQDTPE
VLMDIGLTREVTLELRGDRPVANLTVSVTAYTSAGDGP
WSLPVPLEPWRPGQGQPLHHLVSEPPPRAFSWPWWY
VLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERG
ELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVD
RHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTM
KIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGS
ERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQ
MLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENM
SVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLAD
RVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDY
LRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTE
LREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGA
AGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTP SPAQPADRGSPAAPGQEDGA SEQ ID
NO: 136 511 VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWV Ig2 domain
RQAPGKGLEWVSGISGSGGHTYHADSVKGRFTISRDNS binding Ab
KNTLYLQMNSLRAEDTAVYYCAKDRYDILTGYYNLLDY WGQGTLVTVSS SEQ ID NO: 137
511 VH CDR1 GFTFSSYA SEQ ID NO: 138 511 VH CDR2 ISGSGGHT SEQ ID NO:
139 511 VH CDR3 AKDRYDILTGYYNLLDY SEQ ID NO: 140 511 VL
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQ
KPEEAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQ
PEDFATYYCQQYNSYPLTFGGGAKVEIK SEQ ID NO: 141 511 VL CDR1 QGISSW 511
VL CDR2 AAS SEQ ID NO: 142 511 VL CDR3 QQYNSYPLT SEQ ID NO: 143 061
VH QVQLVQSGAEVKKPGASVKVSCKASGYAFTGYGISWVR Ig1 domain
QAPGQGLEWIGWISAYNGNTNYVQNLQDRVTMTTDT binding Ab
STSTAYMELRSLRSDDTAVYYCARDHISMLRGIIIRNYW GQGTLVTVSS SEQ ID NO: 144
061 VL EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKP
GQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPE
DFAVYYCQQRSSWPRLTFGGGTKVEIK SEQ ID NO: 145 137 VH
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYAISWVR
QAPGQGLEWMGRIIPIVGIANYAQKFQGRVTLTADKST
STAYMELSSLRSEDTAVYYCAREAGYSSSWYAEYFQHW GQGTLVTVSS SEQ ID NO: 146
137 VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQ
KPGQAPRLLIYGASSRATGFPDRFSGSGSGTDFTLTISRL
EPEDFAVYYCQQYGSSPYTFGQGTKLEIK SEQ ID NO: 147 Cynomolgus
AWRCPRMGRVPLAWCLALCGWVCMAPRGTQAEESP monkey AXL
FVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRDG (GenBank
QILELADSTQTQVPLGEDEQDDWIVVSQLRIASLQLSDA number
GQYQCLVFLGHQNFVSQPGYVGLEGLPYFLEEPEDRTV HB387229.1)
AANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHG
PQRNLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQ
QPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLS
DDGMGIQAGEPDPPEEPLTLQASVPPHQLRLGSLHPHT
PYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISA
TRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEV
LMDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGP
WSLPVPLEAWRPGQAQPVHQLVKETSAPAFSWPWW
YILLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVER
GELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMV
DRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKT
MKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQG
SERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQ
MLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENM
SVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLAD
RVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDY
LRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTE
LREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGA
AGGADPPTQLDPKDSCSCLTSAEVHPAGRYVLCPSTAPS PAQPADRGSPAAPGQEDGA
[0727] The present invention is further illustrated by the
following examples which should not be construed as further
limiting.
EXAMPLES
Example 1--Immunization and Generation of AXL Antibodies
Expression Constructs for AXL
[0728] The following codon-optimized constructs for expression of
various full-length AXL variants were generated: human (Homo
sapiens) AXL (Genbank accession no. NP_068713.2), human-cynomolgus
monkey chimeric AXL in which the human extracellular domain (ECD)
was replaced with the ECD of cynomolgus monkey (Macaca
fascicularis) AXL (translation of Genbank accession HB387229.1; aa
1-447), human-mouse chimeric AXL in which the human ECD was
replaced with the ECD of mouse (Mus musculus) AXL (Genbank
accession NP_033491.2; aa 1-441), human-mouse chimeric AXL in which
the human Ig-like domain I (aa 1-134, also termed "lgl domain"
herein) was replaced with the Ig-like domain I of mouse AXL,
human-mouse chimeric AXL in which the human Ig-like domain II (aa
148-194, also termed "Ig2 domain" herein) was replaced by the
Ig-like domain II of mouse AXL, human-mouse chimeric ALX in which
the human FNIII-like domain I (aa 227-329, also termed "FN1 domain"
herein) was replaced with the FNIII-like domain I of mouse AXL,
human-mouse chimeric AXL in which the human FNIII-like domain II
(aa 340-444, also termed "FN2 domain" herein) was replaced by the
FNIII-like domain II of mouse AXL. In addition, the following
codon-optimized constructs for various AXL ECD variants were
generated: the extracellular domain (ECD) of human AXL (aa 1-447)
with a C-terminal His tag (AXLECDHis), the FNIII-like domain II of
human AXL (aa 327-447) with a N-terminal signal peptide and a
C-terminal His tag (AXL-FN2ECDHis), and the Ig1- and Ig2-like
domains of human AXL (aa 1-227) with a C-terminal His tag
(AXL-Ig12ECDHis).
[0729] The constructs contained suitable restriction sites for
cloning and an optimal Kozak (GCCGCCACC) sequence [141]. The
constructs were cloned in the mammalian expression vector pcDNA3.3
(Invitrogen).
AXL Expression in EL4 Cells
[0730] EL4 cells were stable transfected with the pcDNA3.3 vector
containing the full human AXL coding sequence and stable clones
were selected after selection with the antibiotic agent, G418,
(Geneticin).
Purification of His-Tagged AXL
[0731] AXLECDHis, AXL-FN2ECDHis, and AXL-Ig12ECDHis were expressed
in HEK-293F cells. The His-tag enables purification with
immobilized metal affinity chromatography. In this process, a
chelator fixed onto the chromatographic resin is charged with
Co.sup.2+ cations. His-tagged protein containing supernatants were
incubated with the resin in batch mode (i.e. solution). The
His-tagged protein binds strongly to the resin beads, while other
proteins present in the culture supernatant do not bind or bind
weakly compared to the His-tagged proteins. After incubation the
beads are retrieved from the supernatant and packed into a column.
The column is washed in order to remove weakly bound proteins. The
strongly bound His-tagged proteins are then eluted with a buffer
containing imidazole, which competes with the binding of His to
Co.sup.2+. The eluent is removed from the protein by buffer
exchange on a desalting column.
Immunization
[0732] Antibodies IgG1-AXL-061, IgG1-AXL-107, IgG1-AXL-183,
IgG1-AXL-613, and IgG1-AXL-726 were derived from the following
immunizations: HCo12-BalbC (IgG1-AXL-107), HCo17-BalbC
(IgG1-AXL-183, IgG1-AXL-726) and HCo20 (IgG1-AXL-061, IgG1-AXL-613)
transgenic mice (Medarex, San Jose, Calif., USA) which were
immunized alternatingly intraperitoneally (IP) with 20 .mu.g of the
AXLECDHis protein (IgG1-AXL-511, IgG1-AXL-613, IgG1-AXL-183), 20
.mu.g AXL-FN2ECDHIS plus 20 .mu.g AXL-Ig12ECDHis (IgG1-AXL-726), or
20 .mu.g AXL-Ig12ECDHis (IgG1-AXL-107) and subcutaneously (SC; at
the tail base) with the same protein, with an interval of 14 days.
In total 8 immunizations were performed: 4 IP and 4 SC
immunizations. For most immunizations, the first immunization was
performed in complete Freunds' adjuvant (CFA; Difco Laboratories,
Detroit, Mich., USA) and all subsequent immunizations in incomplete
Freunds' adjuvant (IFA; Difco Laboratories, Detroit, Mich., USA).
Antibody IgG1-AXL-183 was derived from immunizations that were all
performed in Sigma adjuvant system (Sigma-Aldrich, St. Louis, Mo.,
USA).
[0733] Antibodies IgG1-AXL-137, IgG1-AXL-148, IgG1-AXL-154,
IgG1-AXL-171, and IgG1-AXL-733 were derived from the following
immunizations: HCo12-BalbC (IgG1-AXL-137, IgG1-AXL-148),
HCo17-BalbC (IgG1-AXL-154, IgG1-AXL-733), and HCo20-BalbC
(IgG1-AXL-171) transgenic mice (Medarex, San Jose, Calif., USA)
were immunized with 20 .mu.g of the AXLECDHis protein in CFA.
Subsequently, mice were immunized alternating intraperitoneally
(IP) with EL4 cells transfected with full length human AXL in PBS
and subcutaneously (SC; at the tail base) with the AXLECDHis
protein in IFA, with an interval of 14 days.
[0734] Mice with at least two sequential AXL specific antibody
titers of 200 (serum dilutions of 1/200) or higher, detected in the
antigen specific screening FMAT assay as described below, were
boosted 3-4 days prior to fusion (10 .mu.g of AXL-derived protein
in PBS injected intravenously).
Homogeneous Antigen Specific Screening Assay
[0735] The presence of anti-AXL antibodies in sera of immunized
mice or HuMab (human monoclonal antibody) hybridoma or transfectoma
culture supernatant was determined by homogeneous antigen specific
screening assays using Fluorometric Micro volume Assay Technology
(FMAT; Applied Biosystems, Foster City, Calif., USA). For this, two
different test designs with combinations of either 4 or 8 cell
based assays were used.
[0736] The 4 cell based assay test design was used for the testing
of sera from immunized mice and as primary screening test for
hybridoma or transfectoma culture supernatant. In the 4 assay test
design samples were analyzed for binding of human antibodies to
A431 (DSMZ) and MDA-MB-231 cells (both expressing AXL at the cell
surface) as well as binding to TH1021-AXL (HEK-293F cells
transiently expressing full length human AXL; produced as described
above) and HEK293 wild-type cells (negative control which does not
express AXL), respectively.
[0737] Hybridoma or transfectoma culture supernatant samples were
additionally subjected to an 8 cell based assay test design. In the
8 assay test design samples were analyzed for binding of human
antibodies to TH1021-hAXL (HEK-293F cells transiently expressing
the human AXL), TH1021-cAXL (HEK-293F cells transiently expressing
human-cynomolgus AXL chimeras in which the human ECD had been
replaced with the ECD of cynomolgus monkey AXL), TH1021-mAXL
(HEK-293F cells transiently expressing human-mouse AXL chimeras in
which the human ECD had been replaced with the ECD of mouse AXL),
TH1021-mIg1 (HEK-293F cells transiently expressing the human AXL
with the Ig-like domain I being replaced by the Ig-like domain I of
mouse AXL), TH1021-mIg2 (HEK-293F cells transiently expressing
human AXL with the Ig-like domain II being replaced by the Ig-like
domain II of mouse AXL), TH1021-mFN1 (HEK-293F cells transiently
expressing human AXL with the FNIII-like domain I being replaced by
the FNIII-like domain I of mouse AXL), TH1021-mFN2 (HEK-293F cells
transiently expressing human AXL with the FNIII-like domain II
being replaced by the FNIII-like domain II of mouse AXL), and
HEK293 wild-type cells (negative control which does not express
AXL), respectively.
[0738] Samples were added to the cells to allow binding to AXL.
Subsequently, binding of HuMab was detected using a fluorescent
conjugate (Goat anti-Human IgG Fc gamma-DyLight649; Jackson
ImmunoResearch). The AXL specific humanized mouse antibody A0704P
(produced in HEK-293F cells) was used as a positive control and
HuMab-mouse pooled serum and ChromPure Human IgG, whole molecule
(Jackson ImmunoResearch), respectively, were used as negative
controls. The samples were scanned using an Applied Biosystems 8200
Cellular Detection System (8200 CDS) and mean fluorescence was used
as read-out. Samples were stated positive when counts were higher
than 50 and counts x fluorescence was at least three times higher
than the negative control.
HuMab Hybridoma Generation
[0739] The HuMab mouse with sufficient antigen-specific titer
development (described above) was sacrificed and the spleen and
lymph nodes flanking the abdominal aorta and vena cava were
collected. Fusion of splenocytes and lymph node cells to a mouse
myeloma cell line (SP2.0 cells) was done by electrofusion using a
CytoPulse CEEF 50 Electrofusion System (Cellectis, Paris, France),
essentially according to the manufacturer's instructions. Next, the
primary wells were sub-cloned using the ClonePix system (Genetix,
Hampshire, UK). To this end, specific primary well hybridomas were
seeded in semisolid medium made from 40% CloneMedia (Genetix,
Hampshire, UK) and 60% HyQ 2.times. complete media (Hyclone,
Waltham, USA). The sub clones were retested according to the
antigen-specific binding assay as described above and scanned using
the IsoCyte sytem (Molecular Devices, LLC, Sunnyvale, Calif.). IgG
levels were measured using an Octet (Fortebio, Menlo Park, USA) in
order to select the best producing clone per primary well for
further expansion. Further expansion and culturing of the resulting
HuMab hybridomas were done based upon standard protocols (e.g. as
described in Coligan J. E., Bierer, B. E., Margulies, D. H.,
Shevach, E. M. and Strober, W., eds. Current Protocols in
Immunology, John Wiley & Sons, Inc., 2006). Clones derived by
this process were designated PC1021.
Mass Spectrometry of Purified Antibodies
[0740] Small 0.8 ml aliquots of antibody containing hybridoma
supernatant from 6-well or Hyperflask stage were purified using
PhyTip columns containing Protein G resin (PhyNexus Inc., San Jose,
USA) on a Sciclone ALH 3000 workstation (Caliper Lifesciences,
Hopkinton, USA). The PhyTip columns were used according to
manufacturer's instructions, but buffers were replaced by: Binding
Buffer PBS (B. Braun, Medical B.V., Oss, Netherlands) and Elution
Buffer 0.1M Glycine-HCl pH 2.7 (Fluka Riedel-de Haen, Buchs,
Germany). After purification, samples were neutralized with 2M
Tris-HCl pH 9.0 (Sigma-Aldrich, Zwijndrecht, Netherlands).
Alternatively, in some cases larger volumes of culture supernatant
were purified using Protein A affinity column chromatography.
[0741] After purification, the samples were placed in a 384-well
plate (Waters, 100 .mu.l square well plate, part #186002631).
Samples were deglycosylated overnight at 37.degree. C. with
N-glycosidase F. DTT (15 mg/ml) was added (1 .mu.l/well) and
incubated for 1 h at 37.degree. C. Samples (5 or 6 .mu.l) were
desalted on an Acquity UPLC.TM. (Waters, Milford, USA) with a
BEH300 C18, 1.7 .mu.m, 2.1.times.50 mm column at 60.degree. C. MQ
water and LC-MS grade acetonitrile (Biosolve, cat no 01204101,
Valkenswaard, The Netherlands) with both 0.1% formic acid (Fluka,
cat no 56302, Buchs, Germany), were used as Eluent A and B,
respectively. Time-of-flight electrospray ionization mass spectra
were recorded on-line on a micrOTOF.TM. mass spectrometer (Bruker,
Bremen, Germany) operating in the positive ion mode. Prior to
analysis, a 900-3000 m/z scale was calibrated with ES tuning mix
(Agilent Technologies, Santa Clara, USA). Mass spectra were
deconvoluted with DataAnalysis.TM. software v. 3.4 (Bruker) using
the Maximal Entropy algorithm searching for molecular weights
between 5 and 80 kDa.
[0742] After deconvolution the resulting heavy and light chain
masses (under reducing conditions) for all samples were compared in
order to find duplicate antibodies. In the comparison of the heavy
chains the possible presence of C-terminal lysine variants was
taken into account. This resulted in a list of unique antibodies,
where unique is defined as a unique combination of heavy and light
chains. In case duplicate antibodies were found, the results from
other tests were used to decide which antibody was the best
material to continue experiments with.
Sequence Analysis of the AXL Antibody Variable Domains and Cloning
in Expression Vectors
[0743] Total RNA was prepared from 0.2 to 5.times.10.sup.6
hybridoma cells and 5'-RACE-Complementary DNA (cDNA) was prepared
from 100 ng total RNA, using the SMART RACE cDNA Amplification kit
(Clontech), according to the manufacturer's instructions. VH and VL
coding regions were amplified by PCR and cloned directly, in frame,
in the pGlf and pKappa expression vectors, by ligation independent
cloning (Aslanidis, C. and P. J. de Jong, Nucleic Acids Res 1990;
18(20): 6069-74). For each antibody, 12 VL clones and 12 VH clones
were sequenced. The resulting sequences are shown in the Table 1.
CDR sequences were defined according to IMGT [22] and [23]. Clones
with a correct Open Reading Frame (ORF) were selected for further
study and expression. Vectors of all combinations of heavy chains
and light chains that were found were transiently co-expressed in
Freestyle.TM. 293-F cells using 293fectin.
[0744] For antibodies IgG1-AXL-154, IgG1-AXL-183 and IgG1-AXL-726,
the following variants with point mutations in the variable domains
were generated: IgG1-AXL-154-M103L, IgG1-AXL-183-N52Q and
IgG1-AXL-726-M101L. Mutants were generated by site-directed
mutagenesis using the Quickchange II mutagenesis kit
(Stratagene).
AXL Control Antibodies
[0745] In some of the Examples a comparison antibody against AXL
was used (IgG1-YW327.6S2) that have been previously described [142]
and [143]. The VH and VL sequences for these AXL-specific
antibodies were cloned into the pG1f and pKappa expression
vectors.
b12 Antibody
[0746] In some of the examples the antibody b12, a gp120 specific
antibody [144] was used as a negative control.
Expression
[0747] Antibodies were expressed as IgG1,.kappa.. Plasmid DNA
mixtures encoding both heavy and light chains of antibodies were
transiently transfected to Freestyle HEK293F cells (Invitrogen, US)
using 293fectin (Invitrogen, US) essentially as described by the
manufacturer.
Purification of Antibodies
[0748] Culture supernatant was filtered over 0.2 .mu.m dead-end
filters, loaded on 5 mL MabSelect SuRe columns (GE Health Care) and
eluted with 0.1 M sodium citrate-NaOH, pH 3. The eluate was
immediately neutralized with 2M Tris-HCl, pH 9 and dialyzed
overnight to 12.6 mM NaH2PO4, 140 mM NaCl, pH 7.4 (B. Braun).
Alternatively, subsequent to purification, the eluate was loaded on
a HiPrep Desalting column and the antibody was exchanged into 12.6
mM NaH2PO4, 140 mM NaCl, pH 7.4 (B. Braun) buffer. After dialysis
or exchange of buffer, samples were sterile filtered over 0.2 .mu.m
dead-end filters. Purity was determined by SDS-PAGE and IgG
concentration was measured using an Octet (Fortebio, Menlo Park,
USA). Purified antibodies were stored at 4.degree. C.
[0749] The antibody IgG1-AXL-511 was generated by the following
method:
Expression Constructs for AXL
[0750] The following codon-optimized constructs for expression of
various full-length AXL variants were generated: human (Homo
sapiens) AXL (Genbank accession no. NP_068713.2), human-cynomolgus
monkey chimeric AXL in which the human extracellular domain (ECD)
was replaced with the ECD of cynomolgus monkey (Macacafascicularis)
AXL (translation of Genbank accession HB387229.1; aa 1-447),
human-mouse chimeric AXL in which the human ECD was replaced with
the ECD of mouse (Mus musculus) AXL (Genbank accession NP_033491.2;
aa 1-441), human-mouse chimeric AXL in which the human Ig-like
domain I (aa 1-147, also termed "lgl domain" herein) was replaced
with the Ig-like domain I of mouse AXL, human-mouse chimeric AXL in
which the human Ig-like domain II (aa 148-227, also termed "Ig2
domain" herein) was replaced by the Ig-like domain II of mouse AXL,
human-mouse chimeric ALX in which the human FNIII-like domain I (aa
228-326, also termed "FN1 domain" herein) was replaced with the
FNIII-like domain I of mouse AXL, human-mouse chimeric AXL in which
the human FNIII-like domain II (aa 327-447, also termed "FN2
domain" herein) was replaced by the FNIII-like domain II of mouse
AXL. In addition, the following codon-optimized constructs for
various AXL ECD variants were generated: the extracellular domain
(ECD) of human AXL (aa 1-447) with a C-terminal His tag
(AXLECDHis), the FNIII-like domain II of human AXL (aa 327-447)
with a N-terminal signal peptide and a C-terminal His tag
(AXL-FN2ECDHis), and the Ig1- and Ig2-like domains of human AXL (aa
1-227) with a C-terminal His tag (AXL-Ig12ECDHis).
[0751] The constructs contained suitable restriction sites for
cloning and an optimal Kozak (GCCGCCACC) sequence (Kozak et al.
(1999) Gene 234: 187-208). The constructs were cloned in the
mammalian expression vector pcDNA3.3 (Invitrogen).
AXL Expression in EL4 Cells
[0752] EL4 cells were stable transfected with the pcDNA3.3 vector
containing the full length human AXL coding sequence and stable
clones were selected after selection with the antibiotic agent,
G418, (Geneticin).
Purification of His-Tagged AXL
[0753] AXLECDHis, AXL-FN2ECDHis, and AXL-Ig12ECDHis were expressed
in HEK293F cells and purified with immobilized metal affinity
chromatography.
Immunization
[0754] Material from 4 transgenic mice expressing human antibody
gene sequences was used for selecting antibodies. Mice immunized
with various immunization protocols and with various antibody
responses and yielding various numbers of antibodies from the
traditional hybridoma process were chosen. Mouse A (3.5% hits in
the hybridoma process) was an HCo17-BALB/c transgenic mouse
(Bristol-Myers Squibb, Redwood City, Calif., USA) was immunized
alternatingly intraperitoneally (IP) with 20 .mu.g AXL-FN2ECDHIS
plus 20 .mu.g AXL-Ig12ECDHis) and subcutaneously (SC) at the tail
base) with the same protein, with an interval of 14 days. In total
8 immunizations were performed: 4 IP and 4 SC immunizations. For
most immunizations, the first immunization was performed in
complete Freunds' adjuvant (CFA; Difco Laboratories, Detroit,
Mich., USA) and all subsequent immunizations in incomplete Freunds'
adjuvant (IFA; Difco Laboratories, Detroit, Mich., USA). Mouse B
(0% hits in the hybridoma process) was a HCo12 transgenic mouse
(Medarex) immunized with 20 .mu.g of the AXLECDHis protein using a
similar immunization protocol as mouse A. Mouse C (38% hits in the
hybridoma process) was a HCo12-BALB/c mouse immunized alternating
intraperitoneally (IP) with EL4 cells transfected with full length
human AXL in PBS and subcutaneously (SC; at the tail base) with the
AXLECDHis protein in IFA, with an interval of 14 days. Mouse D (0%
hits in the hybridoma process) was a HCo12 transgenic mouse
(Medarex) immunized with 20 .mu.g of the AXL-Ig12ECDHis protein in
using a similar immunization protocol as mouse A.
[0755] Mice with at least two sequential AXL specific antibody
titers of 200 (serum dilutions of 1/200) or higher, were boosted
3-4 days prior to fusion (10 .mu.g of AXL-derived protein in PBS
injected intravenously).
Isolation of RNA from Spleen Cells
[0756] Total RNA was isolated from spleen cells using the Mini RNA
easy kit (Qiagen). First strand cDNA for 5'-RACE was synthesized
using 150 ng of RNA using the SMART RACE cDNA Amplification kit
(Clontech, Mountain View, Calif., USA), PrimeScript Reverse
Transcriptase (Clontech) and the SMART IIA oligo and oligodT as
primers. VL encoding regions were amplified by PCR using Advantage
2 polymerase (Clontech), the primers RACEkLIC4shortFW2 (320 nM),
RACEkLIC4LongFW2 (80 nM) and RACEkLICRV_PmlA3 (400 nM), performing
35 cycles of 30 seconds at 95.degree. C., and 1 minute at
68.degree. C. VH encoding regions were amplified by PCR using Pfu
Ultra II Fusion HS DNA polymerase (Stratagene), the primers
RACEG1LIC3shortFW (320 nM), RACEG1LIC3longFW (80 nM) and
RACEG1LIC3RV2 (400 nM), performing 40 cycles of 20 seconds at
95.degree. C., 20 seconds at 66.degree. C. and 30 seconds at
72.degree. C., ending with a finale extension step of 3 minutes at
72.degree. C. VH or VL encoding PCR products were separated using
agarose gel electrophoresis and DNA products of the expected size
were cut from the gel and purified using the Qiagen MiniElute kit.
VH and VL coding regions amplified by PCR were cloned, in frame, in
the mammalian expression vectors pG1f (containing the human IgG1
constant region encoding DNA sequence) for the VH region and pKappa
(containing the kappa light chain constant region encoding DNA
sequence) for the VL region, by ligation independent cloning
(Aslanidis, C. and P. J. de Jong, Nucleic Acids Res 1990; 18(20):
6069-74) in E. coli strain DH5.alpha.T1R (Life technologies),
yielding single bacterial colonies each containing a single HC or
LC expression vector.
Primer sequences
TABLE-US-00002 Primer name Primer sequence SMARTIIA
5'-AAGCAGTGGTATCAACGCAGAGTACGCG GG RACEkLIC4shortFW2
5'-ACGGACGGCAGGACCACT RACEkLIC4LongFW2
5'-ACGGACGGCAGGACCACTAAGCAGTGGT ATCAACGCAGA RACEkLICRV_PmlA3
5'-CAGCAGGCACACCACTGAGGCAGTTCCA GATTTC RACEG1LIC3shortFW
5'-ACGGACGGCAGGACCAGT RACEG1LIC3longFW
5'-ACGGACGGCAGGACCAGTAAGCAGTGGT ATCAACGCAGAGT RACEG1LIC3RV2
5'-GGAGGAGGGCGCCAGTGGGAAGACCGA CMV P f (RRA2)
5'-GCCAGATATACGCGTTGACA TK pA r (RRA2) 5'-GATCTGCTATGGCAGGGCCT
LEE PCR
[0757] Linear expression elements (LEE's) were produced by
amplifying the fragment containing the CMV promoter, HC or LC
encoding regions and the poly A signal containing elements from the
expression plasmids. For this the regions were amplified using
Accuprime Taq DNA polymerase (Life Technologies) and the primers
CMVPf(Bsal)2 and TkpA(Bsal)r, performing 35 cycles of 45 seconds at
94.degree. C., 30 seconds at 55.degree. C. and 2 (LC) or 3 (HC)
minutes at 68.degree. C., using material of E. coli (strain DH5a)
colonies, containing the plasmids, as a DNA template.
Transient Expression in HEK-293 Cells
[0758] Antibodies were expressed as IgG1,.kappa.. Plasmid DNA
mixtures encoding both heavy and light chains of antibodies were
transiently transfected in Freestyle 293-F (HEK293F) cells (Life
technologies, USA) using 293fectin (Life technologies) essentially
as described by Vink, T., et al. (2014) (`A simple, robust and
highly efficient transient expression system for producing
antibodies`, Methods, 65 (1), 5-10).
[0759] For LEE expression of Abs 1 .mu.l of the HC LEE PCR reaction
mixture, 1 .mu.l of the LC PCR reaction mixture and 1 .mu.l of a 30
ng/.mu.l enhancing mix containing a mix of 3 expression enhancing
plasmids as described in Vink, T., et al. (2014), were mixed and
transfected in HEK293F cells in a total volume of 100 .mu.l using
293 fectin as transfection reagent, according to the instructions
of the manufacturer (Life technologies), using 96 well plates as
vessel, essentially as described supra.
AXLECDHis ELISA
[0760] ELISA plates (Greiner, Netherlands) were coated with 100
.mu.l/well of 0.5 .mu.g/ml AXLECDHis in Phosphate buffered saline
(PBS) and incubated for 16 hours at room temperature (RT). The
coating solution was removed and the wells were blocked by adding
150 .mu.l PBSTC (PBS containing 0.1% tween-20 and 2% chicken serum)
well and incubating for 1 hour at RT. The plates were washed three
times with 300 .mu.l PBST (PBS containing 0.1% tween-20)/well and
100 .mu.l of test solution was added, followed by an incubation of
1 hour at RT. After washing three times with 300 .mu.l of
PBST/well, 100 .mu.l antibody goat anti human IgG coupled with
horse radish peroxidase (diluted 1/3000) was added and incubated
for 1 hour at RT. After washing three times with 300 .mu.l of
PBST/well, 100 .mu.l of ABTS (1 mg/ml) solution was added and
incubated at RT until sufficient signal was observed and the
reaction was stopped by adding 100 l of 2% oxalic acid solution. 96
well plates were measured on an ELISA reader at 405 nm.
Diversity Screen
[0761] Samples were analyzed for binding of antibodies to
TH1021-hAXL (HEK293F cells transiently expressing the human AXL),
TH1021-cAXL (HEK293F cells transiently expressing human-cynomolgus
AXL chimeras in which the human ECD had been replaced with the ECD
of cynomolgus monkey AXL), TH1021-mAXL (HEK293F cells transiently
expressing human-mouse AXL chimeras in which the human ECD had been
replaced with the ECD of mouse AXL), TH1021-mIg1 (HEK293F cells
transiently expressing the human AXL with the Ig-like domain I
being replaced by the Ig-like domain I of mouse AXL), TH1021-mIg2
(HEK293F cells transiently expressing human AXL with the Ig-like
domain II being replaced by the Ig-like domain II of mouse AXL),
TH1021-mFN1 (HEK293F cells transiently expressing human AXL with
the FNIII-like domain I being replaced by the FNIII-like domain I
of mouse AXL), TH1021-mFN2 (HEK293F cells transiently expressing
human AXL with the FNIII-like domain II being replaced by the
FNIII-like domain II of mouse AXL), and HEK293F cells (negative
control which does not express AXL), respectively.
[0762] Samples from the LEE expression were added to the cells to
allow binding to the various AXL constructs. Subsequently, binding
of antibodies was detected using a fluorescent conjugate (Goat
anti-Human IgG Fc gamma-DyLight649; Jackson ImmunoResearch). The
samples were scanned using an Applied Biosystems 8200 Cellular
Detection System (8200 CDS) and mean fluorescence was used as
read-out. Samples were stated positive when counts were higher than
50 and counts x fluorescence was at least three times higher than
the negative control.
Provision of HC and LC Pools:
[0763] For each mouse, 352 HC expression vector containing
bacterial colonies and 384 LC expression vector containing
bacterial colonies were picked and amplified by LEE PCR. Part of
the LEE reaction was sequenced (AGOWA). The percentage proper VH
insert containing constructs differed largely between the 4 mice,
mouse A (50%), mouse B (23%), mouse C (90%) and mouse D (14%) and
resembled the variation of hits obtained in the hybridoma process,
see supra. The HC diversity in the mice with only a limited amount
of proper inserts were dominated by a large group of identical HCs,
65/83 in mouse B and 46/49 in mouse D. For mouse B and D the unique
HCs (9 for mouse B, 4 for mouse D) were selected. For mouse A and C
no selection was made.
Co-Transfection of HCs with a LC Pool
[0764] The single HC encoding LEE's were co-transfected with a pool
of 96 LC encoding LEE's using the LEE transfection protocol.
HC Selection of AXL Binding Antibodies
[0765] For mouse B and D, supernatants from the LEE
co-transfections of the single HC with the pooled LCs were analyzed
for AXL binding of the produced antibody mixtures by the AXL ELISA.
7 of the 9 HCs from mouse B resulted in AXL binding and 4 out of 4
of the HC from mouse D resulted in AXL binding.
[0766] For mouse A and C supernatants from the LEE co-transfections
of the single HC with the pooled LCs were analyzed for AXL binding
of the produced antibody mixtures by the diversity screen.
[0767] This screen enabled both the identification of AXL binding
HCs and a rough epitope mapping, by identifying the loss of binding
of antibodies to AXL variants. From mouse A approximately 40% of
the HCs bound to human AXL, most of which lost binding either to
the Ig1 or FNIII-2 domain, when these domains were replaced by the
mouse equivalent. From mouse C approximately 70% of the HCs bound
to human AXL, most of which lost binding either to the Ig1 or Ig2
domain, when these domains were replaced by the mouse equivalent.
Based on binding as determined by AXL ELISA or the diversity
screen, HC sequence information and loss of binding to specific AXL
domains in the diversity screen a total of 12 unique HCs were
selected for determination of the best LC.
Co-Transfection of HCs with Single LCs
[0768] Each single HC LEE of the 12 unique selected HCs was
co-transfected with 96 single LC LEEs from the LC pool of the
corresponding mice.
LC Selection of AXL Binding Antibodies
[0769] Supernatants of the LEE expression of the single HC/LC
combinations were analyzed for AXL binding of the produced antibody
by the AXL ELISA. For each HC at least 6 LCs were found and a
single LC was selected as best, based on both the ELISA results and
the LC sequence information. AXL binding antibodies were identified
from all 4 mice, even the mice which were not successful in the
hybridoma process.
Binding Affinity of Antibody 511
[0770] The affinity of one anti-AXL antibody (clone 511) was
determined.
[0771] Affinity was determined using Bio-Layer Interferometry on a
ForteBio OctetRED384. Anti-human Fc Capture (AHC) biosensors
(ForteBio, Portsmouth, UK; cat no. 18-5064) were loaded for 150 s
with hIgG (1 .mu.g/mL) aiming at a loading response of 1 nm. After
a baseline (150 s) the association (1000 s) and dissociation (2000
s) of AXLECDHis (as described in Example 1) was determined, using a
concentration range of 10 .mu.g/mL-0.16 .mu.g/mL (218 nM-3 nM) with
2-fold dilution steps. For calculations, the theoretical molecular
mass of AXLECDHis based on the amino acid sequence was used, i.e.
46 kDa. Experiments were carried out on an OctetRED384, while
shaking at 1000 rpm and at 30.degree. C. Each antibody was tested
in three independent experiments.
[0772] Data was analyzed with ForteBio Data Analysis Software
v7.0.3.1, using the 1:1 model and a global full fit with 1000 s
association time and 1000 s dissociation time unless stated
otherwise. A dissociation time of 1000 s (instead of the 2000 s
dissociation time that was acquired) was used since this resulted
in better fits. Data traces were corrected by subtraction of a
reference curve (antibody without AXLECDHis), the Y-axis was
aligned to the last 5 s of the baseline, and interstep correction
as well as Savitzky-Golay filtering was applied.
[0773] The affinity (K.sub.D) of clone 511 for AXL was
23*10.sup.-9M (k.sub.on 1.7*10.sup.5 1/Ms and a k.sub.dis of
3.9*10.sup.-3 1/s).
Duostatin-3 Synthesis.
Preparation of Compound 3:
##STR00005##
[0775] To a solution of Boc-L-phenylalanine 1 (5.36 g, 20.2 mmol)
in 30 mL of methylene chloride (DCM), carbonyldiimidazole (CDI,
4.26 g, 26.3 mmol) was added and stirred for 1 hour. Then added a
solution of 2 (3.67 g, 30.3 mmol) and 2,4-diaminobutyric acid (DBU,
4.5 mL, 30 mmol) in 15 mL of DCM. The mixture was heated at
40.degree. C. for 16 hours. The mixture was diluted with 60 mL of
DCM and 40 mL of water, then neutralized to pH 7 with conc. HCl.
The DCM extract was collected, washed with 0.2M HCl (60 mL), then
with brine (60 mL), dried over Na2SO4, and evaporated to give 7.47
g of Boc protected sulfonamide. This material was suspended in 40
mL of methanol, then 200 mL of 6N HCl/isopropanol was added and the
mixture was stirred for 2 hours. The solvent was evaporated under
vacuum, 100 mL of ether was then added. The precipitate was
collected by filtration and dried to give compound 3 as HCl salt
(5.93 g, 96%); MS m/z 269.1 (M+H).
Preparation of Compound 5:
##STR00006##
[0777] To a solution of compound 4 (1.09 g, 1.6 mmol) in 10 mL of
N,N-Dimethylformamide (DMF) was added
2-(IH-7-azabenzotriazol-1-yl)-I,I,3,3-tetramethyl uranium
hexafluorophosphate (HATU, 0.61 g, 1.6 mmol), diisopropylethylamine
(DIEA, 0.56 mL), and compound 3 (0.49 g, 1.6 mmol) in that order.
The mixture was stirred for 1 hour and diluted with 100 mL of water
and 4 mL of acetic acid. The precipitate was collected by
filtration, dried under vacuum and added to 10 mL of 4M
HCl/dioxane. After 30 min, 200 mL of ether was added and insoluble
precipitate was collected and purified by HPLC to give compound 5
as tetrahydrofuran salt (TFA, 1.3 g, 88%); MS m/z 835.5 (M+H).
Compound 5 is referred to as duostatin-3 throughout the
manuscript.
Preparation of Compound 7:
##STR00007##
[0779] To a solution of compound 5 (500 mg, 0.527 mmol) in 5 mL of
DMF was added compound 6 (483 mg, 0.631 mmol),
N-Hydroxybenzotriazole (HOBt, 40 mg, 0.296 mmol), and DIEA (0.27
mL). The mixture was stirred for 16 hours after which 0.4 mL of
piperidine was added. After 1 hour, the mixture was diluted with
100 mL of ether and the precipitate was collected and dried to give
compound 7 as HCl salt (640 mg, 95%); MS m/z 1240.7 (M+H).
Preparation of Compound 9:
##STR00008##
[0781] To a solution of compound 8 (219 mg, 0.62 mmol) in 5 mL of
DMF was added HATU (236 mg, 0.62 mmol), DIEA (0.15 mL), and
compound 7 (316 mg, 1.6 mmol), respectively. After 1 hour, 0.2 mL
of piperidine was added and the mixture was stirred for 30 min,
then purified by HPLC to give compound 9 as TFA salt (235 mg, 64%);
MS m/z 1353.8 (M+H).
Preparation of Compound 11:
##STR00009##
[0783] To a solution of compound 9 (235 mg, 0.16 mmol) in 2 mL of
methanol and 1 mL of water was added a solution of dialdehyde 10
(1.6 mL of 0.3M in iPrOH) and NaCNBH3 (180 mg, 2.85 mmol). The
mixture was stirred for 2 hours at RT, and then purified by HPLC
giving rise to compound 11 as TFA salt (126 mg, 50%); MS m/z 1465.8
(M+H)
[0784] Generation of AXL-specific antibody-drug conjugates
(ADC).
[0785] Purified AXL antibodies IgG1-AXL-148, IgG1-AXL-183 and
IgG1-AXL-726 as well as the negative control antibody IgG1-b12 were
conjugated with Duostatin-3 by Concortis Biosystems, Inc. (San
Diego, Calif.) through covalent conjugation using the K-lock
AV1-valine-citruline (vc) linker [58], [148], and [149].
[0786] The anti-AXL antibody drug conjugates were subsequently
analyzed for concentration (by absorbance at 280 nm), the drug to
antibody ratio (the `DAR`) by reverse phase chromatography
(RP-HPLC) and hydrophobic interaction chromatography (HIC), the
amount of unconjugated drug (by reverse phase chromatography), the
percentage aggregation (by size-exclusion chromatography, SEC-HPLC)
and the endotoxin levels (by LAL). The results were as follows
(Table 2):
TABLE-US-00003 TABLE 2 IgG1-AXL-148- IgG1-AXL-183- IgG1-AXL-726-
IgG1-b12- vcDuostatin3 vcDuostatin3 vcDuostatin3 vcDuostatin3
Concentration 6.57 3.40 5.93 3.36 (mg/mL) DAR by HIC-HPLC 1.71 1.79
1.77 2.05 % unconjugated drug 6.67 4.16 5.38 4.19 % aggregate by
SEC-HPLC 3.71% 3.35 3.42 1.75
Example 2--Binding Characteristics of AXL Antibodies
Binding Affinity of AXL Antibodies
[0787] The affinities of the panel of 9 anti-AXL antibodies as well
as 3 variants of these antibodies with single amino acid mutations
in the variable domains (IgG1-AXL-154-M103L, IgG1-AXL-183-N52Q,
IgG1-AXL-726-M101L), were determined.
[0788] Affinities were determined using Bio-Layer Interferometry on
a ForteBio OctetRED384. Anti-human Fc Capture (AHC) biosensors
(ForteBio, Portsmouth, UK; cat no. 18-5064) were loaded for 150 s
with hIgG (1 .mu.g/mL) aiming at a loading response of 1 nm. After
a baseline (150 s) the association (1000 s) and dissociation (2000
s) of AXLECDHis (as described in Example 1) was determined, using a
concentration range of 10 .mu.g/mL-0.16 .mu.g/mL (218 nM-3 nM) with
2-fold dilution steps. For calculations, the theoretical molecular
mass of AXLECDHis based on the amino acid sequence was used, i.e.
46 kDa. Experiments were carried out on an OctetRED384, while
shaking at 1000 rpm and at 30.degree. C. Each antibody was tested
in three independent experiments.
[0789] Data was analyzed with ForteBio Data Analysis Software
v7.0.3.1, using the 1:1 model and a global full fit with 1000 s
association time and 1000 s dissociation time unless stated
otherwise. A dissociation time of 1000 s (instead of the 2000 s
dissociation time that was acquired) was used since this resulted
in better fits. For antibody IgG1-AXL-154 and IgG1-AXL-154-M103L a
dissociation time of 500 s was used. For IgG1-AXL-012 and
IgG1-AXL-094 dissociation times of 200 s were used. Data traces
were corrected by subtraction of a reference curve (antibody
without AXLECDHis), the Y-axis was aligned to the last 5 s of the
baseline, and interstep correction as well as Savitzky-Golay
filtering was applied.
[0790] The affinities (K.sub.D) of the anti-AXL antibodies ranged
from 0.3*10.sup.-9M to 63*10.sup.-9M (Table 3). For mutant
IgG1-AXL-183-N52Q the K.sub.D was lower than for wild-type
IgG1-AXL-183, due to an approximately 2.5-fold higher dissociation
rate. The observed kinetics of the other two mutants were similar
to the kinetics of the wild-type IgGs.
TABLE-US-00004 TABLE 3 Binding affinity (OCTET) KD Kon Kdis
Antibody (M) (1/Ms) (1/s) IgG1-AXL-107 16 * 10.sup.-9 2.8 *
10.sup.5 4.1 * 10.sup.-3 IgG1-AXL-148 20 * 10.sup.-9 2.3 * 10.sup.5
4.4 * 10.sup.-3 IgG1-AXL-154 7.2 * 10.sup.-9 2.6 * 10.sup.5 1.9 *
10.sup.-3 IgG1-AXL-154-M103L 7.8 * 10.sup.-9 2.7 * 10.sup.5 2.0 *
10.sup.-3 IgG1-AXL-171 17 * 10.sup.-9 1.1 * 10.sup.5 1.8 *
10.sup.-3 IgG1-AXL-183 10.2 * 10.sup.-9 4.1 * 10.sup.4 4.2 *
10.sup.-4 IgG1-AXL-183-N52Q 24 * 10.sup.-9 4.2 * 10.sup.4 1.0 *
10.sup.-3 IgG1-AXL-613 1.5 * 10.sup.-9 5.4 * 10.sup.5 8.0 *
10.sup.-4 IgG1-AXL-726 0.6 * 10.sup.-9 2.4 * 10.sup.5 1.3 *
10.sup.-4 IgG1-AXL-726-M101L 0.3 * 10.sup.-9 2.1 * 10.sup.5 6.9 *
10.sup.-5 IgG1-AXL-733 63 * 10.sup.-9 1.6 * 10.sup.5 9.7 *
10.sup.-3
Binding of AXL Antibodies to Human, Mouse and Cynomolgus AXL
[0791] HEK293T cells were transiently transfected with expression
constructs for full length human AXL, human AXL with a cynomolgus
monkey extracellular domain (ECD) or human AXL with a mouse ECD
(see Example 1). Binding of HuMab-AXL antibodies to these cells was
evaluated by flow cytometry. Transfected HEK293 cells were
incubated with serial dilutions of AXL-antibodies (final
concentration range 0.0024-10 .mu.g/mL) for 30 minutes at 4.degree.
C. After washing three times in PBS/0.1% BSA/0.02% azide, cells
were incubated with R-Phycoerythrin (PE)-conjugated goat-anti-human
IgG F(ab')2 (Jackson ImmunoResearch Laboratories, Inc., West Grove,
Pa.; cat. No. 109-116-098) diluted 1/100 in PBS/0.1% BSA/0.02%
azide (final volume 100 .mu.L). Next, cells were washed twice in
PBS/0.1% BSA/0.02% azide, resuspended in 120 .mu.L PBS/0.1%
BSA/0.02% azide and analyzed on a FACS Cantoll (BD
Biosciences).
[0792] Binding curves were analyzed using non-linear regression
(sigmoidal dose-response with variable slope) using GraphPad Prism
V5.04 software (GraphPad Software, San Diego, Calif., USA).
[0793] FIG. 1A shows that the HuMab-AXL antibodies showed
dose-dependent binding to the HEK293 cells expressing human
AXL-ECD. Furthermore, HuMab-AXL antibodies recognized AXL with a
cynomolgus monkey ECD, with EC50 values in the same range as for
fully human AXL (FIG. 1B). In contrast, binding of HuMabs to AXL
with a mouse ECD was low (IgG1-AXL-107, IgG1-AXL-154,
IgG1-AXL-154-M103L, IgG1-AXL-733, IgG1-AXL-183, IgG1-AXL-183-N52Q)
or not detectable (IgG1-AXL-171, IgG1-AXL-613, IgG1-AXL-726,
IgG1-AXL-726-M101L, IgG1-AXL-148; FIG. 1C). As expected, the
negative control antibody IgG1-b12 showed (FIG. 1) no binding to
cells expressing any of the AXL variants. Table 4 shows the EC50
values and standard deviations for binding of the anti-AXL
antibodies to human AXL or human AXL with a cynomolgus AXL ECD
(determined in at least 3 experiments). EC50 values for binding to
human AXL with a mouse AXL ECD could not be determined to very low
or absent binding.
TABLE-US-00005 TABLE 4 Binding E050 (.mu.g/mL) human AXL cynomolgus
AXL Antibody Average (s.d.) Average (s.d.) IgG1-AXL-107 0.050
(0.004) 0.149 (0.021) IgG1-AXL-154 0.105 (0.003) 0.160 (0.027)
IgG1-AXL-154-M103L 0.110 (0.038) 0.161 (0.042) IgG1-AXL-171 0.073
(0.023) 0.157 (0.057) IgG1-AXL-613 0.040 (0.023) 0.146 (0.023)
IgG1-AXL-726 0.288 (0.206) 0.349 (0.160) IgG1-AXL-726-M101L 0.184
(0.117) 0.250 (0.066) IgG1-AXL-733 0.176 (0.094) 0.254 (0.114)
IgG1-AXL-148 0.094 (0.059) 0.152 (0.080) IgG1-AXL-183 0.526 (0.177)
0.309 (0.086) IgG1-AXL-183-N52Q 0.350 (0.206) 0.324 (0.121)
Competition Between AXL Antibodies and Gas6 for AXL Binding
[0794] It was tested whether the AXL ligand Gas6 interfered with
binding of the AXL antibodies to AXL. Therefore, AXL-positive A431
cells were incubated for 15 minutes at 4.degree. C. with 10 g/mL
recombinant human Gas6 (R&D Systems, Abingdon, UK; cat. No.
885-GS). Subsequently, serial dilutions of AXL antibodies were
prepared (final concentration range 0.014-10 g/mL), added to the
cells and incubated for 30 minutes at 4.degree. C. After washing
three times in PBS/0.1% BSA/0.02% azide, cells were incubated in
100 .mu.L with secondary antibody at 4.degree. C. for 30 min in the
dark. As a secondary antibody binding the Fc region,
R-Phycoerythrin (PE)-conjugated goat-anti-human IgG F(ab')2
(Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.; cat.
No. 109-116-098) diluted 1/100 in PBS/0.1% BSA/0.02% azide, was
used. Next, cells were washed twice in PBS/0.1% BSA/0.02% azide,
resuspended in 120 .mu.L PBS/0.1% BSA/0.02% azide and analyzed on a
FACS Cantoll (BD Biosciences).
[0795] Alternatively, A431 cells were pre-incubated with 10
.mu.g/mL AXL antibodies (15 minutes, 4.degree. C.) to assess if the
AXL ligand Gas6 could still bind in presence of AXL antibodies.
After antibody pre-incubation, serial dilutions of recombinant
human Gas6 (R&D Systems, Abingdon, UK; cat. No. 885-GS) were
added to the cells at final concentrations of 0.001-20 .mu.g/mL and
incubated for 30 minutes at 4.degree. C. After washing three times
in PBS/0.1% BSA/0.02% azide, cells were incubated with mouse
anti-Gas6 IgG2a (R&D Systems; cat no. MAB885) at 4.degree. C.
for 30 min. After washing three times in PBS/0.1% BSA/0.02% azide,
cells were incubated with FITC-labelled goat anti-mouse IgG (Dako,
Heverlee, Belgium; cat no. F049702) at 4.degree. C. for 30 min in
the dark. Next, cells were washed twice in PBS/0.1% BSA/0.02%
azide, resuspended in 120 .mu.L PBS/0.1% BSA/0.02% azide and
analyzed on a FACS Cantoll (BD Biosciences).
[0796] Binding curves were analyzed using non-linear regression
(sigmoidal dose-response with variable slope) using GraphPad Prism
V5.04 software (GraphPad Software, San Diego, Calif., USA).
[0797] In experiments (n=3) in which A431 cells were pre-incubated
with Gas6, the maximal binding values of anti-AXL antibodies was
comparable to antibody binding in absence of Gas6 (maximal binding
after Gas6 pre-incubation was 90-108% of binding without Gas6
pre-incubation) (Table 4). The EC50 values for AXL antibody binding
with or without Gas6 pre-incubation were in the same range, or
somewhat enhanced after Gas6 pre-incubation (Table 5).
[0798] The binding of control AXL antibody YW327.6S2 to A431 cells
was greatly reduced in the presence of Gas6 compared to binding
without Gas. Maximal binding of YW327.6S2 in the presence of Gas6
was 19% of binding without Gas6, and the EC50 value for binding to
A431 cells was 21-fold higher when cells had been pre-incubated
with Gas6.
[0799] In experiments in which A431 cells were pre-incubated with
anti-AXL antibodies, Gas6 binding was evaluated (n=3). Binding of
Gas6 to A431 cells was similar with or without pre-incubation with
HuMab-AXL antibodies. Average EC50 concentrations of Gas6 binding
when cells were pre-incubated with HuMabs (0.34-0.83 g/mL) and
maximal Gas6 binding were similar to Gas6 binding in the presence
of negative control antibody b12 (EC50 concentration: 0.40 g/mL;
95-115% of Gas6 binding in the presence of the b12 control
antibody). The binding of Gas6 to A431 cells was greatly reduced in
the presence of control AXL antibody YW327.6S2 compared to
pre-incubation with b12 (the EC50 concentration was 14-fold
higher). Maximal binding of Gas6 in the presence of control
antibody YW327.6S2 was 17% of binding in the presence of negative
control antibody b12.
TABLE-US-00006 TABLE 5 Antibody binding to A431 cells Gas6 binding
to A431 cells Maximal binding in Maximal binding presence of in
presence of EC50 in Gas6 (% of EC50 in AXL antibodies EC50 w/o
presence of binding in presence of AXL (% of binding in Gas6 Gas6
absence of antibodies prescence of (.mu.g/mL) (.mu.g/mL) Gas6)
(.mu.g/mL) control antibody) Antibody mean (s.d.) mean (s.d.) mean
(s.d.) mean (s.d.) mean (s.d.) IgG1-AXL-107 0.16 (0.17) 0.94 (1.18)
91 (5) 0.78 (0.54) 96 (8) IgG1-AXL-148 0.11 (0.13) 0.20 (0.30) 93
(5) 0.73 (0.52) 106 (7) IgG1-AXL-154 0.42 (0.55) 0.76 (0.78) 99
(13) 0.44 (0.28) 95 (10) IgG1-AXL-171 0.18 (0.21) 0.32 (0.40) 95
(5) 0.69 (0.42) 108 (5) IgG1-AXL-183 0.69 (0.72) 1.19 (1.11) 90
(19) 0.34 (0.13) 115 (8) IgG1-AXL-511 0.12 (0.11) 0.30 (0.31) 93
(15) 0.74 (0.44) 113 (6) IgG1-AXL-613 0.09 (0.09) 0.10 (0.10) 108
(22) 0.57 (0.36) 100 (11) IgG1-AXL-726 0.32 (0.35) 0.55 (0.69) 97
(10) 0.77 (0.58) 98 (10) IgG1-AXL-733 0.49 (0.51) 0.62 (0.23) 93
(5) 0.83 (0.54) 96 (5) YW327.6S2 0.09 (0.09) 1.90 (1.04)* 41 (24)
5.53 (7.09)* 17 (10) b12 n.a..sup.a n.a. n.a. 0.40 (0.11) 100
.sup.an.a., not applicable *EC50 values less accurate due to low
binding.
Example 3--Epitope Mapping Studies Anti-AXL Antibody Panel
Determining the AXL Domain Specificity Using Human-Mouse AXL
Chimeric Molecules
[0800] The AXL domain specificity of the AXL antibodies was
determined using a panel of human-mouse chimeric AXL mutants. Five
different chimeric AXL molecules were generated, in which either
the human Ig-like domain I (Ig1), the Ig-like domain II (Ig2), the
human FNIII-like domain I (FN1) or the human FNIII-like domain II
domain (FN2) were replaced with their murine homologs.
[0801] The following codon-optimized constructs for expression of
the AXL human-mouse chimeras were generated and expressed in
HEK293F cells as described in Example 1:
TABLE-US-00007 Homo sapiens AXL (p33-HAHs-AXL): (SEQ ID NO: 130)
MAWRCPRMGRVPLAWCLALCGWACMYPYDVPDYAAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEP
PEVHWLRDGQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGL-
PYF
LEEPEDRTVAANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTT-
SRT
ATITVLPQQPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSNDGMGIQAGEPDPPEEPLTSQASVPPH-
QLRL
GSLHPHTPYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLA-
YQ
GQDTPEVLMDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAF-
S
WPWWYVLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEE-
LKEKLR
DVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLI-
GV
CFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARN-
CML
NENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVE-
NS
EIYDYLRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGY-
PEP PGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA
Mus musculus AXL (p33-HAMm-AXL): (SEQ ID NO: 131)
MAWRCPRMGRVPLAWCLALCGWACMYPYDVPDYAAHKDTQTEAGSPFVGNPGNITGARGLTGTLRCELQVQGE
PPEVVWLRDGQILELADNTQTQVPLGEDWQDEWKVVSQLRISALQLSDAGEYQCMVHLEGRTFVSQPGFVGLEG-
L
PYFLEEPEDKAVPANTPFNLSCQAQGPPEPVTLLWLQDAVPLAPVTGHSSQHSLQTPGLNKTSSFSCEAHNAKG-
VTT
SRTATITVLPQRPHHLHVVSRQPTELEVAWTPGLSGIYPLTHCNLQAVLSDDGVGIWLGKSDPPEDPLTLQVSV-
PPHQ
LRLEKLLPHTPYHIRISCSSSQGPSPWTHWLPVETTEGVPLGPPENVSAMRNGSQVLVRWQEPRVPLQGTLLGY-
RLA
YRGQDTPEVLMDIGLTREVTLELRGDRPVANLTVSVTAYTSAGDGPWSLPVPLEPWRPGQGQPLHHLVSEPPPR-
AFS
WPWWYVLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEE-
LKEKLR
DVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLI-
GV
CFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARN-
CML
NENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVE-
NS
EIYDYLRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGY-
PEP PGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA
Homo sapiens AXL-Mus musculus Ig1 domain (p33-AXL-mIg1): (SEQ ID
NO: 132)
MGRVPLAWWLALCCWGCAAHKDTQTEAGSPFVGNPGNITGARGLTGTLRCELQVQGEPPEVVWLRDGQILELAD
NTQTQVPLGEDWQDEWKVVSQLRISALQLSDAGEYQCMVHLEGRTFVSQPGFVGLEGLPYFLEEPEDRTVAANT-
PF
NLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQPRN-
LHL
VSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSDDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHTPYHI-
RVAC
TSSQGPSSWTHWLPVETPEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVLMDIGL-
R
QEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYVLLGAVVA
AACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDRH-
KVALGK
TLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFP-
APVV
ILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFG-
LSK
KIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLK-
QPA
DCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQP-
DP KDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA Homo sapiens
AXL-Mus musculus Ig2 domain (p33-AXL-mIg2): (SEQ ID NO: 133)
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPE-
DKAV
PANTPFNLSCQAQGPPEPVTLLWLQDAVPLAPVTGHSSQHSLQTPGLNKTSSFSCEAHNAKGVTTSRTATITVL-
PQQ
PRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSDDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHP-
HTPY
HIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEV-
LM
DIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYVLL
GAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDV-
MVDRHK VALGKTLGEGEFGAVMEGQLNQDDS
ILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLY-
SRLGD
QPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPV-
K
WIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWEL-
NP
QDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAG-
RYV LCPSTTPSPAQPADRGSPAAPGQEDGA Homo sapiens AXL-Mus musculus FN1
domain (p33-AXL-mFN1): (SEQ ID NO: 134)
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPE-
DRTV
AANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVL-
PQR
PHHLHVVSRQPTELEVAWTPGLSGIYPLTHCNLQAVLSDDGVGIWLGKSDPPEDPLTLQVSVPPHQLRLEKLLP-
HTPY
HIRISCSSSQGPSPWTHWLPVETTEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEV-
LM
DIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYVLL
GAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDV-
MVDRHK VALGKTLGEGEFGAVMEGQLNQDDS
ILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLY-
SRLGD
QPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPV-
K
WIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWEL-
NP
QDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAG-
RYV LCPSTTPSPAQPADRGSPAAPGQEDGA Homo sapiens AXL-Mus musculus FN2
domain (p33-AXL-mFN2): (SEQ ID NO: 135)
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRD
GQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPE-
DRTV
AANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVL-
PQQ
PRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSDDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHP-
HTPY
HIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENVSAMRNGSQVLVRWQEPRVPLQGTLLGYRLAYRGQDTPEV-
L
MDIGLTREVTLELRGDRPVANLTVSVTAYTSAGDGPWSLPVPLEPWRPGQGQPLHHLVSEPPPRAFSWPWWYVL-
L
GAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDV-
MVDRHK
VALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSE-
RESF
PAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVC-
VA
DFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLR-
QGN
RLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGA-
DP PTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA
[0802] Binding of 1 .mu.g/mL anti-AXL antibody to the human-mouse
AXL chimeras was determined by flow cytometry, as described in
Example 2. IgG1-b12 was included as an isotype control IgG1.
[0803] All anti-AXL antibodies showed binding to human AXL (FIG.
2A), whereas binding was abrogated or strongly reduced when the
human AXL ECD was replaced with its murine homolog (FIG. 2B). The
human-mouse cross-reactive monoclonal AXL antibody YW327.6S2 was
included to confirm expression of hsAXL-mmECD.
[0804] Anti-AXL antibody 107 and 613 showed strongly reduced
binding to hsAXL-mmIg1 (FIG. 2C), indicating recognition of an
epitope in the AXL Ig1 domain. IgG1-AXL-148 and IgG1-AXL-171 showed
strongly reduced binding to hsAXL-mmIg2 (FIG. 2D), indicating
recognition of an epitope in the AXL Ig2 domain. IgG1-AXL-154,
IgG1-AXL-183 and IgG1-AXL-733 showed reduced binding to hsAXL-mmFN1
(FIG. 2E), indicative of a binding epitope in the AXL FN1 domain.
Finally, binding of IgG1-AXL-726 was lost in hsAXL-mmFN2 (FIG. 2F),
indicating recognition of an epitope within the FN2 domain.
[0805] AXL domain specificity for all anti-AXL antibodies is
summarized in Table 6.
TABLE-US-00008 TABLE 6 AXL domain AXL aa's involved in Antibody
specificity binding IgG1-AXL-107 Ig1 L121-Q129 IgG1-AXL-148 Ig2
D170-R190 IgG1-AXL-154 Fn1 Q272-A287, G297-P301 IgG1-AXL-154-M103L
n.d..sup.a n.d. IgG1-AXL-171 Ig2 P170, T182-R190 IgG1-AXL-183 Fn1
Not resolved IgG1-AXL-183-N52Q n.d. n.d. IgG1-AXL-613 Ig1 T112-Q124
IgG1-AXL-726 Fn2 A359, R386, Q436-K439 IgG1-AXL-726-M101L n.d. n.d.
IgG1-AXL-733 Fn1 Not resolved IgG1-AXL-061 Ig1 I97-Q124
IgG1-AXL-137 Ig1 Q57, E92-T105 YW327.6S2 Ig1 G39-D59 .sup.an.d.,
not determined
High Resolution Epitope Mapping to Identify Amino Acids in the AXL
Extracellular Domain Involved in Binding of AXL Antibodies
[0806] To identify amino acids in the AXL extracellular domain
involved in binding of anti-AXL antibodies, a library of AXL
sequence variants was generated by recombination of AXL sequences
derived from species with variable levels of homology with the
human AXL sequence in the extracellular domain. Briefly, an
expression plasmid encoding human AXL (Hs) was mixed with cloning
plasmids encoding Mus musculus (Mm), Monodelphis domestica (Md;
opossum) Anolis carolinensis (Ac; lizard) and Tetraodon
nigroviridis (Tn; pufferfish) AXL homologs or vice versa. A
combination of two primers specific to either the cloning or the
expression vector was used to perform a PCR amplifying the AXL
extracellular domain (ECD) with abbreviated elongation time,
forcing melting and reannealing of nascent DNA replication strands
during PCR cycling. Full length ECD was amplified using a nested
PCR, again specific to recombination products containing termini
originating from both vectors.
[0807] Resulting AXL ECD PCR products were cloned into an
expression vector creating full length AXL, and resulting plasmids
were sequenced, ranked by maximal difference to the template
vectors and selected to create a minimal ensemble with maximal
differentiation power. Plasmids encoding AXL homologs from Hs, Mm,
Md, Ac and Tn, four human/mouse chimeric plasmids encoding Hs AXL
with murine Ig1, Ig2, Fn1 or Fn2 domains, and the sixteen most
differentiating plasmids from the recombination library were
transfected into HEK293-F cells according to the specifications
supplied by the manufacturer (Life technologies). FACS binding data
using 1 .mu.g/mL anti-AXL antibodies were deconvoluted by scoring
per amino acid if mutation did (+1) or did not (-1) correlate with
loss of binding, after which a baseline correction and
normalization to a scale of -5 to +5 was applied, resulting in an
impact score per amino acid over the full ECD.
[0808] The deconvoluted binding data is summarized in Table 6 as
the amino acids involved in binding. Antibodies of which the
binding site could not be mapped to high resolution due to a lack
of recombination events in the proximity of the binding site, are
indicated as not resolved.
Example 4--Fc-Mediated Effector Functions
Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
[0809] The ability of anti-AXL antibodies to induce ADCC of A431
epidermoid carcinoma cells was determined as explained below. As
effector cells, peripheral blood mononuclear cells from healthy
volunteers (UMC Utrecht, The Netherlands) were used.
Labeling of Target Cells
[0810] A431 cells were collected (5.times.10.sup.6 cells) in
culture medium (RPMI 1640 culture medium supplemented with 10%
fetal calf serum (FSC)), to which 100 .mu.Ci .sup.51Cr
(Chromium-51; Amersham Biosciences Europe GmbH, Roosendaal, The
Netherlands) had been added, and the mixture was incubated in a
37.degree. C. water bath for 1 hour (hr) while shaking. After
washing of the cells (twice in PBS, 1200 rpm, 5 min), the cells
were resuspended in RPM11640/10% FSC and counted by trypan blue
exclusion. Cells were diluted to a density of 1.times.10.sup.5
cells/mL.
Preparation of Effector Cells
[0811] Peripheral blood mononuclear cells (healthy volunteers, UMC
Utrecht, Utrecht, The Netherlands) were isolated from 45 mL of
freshly drawn heparin blood by Ficoll (Bio Whittaker; lymphocyte
separation medium, cat 17-829E) according to the manufacturer's
instructions. After resuspension of cells in RPMI1640/10% FSC,
cells were counted by trypan blue exclusion and diluted to a
density of 1.times.10.sup.7 cells/mL.
ADCC Set Up
[0812] 50 .mu.l of .sup.51Cr-labeled targets cells were pipetted
into 96-well plates, and 50 .mu.l of antibody were added, diluted
in RPM11640/10% FSC (3-fold dilutions at final concentrations range
0.01-10 .mu.g/mL). Cells were incubated (room temperature (RT), 15
min), and 50 .mu.l effector cells were added, resulting in an
effector to target ratio of 100:1 (for determination of maximal
lysis, 100 .mu.l 5% Triton-X100 was added instead of effector
cells; for determination of spontaneous lysis, 50 .mu.L target
cells and 100 .mu.L RPMI1640/10% FSC were used). Cells were
incubated overnight at 37.degree. C. and 5% CO.sub.2. After
spinning down cells (1200 rpm, 10 min), 70 .mu.L of supernatant was
harvested into micronic tubes, and counted in a gamma counter. The
percentage specific lysis was calculated as follows:
% specific lysis=(cpm sample-cpm target cells only)/(cpm maximal
lysis-cpm target cells only)
wherein cpm is counts per minute.
[0813] IgG1-AXL-183-N52Q, and IgG1-AXL-733 induced 15 to 21% ADCC
in A431 cells at a concentration of 10 .mu.g/mL (FIG. 3).
IgG1-AXL-148, IgG1-AXL-726-M101L, IgG1-AXL-171, IgG1-AXL-613,
IgG1-AXL-107, and IgG1-AXL-154-M103L did not induce significant
ADCC in A431 cell at concentrations up to 10 .mu.g/mL (FIG. 3).
Example 5--Binding Characteristics of AXL Antibody-Drug Conjugates
(AXL-ADCs)
[0814] HEK293T cells were transiently transfected with expression
constructs for full-length human AXL (see Example 1). Binding of
anti-AXL antibodies and AXL-ADCs to these cells was evaluated by
flow cytometry. Transiently transfected HEK293 cells were incubated
with serial dilutions of anti-AXL antibodies or AXL-ADCs (4-fold
dilutions; final concentration range 0.003-10 .mu.g/mL) for 30
minutes at 4.degree. C. After washing three times in PBS/0.1%
BSA/0.02% azide, cells were incubated in 100 .mu.L with secondary
antibody at 4.degree. C. for 30 min in the dark. As a secondary
antibody, R-Phycoerythrin (PE)-conjugated goat-anti-human IgG
F(ab')2 (Jackson ImmunoResearch Laboratories, Inc., West Grove,
Pa.; cat. No. 109-116-098) diluted 1/100 in PBS/0.1% BSA/0.02%
azide, was used. Next, cells were washed twice in PBS/0.1%
BSA/0.02% azide, resuspended in 120 .mu.L PBS/0.1% BSA/0.02% azide
and analyzed on a FACS Cantoll (BD Biosciences).
[0815] Binding curves were analyzed using non-linear regression
(sigmoidal dose-response with variable slope) using GraphPad Prism
V5.04 software (GraphPad Software, San Diego, Calif., USA).
[0816] FIG. 4 shows that binding of the anti-AXL antibodies to the
HEK293 cells expressing human AXL-ECD was similar to the binding of
the AXL-ADCs.
Example 6--In Vitro Cytotoxicity Induced by AXL-Specific Antibody
Drug Conjugates
[0817] LCLC-103H cells (human large cell lung cancer) cells were
cultured in RPMI 1640 with L-Glutamine (Cambrex; cat.no. BE12-115F)
supplemented with 10% (vol/vol) heat inactivated Cosmic Calf Serum
(Perbio; cat.no. SH30087.03), 2 mM L-glutamine (Cambrex; cat.no.
US17-905C), 50 IU/mL penicillin, and 50 .mu.g/mL streptomycin
(Cambrex; cat.no. DE17-603E). MDA-MB-231 cells (human breast
cancer) were cultured in DMEM (Cambrex; cat.no. BE12-709F)
supplemented with 10% (vol/vol) heat inactivated Cosmic Calf Serum
(Perbio; cat.no. SH30087.03), 1 mM Sodium Pyruvate (Cambrex;
cat.no. BE13-115E), 2 mM L-glutamine (Cambrex; cat.no. US17-905C),
100 .mu.M MEM NEAA (Invitrogen; cat.no. 11140), 50 IU/mL
penicillin, and 50 .mu.g/mL streptomycin (Cambrex; cat.no.
DE17-603E). The cell lines were maintained at 37.degree. C. in a 5%
(vol/vol) CO2 humidified incubator. LCLC-103H and MDA-MB-231 cells
were cultured to near confluency, after which cells were
trypsinized, resuspended in culture medium and passed through a
cell strainer (BD Falcon, cat.no. 352340) to obtain a single cell
suspension. 1.times.10.sup.3 cells were seeded in each well of a
96-well culture plate, and cells were incubated for 30 min at room
temperature and subsequently for 5 hrs at 37.degree. C., 5% CO2 to
allow adherence to the plate.
[0818] Serial dilutions (4-fold; final concentrations ranging from
0.00015 to 10 .mu.g/mL) of AXL antibody drug conjugates (AXL-ADCs;
see Example 1) were prepared in culture medium and added to the
plates. Incubation of cells with 1 .mu.M staurosporin (# S6942-200,
Sigma) was used as reference for 100% tumor cell kill. Untreated
cells were used as reference for 0% tumor cell kill. Plates were
incubated for 5 days at 37.degree. C., 5% CO2. Next, CellTiter-Glo
Reagent (Promega; cat.no. G7571) was added to the wells (20 .mu.L
per well) and plates were incubated for 1.5 hours at 37.degree. C.,
5% CO2. Subsequently, 180 .mu.L per well was transferred to white
96-well Optiplate.TM. plates (PerkinElmer, Waltham, Mass.; cat.no.
6005299), which were incubated for 30 min at room temperature.
Finally, luminescence was measured on an EnVision multiplate reader
(Envision, Perkin Elmer).
[0819] AXL-ADCs IgG1-AXL-148-vcDuo3, IgG1-AXL-183-vcDuo3, and
IgG1-AXL-726-vcDuo3 induced cytotoxicity in LCLC-103H cells, with
IC50 values between 0.01 and 0.06 .mu.g/mL, as shown in FIG. 5A.
Similarly, FIG. 5B shows that these AXL-ADCs induced cytoxicity of
MDA-MB-231 cells with IC50 values between 0.005 and 0.015
.mu.g/mL.
Example 7--Antibody VH and VL Variants that Allow Binding to
AXL
[0820] Protein sequences of the VH and VL regions of the anti-AXL
antibody panel (described in Example 1) were aligned and compared
for AXL binding to identify critical or permissive changes of amino
acid residues in the VH or VL regions. Therefore, antibodies with
identical VH or VL regions were grouped and compared for binding to
human AXL and differences in VL or VH sequences, respectively.
Binding to human AXL transiently expressed by HEK-293F cells was
assessed in the homogeneous antigen specific screening assay as
described in Example 1. Numbering of amino acid positions for the
alignments done in the present example was done based on the
sequences put forth in FIG. 6, i.e. the first amino acid in the
shown sequence was numbered as position `1`, the second as position
`2`, etc.
[0821] First, antibodies with identical VL sequences were
grouped.
[0822] IgG1-AXL-148 and IgG1-AXL-140 were found to have an
identical VL sequence, and showed 1 amino acid difference in the HC
CDR3 region (F for I at amino acid position 109; FIG. 6A). Both
antibodies bound to human AXL (Table 7), indicating that the amino
acid at position 109 is not essential for antibody binding,
assuming that a mutation identified in the CDR2 region (G for A at
the amino acid position 56) does not compensate for loss of binding
(FIG. 6A).
[0823] IgG1-AXL-726 and IgG1-AXL-187 were found to have an
identical VL sequence and both antibodies bound to human AXL (Table
7). Two amino acid residue changes in the HC CDR3 region (R for S
at position 97 and A for T at position 105; FIG. 6B) were allowed
without losing binding, assuming that mutations identified in the
CDR1 (Y for H at position 32) and/or in the framework regions (P3Q,
V241, Y25D, T86A and T117A) do not compensate for loss of binding
(FIG. 6B).
[0824] IgG1-AXL-171, IgG1-AXL-172 and IgG1-AXL-181 were found to
have an identical VL sequence and all antibodies bound to human AXL
(Table 7). The CDR3 regions of these three antibodies were
identical, but an amino acid residue change in the HC CDR1 (S for N
at position 31) or the framework region (H for Q at position 82)
was allowed without losing binding (FIG. 6C).
[0825] IgG1-AXL-613, IgG1-AXL-608-01, IgG1-AXL-610-01 and
IgG1-AXL-620-06 were found to have an identical VL sequence, and
showed one amino acid difference in the HC CDR3 region (N for D at
amino acid position 101; FIG. 6D). All antibodies bound to human
AXL (Table 7), indicating that the amino acid at position 101 is
not essential, assuming that mutations identified in the HC CDR2 (V
for A at position 58) and/or in the framework regions (N35S, M37V,
A61V, L701, S88A) do not compensate for loss of binding (FIG.
6D).
[0826] Next, antibodies with identical VH sequences were
grouped.
[0827] IgG1-AXL-613 and IgG1-AXL-613-08 were found to have an
identical VH sequence, and showed five amino acid differences in
the CDR3 region of the LC (RSNWL for YGSSY at positions 92 to 96;
FIG. 6E). Both antibodies bound to human AXL (Table 7), indicating
that the variation of amino acid at positions 92 to 96 are allowed
and do not affect antibody binding, assuming that mutations
identified in the CDR1 (deletion of the S at position 30), CDR2
(G51D), and/or in the framework regions (G9A, S54N, R78S, Q100G,
L104V) do not compensate for loss of binding (FIG. 6E).
TABLE-US-00009 TABLE 7 EC50 Maximal binding Antibody (.mu.g/mL)
(Arbitrary units) IgG1-AXL-140 0.0026 2889 IgG1-AXL-148 0.0036 3499
IgG1-AXL-171 0.003 2575 IgG1-AXL-172 0.0055 5378 IgG1-AXL-181 0.008
3598 IgG1-AXL-187 0.0065 2563 IgG1-AXL-608-01 0.0035 3318
IgG1-AXL-610-01 0.0023 2947 IgG1-AXL-613 0.0072 5211
IgG1-AXL-613-08 0.0242 2209 IgG1-AXL-620-06 0.0034 4352
IgG1-AXL-726 0.0471 3154
Example 8--In Vitro Cytotoxicity Induced by MMAE-Conjugated AXL
Antibodies
Conjugation of MMAE to Anti-AXL Antibodies
[0828] Anti-AXL antibodies were purified by Protein A
chromatography according to standard procedures and conjugated to
vcMMAE. The drug-linker vcMMAE was alkylated to the cysteines of
the reduced antibodies according to procedures described in the
literature (see [150], [151], and [152]). The reaction was quenched
by the addition of an excess of N-acetylcysteine. Any residual
unconjugated drug was removed by purification and the final
anti-AXL antibody drug conjugates were formulated in PBS. The
anti-AXL antibody drug conjugates were subsequently analyzed for
concentration (by absorbance at 280 nm), the drug to antibody ratio
(DAR) by reverse phase chromatography (RP-HPLC) and hydrophobic
interaction chromatography (HIC), the amount of unconjugated drug
(by reverse phase chromatography), the percentage aggregation (by
size-exclusion chromatography, SEC-HPLC) and the endotoxin levels
(by LAL). The results are shown below in Table 8.
TABLE-US-00010 TABLE 8 Overview of different characteristics of the
antibody-drug conjugates. ADC IgG1- IgG1- IgG1- IgG1- IgG1- AXL-
IgG1- AXL- IgG1- IgG1- AXL- IgG1- AXL- AXL- 154- AXL- 183- AXL-
AXL- 726- AXL- IgG1- Assay 107 148 M103L 171 N52Q 511 613 M101L 733
b12 Concentration 7.18 9.63 6.57 3.69 6.71 5.77 6.17 7.37 7.71 1.58
(mg/mL) DAR by HIC 3.97 3.96 3.71 3.65 3.92 3.87 4.23 4.12 4.08
4.00 % unconjugated 4.68 5.58 6.13 7.11 8.68 8.35 5.13 4.99 3.74
1.89 antibody % aggregate by 6.3 2.28 2.9 3.3 5.2 5.1 6.4 4.0 3.5
2.5 SEC-HPLC Endotoxin 2.3 1.2 2.6 3.1 5.9 4.5 2.0 3.6 7.6 11.5
(EU/mg)
Cell Culture
[0829] LCLC
[0830] -103H cells (human large cell lung cancer) and A431 cells
(DMSZ, Braunschweig, Germany) were cultured in RPMI 1640 with
L-Glutamine (Cambrex; cat.no. BE12-115F) supplemented with 10%
(vol/vol) heat inactivated Cosmic Calf Serum (Perbio; cat.no.
SH30087.03), 2 mM L-glutamine (Cambrex; cat.no. US17-905C), 50
IU/mL penicillin, and 50 .mu.g/mL streptomycin (Cambrex; cat.no.
DE17-603E). MDA-MB231 cells were cultured in DMEM with high glucose
and HEPES (Lonza # BE12-709F), Donor Bovine Serum with Iron (Life
Technologies #10371-029), 2 mM L-glutamine (Lonza # BE17-605E), 1
mM Sodium Pyruvate (Lonza # BE13-115E), and MEM Non-Essential Amino
Acids Solution (Life Technologies #11140). The cell lines were
maintained at 37.degree. C. in a 5% (vol/vol) CO.sub.2 humidified
incubator. LCLC-103H, A431 and MDA-MB231 cells were cultured to
near confluency, after which cells were trypsinized, resuspended in
culture medium and passed through a cell strainer (BD Falcon,
cat.no. 352340) to obtain a single cell suspension.
1.times.10.sup.3 cells were seeded in each well of a 96-well
culture plate, and cells were incubated for 30 min at room
temperature and subsequently for 5 hrs at 37.degree. C., 5%
CO.sub.2 to allow adherence to the plate.
Cytotoxicity Assay
[0831] Serial dilutions (final concentrations ranging from 0.00015
to 10 .mu.g/mL) of MMAE-conjugated AXL-antibodies were prepared in
culture medium and added to the plates. Incubation of cells with 1
.mu.M staurosporin (# S6942-200, Sigma) was used as reference for
100% tumor cell kill. Untreated cells were used as reference for
100% cell growth. Plates were incubated for 5 days at 37.degree.
C., 5% CO.sub.2. Next, CellTiter-Glo Reagent (Promega; cat.no.
G7571) was added to the wells (20 .mu.L per well) and plates were
incubated for 1.5 hours at 37.degree. C., 5% CO.sub.2.
Subsequently, 180 .mu.L per well was transferred to white 96-well
Optiplate.TM. plates (PerkinElmer, Waltham, Mass.; cat.no.
6005299), which were incubated for 30 min at room temperature.
Finally, luminescence was measured on an EnVision multiplate reader
(Envision, Perkin Elmer).
[0832] MMAE-conjugated AXL-antibodies induced 50% cell kill in
LCLC-103H cells at concentrations between 0.004 and 0.219 .mu.g/mL
as shown in Table 9a and FIG. 7.
[0833] Similarly, AXL-ADCs efficiently induced cytotoxicity in A431
cells (Table 9b) and FIG. 15A) and MDA-MB231 cells (Table 9b and
FIG. 15B).
TABLE-US-00011 TABLE 9a Cytotoxicity of
MMAE-conjugated-AXL-antibodies in LCLC-103H cells (EC50 values) ADC
EC50 (.mu.g/mL) IgG1-AXL-613-vcMMAE 0.004 IgG1-AXL-148-vcMMAE 0.012
IgG1-AXL-171-vcMMAE 0.018 IgG1-AXL-726-M 101L-vcMMAE 0.018
IgG1-AXL-107-vcMMAE 0.022 IgG1-AXL-511-vcMMAE 0.032 IgG1-AXL-154-M
103L-vcMMAE 0.044 IgG1-AXL-183-N52Q-vcMMAE 0.113
IgG1-AXL-733-vcMMAE 0.219
TABLE-US-00012 TABLE 9b Cytotoxicity of MMAE-conjugated AXL
antibodies in A431 and MDA-MB-231 cells (EC50 values). EC50
(.mu.g/mL) A431 (n = 3) MDA-MB231 (n = 2) ADC Mean s.d. Mean s.d.
IgG1-AXL-107-vcMMAE 0.154 0.066 0.037 0.005 IgG1-AXL-148-vcMMAE
0.070 0.013 0.012 0.004 IgG1-AXL-154-M103L-vcMMAE 0.719 0.091 0.396
0.195 IgG1-AXL-171-vcMMAE 0.206 0.074 0.035 0.006
IgG1-AXL-183-N52Q-vcMMAE 1.157 0.160 0.139 0.028
IgG1-AXL-511-vcMMAE 0.093 0.020 0.052 0.003 IgG1-AXL-613-vcMMAE
0.109 0.078 0.005 0.001 IgG1-AXL-726-M101L-vcMMAE 0.270 0.157 0.022
0.002 IgG1-AXL-733-vcMMAE 1.253 0.228 0.881 0.182
Example 9--Therapeutic Treatment of LCLC-103H Tumor Xenografts in
SCID Mice with MMAE-Conjugated Anti-AXL Antibodies
[0834] The in vivo efficacy of MMAE-conjugated anti-AXL antibodies
was determined in established subcutaneous (SC) LCLC-103H xenograft
tumors in SCID mice. 5.times.10.sup.6 LCLC-103H (large cell lung
carcinoma) tumor cells (obtained from Leibniz-lnstitut
DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
(DSMZ)) in 200 .mu.L PBS were injected subcutaneously in the right
flank of female SCID mice. Starting 14-21 days after tumor cell
inoculation, when the average tumor size was >100-200 mm.sup.3
and distinct tumor growth was observed, a single injection with 1
mg/kg (20 .mu.g/mouse) IgG1-AXL-vcMMAE antibodies (as described in
Supplementary Example 1) or control (unconjugated IgG1-b12) was
given intraperitoneally (100 aL/mouse). Tumor volume was determined
at least two times per week. Tumor volumes (mm.sup.3) were
calculated from caliper (PLEXX) measurements as:
0.52.times.(length).times.(width).sup.2.
[0835] The panel of anti-AXL-vcMMAE antibodies showed a broad range
of anti-tumor activity in established SC LCLC-103H tumors (FIG. 8).
Clones IgG1-AXL-733-vcMMAE, IgG1-AXL-107-vcMMAE and
IgG1-AXL-148-vcMMAE induced tumor regression, clones
AXL-171-vcMMAE, IgG1-AXL-511-vcMMAE and IgG1-AXL-613-vcMMAE induced
tumor growth inhibition, and clones IgG1-AXL-154-M103L-vcMMAE,
IgG1-AXL-183-N52Q-vcMMAE, and IgG1-AXL-726-M101L-vcMMAE showed no
or only minor tumor growth inhibition.
[0836] Statistical analysis on the last day that all groups were
intact (day 30) using One Way ANOVA (Dunnett's multiple comparisons
test versus control IgG1-b12) indicated a highly significant
difference (p<0.0001) in tumor volume between IgG1-b12 versus
IgG1-AXL-733-vcMMAE, IgG1-AXL-107-vcMMAE and IgG1-AXL-148-vcMMAE.
Treatment with these clones led in some mice within these groups to
complete tumor reduction. Treatment with clones
IgG1-AXL-171-vcMMAE, IgG1-AXL-511-vcMMAE and IgG1-AXL-613-vcMMAE
also showed significant tumor growth inhibition compared to
IgG1-b12, but the differences were less pronounced (p<0.05 to
p<0.001). The tumor growth of mice treated with clones
IgG1-AXL-154-M103L-vcMMAE, IgG1-AXL-183-N52Q-vcMMAE, and
IgG1-AXL-726-M101L-vcMMAE was not significant affected compared to
the IgG1-b12 control.
[0837] Anti-tumor activity of anti-AXL-vcMMAE antibodies was
observed in various other in vivo tumor models. In two cell
line-derived xenograft models (A431; epidermoid adenocarcinoma, and
MDA-MB-231; breast cancer) anti-AXL-vcMMAE antibodies induced tumor
growth inhibition, and tumor regression was induced by
anti-AXL-vcMMAE antibodies in two patient-derived xenograft models
from patients with pancreas cancer and cervical cancer.
Example 10--Anti-Tumor Efficacy of AXL-ADCs in a Pancreas Cancer
Patient-Derived Xenograft (PDX) Model with Heterogeneous Target
Expression
[0838] The anti-tumor activity of IgG1-AXL-107-vcMMAE,
IgG1-AXL-148-vcMMAE, and IgG1-AXL-733-vcMMAE was determined in the
PAXF1657 pancreas cancer PDX model (experiments performed by
Oncotest, Freiburg, Germany). Human pancreas tumor tissue was
subcutaneously implanted in the left flank of 5-7 weeks old female
NMRI nu/nu mice. Randomization of animals was performed as follows:
animals bearing a tumor with a volume between 50-250 mm.sup.3,
preferably 80-200 mm.sup.3, were distributed in 7 experimental
groups (8 animals per group), considering a comparable median and
mean of group tumor volume. At day of randomization (day 0), the 3
ADCs were dosed intravenously (i.v.) at either 4 mg/kg or 2 mg/kg,
and the control group received a single dose of IgG1-b12 (4 mg/kg).
Tumor volumes (mm.sup.3) were monitored twice weekly and were
calculated from caliper (PLEXX) measurements as:
0.52.times.(length).times.(width).sup.2.
[0839] Staining of PAXF1657 tumors was performed with standard
immunohistochemistry techniques. Briefly, frozen tissues were
fixated with acetone for 10 minutes and endogenous peroxidase was
exhausted using hydrogen peroxidase. Subsequently, tissue sections
were blocked with normal mouse serum and staining was performed by
incubation with 5 .mu.g/mL of a pool of 5 IgG1-AXL antibodies
(IgG1-AXL-061, IgG1-AXL-137, IgG1-AXL-148, IgG1-AXL-183,
IgG1-AXL-726). After incubation with the secondary, horseradish
peroxidase (HRP) conjugated antibody, HRP was visualized with
amino-ethyl carbazole (AEC; resulting in a red color). Each slide
was counterstained with hematoxylin (blue) to identify nuclei and
coverslipped in glycergel. Immunostained tissue slices were
digitized on manual Zeiss microscope (AxioSkop) at 10.times. and
40.times. magnifications.
[0840] FIG. 9 shows heterogeneous AXL expression in PAXF1657
tumors. Whereas strong AXL staining is observed in some tumor
cells, other cells do not show AXL staining. In black and white
photo the AXL staining appears as dark grey. Hematoxylin staining
(nuclei) appears as light grey.
[0841] FIG. 10A shows that treatment of mice with 2 mg/kg
IgG1-AXL-107-vcMMAE, IgG1-AXL-148-vcMMAE and IgG1-AXL-733-vcMMAE
significantly reduced the growth of PAXF1657 tumors compared to the
control group. At a dose of 4 mg/kg IgG1-AXL-107-vcMMAE,
IgG1-AXL-148-vcMMAE and IgG1-AXL-733-vcMMAE induced tumor
regression of PAXF1657 tumors. On day 14 after treatment, the
average tumor size in mice that had been treated with 2 mg/kg or 4
mg/kg IgG1-AXL-107-MMAE, IgG1-AXL-148-MMAE or IgG1-AXL-733-MMAE was
significantly smaller than in mice that had been treated with an
isotype control IgG (IgG1-b12) (p<0.001; Tukey's multiple
comparison test).
[0842] Treatment of mice with unconjugated IgG1-AXL-148 did not
result in anti-tumor activity in the PAXF1657 model (FIG. 10B).
Conjugated IgG1-AXL-148-vcMMAE, however, induced dose-dependent
antitumor activity in this model (FIG. 10B), illustrating that the
therapeutic capacity of AXL-ADCs is dependent on the cytotoxic
activity of MMAE.
[0843] Moreover, treatment of mice with the untargeted ADC
IgG1-b12-vcMMAE did not show anti-tumor activity in the PAXF1657
model (FIG. 10C), illustrating that the therapeutic capacity of
AXL-ADCs also depends on specific target binding.
Example 11--AXL Antibodies Binding to the Ig1 Domain
[0844] The AXL domain specificity of AXL antibodies IgG1-AXL-061,
IgG1-AXL-107, IgG1-AXL-137, and IgG1-AXL-613 was determined using a
panel of human-mouse chimeric AXL mutants. The human-mouse
cross-reactive monoclonal AXL antibody YW327.6S2 was included to
confirm expression of hsAXL-mmECD. IgG1-b12 was included as isotype
control antibody. Five different chimeric AXL molecules were
generated and expressed in HEK293F as described in Example 3. In
brief, the human Ig-like domain I (Ig1), the Ig-like domain II
(Ig2), the human FNIII-like domain I (FN1) or the human FNIII-like
domain II domain (FN2) were replaced with their murine homologs.
Binding of 1 .mu.g/mL anti-AXL antibody to the human-mouse AXL
chimeras was determined by flow cytometry, as described in Example
2.
[0845] All anti-AXL antibodies showed binding to human AXL (FIG.
11A), whereas binding was abrogated when the human AXL ECD was
replaced with its murine homolog (FIG. 11B). As expected, the
human-mouse cross-reactive monoclonal AXL antibody YW327.6S2 showed
binding to hsAXL-mmECD, confirming proper expression of
hsAXL-mmECD.
[0846] AXL antibodies IgG1-AXL-061, IgG1-AXL-107, IgG1-AXL-137, and
IgG1-AXL-613 showed strongly reduced binding to hsAXL-mmIg1 (FIG.
11C), illustrating recognition of an epitope in the AXL Ig1 domain.
In line with this, binding of IgG1-AXL-061, IgG1-AXL-107,
IgG1-AXL-137, and IgG1-AXL-613 to hsAXL-mmIg2 (FIG. 11D),
hsAXL-mmFN1 (FIG. 11E) or hsAXL-mmFN2 (FIG. 11F) was not affected.
The human-mouse cross-reactive monoclonal AXL antibody YW327.6S2
showed binding to all chimeric AXL variants, confirming proper
expression of these proteins.
Example 12--AXL Antibodies IgG1-AXL-107 and IgG1-AXL-613 Bind to
the Ig1 Domain but do not Compete with Gas6 Binding
[0847] It was tested whether the binding of the AXL antibodies
IgG1-AXL-061, IgG1-AXL-107, IgG1-AXL-137, or IgG1-AXL-613
interfered with binding of AXL ligand Gas6 to AXL. Therefore,
binding of Gas6 to A431 cells that had been pre-incubated with 10
.mu.g/mL AXL antibodies was tested as described in Example 2.
Pre-incubation with AXL antibody YW327.6S2, that was described to
compete with Gas6 for AXL binding, IgG1-b12 (isotype control) or
medium (negative control) were included as controls.
[0848] Binding curves were analyzed using non-linear regression
(sigmoidal dose-response with variable slope) using GraphPad Prism
V5.04 software (GraphPad Software, San Diego, Calif., USA).
[0849] FIG. 12 and Table 11 shows that binding of Gas6 to A431
cells that had been pre-incubated with IgG1-AXL-107 and
IgG1-AXL-613 antibodies was similar to the IgG1-b12 and medium
controls. This illustrates that binding of IgG1-AXL-107 and
IgG1-AXL-613 to AXL does not interfere with Gas6 binding, as shown
in Example 2. The binding of Gas6 to A431 cells was largely reduced
in the presence of IgG1-AXL-061, IgG1-AXL-137 and control AXL
antibody YW327.6S2 compared to the IgG1-b12 and medium
controls.
[0850] In experiments in which A431 cells were pre-incubated with
Gas6, the maximal binding values of IgG1-AXL-107 and IgG1-AXL-613
were comparable to antibody binding in absence of Gas6 (maximal
binding after Gas6 pre-incubation was 91-108% of binding without
Gas6 pre-incubation) (Table 11). The EC50 values for IgG1-AXL-107
and IgG1-AXL-613 binding with or without Gas6 pre-incubation were
in the same range, or somewhat higher after Gas6 pre-incubation
(Table 11), illustrating that IgG1-AXL-107 and IgG1-AXL-613 do not
compete with Gas6 binding.
[0851] Similar to control antibody YW327.6S2, the binding of
IgG1-AXL-061 and IgG1-AXL-137 to A431 cells was greatly reduced in
the presence of Gas6 compared to binding without Gas6 (maximal
binding after Gas6 pre-incubation was 40-43% of binding without
Gas6 pre-incubation; Table 11). The EC50 values for IgG1-AXL-061
and IgG1-AXL-137 could not properly be determined after Gas6
pre-incubation (Table 11). This shows that IgG1-AXL-061 and
IgG1-AXL-137 compete with Gas6 for binding to AXL.
[0852] These data demonstrate that antibodies binding to the AXL
Ig1 domain have differential effect on Gas6 binding.
TABLE-US-00013 TABLE 11 Antibody binding to A431 cells Gas6 binding
to A431 cells Maximal binding in Maximal binding in EC50 w/o
presence of presence of AXL Gas6 EC50 in Gas6 (% of EC50 in
antibodies EC50 presence of binding in presence of (% of binding in
(.mu.g/mL) Gas6 absence of AXL antibodies presence of control mean
(.mu.g/mL) Gas6) (.mu.g/mL) antibody) Antibody (s.d.) mean (s.d.)
mean (s.d.) mean (s.d.) mean (s.d.) IgG1-AXL-061 0.15 (n.a.) n.a.
43 (28) n.a. 22 (8) IgG1-AXL-107 0.16 (0.17) 0.94 (1.18) 91 (5)
0.78 (0.54) 96 (8) IgG1-AXL-137 0.11 (0.10) n.a. 40 (18) n.a 36 (4)
IgG1-AXL-613 0.09 (0.09) 0.10 (0.10) 108 (22) 0.57 (0.36) 100 (11)
YW327.6S2 0.09 (0.09) 1.90 (1.04)* 41 (24) 5.53 (7.09)* 17 (10) b12
n.a..sup.a n.a. n.a. 0.40 (0.11) 100 .sup.an.a., not applicable *
EC50 values less accurate due to low binding.
Example 13--In Vivo Anti-Tumor Efficacy of AXL-ADCs in Xenograft
Models with and without Autocrine (Endogenous) Gas6 Production
Gas6 Production of A431 and LCLC-103H Tumor Cells
[0853] It was tested whether A431 cells and LCLC-103H cells produce
Gas6. Therefore, cells were grown in complete culture medium for 3
days. Gas6 levels in supernatant were determined using the
Quantikine Human Gas6 ELISA (R&D Systems, Minneapolis, Minn.)
according to manufacturer's instructions. This assay uses the
quantitative sandwich ELISA technique. A monoclonal Ab specific for
human Gas6 has been pre-coated onto a microplate. Standards and
samples are pipetted into the wells and any human Gas6 present is
bound by the immobilized Ab. After washing away any unbound
substances, an enzyme-linked polyclonal Ab specific for human Gas6
is added to the wells. Following a wash to remove any unbound
Ab-enzym reagent, a substrate is added to the wells and color
develops in proportion to the amount of human Gas6 bound in the
initial step. The color development is stopped and the intensity of
the color is measured.
[0854] Cell culture medium conditioned by A431 cells was found to
contain 2576 ng/mL Gas6, while the concentration of Gas6 in medium
conditioned by LCLC-103H cells was more than 20-fold less (Table
12).
TABLE-US-00014 TABLE 12 Gas6 production in tumor cell conditioned
medium. Gas6 in supernatant Cell line (ng/mL) LCLC-103H 126 A431
2576
Anti-Tumor Activity of AXL-ADCs In Vivo
[0855] The in vivo anti-tumor activity of IgG1-AXL-061-vcMMAE (Ig1
binder), IgG1-AXL-107-vcMMAE (Ig1-binder), IgG1-AXL-137-vcMMAE
(Ig1-binder), IgG1-AXL-148-vcMMAE (Ig2-binder), IgG1-AXL-183-vcMMAE
(FN1-binder), and IgG1-AXL-726-vcMMAE (FN2-binder) was determined
in the A431 (epidermoid carcinoma) tumor model, that produces high
levels of Gas6, and the LCLC-103H (large cell lung carcinoma) tumor
model, that produces low levels of Gas6.
[0856] Tumor induction was performed by subcutaneous injection of
5.times.10.sup.6 A431 or LCLC-103H tumor cells (both obtained from
Leibniz-lnstitut--Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DSMZ)) in 200 .mu.L PBS in the right flank of
female SCID mice. Treatment was started 14-21 days after tumor cell
inoculation, when the average tumor size was >100-200 mm.sup.3
and distinct tumor growth was observed. Mice received a single
injection or a total of 4 biweekly intraperitoneal injections with
IgG1-AXL-vcMMAE ADCs or control antibody (unconjugated IgG1-b12),
as indicated. Tumor volume was determined at least two times per
week. Tumor volumes (mm.sup.3) were calculated from caliper (PLEXX)
measurements as: 0.52.times.(length).times.(width).sup.2.
[0857] FIG. 13A shows that treatment of mice with 3 mg/kg
IgG1-AXL-107-vcMMAE, IgG1-AXL-148-vcMMAE and IgG1-AXL-733-vcMMAE
induced growth inhibition of A431 tumors.
[0858] FIG. 13B shows that treatment of mice with 3 mg/kg
IgG1-AXL-148-vcMMAE, IgG1-AXL-183-vcMMAE (FN1 binder) and
IgG1-AXL-726-vcMMAE (FN2 binder) induced growth inhibition of A431
tumors. In contrast, clones IgG1-AXL-061-vcMMAE and
IgG1-AXL-137-vcMMAE did not show anti-tumor activity in the A431
xenograft model.
[0859] FIG. 14A shows that treatment of mice with 3 mg/kg
IgG1-AXL-061-vcMMAE, IgG1-AXL-137-vcMMAE, IgG1-AXL-148-vcMMAE,
IgG1-AXL-183-vcMMAE and IgG1-AXL-726-vcMMAE induced tumor
regression in the LCLC-103H xenograft model. Similarly, treatment
of mice with 1 mg/kg IgG1-AXL-107-vcMMAE or 1 mg/kg
IgG1-AXL-613-vcMMAE induced regression of LCLC-103H tumors (FIG.
14B).
[0860] In summary, all AXL-ADCs showed anti-tumor activity in the
LCLC-103H xenograft model that produces low levels of Gas6. In the
A431 xenograft model, that produces high levels of Gas6, anti-tumor
activity was only observed for those AXL-ADCs that did not compete
with the AXL ligand Gas6.
Example 14--AXL Expression in Different Tumor Indications
[0861] Expression of AXL was evaluated in freshly cut paraffin
embedded and formalin fixated (FFPE) tumor tissue micro arrays
(TMA) comprising tissue cores from patients with thyroid,
esophageal, ovarian, pancreatic, lung, breast, cervical or
endometrial cancer, or malignant melanoma. TMAs were obtained from
US BioMax.
[0862] FFPE tumor array slides were deparaffinized and subjected to
antigen retrieval (pH 6) and endogenous peroxidase was exhausted by
incubation with 0.1% H.sub.2O.sub.2 in citrate/phosphate buffer. To
detect AXL expression, the TMAs were incubated with rabbit-anti-AXL
(Santa Cruz, cat nr: sc-20741) at a concentration of 1 .mu.g/mL for
60 min (room temperature (RT)). To identify (tumor) cells of
epithelial origin, TMAs were incubated with rabbit-anti-cytokeratin
(Abcam, cat. Nr. ab9377) at a dilution of 1:50 for 60 min (RT).
After a washing step, the TMAs were incubated with peroxidase
conjugated, anti-rabbit IgG dextran polymer (ImmunoLogic, cat no:
DPVR55HRP) to detect binding of rabbit Anti-AXL and rabbit
anti-cytokeratin antibodies. Finally, binding of anti-rabbit IgG
dextran polymer was visualized with di-amino-benzadine (DAB; brown
color; DAKO, cat no: K346811). In the TMA with malignant melanoma
tissue cores, binding of anti-rabbit IgG dextran polymer was
visualized with amino-ethyl carbazole (AEC; red color; Vector,
SK4200). Nuclei in TMAs were visualized with hematoxylin (blue
color).
[0863] AXL and cytokeratin immunostained TMAs were digitized with
an Aperio slide scanner at 20.times. magnification and
immunostaining was quantified with tissue image analysis software
(Definiens Tissue Studio software, version 3.6.1), using a
cell-based algorithm. The algorithm was designed to identify and
quantify the percentage of AXL- or cytokeratin-positive cells in
the biopsies (range 0-100%) and to quantify AXL staining intensity
in AXL-positive tumor cells (optical density (OD); range 0-3) in
each tumor core. Tumor cells were scored AXL positive, when AXL OD
was at least 0.1. The percentage of AXL positive tumor cells per
tumor core (range 0-100%) was calculated by dividing the total
number of AXL positive cells by the total number of
cytokeratin-positive cells in sequential tumor cores. The average
AXL staining intensity (OD) in each tumor core was calculated by
dividing the sum of AXL OD of all AXL positive tumor cells by the
number of AXL positive tumor cells.
[0864] Tumor array from patients with malignant melanoma were
scored manually. AXL staining intensity was scored as either weak
(1+), moderate (2+) or strong (3+) and the percentage AXL positive
melanoma cells was scored in 10% intervals (range 0-100%).
[0865] FIG. 16 provides a graphical representation of AXL
expression in tumor cores of thyroid, esophageal, ovarian, breast,
lung, pancreatic, cervical and endometrial cancer. Table 13 shows
the percentage of tumor cores that showed AXL expression in more
than 10% of tumor cells, for each indication. FIG. 17 shows a
representative example of a tissue core immunostained for AXL, for
each indication. The figures illustrate heterogeneous expression of
AXL in the tumor issue.
TABLE-US-00015 TABLE 13 % tumor cores (patients) with >10%
AXL-positive Tumor indication Subtype tumor cells Esophageal cancer
Adenocarcinoma (n = 19) 73 Squamous cell carcinoma (n = 60) 55
Ovarian cancer All subtypes (n = 52) 90 Pancreatic cancer All
subtypes (n = 58) 60 Lung cancer (NSCLC) Squamous cell carcinoma
SSC (n = 52) 63 Adenocarcinoma (n = 48) 67 Lung cancer (SCLC) SCLC
(n = 5) 60 Thyroid cancer All subtypes (n = 48) 92 Uterine cancer
All subtypes (n = 60) 88 Breast cancer TNBC (n = 54) 24 Cervical
cancer All subtypes (n = 54) 93 Melanoma Malignant melanoma (n =
67) 6 Abbreviations used: NSCLC, non small cell lung cancer; SLCL,
small cell lung cancer; TNBC, triple negative breast cancer
Example 15--AXL Antibodies Specifically Bind AXL but not Other TAM
Receptor Family Members
Expression of Human AXL, MER, and TYRO3 in HEK-293F Cells
[0866] The following codon-optimized constructs for expression of
various full-length proteins were generated: human (Homo sapiens)
AXL (Genbank accession no. NP_068713.2), human MER (Genbank
accession no. EAW52096.1, and human TYRO3 (Genbank accession no.
Q06418.1). The constructs contained suitable restriction sites for
cloning and an optimal Kozak (GCCGCCACC) sequence [Kozak et al.
(1999) Gene 234: 187-208]. The constructs were cloned in the
mammalian expression vector pcDNA3.3 (Invitrogen)
[0867] Freestyle.TM. 293-F (a HEK-293 subclone adapted to
suspension growth and chemically defined Freestyle medium,
(HEK-293F)) cells were obtained from Invitrogen and transfected
with the expression plasmids using 293fectin (Invitrogen),
according to the manufacturer's instructions and grown for 24-48
hours.
Binding Study of AXL Antibodies to Human AXL, Human MER, or Human
TYRO3
[0868] HEK-293F cells transiently transfected with expression
constructs for full length human AXL, MER, or TYRO3 were evaluated
for binding of HuMab-AXL antibodies by flow cytometry. Transfected
HEK-293F cells were incubated with serial dilutions of
AXL-antibodies (4-fold dilutions; final concentration range
0.002-10 g/mL) for 30 minutes at 4.degree. C. After washing three
times in PBS/0.1% BSA/0.02% azide, cells were incubated with
R-Phycoerythrin (PE)-conjugated goat-anti-human IgG F(ab')2
(Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.; cat.
No. 109-116-098) diluted 1/100 in PBS/0.1% BSA/0.02% azide (final
volume 100 lIL). Next, cells were washed twice in PBS/0.1%
BSA/0.02% azide, resuspended in 120 .mu.L PBS/0.1% BSA/0.02% azide
and analyzed on a FACS Cantoll (BD Biosciences). Staining with
mouse anti-human Mer (R&D Systems, cat. Mab8912) and mouse
anti-human Tyro3 (Dtk) (R&D Systems, cat. MAB859) were included
as controls for expression, IgG1-b12 was included as a non-binding
isotype control antibody. Binding curves were analyzed using
non-linear regression (sigmoidal dose-response with variable slope)
using GraphPad Prism V5.04 software (GraphPad Software, San Diego,
Calif., USA).
[0869] FIG. 18A shows that Humab-AXL antibodies showed
dose-dependent binding to the HEK293 cells expressing human AXL. In
contrast, no binding of HuMab-AXL antibodies to cells expressing
MER (FIG. 18B) or TYRO3 (FIG. 18C) or to untransfected HEK293 cells
(FIG. 18D) was observed. Staining with MER- and Tyro3-specific
antibodies confirmed that transfected cells showed proper
expression of MER (FIG. 18F) or TYRO3 (FIG. 18G), respectively.
Example 16--Internalization of Cell Surface Bound AXL
Antibodies
Internalization of Cell Surface Bound HuMab-AXL Evaluated by Flow
Cvtometry.
[0870] Internalization of cell surface bound HuMab-AXL antibodies
to MDA-MB-231 and Calu-1 cells (human lung carcinoma cell line;
ATCC, catalognumber HTB-54) was evaluated by flow cytometry. 50,000
cells were seeded in 96-well tissue culture plates and allowed to
attach for 6 hrs at 37.degree. C. Plates were incubated at
4.degree. C. for 30 minutes before incubation with serial dilutions
of AXL-antibodies (final concentration range 0.0032-10 .mu.g/mL) at
4.degree. C. for 1 hour. Subsequently, the medium was replaced by
tissue culture medium without antibody and cells were incubated
overnight (16-18 hours) at 37.degree. C. or 4.degree. C.
Subsequently, the cells were detached with 40 .mu.L warm trypsin
solution, washed with ice-cold PBS/0.1% BSA/0.02% azide, and
incubated for 30 minutes at 4.degree. C. with R-Phycoerythrin
(PE)-conjugated goat-anti-human IgG F(ab')2 (Jackson ImmunoResearch
Laboratories, Inc., West Grove, Pa.; cat. No. 109-116-098) diluted
1/100 in PBS/0.1% BSA/0.02% azide (final volume 100 .mu.L), to
detect AXL-antibodies on the cell surface. Finally, cells were
washed twice in PBS/0.1% BSA/0.02% azide, resuspended in 120 .mu.L
PBS/0.1% BSA/0.02% azide and analyzed on a FACS Cantoll (BD
Biosciences).
[0871] Binding curves were analyzed using non-linear regression
(sigmoidal dose-response with variable slope) using GraphPad Prism
V5.04 software (GraphPad Software, San Diego, Calif., USA).
[0872] FIG. 19 shows that, for all AXL HuMab antibodies and at all
concentrations tested, more antibody was detected on the plasma
membrane of cells that had been incubated at 4.degree. C. after
antibody binding, compared to cells that had been incubated at
37.degree. C. This illustrates that, at 37.degree. C., AXL
antibodies are internalized upon binding to the plasma
membrane.
Fab-TAMRA/QSY7 Internalization and Intracellular Degradation
Assay
[0873] Internalization of AXL antibodies was assessed in the
Fab-TAMRA/QSY7 internalization assay. This assay uses a fluorophore
(TAMRA) and quencher (QSY7) pair. In close proximity, for example,
upon conjugation to the same protein, TAMRA fluorescence is
quenched by QSY7. In this example, goat-anti-human IgG
Fab-fragments (Jackson Immunoresearch) were conjugated with
TAMRA/QSY7 (Fab-TAMRA/QSY7) as described (Ogawa et al. Mol Pharm
2009; 6(2):386-395), and AXL HuMab (1.5 .mu.g/mL) were preincubated
with Fab-TAMRA/QSY7 (12 .mu.g/mL; 30 min, 42C). The complex was
subsequently added to LCLC-103H cells and incubated for 24 h
incubation in the dark, under shaking conditions (200 rpm, 372C).
Internalization of the HuMab-Fab-TAMRA/QSY7 complex and
intracellular degradation in the endosomes and lysosomes causes
dissociation of TAMRA/QSY7, resulting in dequenching of TAMRA.
TAMRA fluorescence of LCLC-103H cells that had been incubated with
AXL antibodies complexed with Fab-TAMRA/QSY7 was measured on a FACS
Canto-II (BD Biosciences).
[0874] As shown in FIG. 20, the fluorescence intensity of LCLC-103H
cells was enhanced upon incubation with AXL-antibody-Fab-TAMRA/QSY7
complex, compared to IgG1-b12-Fab-TAMRA/QSY7 or Fab-TAMRA/QSY7
alone. This illustrates that AXL antibodies are internalized upon
binding to LCLC-103H cells.
Example 17--Anti-Tumor Efficacy of AXL-ADCs in an Esophageal Cancer
Patient-Derived Xenograft (PDX) Model
[0875] The anti-tumor activity of IgG1-AXL-107-vcMMAE was evaluated
in the subcutaneous esophageal PDX model ES0195 in BALB/c nude mice
(experiments performed by Crown Bioscience. Taicang Jiangsu
Province, China). Tumor fragments from donor mice bearing
patient-derived esophageal xenografts (ES0195) were used for
inoculation into BALB/c nude mice. Each mouse was inoculated
subcutaneously at the right flank with one tumor fragment (2-3 mm
in diameter) and tumors were allowed to grow until the tumor volume
was about 150 mm.sup.3. Randomization of animals was performed as
follows: animals bearing a tumor with a volume of about 150
mm.sup.3 were distributed in 5 experimental groups (8 animals per
group), considering a comparable median and mean of group tumor
volume. The treatment groups were: IgG1-b12, IgG1-b12-vcMMAE,
IgG1-AXL-107, IgG1-AXL-107-vcMMAE, and paclitaxel. The antibodies
and ADCs were dosed intravenously (i.v.) at 4 mg/kg at day of
randomization (day 0) and day 7. Paclitaxel was dosed
intra-peritoneally (i.p.) at 20 mg/kg at day 0, 7, and 14. Tumor
volumes (mm.sup.3) were monitored twice weekly and were calculated
from caliper (PLEXX) measurements as:
0.52.times.(length).times.(width)2.
[0876] FIG. 21 shows that treatment of mice with
IgG1-AXL-107-vcMMAE induced tumor regression of ES0195 tumors
compared to the IgG1-b12 and IgG1-b12-MMAE control groups
(p<0.001 at day 23, one-way ANOVA test). Treatment of mice with
the untargeted ADC IgG1-b12-vcMMAE did not show anti-tumor activity
in this model, illustrating that the therapeutic capacity of
AXL-ADCs depends on specific target binding. Mice that were treated
with paclitaxel showed tumor growth inhibition, but this was less
effective compared to treatment with IgG1-AXL-107-vcMMAE (p<0.05
at day 23, one-way ANOVA test).
Example 18--Anti-Tumor Efficacy of AXL-ADCs in a Cervical Cancer
Patient-Derived Xenograft (PDX) Model
[0877] The anti-tumor activity of IgG1-AXL-183-vcMMAE and
IgG1-AXL-726-vcMMAE was evaluated in the patient derived cervix
carcinoma xenograft CEXF 773 model in NMRI nu/nu mice (Harlan,
Netherlands). Experiments were performed by Oncotest (Freiburg,
Germany).
[0878] Tumor fragments were obtained from xenografts in serial
passage in nude mice. After removal from donor mice, tumors were
cut into fragments (4-5 mm diameter) and placed in PBS (with 10%
penicillin/streptomycin) until subcutaneous implantation. Mice
under isofluorane anesthesia received unilateral, subcutaneous
tumor implants in the flank. Tumors were allowed to grow until the
tumor volume was 50-250 mm.sup.3.
[0879] Randomization of animals was performed as follows: animals
bearing a tumor with a volume of 50-250 mm.sup.3 were distributed
in 4 experimental groups (8 animals per group), considering a
comparable median and mean of group tumor volume. The treatment
groups were: IgG1-b12, IgG1-b12-vcMMAE, IgG1-AXL-183-vcMMAE and
IgG1-AXL-726-vcMMAE. The antibodies and ADCs were dosed
intravenously (i.v.) at 4 mg/kg on the day of randomization (day 0)
and on day 7. Tumor volumes (mm.sup.3) were monitored twice weekly
and were calculated from caliper (PLEXX) measurements as:
0.52.times.(length).times.(width).sup.2.
[0880] FIG. 22 shows that treatment of mice with
IgG1-AXL-183-vcMMAE or IgG1-AXL-726-vcMMAE induced tumor regression
of CEXF 773 tumors compared to the IgG1-b12 and IgG1-b12-MMAE
control groups. Treatment of mice with the untargeted ADC
IgG1-b12-vcMMAE did not show anti-tumor activity in this model,
illustrating that the therapeutic capacity of AXL-ADCs depends on
specific target binding. Statistical analysis of tumor size at day
28 (Kruskal-Wallis and Mantel-Cox using a tumor size cut-off 500
mm.sup.3), showed that the average tumor size in mice treated with
IgG1-AXL-183-vcMMAE or IgG1-AXL-726-vcMMAE was significantly
smaller than in mice that had been treated with IgG1-b12 and
IgG1-b12-vcMMAE (p<0.001). IgG1-AXL-183-vcMMAE and
IgG1-AXL-726-vcMMAE were equally effective.
Example 19--Anti-Tumor Efficacy of AXL-ADCs in an Orthotopic Breast
Cancer Xenograft Model
[0881] The anti-tumor activity of IgG1-AXL-183-vcMMAE and
IgG1-AXL-726-vcMMAE was evaluated in in an orthotopic MDA-MB-231
D3H2LN xenograft model.
[0882] MDA-MB-231-luc D3H2LN Bioware cells (mammary gland
adenocarcinoma; Perkin Elmer, Waltham, Mass.) were implanted in the
mammary fat pad of 6-11 week old, female SCID
(C.B-17/IcrPrkdc-scid/CRL) mice (Charles-River) under isofluorane
anesthesia. Tumors were allowed to grow and mice were randomized
when tumors reached a volume of .sup..about.325 mm.sup.3.
Therefore, mice were distributed in 4 experimental groups (6-7
animals per group), considering a comparable median and mean of
group tumor volume. The treatment groups were: IgG1-b12,
IgG1-b12-vcMMAE, IgG1-AXL-183-vcMMAE and IgG1-AXL-726-vcMMAE. The
animals received a total of 4 biweekly doses of 3 mg/kg antibody or
ADC starting at the day of randomization. Tumor volumes (mm.sup.3)
were monitored twice weekly and were calculated from caliper
(PLEXX) measurements as:
0.52.times.(length).times.(width).sup.2.
[0883] FIG. 23 shows that treatment of mice with
IgG1-AXL-183-vcMMAE or IgG1-AXL-726-vcMMAE induced tumor regression
of MDA-MB-231 tumors compared to the IgG1-b12 and IgG1-b12-MMAE
control groups. Treatment of mice with the untargeted ADC
IgG1-b12-vcMMAE did not show anti-tumor activity in this model,
showing that the therapeutic capacity of AXL-ADCs depends on
specific target binding. Statistical analysis of tumor size at day
32 (One Way Anova test), showed that the average tumor size in mice
that had been treated with IgG1-AXL-183-vcMMAE or
IgG1-AXL-726-vcMMAE was significantly smaller than in mice that had
been treated with IgG1-b12 and IgG1-b12-vcMMAE (P<0.001). No
differences were observed between the IgG1-AXL-183-vcMMAE and
IgG1-AXL-726-vcMMAE treatment groups, illustrating that these
induced equally effective anti-tumor activity.
Example 20--In Vitro Cytotoxicity Induced by AXL-Specific Antibody
Drug Conjugates is Dependent on Target Expression
[0884] The in vitro cytotoxicity of IgG1-AXL-107-vcMMAE was tested
in human tumor cell lines with different levels of AXL
expression.
Cell Culture
[0885] LS174T cells (human colorectal adenocarcinoma cell line;
ATCC, cat no CL-188) were cultured in Minimum Essential Medium
(MEM) with Glutamax, Hepes and Phenol Red (Life Technologies, cat
no 42360-024). Components are 10% Donor Bovine Serium with Iron
(DBSI) (Life Technologies, cat no 10371-029) and 1% Sodium Pyruvate
(100 mM; Lonza, cat no BE13-115E) and 1% Penicillin/Streptomycin
(Lonza, cat no DE17-603E).
[0886] NCI-H226 cells (human lung squamous cell carcinoma; ATCC,
cat no CRL-5826), NCI-H661 cells (human large cell lung cancer;
ATCC, cat no HTB-183), and NCI-H1299 cells (human non-small cell
lung cancer; ATCC, cat no CRL-5803) were cultured in RPMI 1640
Medium (ATCC Modification; Life Technologies, cat no A10491-01).
Components are 10% Donor Bovine Serium with Iron (DBSI; Life
Technologies, cat no 10371-029) and 1% Penicillin/Streptomycin
(Lonza, cat no DE17-603E).
[0887] SKOV-3 cells (human ovarian adenocarcinoma; ATCC, cat no
HTB-77) were cultured in McCoy's 5A Medium with L-glutamine and
HEPES (Lonza, cat no BE12-168F). Components are 10% Donor Bovine
Serium with Iron (DBSI; Life Technologies, cat no 10371-029) and 1%
Penicillin/Streptomycin (Lonza, cat no DE17-603E).
[0888] Calu-1 cells (human lung epidermoid carcinoma; ATCC, cat no
HTB-54) were cultured in McCoy's 5A Medium with Catopeptone,
without HEPES (Life Technologies, cat no 26600-023). Components are
10% Donor Bovine Serium with Iron (DBSI; Life Technologies, cat no
10371-029) and 1% L-glutamine (200 nM) in 0.85% NaCl solution
(Lonza, cat no BE17-605F) and 1% Penicillin/Streptomycin (Lonza,
cat no DE17-603E). Calu-1 cells are resistant to EGFR targeted
therapy.
[0889] LCLC-103H cells (human large cell lung cancer), A431 cells
(human epidermoid adenocarcinoma) and MDA-MB-231 cells (human
breast cancer) were cultured as described in Example 8.
Quantification of AXL Expression on the Plasma Membrane of Human
Tumor Cell Lines
[0890] AXL expression on the plasma membrane of human tumor cell
lines was assessed by indirect immunofluorescence using QIFIKIT
(DAKO, Cat nr K0078) with mouse monoclonal antibody Z49M (Santa
Cruz biotechnology, Cat nr sc-73719). Adherent cells were
trypsinized and passed through a cell strainer to obtain single
cell suspensions. Cells were pelleted by centrifugation for 5
minutes at 1,200 rpm, washed with PBS and resuspended at a
concentration of 1.times.10.sup.6 cells/mL. The next steps were
performed on ice. 100 .mu.L of the single cell suspensions (100,000
cells per well) were seeded in polystyrene 96-well round-bottom
plates (Greiner Bio-One, Cat nr 650101). Cells were pelleted by
centrifugation for 3 minutes at 300.times.g and resuspended in 50
.mu.L antibody sample or mouse IgG1 isotype control sample
(BD/Pharmingen, Cat nr 555746) at a concentration of 10 .mu.g/mL.
After an incubation of 30 minutes at 4.degree. C., cells were
pelleted and resuspended in 150 .mu.L FACS buffer. Set-up and
calibration beads were added to the plate according to the
manufacturer's instructions. Cells and beads in parallel were
washed two more times with 150 .mu.L FACS buffer and resuspended in
50 .mu.L FITC-conjugated goat-anti-mouse IgG (1/50; DAKO, Cat nr
K0078). Secondary antibody was incubated for 30 minutes at
4.degree. C. in the dark. Cells and beads were washed twice with
150 .mu.L FACS buffer and resuspended in 100 .mu.L FACS buffer.
Immunofluorescence was measured on a FACS Canto II (BD Biosciences)
by recording 10,000 events within the gate of viable cells. The
mean fluorescence intensity of the calibration beads was used to
calculate the calibration curve using GraphPad Prism software
(GraphPad Software, San Diego, Calif., USA). For each cell line,
the antibody binding capacity (ABC), an estimate for the number of
AXL molecules expressed on the plasma membrane, was calculated
using the mean fluorescence intensity of the AXL antibody-stained
cells, based on the equation of the calibration curve
(interpolation of unknowns from the standard curve, using GraphPad
Software).
Cytotoxicity Assay
[0891] For LCLC-103H, A431, MDA-MB-231, NCI-H226, NCI-H661,
NCI-H1299, LS174T and SKOV-3 cells, the in vitro cytotoxicity assay
was performed as described in Example 8. For Calu-1, the
cytotoxicity assay was performed as described in Example 8, with
the adaptation that the cell cultures were incubated for 11 instead
of 5 days. Dose-response curves were generated using Graphpad Prism
software, using non-linear regression analysis. The percentage of
viable cells at an IgG1-AXL-107-vcMMAE concentration of 1 .mu.g/mL
was interpolated from the dose-response curves.
[0892] As shown in FIG. 24, IgG1-AXL-107-vcMMAE induced the most
potent cytotoxicity in cell lines with high AXL expression, whereas
cytotoxicity was low or absent in cell lines with low AXL
expression. The figure also illustrates that IgG1-AXL-107-vcMMAE is
effective in induction of cytotoxicity in cells resistant to EGFR
targeted therapy, such as Calu-1.
REFERENCES
[0893] [1] Paccez et al, Int. J. Cancer: 134, 1024-1033 (2013)
[0894] [2] Leconet et al, Oncogene, 1-10 (2013) [0895] [3] Linger
et al, Expert Opin. Ther. Targets, 14(10):1073-1090 (2010) [0896]
[4] Li et al, Oncogene, 28, 3442-3455 (2009) [0897] [5] Ye et al,
Oncogene, 1-11 (2010) [0898] [6] Alley et al, Current Opinion in
Chem. Bio., 4, 529-537 (2010) [0899] [7] lida et al, Anticancer
Research, 34:1821-1828 (2014) [0900] [8] WO 2012/175691; INSERM
[0901] [9] WO 2012/175692; INSERM [0902] [10] WO 2013/064685; PF
Medicament [0903] [11] WO 2013/090776; INSERM [0904] [12] WO
2009/063965; Chugain Pharmaceuticals [0905] [13] WO 2010/131733
[0906] [14] Hfizi et al., 2006, FEBS Journal, 273; 5231-5244 [0907]
[15] WO 2007/059782; Genmab A/S [0908] [16] Ward et al., Nature
341, 544-546 (1989) [0909] [17] Holt et al; Trends Biotechnol. 2003
November; 21(11):484-90 [0910] [18] Revets et al; Expert Opin Biol
Ther. 2005 January; 5(1):111-24 [0911] [19] Bird et al., Science
242, 423-426 (1988) [0912] [20] Huston et al., PNAS USA 85,
5879-5883 (1988) [0913] [21] Fundamental Immunology Ch. 7 (Paul,
W., ed., 2nd ed. Raven Press, N.Y. (1989) [0914] [22] Lefranc M P.
et al., Nucleic Acids Research, 27, 209-212, 1999 [0915] [23]
Brochet X. Nucl. Acids Res. 36, W503-508 (2008) [0916] [24]
Korshunov et al, Clinical Science, 2012 [0917] [25] Sambrook et al,
Molecular Cloning: A laboratory Manual, New York: Cold Spring
Harbor Laboratory Press, 1989, Ch. 15 [0918] [26] Kabat, E. A. et
al., Sequences of proteins of immunological interest. 5th
Edition--US Department of Health and Human Services, NIH
publication No. 91-3242, pp 662, 680, 689 (1991) [0919] [27] WO
2004/010957; Seattle Genetics, Inc. [0920] [28] U.S. Pat. No.
7,659,241; Seattle Genetics, Inc. [0921] [29] Wu et al., Generation
and Characterization of a Dual Variable Domain Immunoglobulin
(DVD-Ig.TM.) [0922] Molecule, In: Antibody Engineering, Springer
Berlin Heidelberg (2010) [0923] [30] WO 2011/131746; Genmab A/S
[0924] [31] WO/2002/020039; Trion Pharma/Fresenius Biotech [0925]
[32] WO9850431; Genetech [0926] [33] WO2011117329; Roche [0927]
[34] EP1870459; Amgen [0928] [35] WO2009089004; Amgen [0929] [36]
US201000155133; Chugai [0930] [37] WO2010129304; Oncomed [0931]
[38] WO2007110205; EMD Serono [0932] [39] WO 2010/015792; Regeneron
[0933] [40] WO11143545; Pfizer/Rinat [0934] [41] WO2012058768:
Zymeworks/Merck [0935] [42] WO2011028952; Xencor [0936] [43] WO
2009/080254; Roche [0937] [44] WO2008003116; F-Star [0938] [45]
U.S. Pat. No. 7,262,028; Crucell/Merus [0939] [46] U.S. Pat. No.
7,612,181; Abbott [0940] [47] WO20100226923; Unilever, Sanofi
Aventis [0941] [48] US007951918; Biogen Idec [0942] [49] CN
102250246; Changzhou Adam Biotech Inc [0943] [50] WO2012025525;
Roche [0944] [51] WO2012025530; Roche [0945] [52] WO2008157379;
Macrogenics [0946] [53] WO2010/080538; Macrogenics [0947] [54]
Goodman et al., Goodman and Gilman's The Pharmacological Basis Of
Therapeutics, 8th Ed., Macmillan Publishing Co., 1990 [0948] [55]
Vitetta, Immunol. Today 14, 252 (1993) [0949] [56] U.S. Pat. No.
5,194,594 [0950] [57] US 2005/0238649 [0951] [58] WO 2013/173391;
Concortis Biosystems, Corp. [0952] [59] Junghans et al., in Cancer
Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo,
eds., Lippincott Raven (1996)) [0953] [60] U.S. Pat. No. 4,681,581
[0954] [61] U.S. Pat. No. 4,735,210 [0955] [62] U.S. Pat. No.
5,101,827 [0956] [63] U.S. Pat. No. 5,102,990 [0957] [64] U.S. Pat.
No. 5,648,471 [0958] [65] U.S. Pat. No. 5,697,902 [0959] [66] U.S.
Pat. No. 4,766,106 [0960] [67] U.S. Pat. No. 4,179,337 [0961] [68]
U.S. Pat. No. 4,495,285 [0962] [69] U.S. Pat. No. 4,609,546 [0963]
[70] Hunter et al., Nature 144, 945 (1962), David et al.,
Biochemistry 13, 1014 (1974) [0964] [71] Pain et al., J. Immunol.
Meth. 40, 219 (1981) [0965] [72] Nygren, J. Histochem. and
Cytochem. 30, 407 (1982) [0966] [73] Antibody Engineering Handbook,
edited by Osamu Kanemitsu, published by Chijin Shokan (1994) [0967]
[74] WO 2002/083180; Syngenta BV [0968] [75] WO 2004/043493;
Syngenta BV [0969] [76] WO 2007/018431; Syngenta BV [0970] [77] WO
2007/089149; Syngenta BV [0971] [78] WO 2009/017394; Syngenta BV
[0972] [79] WO 2010/62171; Syngenta BV [0973] [80] U.S. Pat. No.
6,989,452; Medarex [0974] [81] Remington: The Science and Practice
of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co.,
Easton, Pa., 1995 [0975] [82] Sustained and Controlled Release Drug
Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New
York, 1978 [0976] [83] Sykes and Johnston, Nat Biotech 17, 355-59
(1997) [0977] [84] U.S. Pat. No. 6,077,835 [0978] [85] WO 00/70087
[0979] [86] Schakowski et al., Mol Ther 3 793-800 (2001) [0980]
[87] WO 00/46147 [0981] [88] Benvenisty and Reshef, PNAS USA 83,
9551-55 (1986) [0982] [89] Wigler et al., Cell 14, 725 (1978)
[0983] [90] Coraro and Pearson, Somatic Cell Genetics 7, 603 (1981)
[0984] [91] U.S. Pat. No. 5,589,466 [0985] [92] U.S. Pat. No.
5,973,972 [0986] [93] Van Heeke & Schuster, J Biol Chem 264,
5503-5509 (1989) [0987] [94] F. Ausubel et al., ed. Current
Protocols in Molecular Biology, Greene Publishing and Wiley
InterScience New York (1987) [0988] [95] Grant et al., Methods in
Enzymol 153, 516-544 (1987) [0989] [96] Lonberg, N. et al., Nature
368, 856 859 (1994) [0990] [97] Lonberg, N. Handbook of
Experimental Pharmacology 113, 49 101 (1994) [0991] [98] Lonberg,
N. and Huszar, D., Intern. Rev. Immunol. Vol. 13 65 93 (1995)
[0992] [99] Harding, F. and Lonberg, N. Ann. N.Y. Acad. Sci 764 536
546 (1995) [0993] [100] Taylor, L. et al., Nucleic Acids Research
20, 6287 6295 (1992) [0994] [101] Chen, J. et al., International
Immunology 5, 647 656 (1993) [0995] [102] Tuaillon et al., J.
Immunol. 152, 2912 2920 (1994) [0996] [103] Taylor, L. et al.,
International Immunology 6, 579 591 (1994) [0997] [104] Fishwild,
D. et al., Nature Biotechnology 14, 845 851 (1996) [0998] [105]
U.S. Pat. No. 5,545,806 [0999] [106] U.S. Pat. No. 5,569,825 [1000]
[107] U.S. Pat. No. 5,625,126 [1001] [108] U.S. Pat. No. 5,633,425
[1002] [109] U.S. Pat. No. 5,789,650 [1003] [110] U.S. Pat. No.
5,877,397 [1004] [111] U.S. Pat. No. 5,661,016 [1005] [112] U.S.
Pat. No. 5,814,318 [1006] [113] U.S. Pat. No. 5,874,299 [1007]
[114] U.S. Pat. No. 5,770,429 [1008] [115] U.S. Pat. No. 5,545,807
[1009] [116] WO 98/024884 [1010] [117] WO 94/025585 [1011] [118] WO
93/001227 [1012] [119] WO 92/022645 [1013] [120] WO 92/003918
[1014] [121] WO 01/009187. [1015] [122] Shieh, Neoplasia 2005
[1016] [123] Koorstra, Cancer Biol Ther 2009 [1017] [124] Hector,
Cancer Biol Ther 2010 [1018] [125] Sun, Ann Oncol 2003 [1019] [126]
Srivastava (ed.), Radiolabeled Monoclonal Antibodies For Imaging
And Therapy (Plenum Press 1988), Chase [1020] [127] "Medical
Applications of Radioisotopes," in Remington's Pharmaceutical
Sciences, 18th Edition, Gennaro et al., (eds.), pp. 624-652 (Mack
Publishing Co., 1990) [1021] [128] Brown, "Clinical Use of
Monoclonal Antibodies," in Biotechnology And Pharmacy 227-49,
Pezzuto et al., (eds.) (Chapman & Hall 1993) [1022] [129] U.S.
Pat. No. 5,057,313 [1023] [130] U.S. Pat. No. 6,331,175 [1024]
[131] U.S. Pat. No. 5,635,483 [1025] [132] U.S. Pat. No. 5,780,588
[1026] [133] Woyke et al (2001) Antimicrob. Agents and Chemother.
45(12): 3580-3584 [1027] [134] U.S. Pat. No. 5,663,149 [1028] [135]
Pettit et al., (1998) Antimicrob. Agents and Chemother.
42:2961-2965 [1029] [136] Senter et al., Proceedings of the
American Association for Cancer Research. Volume 45, abstract
number 623, presented Mar. 28, 2004 [1030] [137] US 2005/0238649
[1031] [138] U.S. Pat. No. 7,498,298; Seattle Genetics, Inc. [1032]
[139] U.S. Ser. No. 11/833,954; Seattle Genetics, Inc. [1033] [140]
WO 2005/081711; Seattle Genetics, Inc. [1034] [141] Kozak et al.
(1999) Gene 234: 187-208 [1035] [142] EP 2 220 131; U3 Pharma
[1036] [143] WO 2011/159980; Genentech [1037] [144] Barbas, CF. J
Mol Biol. 1993 Apr. 5; 230(3):812-23 [1038] [145] U.S. Pat. No.
7,829,531; Seattle Genetics, Inc. [1039] [146] U.S. Pat. No.
7,851,437; Seattle Genetics, Inc. [1040] [147] U.S. Ser. No.
11/833,028; Seattle Genetics, Inc. [1041] [148] WO 2013/173392;
Concortis Biosystems, Corp. [1042] [149] WO 2013/173393; Concortis
Biosystems, Corp. [1043] [150] Sun et al. (2005) Bioconjugate Chem.
16: 1282-1290 [1044] [151] McDonagh et al., (2006) Protein Eng.
Design Sel. 19: 299-307 [1045] [152] Alley et al., (2008)
Bioconjugate Chem. 19: 759-765
Sequence CWU 1
1
1471116PRThomo sapiens 1Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Thr Thr Ser Gly Ser Gly Ala
Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Ile Trp
Ile Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val 100 105 110Thr Val
Ser Ser 1152108PRThomo sapiens 2Glu Ile Val Leu Thr Gln Ser Pro Gly
Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser
Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp
Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95Tyr Thr
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 1053120PRThomo sapiens
3Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5
10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ser Ala Ile Ser Ile Ser Gly Ala Ser Thr Phe Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Ser65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Phe Cys 85 90 95Arg Gly Tyr Ser Gly Tyr Val Tyr Asp
Ala Phe Asp Ile Trp Gly Gln 100 105 110Gly Thr Met Val Thr Val Ser
Ser 115 1204107PRThomo sapiens 4Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Asn Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys
Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu
Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 85 90 95Thr Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 1055120PRThomo sapiens 5Glu
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ser Ala Ile Ser Ile Ser Gly Gly Ser Thr Phe Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Arg Gly Tyr Ser Gly Tyr Val Tyr Asp Ala
Phe Asp Phe Trp Gly Gln 100 105 110Gly Thr Met Val Thr Val Ser Ser
115 1206107PRThomo sapiens 6Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Asn Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 1057121PRThomo sapiens 7Glu Val
Gln Leu Leu Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25
30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Ala Ile Ser Ile Gly Gly Gly Asn Ala Tyr Tyr Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Lys Pro Gly Phe Ile Met Val Arg Gly Pro
Leu Asp Tyr Trp Gly 100 105 110Gln Gly Ala Leu Val Thr Val Ser Ser
115 1208121PRThomo sapiens 8Glu Val Gln Leu Leu Asp Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Ser Ile Gly Gly
Gly Asn Ala Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn
Ser Leu Arg Ala Ala Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Pro
Gly Phe Ile Leu Val Arg Gly Pro Leu Asp Tyr Trp Gly 100 105 110Gln
Gly Ala Leu Val Thr Val Ser Ser 115 1209108PRThomo sapiens 9Glu Ile
Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu
Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Ser 20 25
30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe
Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg
Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
Gly Ser Ser Pro 85 90 95Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 10510125PRThomo sapiens 10Glu Val Gln Leu Leu Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Asp Ile Ser Val
Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Lys Glu Gly Tyr Ile Trp Phe Gly Glu Ser Leu Ser Tyr Ala Phe 100 105
110Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120
12511107PRThomo sapiens 11Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg
Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Phe 85 90 95Thr Phe Gly
Pro Gly Thr Lys Val Asp Ile Lys 100 10512125PRThomo sapiens 12Glu
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ser Asp Ile Ser Val Ser Gly Gly Ser Thr Tyr Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Lys Glu Gly Tyr Ile Trp Phe Gly Glu
Ser Leu Ser Tyr Ala Phe 100 105 110Asp Ile Trp Gly Gln Gly Thr Met
Val Thr Val Ser Ser 115 120 12513107PRThomo sapiens 13Glu Ile Val
Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40
45Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu
Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly
Arg Ser Phe 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100
10514125PRThomo sapiens 14Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Asp Ile Ser Val Ser Gly
Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu His Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Glu
Gly Tyr Ile Trp Phe Gly Glu Ser Leu Ser Tyr Ala Phe 100 105 110Asp
Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120
12515107PRThomo sapiens 15Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg
Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Phe 85 90 95Thr Phe Gly
Pro Gly Thr Lys Val Asp Ile Lys 100 10516117PRThomo sapiens 16Gln
Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu1 5 10
15Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr
20 25 30Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
Ile 35 40 45Gly Glu Ile Asn Gln Ser Gly Ser Thr Asn Tyr Asn Pro Ser
Leu Lys 50 55 60Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
Phe Ser Leu65 70 75 80Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ser
Val Tyr Tyr Cys Ala 85 90 95Ser Gly Asn Trp Asp His Phe Phe Asp Tyr
Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ser
11517117PRThomo sapiens 17Gln Val Gln Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Ala Val Tyr
Gly Gly Ser Phe Ser Gly Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln Pro
Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile Gln Gln Ser Gly
Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Ile Ser
Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser Ser
Val Thr Ala Ala Asp Thr Ser Val Tyr Tyr Cys Ala 85 90 95Ser Gly Asn
Trp Asp His Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val
Thr Val Ser Ser 11518107PRThomo sapiens 18Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Val Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile
Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30Leu Ala Trp Tyr
Gln His Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ala Thr
Ser Ser Leu Gln Ser Gly Val Thr Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Lys Ser Phe Pro Trp
85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10519123PRThomo sapiens 19Gln Val Pro Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Ala Val Tyr
Gly Gly Ser Phe Ser Gly Tyr 20 25 30His Trp Ser Trp Ile Arg Gln Pro
Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile Ser His Ser Gly
Arg Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Ile Ser
Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser Ser
Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Phe Ile
Thr Met Ile Arg Gly Thr Ile Ile Thr His Phe Asp Tyr 100 105 110Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12020107PRThomo sapiens
20Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Tyr His Ser Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu
Ile Lys 100 10521124PRThomo sapiens 21Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys
Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Arg Ile Ile
Pro Ile Phe Gly Ile Ala Asn Tyr Val Gln Lys Phe 50 55 60Gln Gly Arg
Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75 80Met
Glu Leu Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95Ala Arg Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe Asp
100 105 110Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115
12022107PRThomo sapiens 22Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro
Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser
Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro
Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Tyr Gly Ser Ser Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Leu
Glu Ile Lys 100 10523124PRThomo sapiens 23Gln Val Gln Leu Val Gln
Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser Trp
Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Arg Ile
Ile Pro Ile Phe Gly Ile Ala Asn Tyr Val Gln Lys Phe 50 55 60Gln Gly
Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Arg Gly Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe
Asp 100 105 110Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115
12024107PRThomo sapiens 24Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg
Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Tyr 85 90 95Thr Phe Gly
Gln Gly Thr Lys Leu Glu Ile Lys 100 10525124PRThomo sapiens 25Gln
Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30Ala Ile Asn Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
Met 35 40 45Gly Arg Ile Ile Pro Ile Phe Gly Ile Val Asn Tyr Ala Gln
Lys Phe 50 55 60Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser
Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Gly Asn Tyr Tyr Gly Ser Gly
Ser Pro Asp Val Phe Asp 100 105 110Ile Trp Gly Gln Gly Thr Met Val
Thr Val Ser Ser 115 12026107PRThomo sapiens 26Glu Ile Val Leu Thr
Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr
Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75
80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Tyr
85 90 95Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
10527124PRThomo sapiens 27Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Asn Trp Met Arg Gln Ala
Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Arg Ile Ile Pro Ile Phe
Gly Ile Val Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Leu
Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser
Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg
Gly Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe Asp 100 105 110Ile
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 12028106PRThomo
sapiens 28Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser
Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val
Ser Ser Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Arg Ser Asn Trp Leu Thr 85 90 95Phe Gly Gly Gly Thr Lys Val
Glu Ile Lys 100 10529124PRThomo sapiens 29Gln Val Gln Leu Val Gln
Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser Trp
Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Arg Ile
Ile Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly
Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Arg Gly Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe
Asp 100 105 110Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115
12030107PRThomo sapiens 30Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg
Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Tyr 85 90 95Thr Phe Gly
Gln Gly Thr Lys Leu Glu Ile Lys 100 10531123PRThomo sapiens 31Gln
Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu1 5 10
15Thr Leu Ser Leu Thr Cys Ala Ile Asp Gly Gly Ser Phe Ser Gly Tyr
20 25 30Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp
Ile 35 40 45Gly Glu Ile Ser His Ser Gly Arg Thr Asn Tyr Asn Pro Ser
Leu Lys 50 55 60Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln
Phe Ser Leu65 70 75 80Lys Leu Ser Ser Val Ala Ala Ala Asp Thr Ala
Val Tyr Tyr Cys Ala 85 90 95Arg Phe Ile Thr Met Ile Arg Gly Ala Ile
Ile Thr His Phe Asp Tyr 100 105 110Trp Gly Gln Gly Ala Leu Val Thr
Val Ser Ser 115 12032123PRThomo sapiens 32Gln Val Gln Leu Gln Gln
Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr
Cys Ala Ile Asp Gly Gly Ser Phe Ser Gly Tyr 20 25 30Tyr Trp Ser Trp
Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile
Ser His Ser Gly Arg Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg
Val Thr Ile Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75
80Lys Leu Ser Ser Val Ala Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95Arg Phe Ile Thr Leu Ile Arg Gly Ala Ile Ile Thr His Phe Asp
Tyr 100 105 110Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser 115
12033107PRThomo sapiens 33Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr 85 90 95Thr Phe Gly
Gln Gly Thr Lys Leu Glu Ile Lys 100 10534120PRThomo sapiens 34Gln
Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Thr Tyr
20 25 30Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ala Val Ile Ser Tyr Asp Gly Asp Asn Lys Tyr Ser Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Arg Lys Leu Gly Ile Asp Ala
Phe Asp Ile Trp Gly Gln 100 105 110Gly Thr Met Val Thr Val Ser Ser
115 12035107PRThomo sapiens 35Ala Ile Gln Leu Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Ala 20 25 30Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Asp Ala Ser Ser Leu
Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro65 70 75 80Glu Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Phe 85 90 95Thr Phe
Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105368PRThomo sapiens 36Gly
Phe Thr Phe Ser Ser Tyr Ala1 5378PRThomo sapiens 37Thr Ser Gly Ser
Gly Ala Ser Thr1 5389PRThomo sapiens 38Ala Lys Ile Trp Ile Ala Phe
Asp Ile1 5397PRThomo sapiens 39Gln Ser Val Ser Ser Ser Tyr1
5409PRThomo sapiens 40Gln Gln Tyr Gly Ser Ser Pro Tyr Thr1
5418PRThomo sapiens 41Gly Phe Thr Phe Ser Ser Tyr Ala1 5428PRThomo
sapiens 42Ile Ser Ile Ser Gly Ala Ser Thr1 54313PRThomo sapiens
43Arg Gly Tyr Ser Gly Tyr Val Tyr Asp Ala Phe Asp Ile1 5
10446PRThomo sapiens 44Gln Gly Ile Ser Asn Trp1 5459PRThomo sapiens
45Gln Gln Tyr Asn Ser Tyr Pro Leu Thr1 5468PRThomo sapiens 46Gly
Phe Thr Phe Ser Ser Tyr Ala1 5478PRThomo sapiens 47Ile Ser Ile Ser
Gly Gly Ser Thr1 54813PRThomo sapiens 48Arg Gly Tyr Ser Gly Tyr Val
Tyr Asp Ala Phe Asp Phe1 5 10496PRThomo sapiens 49Gln Gly Ile Ser
Asn Trp1 5509PRThomo sapiens 50Gln Gln Tyr Asn Ser Tyr Pro Leu Thr1
5518PRThomo sapiens 51Gly Phe Thr Phe Ser Ser Tyr Ala1 5528PRThomo
sapiens 52Ile Ser Ile Gly Gly Gly Asn Ala1 55314PRThomo sapiens
53Ala Lys Pro Gly Phe Ile Met Val Arg Gly Pro Leu Asp Tyr1 5
105414PRThomo sapiens 54Ala Lys Pro Gly Phe Ile Leu Val Arg Gly Pro
Leu Asp Tyr1 5 10557PRThomo sapiens 55Gln Ser Val Ser Asn Ser Tyr1
5569PRThomo sapiens 56Gln Gln Tyr Gly Ser Ser Pro Tyr Thr1
5578PRThomo sapiens 57Gly Phe Thr Phe Ser Ser Tyr Ala1 5588PRThomo
sapiens 58Ile Ser Val Ser Gly Gly Ser Thr1 55918PRThomo sapiens
59Ala Lys Glu Gly Tyr Ile Trp Phe Gly Glu Ser Leu Ser Tyr Ala Phe1
5 10 15Asp Ile607PRThomo sapiens 60Gln Ser Val Ser Ser Ser Tyr1
5618PRThomo sapiens 61Gln Gln Tyr Gly Arg Ser Phe Thr1 5628PRThomo
sapiens 62Gly Phe Thr Phe Ser Asn Tyr Ala1 5638PRThomo sapiens
63Ile Ser Val Ser Gly Gly Ser Thr1 56418PRThomo sapiens 64Ala Lys
Glu Gly Tyr Ile Trp Phe Gly Glu Ser Leu Ser Tyr Ala Phe1 5 10 15Asp
Ile657PRThomo sapiens 65Gln Ser Val Ser Ser Ser Tyr1 5668PRThomo
sapiens 66Gln Gln Tyr Gly Arg Ser Phe Thr1 5678PRThomo sapiens
67Gly Phe Thr Phe Ser Ser Tyr Ala1 5688PRThomo sapiens 68Ile Ser
Val Ser Gly Gly Ser Thr1 56918PRThomo sapiens 69Ala Lys Glu Gly Tyr
Ile Trp Phe Gly Glu Ser Leu Ser Tyr Ala Phe1 5 10 15Asp
Ile707PRThomo sapiens 70Gln Ser Val Ser Ser Ser Tyr1 5718PRThomo
sapiens 71Gln Gln Tyr Gly Arg Ser Phe Thr1 5728PRThomo sapiens
72Gly Gly Ser Phe Ser Gly Tyr Tyr1 5735PRThomo sapiens 73Ile Asn
Gln Ser Gly1 5747PRThomo sapiens 74Ile Gln Gln Ser Gly Ser Thr1
57511PRThomo sapiens 75Ala Ser Gly Asn Trp Asp His Phe Phe Asp Tyr1
5 10766PRThomo sapiens 76Gln Gly Ile Ser Ser Trp1 5779PRThomo
sapiens 77Gln Gln Ala Lys Ser Phe Pro Trp Thr1 5788PRThomo sapiens
78Gly Gly Ser Phe Ser Gly Tyr His1 5797PRThomo sapiens 79Ile Ser
His Ser Gly Arg Thr1 58017PRThomo sapiens 80Ala Ser Phe Ile Thr Met
Ile Arg Gly Thr Ile Ile Thr His Phe Asp1 5 10 15Tyr816PRThomo
sapiens 81Gln Gly Ile Ser Ser Trp1 5829PRThomo sapiens 82Gln Gln
Tyr His Ser Tyr Pro Tyr Thr1 5838PRThomo sapiens 83Gly Gly Thr Phe
Ser Ser Tyr Ala1 5848PRThomo sapiens 84Ile Ile Pro Ile Phe Gly Ile
Ala1 58517PRThomo sapiens 85Ala Arg Arg Gly Asp Tyr Tyr Gly Ser Gly
Ser Pro Asp Val Phe Asp1 5 10 15Ile867PRThomo sapiens 86Gln Ser Val
Ser Ser Ser Tyr1 5878PRThomo sapiens 87Gln Gln Tyr Gly Ser Ser Tyr
Thr1 5888PRThomo sapiens 88Gly Gly Thr Phe Ser Ser Tyr Ala1
5898PRThomo sapiens 89Ile Ile Pro Ile Phe Gly Ile Ala1 59017PRThomo
sapiens 90Ala Arg Arg Gly Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val
Phe Asp1 5 10 15Ile917PRThomo sapiens 91Gln Ser Val Ser Ser Ser
Tyr1 5928PRThomo sapiens 92Gln Gln Tyr Gly Ser Ser Tyr Thr1
5938PRThomo sapiens 93Gly Gly Thr Phe Ser Ser Tyr Ala1 5948PRThomo
sapiens 94Ile Ile Pro Ile Phe Gly Ile Val1 59517PRThomo sapiens
95Ala Arg Arg Gly Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe Asp1
5 10 15Ile967PRThomo sapiens 96Gln Ser Val Ser Ser Ser Tyr1
5978PRThomo sapiens 97Gln Gln Tyr Gly Ser Ser Tyr Thr1 5988PRThomo
sapiens 98Gly Gly Thr Phe Ser Ser Tyr Ala1 5998PRThomo sapiens
99Ile Ile Pro Ile Phe Gly Ile Val1 510017PRThomo sapiens 100Ala Arg
Arg Gly Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe Asp1 5 10
15Ile1016PRThomo sapiens 101Gln Ser Val Ser Ser Tyr1 51028PRThomo
sapiens 102Gln Gln Arg Ser Asn Trp Leu Thr1 51038PRThomo sapiens
103Gly Gly Thr Phe Ser Ser Tyr Ala1 51048PRThomo sapiens 104Ile Ile
Pro Ile Phe Gly Ile Ala1 510518PRThomo sapiens 105Ala Arg Arg Gly
Asn Tyr Tyr Gly Ser Gly Ser Pro Asp Val Phe Asp1 5 10 15Ile
Ser1067PRThomo sapiens 106Gln Ser Val Ser Ser Ser Tyr1 51078PRThomo
sapiens 107Gln Gln Tyr Gly Ser Ser Tyr Thr1 51088PRThomo sapiens
108Gly Gly Ser Phe Ser Gly Tyr Tyr1 51097PRThomo sapiens 109Ile Ser
His Ser Gly Arg Thr1
511017PRThomo sapiens 110Ala Arg Phe Ile Thr Met Ile Arg Gly Ala
Ile Ile Thr His Phe Asp1 5 10 15Tyr11117PRThomo sapiens 111Ala Arg
Phe Ile Thr Leu Ile Arg Gly Ala Ile Ile Thr His Phe Asp1 5 10
15Tyr1126PRThomo sapiens 112Gln Gly Ile Ser Ser Trp1 51139PRThomo
sapiens 113Gln Gln Tyr His Ser Tyr Pro Tyr Thr1 51148PRThomo
sapiens 114Gly Phe Ser Phe Ser Thr Tyr Ala1 51158PRThomo sapiens
115Ile Ser Tyr Asp Gly Asp Asn Lys1 511613PRThomo sapiens 116Ala
Arg Gly Arg Lys Leu Gly Ile Asp Ala Phe Asp Ile1 5 101176PRThomo
sapiens 117Gln Gly Ile Ser Ser Ala1 51189PRThomo sapiens 118Gln Gln
Phe Asn Ser Tyr Pro Phe Thr1 51198PRThomo
sapiensMISC_FEATURE(6)..(6)Wherein X is A or G 119Ile Ser Ile Ser
Gly Xaa Ser Thr1 512013PRThomo sapiensMisc(13)..(13)Wherein X is I
of F 120Arg Gly Tyr Ser Gly Tyr Val Tyr Asp Ala Phe Asp Xaa1 5
101218PRThomo sapiensMISC_FEATURE(8)..(8)Wherein X is I or F 121Gly
Gly Ser Phe Ser Gly Tyr Xaa1 512217PRThomo
sapiensMISC_FEATURE(2)..(2)Wherein X is S or
RMISC_FEATURE(10)..(10)Wherein X is T or A 122Ala Xaa Phe Ile Thr
Met Ile Arg Gly Xaa Ile Ile Thr His Phe Asp1 5 10 15Tyr1238PRThomo
sapiensMISC_FEATURE(6)..(6)Wherein X is S or N 123Gly Phe Thr Phe
Ser Xaa Tyr Ala1 51248PRThomo sapiens 124Ile Ser Val Ser Gly Gly
Ser Thr1 512518PRThomo sapiens 125Ala Lys Glu Gly Tyr Ile Trp Phe
Gly Glu Ser Leu Ser Tyr Ala Phe1 5 10 15Asp Ile1268PRThomo
sapiensMISC_FEATURE(8)..(8)Wherein X is A or V 126Ile Ile Pro Ile
Phe Gly Ile Xaa1 512717PRThomo sapiensMISC_FEATURE(5)..(5)Wherein X
is D or N 127Ala Arg Arg Gly Xaa Tyr Tyr Gly Ser Gly Ser Pro Asp
Val Phe Asp1 5 10 15Ile1287PRThomo
sapiensMISC_FEATURE(4)..(4)Wherein X is S or deleted 128Gln Ser Val
Xaa Ser Ser Tyr1 51298PRThomo sapiensMISC_FEATURE(3)..(3)Wherein X
is R or YMISC_FEATURE(4)..(4)Wherein X is Sor
GMISC_FEATURE(4)..(4)Wherein X is Sor GMISC_FEATURE(5)..(5)Wherein
X is N or SMISC_FEATURE(6)..(6)Wherein X is W or
SMISC_FEATURE(6)..(6)Wherein X is W or SMISC_FEATURE(7)..(7)Wherein
X is L or Y 129Gln Gln Xaa Xaa Xaa Xaa Xaa Thr1 5130894PRThomo
sapiens 130Met Ala Trp Arg Cys Pro Arg Met Gly Arg Val Pro Leu Ala
Trp Cys1 5 10 15Leu Ala Leu Cys Gly Trp Ala Cys Met Ala Pro Arg Gly
Thr Gln Ala 20 25 30Glu Glu Ser Pro Phe Val Gly Asn Pro Gly Asn Ile
Thr Gly Ala Arg 35 40 45Gly Leu Thr Gly Thr Leu Arg Cys Gln Leu Gln
Val Gln Gly Glu Pro 50 55 60Pro Glu Val His Trp Leu Arg Asp Gly Gln
Ile Leu Glu Leu Ala Asp65 70 75 80Ser Thr Gln Thr Gln Val Pro Leu
Gly Glu Asp Glu Gln Asp Asp Trp 85 90 95Ile Val Val Ser Gln Leu Arg
Ile Thr Ser Leu Gln Leu Ser Asp Thr 100 105 110Gly Gln Tyr Gln Cys
Leu Val Phe Leu Gly His Gln Thr Phe Val Ser 115 120 125Gln Pro Gly
Tyr Val Gly Leu Glu Gly Leu Pro Tyr Phe Leu Glu Glu 130 135 140Pro
Glu Asp Arg Thr Val Ala Ala Asn Thr Pro Phe Asn Leu Ser Cys145 150
155 160Gln Ala Gln Gly Pro Pro Glu Pro Val Asp Leu Leu Trp Leu Gln
Asp 165 170 175Ala Val Pro Leu Ala Thr Ala Pro Gly His Gly Pro Gln
Arg Ser Leu 180 185 190His Val Pro Gly Leu Asn Lys Thr Ser Ser Phe
Ser Cys Glu Ala His 195 200 205Asn Ala Lys Gly Val Thr Thr Ser Arg
Thr Ala Thr Ile Thr Val Leu 210 215 220Pro Gln Gln Pro Arg Asn Leu
His Leu Val Ser Arg Gln Pro Thr Glu225 230 235 240Leu Glu Val Ala
Trp Thr Pro Gly Leu Ser Gly Ile Tyr Pro Leu Thr 245 250 255His Cys
Thr Leu Gln Ala Val Leu Ser Asp Asp Gly Met Gly Ile Gln 260 265
270Ala Gly Glu Pro Asp Pro Pro Glu Glu Pro Leu Thr Ser Gln Ala Ser
275 280 285Val Pro Pro His Gln Leu Arg Leu Gly Ser Leu His Pro His
Thr Pro 290 295 300Tyr His Ile Arg Val Ala Cys Thr Ser Ser Gln Gly
Pro Ser Ser Trp305 310 315 320Thr His Trp Leu Pro Val Glu Thr Pro
Glu Gly Val Pro Leu Gly Pro 325 330 335Pro Glu Asn Ile Ser Ala Thr
Arg Asn Gly Ser Gln Ala Phe Val His 340 345 350Trp Gln Glu Pro Arg
Ala Pro Leu Gln Gly Thr Leu Leu Gly Tyr Arg 355 360 365Leu Ala Tyr
Gln Gly Gln Asp Thr Pro Glu Val Leu Met Asp Ile Gly 370 375 380Leu
Arg Gln Glu Val Thr Leu Glu Leu Gln Gly Asp Gly Ser Val Ser385 390
395 400Asn Leu Thr Val Cys Val Ala Ala Tyr Thr Ala Ala Gly Asp Gly
Pro 405 410 415Trp Ser Leu Pro Val Pro Leu Glu Ala Trp Arg Pro Gly
Gln Ala Gln 420 425 430Pro Val His Gln Leu Val Lys Glu Pro Ser Thr
Pro Ala Phe Ser Trp 435 440 445Pro Trp Trp Tyr Val Leu Leu Gly Ala
Val Val Ala Ala Ala Cys Val 450 455 460Leu Ile Leu Ala Leu Phe Leu
Val His Arg Arg Lys Lys Glu Thr Arg465 470 475 480Tyr Gly Glu Val
Phe Glu Pro Thr Val Glu Arg Gly Glu Leu Val Val 485 490 495Arg Tyr
Arg Val Arg Lys Ser Tyr Ser Arg Arg Thr Thr Glu Ala Thr 500 505
510Leu Asn Ser Leu Gly Ile Ser Glu Glu Leu Lys Glu Lys Leu Arg Asp
515 520 525Val Met Val Asp Arg His Lys Val Ala Leu Gly Lys Thr Leu
Gly Glu 530 535 540Gly Glu Phe Gly Ala Val Met Glu Gly Gln Leu Asn
Gln Asp Asp Ser545 550 555 560Ile Leu Lys Val Ala Val Lys Thr Met
Lys Ile Ala Ile Cys Thr Arg 565 570 575Ser Glu Leu Glu Asp Phe Leu
Ser Glu Ala Val Cys Met Lys Glu Phe 580 585 590Asp His Pro Asn Val
Met Arg Leu Ile Gly Val Cys Phe Gln Gly Ser 595 600 605Glu Arg Glu
Ser Phe Pro Ala Pro Val Val Ile Leu Pro Phe Met Lys 610 615 620His
Gly Asp Leu His Ser Phe Leu Leu Tyr Ser Arg Leu Gly Asp Gln625 630
635 640Pro Val Tyr Leu Pro Thr Gln Met Leu Val Lys Phe Met Ala Asp
Ile 645 650 655Ala Ser Gly Met Glu Tyr Leu Ser Thr Lys Arg Phe Ile
His Arg Asp 660 665 670Leu Ala Ala Arg Asn Cys Met Leu Asn Glu Asn
Met Ser Val Cys Val 675 680 685Ala Asp Phe Gly Leu Ser Lys Lys Ile
Tyr Asn Gly Asp Tyr Tyr Arg 690 695 700Gln Gly Arg Ile Ala Lys Met
Pro Val Lys Trp Ile Ala Ile Glu Ser705 710 715 720Leu Ala Asp Arg
Val Tyr Thr Ser Lys Ser Asp Val Trp Ser Phe Gly 725 730 735Val Thr
Met Trp Glu Ile Ala Thr Arg Gly Gln Thr Pro Tyr Pro Gly 740 745
750Val Glu Asn Ser Glu Ile Tyr Asp Tyr Leu Arg Gln Gly Asn Arg Leu
755 760 765Lys Gln Pro Ala Asp Cys Leu Asp Gly Leu Tyr Ala Leu Met
Ser Arg 770 775 780Cys Trp Glu Leu Asn Pro Gln Asp Arg Pro Ser Phe
Thr Glu Leu Arg785 790 795 800Glu Asp Leu Glu Asn Thr Leu Lys Ala
Leu Pro Pro Ala Gln Glu Pro 805 810 815Asp Glu Ile Leu Tyr Val Asn
Met Asp Glu Gly Gly Gly Tyr Pro Glu 820 825 830Pro Pro Gly Ala Ala
Gly Gly Ala Asp Pro Pro Thr Gln Pro Asp Pro 835 840 845Lys Asp Ser
Cys Ser Cys Leu Thr Ala Ala Glu Val His Pro Ala Gly 850 855 860Arg
Tyr Val Leu Cys Pro Ser Thr Thr Pro Ser Pro Ala Gln Pro Ala865 870
875 880Asp Arg Gly Ser Pro Ala Ala Pro Gly Gln Glu Asp Gly Ala 885
890131904PRTMus Musculus 131Met Ala Trp Arg Cys Pro Arg Met Gly Arg
Val Pro Leu Ala Trp Cys1 5 10 15Leu Ala Leu Cys Gly Trp Ala Cys Met
Tyr Pro Tyr Asp Val Pro Asp 20 25 30Tyr Ala Ala His Lys Asp Thr Gln
Thr Glu Ala Gly Ser Pro Phe Val 35 40 45Gly Asn Pro Gly Asn Ile Thr
Gly Ala Arg Gly Leu Thr Gly Thr Leu 50 55 60Arg Cys Glu Leu Gln Val
Gln Gly Glu Pro Pro Glu Val Val Trp Leu65 70 75 80Arg Asp Gly Gln
Ile Leu Glu Leu Ala Asp Asn Thr Gln Thr Gln Val 85 90 95Pro Leu Gly
Glu Asp Trp Gln Asp Glu Trp Lys Val Val Ser Gln Leu 100 105 110Arg
Ile Ser Ala Leu Gln Leu Ser Asp Ala Gly Glu Tyr Gln Cys Met 115 120
125Val His Leu Glu Gly Arg Thr Phe Val Ser Gln Pro Gly Phe Val Gly
130 135 140Leu Glu Gly Leu Pro Tyr Phe Leu Glu Glu Pro Glu Asp Lys
Ala Val145 150 155 160Pro Ala Asn Thr Pro Phe Asn Leu Ser Cys Gln
Ala Gln Gly Pro Pro 165 170 175Glu Pro Val Thr Leu Leu Trp Leu Gln
Asp Ala Val Pro Leu Ala Pro 180 185 190Val Thr Gly His Ser Ser Gln
His Ser Leu Gln Thr Pro Gly Leu Asn 195 200 205Lys Thr Ser Ser Phe
Ser Cys Glu Ala His Asn Ala Lys Gly Val Thr 210 215 220Thr Ser Arg
Thr Ala Thr Ile Thr Val Leu Pro Gln Arg Pro His His225 230 235
240Leu His Val Val Ser Arg Gln Pro Thr Glu Leu Glu Val Ala Trp Thr
245 250 255Pro Gly Leu Ser Gly Ile Tyr Pro Leu Thr His Cys Asn Leu
Gln Ala 260 265 270Val Leu Ser Asp Asp Gly Val Gly Ile Trp Leu Gly
Lys Ser Asp Pro 275 280 285Pro Glu Asp Pro Leu Thr Leu Gln Val Ser
Val Pro Pro His Gln Leu 290 295 300Arg Leu Glu Lys Leu Leu Pro His
Thr Pro Tyr His Ile Arg Ile Ser305 310 315 320Cys Ser Ser Ser Gln
Gly Pro Ser Pro Trp Thr His Trp Leu Pro Val 325 330 335Glu Thr Thr
Glu Gly Val Pro Leu Gly Pro Pro Glu Asn Val Ser Ala 340 345 350Met
Arg Asn Gly Ser Gln Val Leu Val Arg Trp Gln Glu Pro Arg Val 355 360
365Pro Leu Gln Gly Thr Leu Leu Gly Tyr Arg Leu Ala Tyr Arg Gly Gln
370 375 380Asp Thr Pro Glu Val Leu Met Asp Ile Gly Leu Thr Arg Glu
Val Thr385 390 395 400Leu Glu Leu Arg Gly Asp Arg Pro Val Ala Asn
Leu Thr Val Ser Val 405 410 415Thr Ala Tyr Thr Ser Ala Gly Asp Gly
Pro Trp Ser Leu Pro Val Pro 420 425 430Leu Glu Pro Trp Arg Pro Gly
Gln Gly Gln Pro Leu His His Leu Val 435 440 445Ser Glu Pro Pro Pro
Arg Ala Phe Ser Trp Pro Trp Trp Tyr Val Leu 450 455 460Leu Gly Ala
Val Val Ala Ala Ala Cys Val Leu Ile Leu Ala Leu Phe465 470 475
480Leu Val His Arg Arg Lys Lys Glu Thr Arg Tyr Gly Glu Val Phe Glu
485 490 495Pro Thr Val Glu Arg Gly Glu Leu Val Val Arg Tyr Arg Val
Arg Lys 500 505 510Ser Tyr Ser Arg Arg Thr Thr Glu Ala Thr Leu Asn
Ser Leu Gly Ile 515 520 525Ser Glu Glu Leu Lys Glu Lys Leu Arg Asp
Val Met Val Asp Arg His 530 535 540Lys Val Ala Leu Gly Lys Thr Leu
Gly Glu Gly Glu Phe Gly Ala Val545 550 555 560Met Glu Gly Gln Leu
Asn Gln Asp Asp Ser Ile Leu Lys Val Ala Val 565 570 575Lys Thr Met
Lys Ile Ala Ile Cys Thr Arg Ser Glu Leu Glu Asp Phe 580 585 590Leu
Ser Glu Ala Val Cys Met Lys Glu Phe Asp His Pro Asn Val Met 595 600
605Arg Leu Ile Gly Val Cys Phe Gln Gly Ser Glu Arg Glu Ser Phe Pro
610 615 620Ala Pro Val Val Ile Leu Pro Phe Met Lys His Gly Asp Leu
His Ser625 630 635 640Phe Leu Leu Tyr Ser Arg Leu Gly Asp Gln Pro
Val Tyr Leu Pro Thr 645 650 655Gln Met Leu Val Lys Phe Met Ala Asp
Ile Ala Ser Gly Met Glu Tyr 660 665 670Leu Ser Thr Lys Arg Phe Ile
His Arg Asp Leu Ala Ala Arg Asn Cys 675 680 685Met Leu Asn Glu Asn
Met Ser Val Cys Val Ala Asp Phe Gly Leu Ser 690 695 700Lys Lys Ile
Tyr Asn Gly Asp Tyr Tyr Arg Gln Gly Arg Ile Ala Lys705 710 715
720Met Pro Val Lys Trp Ile Ala Ile Glu Ser Leu Ala Asp Arg Val Tyr
725 730 735Thr Ser Lys Ser Asp Val Trp Ser Phe Gly Val Thr Met Trp
Glu Ile 740 745 750Ala Thr Arg Gly Gln Thr Pro Tyr Pro Gly Val Glu
Asn Ser Glu Ile 755 760 765Tyr Asp Tyr Leu Arg Gln Gly Asn Arg Leu
Lys Gln Pro Ala Asp Cys 770 775 780Leu Asp Gly Leu Tyr Ala Leu Met
Ser Arg Cys Trp Glu Leu Asn Pro785 790 795 800Gln Asp Arg Pro Ser
Phe Thr Glu Leu Arg Glu Asp Leu Glu Asn Thr 805 810 815Leu Lys Ala
Leu Pro Pro Ala Gln Glu Pro Asp Glu Ile Leu Tyr Val 820 825 830Asn
Met Asp Glu Gly Gly Gly Tyr Pro Glu Pro Pro Gly Ala Ala Gly 835 840
845Gly Ala Asp Pro Pro Thr Gln Pro Asp Pro Lys Asp Ser Cys Ser Cys
850 855 860Leu Thr Ala Ala Glu Val His Pro Ala Gly Arg Tyr Val Leu
Cys Pro865 870 875 880Ser Thr Thr Pro Ser Pro Ala Gln Pro Ala Asp
Arg Gly Ser Pro Ala 885 890 895Ala Pro Gly Gln Glu Asp Gly Ala
900132894PRThomo sapiens 132Met Ala Trp Arg Cys Pro Arg Met Gly Arg
Val Pro Leu Ala Trp Cys1 5 10 15Leu Ala Leu Cys Gly Trp Ala Cys Met
Ala Pro Arg Gly Thr Gln Ala 20 25 30Glu Glu Ser Pro Phe Val Gly Asn
Pro Gly Asn Ile Thr Gly Ala Arg 35 40 45Gly Leu Thr Gly Thr Leu Arg
Cys Gln Leu Gln Val Gln Gly Glu Pro 50 55 60Pro Glu Val His Trp Leu
Arg Asp Gly Gln Ile Leu Glu Leu Ala Asp65 70 75 80Ser Thr Gln Thr
Gln Val Pro Leu Gly Glu Asp Glu Gln Asp Asp Trp 85 90 95Ile Val Val
Ser Gln Leu Arg Ile Thr Ser Leu Gln Leu Ser Asp Thr 100 105 110Gly
Gln Tyr Gln Cys Leu Val Phe Leu Gly His Gln Thr Phe Val Ser 115 120
125Gln Pro Gly Tyr Val Gly Leu Glu Gly Leu Pro Tyr Phe Leu Glu Glu
130 135 140Pro Glu Asp Lys Ala Val Pro Ala Asn Thr Pro Phe Asn Leu
Ser Cys145 150 155 160Gln Ala Gln Gly Pro Pro Glu Pro Val Thr Leu
Leu Trp Leu Gln Asp 165 170 175Ala Val Pro Leu Ala Pro Val Thr Gly
His Ser Ser Gln His Ser Leu 180 185 190Gln Thr Pro Gly Leu Asn Lys
Thr Ser Ser Phe Ser Cys Glu Ala His 195 200 205Asn Ala Lys Gly Val
Thr Thr Ser Arg Thr Ala Thr Ile Thr Val Leu 210 215 220Pro Gln Gln
Pro Arg Asn Leu His Leu Val Ser Arg Gln Pro Thr Glu225 230 235
240Leu Glu Val Ala Trp Thr Pro Gly Leu Ser Gly Ile Tyr Pro Leu Thr
245 250 255His Cys Thr Leu Gln Ala Val Leu Ser Asp Asp Gly Met Gly
Ile Gln 260 265 270Ala Gly Glu Pro Asp Pro Pro Glu Glu Pro Leu Thr
Ser Gln Ala Ser 275 280 285Val Pro Pro His Gln Leu Arg Leu Gly Ser
Leu His Pro His Thr Pro 290 295 300Tyr His Ile Arg Val Ala Cys Thr
Ser Ser Gln Gly Pro Ser Ser Trp305
310 315 320Thr His Trp Leu Pro Val Glu Thr Pro Glu Gly Val Pro Leu
Gly Pro 325 330 335Pro Glu Asn Ile Ser Ala Thr Arg Asn Gly Ser Gln
Ala Phe Val His 340 345 350Trp Gln Glu Pro Arg Ala Pro Leu Gln Gly
Thr Leu Leu Gly Tyr Arg 355 360 365Leu Ala Tyr Gln Gly Gln Asp Thr
Pro Glu Val Leu Met Asp Ile Gly 370 375 380Leu Arg Gln Glu Val Thr
Leu Glu Leu Gln Gly Asp Gly Ser Val Ser385 390 395 400Asn Leu Thr
Val Cys Val Ala Ala Tyr Thr Ala Ala Gly Asp Gly Pro 405 410 415Trp
Ser Leu Pro Val Pro Leu Glu Ala Trp Arg Pro Gly Gln Ala Gln 420 425
430Pro Val His Gln Leu Val Lys Glu Pro Ser Thr Pro Ala Phe Ser Trp
435 440 445Pro Trp Trp Tyr Val Leu Leu Gly Ala Val Val Ala Ala Ala
Cys Val 450 455 460Leu Ile Leu Ala Leu Phe Leu Val His Arg Arg Lys
Lys Glu Thr Arg465 470 475 480Tyr Gly Glu Val Phe Glu Pro Thr Val
Glu Arg Gly Glu Leu Val Val 485 490 495Arg Tyr Arg Val Arg Lys Ser
Tyr Ser Arg Arg Thr Thr Glu Ala Thr 500 505 510Leu Asn Ser Leu Gly
Ile Ser Glu Glu Leu Lys Glu Lys Leu Arg Asp 515 520 525Val Met Val
Asp Arg His Lys Val Ala Leu Gly Lys Thr Leu Gly Glu 530 535 540Gly
Glu Phe Gly Ala Val Met Glu Gly Gln Leu Asn Gln Asp Asp Ser545 550
555 560Ile Leu Lys Val Ala Val Lys Thr Met Lys Ile Ala Ile Cys Thr
Arg 565 570 575Ser Glu Leu Glu Asp Phe Leu Ser Glu Ala Val Cys Met
Lys Glu Phe 580 585 590Asp His Pro Asn Val Met Arg Leu Ile Gly Val
Cys Phe Gln Gly Ser 595 600 605Glu Arg Glu Ser Phe Pro Ala Pro Val
Val Ile Leu Pro Phe Met Lys 610 615 620His Gly Asp Leu His Ser Phe
Leu Leu Tyr Ser Arg Leu Gly Asp Gln625 630 635 640Pro Val Tyr Leu
Pro Thr Gln Met Leu Val Lys Phe Met Ala Asp Ile 645 650 655Ala Ser
Gly Met Glu Tyr Leu Ser Thr Lys Arg Phe Ile His Arg Asp 660 665
670Leu Ala Ala Arg Asn Cys Met Leu Asn Glu Asn Met Ser Val Cys Val
675 680 685Ala Asp Phe Gly Leu Ser Lys Lys Ile Tyr Asn Gly Asp Tyr
Tyr Arg 690 695 700Gln Gly Arg Ile Ala Lys Met Pro Val Lys Trp Ile
Ala Ile Glu Ser705 710 715 720Leu Ala Asp Arg Val Tyr Thr Ser Lys
Ser Asp Val Trp Ser Phe Gly 725 730 735Val Thr Met Trp Glu Ile Ala
Thr Arg Gly Gln Thr Pro Tyr Pro Gly 740 745 750Val Glu Asn Ser Glu
Ile Tyr Asp Tyr Leu Arg Gln Gly Asn Arg Leu 755 760 765Lys Gln Pro
Ala Asp Cys Leu Asp Gly Leu Tyr Ala Leu Met Ser Arg 770 775 780Cys
Trp Glu Leu Asn Pro Gln Asp Arg Pro Ser Phe Thr Glu Leu Arg785 790
795 800Glu Asp Leu Glu Asn Thr Leu Lys Ala Leu Pro Pro Ala Gln Glu
Pro 805 810 815Asp Glu Ile Leu Tyr Val Asn Met Asp Glu Gly Gly Gly
Tyr Pro Glu 820 825 830Pro Pro Gly Ala Ala Gly Gly Ala Asp Pro Pro
Thr Gln Pro Asp Pro 835 840 845Lys Asp Ser Cys Ser Cys Leu Thr Ala
Ala Glu Val His Pro Ala Gly 850 855 860Arg Tyr Val Leu Cys Pro Ser
Thr Thr Pro Ser Pro Ala Gln Pro Ala865 870 875 880Asp Arg Gly Ser
Pro Ala Ala Pro Gly Gln Glu Asp Gly Ala 885 890133894PRThomo
sapiens 133Met Ala Trp Arg Cys Pro Arg Met Gly Arg Val Pro Leu Ala
Trp Cys1 5 10 15Leu Ala Leu Cys Gly Trp Ala Cys Met Ala Pro Arg Gly
Thr Gln Ala 20 25 30Glu Glu Ser Pro Phe Val Gly Asn Pro Gly Asn Ile
Thr Gly Ala Arg 35 40 45Gly Leu Thr Gly Thr Leu Arg Cys Gln Leu Gln
Val Gln Gly Glu Pro 50 55 60Pro Glu Val His Trp Leu Arg Asp Gly Gln
Ile Leu Glu Leu Ala Asp65 70 75 80Ser Thr Gln Thr Gln Val Pro Leu
Gly Glu Asp Glu Gln Asp Asp Trp 85 90 95Ile Val Val Ser Gln Leu Arg
Ile Thr Ser Leu Gln Leu Ser Asp Thr 100 105 110Gly Gln Tyr Gln Cys
Leu Val Phe Leu Gly His Gln Thr Phe Val Ser 115 120 125Gln Pro Gly
Tyr Val Gly Leu Glu Gly Leu Pro Tyr Phe Leu Glu Glu 130 135 140Pro
Glu Asp Lys Ala Val Pro Ala Asn Thr Pro Phe Asn Leu Ser Cys145 150
155 160Gln Ala Gln Gly Pro Pro Glu Pro Val Thr Leu Leu Trp Leu Gln
Asp 165 170 175Ala Val Pro Leu Ala Pro Val Thr Gly His Ser Ser Gln
His Ser Leu 180 185 190Gln Thr Pro Gly Leu Asn Lys Thr Ser Ser Phe
Ser Cys Glu Ala His 195 200 205Asn Ala Lys Gly Val Thr Thr Ser Arg
Thr Ala Thr Ile Thr Val Leu 210 215 220Pro Gln Gln Pro Arg Asn Leu
His Leu Val Ser Arg Gln Pro Thr Glu225 230 235 240Leu Glu Val Ala
Trp Thr Pro Gly Leu Ser Gly Ile Tyr Pro Leu Thr 245 250 255His Cys
Thr Leu Gln Ala Val Leu Ser Asp Asp Gly Met Gly Ile Gln 260 265
270Ala Gly Glu Pro Asp Pro Pro Glu Glu Pro Leu Thr Ser Gln Ala Ser
275 280 285Val Pro Pro His Gln Leu Arg Leu Gly Ser Leu His Pro His
Thr Pro 290 295 300Tyr His Ile Arg Val Ala Cys Thr Ser Ser Gln Gly
Pro Ser Ser Trp305 310 315 320Thr His Trp Leu Pro Val Glu Thr Pro
Glu Gly Val Pro Leu Gly Pro 325 330 335Pro Glu Asn Ile Ser Ala Thr
Arg Asn Gly Ser Gln Ala Phe Val His 340 345 350Trp Gln Glu Pro Arg
Ala Pro Leu Gln Gly Thr Leu Leu Gly Tyr Arg 355 360 365Leu Ala Tyr
Gln Gly Gln Asp Thr Pro Glu Val Leu Met Asp Ile Gly 370 375 380Leu
Arg Gln Glu Val Thr Leu Glu Leu Gln Gly Asp Gly Ser Val Ser385 390
395 400Asn Leu Thr Val Cys Val Ala Ala Tyr Thr Ala Ala Gly Asp Gly
Pro 405 410 415Trp Ser Leu Pro Val Pro Leu Glu Ala Trp Arg Pro Gly
Gln Ala Gln 420 425 430Pro Val His Gln Leu Val Lys Glu Pro Ser Thr
Pro Ala Phe Ser Trp 435 440 445Pro Trp Trp Tyr Val Leu Leu Gly Ala
Val Val Ala Ala Ala Cys Val 450 455 460Leu Ile Leu Ala Leu Phe Leu
Val His Arg Arg Lys Lys Glu Thr Arg465 470 475 480Tyr Gly Glu Val
Phe Glu Pro Thr Val Glu Arg Gly Glu Leu Val Val 485 490 495Arg Tyr
Arg Val Arg Lys Ser Tyr Ser Arg Arg Thr Thr Glu Ala Thr 500 505
510Leu Asn Ser Leu Gly Ile Ser Glu Glu Leu Lys Glu Lys Leu Arg Asp
515 520 525Val Met Val Asp Arg His Lys Val Ala Leu Gly Lys Thr Leu
Gly Glu 530 535 540Gly Glu Phe Gly Ala Val Met Glu Gly Gln Leu Asn
Gln Asp Asp Ser545 550 555 560Ile Leu Lys Val Ala Val Lys Thr Met
Lys Ile Ala Ile Cys Thr Arg 565 570 575Ser Glu Leu Glu Asp Phe Leu
Ser Glu Ala Val Cys Met Lys Glu Phe 580 585 590Asp His Pro Asn Val
Met Arg Leu Ile Gly Val Cys Phe Gln Gly Ser 595 600 605Glu Arg Glu
Ser Phe Pro Ala Pro Val Val Ile Leu Pro Phe Met Lys 610 615 620His
Gly Asp Leu His Ser Phe Leu Leu Tyr Ser Arg Leu Gly Asp Gln625 630
635 640Pro Val Tyr Leu Pro Thr Gln Met Leu Val Lys Phe Met Ala Asp
Ile 645 650 655Ala Ser Gly Met Glu Tyr Leu Ser Thr Lys Arg Phe Ile
His Arg Asp 660 665 670Leu Ala Ala Arg Asn Cys Met Leu Asn Glu Asn
Met Ser Val Cys Val 675 680 685Ala Asp Phe Gly Leu Ser Lys Lys Ile
Tyr Asn Gly Asp Tyr Tyr Arg 690 695 700Gln Gly Arg Ile Ala Lys Met
Pro Val Lys Trp Ile Ala Ile Glu Ser705 710 715 720Leu Ala Asp Arg
Val Tyr Thr Ser Lys Ser Asp Val Trp Ser Phe Gly 725 730 735Val Thr
Met Trp Glu Ile Ala Thr Arg Gly Gln Thr Pro Tyr Pro Gly 740 745
750Val Glu Asn Ser Glu Ile Tyr Asp Tyr Leu Arg Gln Gly Asn Arg Leu
755 760 765Lys Gln Pro Ala Asp Cys Leu Asp Gly Leu Tyr Ala Leu Met
Ser Arg 770 775 780Cys Trp Glu Leu Asn Pro Gln Asp Arg Pro Ser Phe
Thr Glu Leu Arg785 790 795 800Glu Asp Leu Glu Asn Thr Leu Lys Ala
Leu Pro Pro Ala Gln Glu Pro 805 810 815Asp Glu Ile Leu Tyr Val Asn
Met Asp Glu Gly Gly Gly Tyr Pro Glu 820 825 830Pro Pro Gly Ala Ala
Gly Gly Ala Asp Pro Pro Thr Gln Pro Asp Pro 835 840 845Lys Asp Ser
Cys Ser Cys Leu Thr Ala Ala Glu Val His Pro Ala Gly 850 855 860Arg
Tyr Val Leu Cys Pro Ser Thr Thr Pro Ser Pro Ala Gln Pro Ala865 870
875 880Asp Arg Gly Ser Pro Ala Ala Pro Gly Gln Glu Asp Gly Ala 885
890134894PRThomo sapiens 134Met Ala Trp Arg Cys Pro Arg Met Gly Arg
Val Pro Leu Ala Trp Cys1 5 10 15Leu Ala Leu Cys Gly Trp Ala Cys Met
Ala Pro Arg Gly Thr Gln Ala 20 25 30Glu Glu Ser Pro Phe Val Gly Asn
Pro Gly Asn Ile Thr Gly Ala Arg 35 40 45Gly Leu Thr Gly Thr Leu Arg
Cys Gln Leu Gln Val Gln Gly Glu Pro 50 55 60Pro Glu Val His Trp Leu
Arg Asp Gly Gln Ile Leu Glu Leu Ala Asp65 70 75 80Ser Thr Gln Thr
Gln Val Pro Leu Gly Glu Asp Glu Gln Asp Asp Trp 85 90 95Ile Val Val
Ser Gln Leu Arg Ile Thr Ser Leu Gln Leu Ser Asp Thr 100 105 110Gly
Gln Tyr Gln Cys Leu Val Phe Leu Gly His Gln Thr Phe Val Ser 115 120
125Gln Pro Gly Tyr Val Gly Leu Glu Gly Leu Pro Tyr Phe Leu Glu Glu
130 135 140Pro Glu Asp Arg Thr Val Ala Ala Asn Thr Pro Phe Asn Leu
Ser Cys145 150 155 160Gln Ala Gln Gly Pro Pro Glu Pro Val Asp Leu
Leu Trp Leu Gln Asp 165 170 175Ala Val Pro Leu Ala Thr Ala Pro Gly
His Gly Pro Gln Arg Ser Leu 180 185 190His Val Pro Gly Leu Asn Lys
Thr Ser Ser Phe Ser Cys Glu Ala His 195 200 205Asn Ala Lys Gly Val
Thr Thr Ser Arg Thr Ala Thr Ile Thr Val Leu 210 215 220Pro Gln Arg
Pro His His Leu His Val Val Ser Arg Gln Pro Thr Glu225 230 235
240Leu Glu Val Ala Trp Thr Pro Gly Leu Ser Gly Ile Tyr Pro Leu Thr
245 250 255His Cys Asn Leu Gln Ala Val Leu Ser Asp Asp Gly Val Gly
Ile Trp 260 265 270Leu Gly Lys Ser Asp Pro Pro Glu Asp Pro Leu Thr
Leu Gln Val Ser 275 280 285Val Pro Pro His Gln Leu Arg Leu Glu Lys
Leu Leu Pro His Thr Pro 290 295 300Tyr His Ile Arg Ile Ser Cys Ser
Ser Ser Gln Gly Pro Ser Pro Trp305 310 315 320Thr His Trp Leu Pro
Val Glu Thr Thr Glu Gly Val Pro Leu Gly Pro 325 330 335Pro Glu Asn
Ile Ser Ala Thr Arg Asn Gly Ser Gln Ala Phe Val His 340 345 350Trp
Gln Glu Pro Arg Ala Pro Leu Gln Gly Thr Leu Leu Gly Tyr Arg 355 360
365Leu Ala Tyr Gln Gly Gln Asp Thr Pro Glu Val Leu Met Asp Ile Gly
370 375 380Leu Arg Gln Glu Val Thr Leu Glu Leu Gln Gly Asp Gly Ser
Val Ser385 390 395 400Asn Leu Thr Val Cys Val Ala Ala Tyr Thr Ala
Ala Gly Asp Gly Pro 405 410 415Trp Ser Leu Pro Val Pro Leu Glu Ala
Trp Arg Pro Gly Gln Ala Gln 420 425 430Pro Val His Gln Leu Val Lys
Glu Pro Ser Thr Pro Ala Phe Ser Trp 435 440 445Pro Trp Trp Tyr Val
Leu Leu Gly Ala Val Val Ala Ala Ala Cys Val 450 455 460Leu Ile Leu
Ala Leu Phe Leu Val His Arg Arg Lys Lys Glu Thr Arg465 470 475
480Tyr Gly Glu Val Phe Glu Pro Thr Val Glu Arg Gly Glu Leu Val Val
485 490 495Arg Tyr Arg Val Arg Lys Ser Tyr Ser Arg Arg Thr Thr Glu
Ala Thr 500 505 510Leu Asn Ser Leu Gly Ile Ser Glu Glu Leu Lys Glu
Lys Leu Arg Asp 515 520 525Val Met Val Asp Arg His Lys Val Ala Leu
Gly Lys Thr Leu Gly Glu 530 535 540Gly Glu Phe Gly Ala Val Met Glu
Gly Gln Leu Asn Gln Asp Asp Ser545 550 555 560Ile Leu Lys Val Ala
Val Lys Thr Met Lys Ile Ala Ile Cys Thr Arg 565 570 575Ser Glu Leu
Glu Asp Phe Leu Ser Glu Ala Val Cys Met Lys Glu Phe 580 585 590Asp
His Pro Asn Val Met Arg Leu Ile Gly Val Cys Phe Gln Gly Ser 595 600
605Glu Arg Glu Ser Phe Pro Ala Pro Val Val Ile Leu Pro Phe Met Lys
610 615 620His Gly Asp Leu His Ser Phe Leu Leu Tyr Ser Arg Leu Gly
Asp Gln625 630 635 640Pro Val Tyr Leu Pro Thr Gln Met Leu Val Lys
Phe Met Ala Asp Ile 645 650 655Ala Ser Gly Met Glu Tyr Leu Ser Thr
Lys Arg Phe Ile His Arg Asp 660 665 670Leu Ala Ala Arg Asn Cys Met
Leu Asn Glu Asn Met Ser Val Cys Val 675 680 685Ala Asp Phe Gly Leu
Ser Lys Lys Ile Tyr Asn Gly Asp Tyr Tyr Arg 690 695 700Gln Gly Arg
Ile Ala Lys Met Pro Val Lys Trp Ile Ala Ile Glu Ser705 710 715
720Leu Ala Asp Arg Val Tyr Thr Ser Lys Ser Asp Val Trp Ser Phe Gly
725 730 735Val Thr Met Trp Glu Ile Ala Thr Arg Gly Gln Thr Pro Tyr
Pro Gly 740 745 750Val Glu Asn Ser Glu Ile Tyr Asp Tyr Leu Arg Gln
Gly Asn Arg Leu 755 760 765Lys Gln Pro Ala Asp Cys Leu Asp Gly Leu
Tyr Ala Leu Met Ser Arg 770 775 780Cys Trp Glu Leu Asn Pro Gln Asp
Arg Pro Ser Phe Thr Glu Leu Arg785 790 795 800Glu Asp Leu Glu Asn
Thr Leu Lys Ala Leu Pro Pro Ala Gln Glu Pro 805 810 815Asp Glu Ile
Leu Tyr Val Asn Met Asp Glu Gly Gly Gly Tyr Pro Glu 820 825 830Pro
Pro Gly Ala Ala Gly Gly Ala Asp Pro Pro Thr Gln Pro Asp Pro 835 840
845Lys Asp Ser Cys Ser Cys Leu Thr Ala Ala Glu Val His Pro Ala Gly
850 855 860Arg Tyr Val Leu Cys Pro Ser Thr Thr Pro Ser Pro Ala Gln
Pro Ala865 870 875 880Asp Arg Gly Ser Pro Ala Ala Pro Gly Gln Glu
Asp Gly Ala 885 890135894PRThomo sapiens 135Met Ala Trp Arg Cys Pro
Arg Met Gly Arg Val Pro Leu Ala Trp Cys1 5 10 15Leu Ala Leu Cys Gly
Trp Ala Cys Met Ala Pro Arg Gly Thr Gln Ala 20 25 30Glu Glu Ser Pro
Phe Val Gly Asn Pro Gly Asn Ile Thr Gly Ala Arg 35 40 45Gly Leu Thr
Gly Thr Leu Arg Cys Gln Leu Gln Val Gln Gly Glu Pro 50 55 60Pro Glu
Val His Trp Leu Arg Asp Gly Gln Ile Leu Glu Leu Ala Asp65 70 75
80Ser Thr Gln Thr Gln Val Pro Leu Gly Glu Asp Glu Gln Asp Asp Trp
85 90
95Ile Val Val Ser Gln Leu Arg Ile Thr Ser Leu Gln Leu Ser Asp Thr
100 105 110Gly Gln Tyr Gln Cys Leu Val Phe Leu Gly His Gln Thr Phe
Val Ser 115 120 125Gln Pro Gly Tyr Val Gly Leu Glu Gly Leu Pro Tyr
Phe Leu Glu Glu 130 135 140Pro Glu Asp Arg Thr Val Ala Ala Asn Thr
Pro Phe Asn Leu Ser Cys145 150 155 160Gln Ala Gln Gly Pro Pro Glu
Pro Val Asp Leu Leu Trp Leu Gln Asp 165 170 175Ala Val Pro Leu Ala
Thr Ala Pro Gly His Gly Pro Gln Arg Ser Leu 180 185 190His Val Pro
Gly Leu Asn Lys Thr Ser Ser Phe Ser Cys Glu Ala His 195 200 205Asn
Ala Lys Gly Val Thr Thr Ser Arg Thr Ala Thr Ile Thr Val Leu 210 215
220Pro Gln Gln Pro Arg Asn Leu His Leu Val Ser Arg Gln Pro Thr
Glu225 230 235 240Leu Glu Val Ala Trp Thr Pro Gly Leu Ser Gly Ile
Tyr Pro Leu Thr 245 250 255His Cys Thr Leu Gln Ala Val Leu Ser Asp
Asp Gly Met Gly Ile Gln 260 265 270Ala Gly Glu Pro Asp Pro Pro Glu
Glu Pro Leu Thr Ser Gln Ala Ser 275 280 285Val Pro Pro His Gln Leu
Arg Leu Gly Ser Leu His Pro His Thr Pro 290 295 300Tyr His Ile Arg
Val Ala Cys Thr Ser Ser Gln Gly Pro Ser Ser Trp305 310 315 320Thr
His Trp Leu Pro Val Glu Thr Pro Glu Gly Val Pro Leu Gly Pro 325 330
335Pro Glu Asn Val Ser Ala Met Arg Asn Gly Ser Gln Val Leu Val Arg
340 345 350Trp Gln Glu Pro Arg Val Pro Leu Gln Gly Thr Leu Leu Gly
Tyr Arg 355 360 365Leu Ala Tyr Arg Gly Gln Asp Thr Pro Glu Val Leu
Met Asp Ile Gly 370 375 380Leu Thr Arg Glu Val Thr Leu Glu Leu Arg
Gly Asp Arg Pro Val Ala385 390 395 400Asn Leu Thr Val Ser Val Thr
Ala Tyr Thr Ser Ala Gly Asp Gly Pro 405 410 415Trp Ser Leu Pro Val
Pro Leu Glu Pro Trp Arg Pro Gly Gln Gly Gln 420 425 430Pro Leu His
His Leu Val Ser Glu Pro Pro Pro Arg Ala Phe Ser Trp 435 440 445Pro
Trp Trp Tyr Val Leu Leu Gly Ala Val Val Ala Ala Ala Cys Val 450 455
460Leu Ile Leu Ala Leu Phe Leu Val His Arg Arg Lys Lys Glu Thr
Arg465 470 475 480Tyr Gly Glu Val Phe Glu Pro Thr Val Glu Arg Gly
Glu Leu Val Val 485 490 495Arg Tyr Arg Val Arg Lys Ser Tyr Ser Arg
Arg Thr Thr Glu Ala Thr 500 505 510Leu Asn Ser Leu Gly Ile Ser Glu
Glu Leu Lys Glu Lys Leu Arg Asp 515 520 525Val Met Val Asp Arg His
Lys Val Ala Leu Gly Lys Thr Leu Gly Glu 530 535 540Gly Glu Phe Gly
Ala Val Met Glu Gly Gln Leu Asn Gln Asp Asp Ser545 550 555 560Ile
Leu Lys Val Ala Val Lys Thr Met Lys Ile Ala Ile Cys Thr Arg 565 570
575Ser Glu Leu Glu Asp Phe Leu Ser Glu Ala Val Cys Met Lys Glu Phe
580 585 590Asp His Pro Asn Val Met Arg Leu Ile Gly Val Cys Phe Gln
Gly Ser 595 600 605Glu Arg Glu Ser Phe Pro Ala Pro Val Val Ile Leu
Pro Phe Met Lys 610 615 620His Gly Asp Leu His Ser Phe Leu Leu Tyr
Ser Arg Leu Gly Asp Gln625 630 635 640Pro Val Tyr Leu Pro Thr Gln
Met Leu Val Lys Phe Met Ala Asp Ile 645 650 655Ala Ser Gly Met Glu
Tyr Leu Ser Thr Lys Arg Phe Ile His Arg Asp 660 665 670Leu Ala Ala
Arg Asn Cys Met Leu Asn Glu Asn Met Ser Val Cys Val 675 680 685Ala
Asp Phe Gly Leu Ser Lys Lys Ile Tyr Asn Gly Asp Tyr Tyr Arg 690 695
700Gln Gly Arg Ile Ala Lys Met Pro Val Lys Trp Ile Ala Ile Glu
Ser705 710 715 720Leu Ala Asp Arg Val Tyr Thr Ser Lys Ser Asp Val
Trp Ser Phe Gly 725 730 735Val Thr Met Trp Glu Ile Ala Thr Arg Gly
Gln Thr Pro Tyr Pro Gly 740 745 750Val Glu Asn Ser Glu Ile Tyr Asp
Tyr Leu Arg Gln Gly Asn Arg Leu 755 760 765Lys Gln Pro Ala Asp Cys
Leu Asp Gly Leu Tyr Ala Leu Met Ser Arg 770 775 780Cys Trp Glu Leu
Asn Pro Gln Asp Arg Pro Ser Phe Thr Glu Leu Arg785 790 795 800Glu
Asp Leu Glu Asn Thr Leu Lys Ala Leu Pro Pro Ala Gln Glu Pro 805 810
815Asp Glu Ile Leu Tyr Val Asn Met Asp Glu Gly Gly Gly Tyr Pro Glu
820 825 830Pro Pro Gly Ala Ala Gly Gly Ala Asp Pro Pro Thr Gln Pro
Asp Pro 835 840 845Lys Asp Ser Cys Ser Cys Leu Thr Ala Ala Glu Val
His Pro Ala Gly 850 855 860Arg Tyr Val Leu Cys Pro Ser Thr Thr Pro
Ser Pro Ala Gln Pro Ala865 870 875 880Asp Arg Gly Ser Pro Ala Ala
Pro Gly Gln Glu Asp Gly Ala 885 890136124PRThomo sapiens 136Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25
30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Ser Gly Ser Gly Gly His Thr Tyr His Ala Asp Ser
Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95Ala Lys Asp Arg Tyr Asp Ile Leu Thr Gly Tyr
Tyr Asn Leu Leu Asp 100 105 110Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser 115 1201378PRThomo sapiens 137Gly Phe Thr Phe Ser Ser
Tyr Ala1 51388PRThomo sapiens 138Ile Ser Gly Ser Gly Gly His Thr1
513917PRThomo sapiens 139Ala Lys Asp Arg Tyr Asp Ile Leu Thr Gly
Tyr Tyr Asn Leu Leu Asp1 5 10 15Tyr140107PRThomo sapiens 140Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp
Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25
30Leu Ala Trp Tyr Gln Gln Lys Pro Glu Glu Ala Pro Lys Ser Leu Ile
35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Ala Lys Val Glu Ile Lys
100 1051416PRThomo sapiens 141Gln Gly Ile Ser Ser Trp1 51429PRThomo
sapiens 142Gln Gln Tyr Asn Ser Tyr Pro Leu Thr1 5143123PRThomo
sapiens 143Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe
Thr Gly Tyr 20 25 30Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn
Tyr Val Gln Asn Leu 50 55 60Gln Asp Arg Val Thr Met Thr Thr Asp Thr
Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Arg Ser Leu Arg Ser
Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp His Ile Ser Met
Leu Arg Gly Ile Ile Ile Arg Asn Tyr 100 105 110Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser 115 120144108PRThomo sapiens 144Glu Ile Val
Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40
45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Ser
Trp Pro Arg 85 90 95Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105145124PRThomo sapiens 145Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Gly Thr Phe Ser Arg Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln
Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Arg Ile Ile Pro Ile
Val Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr
Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg
Glu Ala Gly Tyr Ser Ser Ser Trp Tyr Ala Glu Tyr Phe Gln 100 105
110His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
120146108PRThomo sapiens 146Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Asn 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg
Ala Thr Gly Phe Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95Tyr Thr Phe
Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105147893PRTMacaca
fascicularis 147Ala Trp Arg Cys Pro Arg Met Gly Arg Val Pro Leu Ala
Trp Cys Leu1 5 10 15Ala Leu Cys Gly Trp Val Cys Met Ala Pro Arg Gly
Thr Gln Ala Glu 20 25 30Glu Ser Pro Phe Val Gly Asn Pro Gly Asn Ile
Thr Gly Ala Arg Gly 35 40 45Leu Thr Gly Thr Leu Arg Cys Gln Leu Gln
Val Gln Gly Glu Pro Pro 50 55 60Glu Val His Trp Leu Arg Asp Gly Gln
Ile Leu Glu Leu Ala Asp Ser65 70 75 80Thr Gln Thr Gln Val Pro Leu
Gly Glu Asp Glu Gln Asp Asp Trp Ile 85 90 95Val Val Ser Gln Leu Arg
Ile Ala Ser Leu Gln Leu Ser Asp Ala Gly 100 105 110Gln Tyr Gln Cys
Leu Val Phe Leu Gly His Gln Asn Phe Val Ser Gln 115 120 125Pro Gly
Tyr Val Gly Leu Glu Gly Leu Pro Tyr Phe Leu Glu Glu Pro 130 135
140Glu Asp Arg Thr Val Ala Ala Asn Thr Pro Phe Asn Leu Ser Cys
Gln145 150 155 160Ala Gln Gly Pro Pro Glu Pro Val Asp Leu Leu Trp
Leu Gln Asp Ala 165 170 175Val Pro Leu Ala Thr Ala Pro Gly His Gly
Pro Gln Arg Asn Leu His 180 185 190Val Pro Gly Leu Asn Lys Thr Ser
Ser Phe Ser Cys Glu Ala His Asn 195 200 205Ala Lys Gly Val Thr Thr
Ser Arg Thr Ala Thr Ile Thr Val Leu Pro 210 215 220Gln Gln Pro Arg
Asn Leu His Leu Val Ser Arg Gln Pro Thr Glu Leu225 230 235 240Glu
Val Ala Trp Thr Pro Gly Leu Ser Gly Ile Tyr Pro Leu Thr His 245 250
255Cys Thr Leu Gln Ala Val Leu Ser Asp Asp Gly Met Gly Ile Gln Ala
260 265 270Gly Glu Pro Asp Pro Pro Glu Glu Pro Leu Thr Leu Gln Ala
Ser Val 275 280 285Pro Pro His Gln Leu Arg Leu Gly Ser Leu His Pro
His Thr Pro Tyr 290 295 300His Ile Arg Val Ala Cys Thr Ser Ser Gln
Gly Pro Ser Ser Trp Thr305 310 315 320His Trp Leu Pro Val Glu Thr
Pro Glu Gly Val Pro Leu Gly Pro Pro 325 330 335Glu Asn Ile Ser Ala
Thr Arg Asn Gly Ser Gln Ala Phe Val His Trp 340 345 350Gln Glu Pro
Arg Ala Pro Leu Gln Gly Thr Leu Leu Gly Tyr Arg Leu 355 360 365Ala
Tyr Gln Gly Gln Asp Thr Pro Glu Val Leu Met Asp Ile Gly Leu 370 375
380Arg Gln Glu Val Thr Leu Glu Leu Gln Gly Asp Gly Ser Val Ser
Asn385 390 395 400Leu Thr Val Cys Val Ala Ala Tyr Thr Ala Ala Gly
Asp Gly Pro Trp 405 410 415Ser Leu Pro Val Pro Leu Glu Ala Trp Arg
Pro Gly Gln Ala Gln Pro 420 425 430Val His Gln Leu Val Lys Glu Thr
Ser Ala Pro Ala Phe Ser Trp Pro 435 440 445Trp Trp Tyr Ile Leu Leu
Gly Ala Val Val Ala Ala Ala Cys Val Leu 450 455 460Ile Leu Ala Leu
Phe Leu Val His Arg Arg Lys Lys Glu Thr Arg Tyr465 470 475 480Gly
Glu Val Phe Glu Pro Thr Val Glu Arg Gly Glu Leu Val Val Arg 485 490
495Tyr Arg Val Arg Lys Ser Tyr Ser Arg Arg Thr Thr Glu Ala Thr Leu
500 505 510Asn Ser Leu Gly Ile Ser Glu Glu Leu Lys Glu Lys Leu Arg
Asp Val 515 520 525Met Val Asp Arg His Lys Val Ala Leu Gly Lys Thr
Leu Gly Glu Gly 530 535 540Glu Phe Gly Ala Val Met Glu Gly Gln Leu
Asn Gln Asp Asp Ser Ile545 550 555 560Leu Lys Val Ala Val Lys Thr
Met Lys Ile Ala Ile Cys Thr Arg Ser 565 570 575Glu Leu Glu Asp Phe
Leu Ser Glu Ala Val Cys Met Lys Glu Phe Asp 580 585 590His Pro Asn
Val Met Arg Leu Ile Gly Val Cys Phe Gln Gly Ser Glu 595 600 605Arg
Glu Ser Phe Pro Ala Pro Val Val Ile Leu Pro Phe Met Lys His 610 615
620Gly Asp Leu His Ser Phe Leu Leu Tyr Ser Arg Leu Gly Asp Gln
Pro625 630 635 640Val Tyr Leu Pro Thr Gln Met Leu Val Lys Phe Met
Ala Asp Ile Ala 645 650 655Ser Gly Met Glu Tyr Leu Ser Thr Lys Arg
Phe Ile His Arg Asp Leu 660 665 670Ala Ala Arg Asn Cys Met Leu Asn
Glu Asn Met Ser Val Cys Val Ala 675 680 685Asp Phe Gly Leu Ser Lys
Lys Ile Tyr Asn Gly Asp Tyr Tyr Arg Gln 690 695 700Gly Arg Ile Ala
Lys Met Pro Val Lys Trp Ile Ala Ile Glu Ser Leu705 710 715 720Ala
Asp Arg Val Tyr Thr Ser Lys Ser Asp Val Trp Ser Phe Gly Val 725 730
735Thr Met Trp Glu Ile Ala Thr Arg Gly Gln Thr Pro Tyr Pro Gly Val
740 745 750Glu Asn Ser Glu Ile Tyr Asp Tyr Leu Arg Gln Gly Asn Arg
Leu Lys 755 760 765Gln Pro Ala Asp Cys Leu Asp Gly Leu Tyr Ala Leu
Met Ser Arg Cys 770 775 780Trp Glu Leu Asn Pro Gln Asp Arg Pro Ser
Phe Thr Glu Leu Arg Glu785 790 795 800Asp Leu Glu Asn Thr Leu Lys
Ala Leu Pro Pro Ala Gln Glu Pro Asp 805 810 815Glu Ile Leu Tyr Val
Asn Met Asp Glu Gly Gly Gly Tyr Pro Glu Pro 820 825 830Pro Gly Ala
Ala Gly Gly Ala Asp Pro Pro Thr Gln Leu Asp Pro Lys 835 840 845Asp
Ser Cys Ser Cys Leu Thr Ser Ala Glu Val His Pro Ala Gly Arg 850 855
860Tyr Val Leu Cys Pro Ser Thr Ala Pro Ser Pro Ala Gln Pro Ala
Asp865 870 875 880Arg Gly Ser Pro Ala Ala Pro Gly Gln Glu Asp Gly
Ala 885 890
* * * * *